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Abstract 
Reversible protein phosphorylation is a highly conserved mechanism that 
regulates the majority of proteins in a eukaryotic cell. Protein phosphorylation has been 
implicated in various cellular processes including glycogen metabolism, cell cycle 
control, RNA splicing, DNA synthesis, muscle contraction and mitosis. Protein kinases 
and phosphatases regulate the phosphorylation status of proteins in response to intra- 
and extracellular stimuli such as hormones and growth factors.  
In chapter 3, I explore the regulation of protein phosphatases when the cAMP–
PKA signalling pathway is activated and study the isoform specificity of PP1. Most 
protein phosphatases of the PPP family do not exist as free catalytic subunits: instead, 
they interact with regulatory subunits, which specify, target and/or inhibit their 
activities. Protein phosphatases of the PPP family such as PP1 and PP2, act specifically 
on serine/threonine phosphorylations; our understanding of phosphatase regulation 
stems from the regulation of members of the PPP family upon activation of the cAMP 
signalling pathway through protein kinase A. We wanted to find out whether there were 
more proteins that would regulate phosphatase activity when the cAMP–PKA pathway 
is activated and so started by doing a microcystin-affinity purification. Microcystin is a 
potent inhibitor of most PPP phosphatases and has been adapted to purify protein 
phosphatases from cellular extracts. I used the cAMP agonist forskolin to trigger 
activation of the cAMP–PKA pathway and used the H-89 inhibitor to block PKA 
activity. Although several protein phosphatases were identified along with their 
regulatory subunits, I could not find any striking enrichment of proteins upon activation 
or inhibition of the cAMP–PKA signalling pathway.  
I also purified protein phosphatase 1 complexes from a cell line stably 
expressing GFP-TAP- PP1β with the aim of identifying PP1-regulatory subunits which 
would indicate potential PKA-mediated regulatory events. Again, cells were stimulated 
with forskolin and H-89 to monitor changes in the cAMP–PKA signalling pathway. 
Many known PP1 interacting proteins were identified including MYPT1, NIPP1, 
Inhibitor-2 and Staufen. Interestingly, three glycogen-related proteins, namely R6, 
glycogenin and glycogen synthase, were found to be highly enriched upon forskolin 
treatment which included prior inhibition of the pathway with H-89. R6 is a glycogen-
targeting subunit of PP1 while glycogenin acts as the primer during glycogen synthesis; 
these glycogen moieties are then elongated by glycogen synthase. We think the 
enrichment of glycogen synthase and glycogenin from PP1 immunoprecipitates treated 
xii 
 
with H-89 and forskolin could be linked to increased amounts of the R6-glycogen 
targeting subunit under the same conditions. Further experiments are required to check 
the correlation between R6 and the enzymes of glycogen synthesis. 
PP1 isoforms alpha, beta and gamma are 97% identical in their catalytic 
residues, raising an important question of how these isoforms exert specificity in their 
substrates. Isoform specificity has been implicated in a number of regulatory processes 
including the selective nuclear targeting of the PP1γ subunit by Repo-Man and the 
preferential association of MYPT1 with PP1β to control muscle contraction. With such 
a high degree of similarity among PP1 isoforms, I wanted to evaluate whether the three 
isoforms varied much in their isoform specificity or whether they could be redundant in 
their substrates. For this, I stably expressed the three isoforms with an N-terminal GFP-
TAP tag and analysed the immunoprecipitated protein complexes for each isoform. We 
found that there was no significant pattern of enrichment for any protein that could be 
used to specify isoform preference. Nonetheless, we did find higher amounts of MYPT1 
with the beta isoform compared to alpha and gamma, in agreement with the reports of 
preferential PP1 beta binding to the ankyrin repeats of MYPT1. Overall though, these 
studies suggest that isoform specificity of the PP1 catalytic subunits may not be clear 
cut; in fact, most studies reporting PP1 isoform selectivity use bacterially-expressed 
PP1 proteins which have been shown to exhibit different properties to the native 
enzymes.  
 Protein phosphorylation creates binding sites for proteins such as 14-3-3s, 
which have been shown to dock onto dually-phosphorylated serine/threonine residues 
on target proteins. In chapter 4, I looked at the regulation of 14-3-3-binding proteins 
when the cAMP–PKA signalling pathway was activated. Again, I used forskolin as a 
cAMP agonist and H-89 as the non-specific PKA inhibitor to monitor changes in 
proteins involved in 14-3-3-binding in this pathway. 14-3-3s are involved in regulating 
various cellular proteins involved in insulin signalling, transcription, translation, 
glycogen metabolism, autophagy, vesicle and protein trafficking among others. 
Previous experiments in our laboratory explored the binding of 14-3-3s to its targets 
upon stimulation with hormones and growth factors such as insulin, IGF-1 and EGF, to 
monitor how changes in these pathways altered proteins involved in survival and 
growth promoting pathways. Understanding how and when 14-3-3s impact on these 
signalling targets enables us to gain regulatory insights into many areas of 14-3-3 
biology. Since many proteins had already been observed to bind 14-3-3s upon forskolin 
xiii 
 
stimulation, I performed a large-scale 14-3-3-affinity pull-down to explore proteins in 
the cAMP–PKA proliferation-promoting pathway. Interestingly, many forskolin/H-89-
regulated proteins were identified and I went on to validate a few of these candidate 
proteins as 14-3-3-binding targets, including the DENND4 family, EML3 and Atg9. 
The DENND4 proteins are guanine nucleotide exchange factors for Rab proteins, while 
Atg9 is a component of the autophagosome. Therefore, my findings indicate novel roles 
for 14-3-3s in regulation of intracellular membrane dynamics. My studies indicate that 
there are still many targets of 14-3-3s to be characterised and I hope that the data 
presented in my thesis will be extended in future and contribute towards our 
understanding of protein phosphorylation and14-3-3 biology. 
xiv 
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MYPT1 myosin phosphatase-targeting subunit 1 
NLS  nuclear localization sequence 
NOM1  nucleolar MIF4G domain-containing protein 1 
N-terminus  amino terminus 
O. sativa  
indica  Oryza sativa indica 
PAS  phospho-Akt substrate  
xvi 
 
p70 S6K p70 ribosomal protein S6 kinase 
PAGE  polyacrylamide gel electrophoresis 
PANK2 pantothenate kinase 2, mitochondrial 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PDK1  3'-phosphoinositide-dependent protein kinase 1  
PI 3-kinase phosphatidylinositol 3-kinase 
PKA   protein kinase A 
PKB   protein kinase B (also known as Akt) 
PKC   protein kinase C 
PKD  protein kinase D 
PKG  protein kinase G 
PMSF  phenylmethanesulphonylfluoride 
pNUTS serine/threonine-protein phosphatase 1 regulatory subunit 10 
PP  protein phosphatase 
PPKL  PP1 and kelch-like phosphatases 
PPP  phosphor-protein phosphatase 
PRAS40 proline rich Akt substrate of 40 kDa 
pSer    phosphorylated serine residue 
PtdIns          phosphatidylinositol                          
PTEN  phosphatase and tensin homologue deleted on chromosome 10 
pThr   phosphorylated threonine residue 
RBM15 RNA-binding motif 15 
RTK              receptor tyrosine kinase 
SAC  soluble adenylyl cyclase 
S.cerevisiae Saccharomyces cerevisiae 
SDS  sodium dodecyl sulphate 
SH2                 src homology 2 domain 
SILAC stable isotope labelling with amino acids in cell culture 
siRNA  small interfering RNA 
SPEN  split-end 
TAE  Tris-acetate, EDTA 
TAP  tandem affinity purification 
TAK1  transforming growth factor beta-activated kinase 1 
TBC domain Tre-21/Bub21/Cdc 16 domain 
TBC1D4 TBC1 domain family member 4 
TBS  Tris-buffered saline 
TBS-T  Tris-buffered saline-Tween 
TE  Tris, EDTA 
TFA  trifluoroacetic acid 
TGN  trans Golgi network 
TLC  thin layer chromatography 
tmAC  transmembrane adenylyl cyclase 
TOF  time-of-flight 
Tris  Tris(hydroxymethyl)methylamine 
TSC  tuberous sclerosis complex 
Tween  polyethylene glycol sorbitan monolaurate 
U  unit 
ULK1  Unc51-like kinase 1 
VASP   vasodilator-stimulated phosphoprotein 
Vol  volume 
xvii 
 
Vps34  phosphatidylinositol 3-kinase catalytic subunit type 3 
w/v  weight to volume 
WD40-repeat tryptophan/ aspartic acid repeat 
Y2H  yeast 2-hybrid 
ZNRF2 E3 ubiquitin-protein ligase ZNRF2 
xviii 
 
Amino acid code 
Amino acid or residue  Three letter symbol  One letter symbol 
Alanine    Ala    A 
Arginine     Arg     R 
Asparagine     Asn     N 
Aspartate     Asp     D 
Cysteine     Cys     C 
Glutamate     Glu     E 
Glutamine    Gln     Q 
Glycine     Gly     G 
Histidine    His    H 
Isoleucine    Ile    I 
Leucine     Leu     L 
Lysine     Lys     K 
Methionine     Met     M 
Phenylalanine    Phe    F 
Proline    Pro    P 
Serine     Ser    S 
Threonine    Thr    T 
Tryptophan    Trp    W 
Tyrosine    Tyr    Y 
Valine        Val                             V 
 
Other amino acid residue symbols 
Aliphatic residue (such as L, M or F)      
Unknown or any residue      X 
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1.1 Reversible protein phosphorylation in eukaryotes 
Cells respond to extracellular stimuli via signalling pathways that regulate 
enzyme activities and direct rearrangements of multicomponent complexes. Protein 
phosphorylation is one of the major regulatory mechanisms that enact these changes. 
The regulatory mechanism of protein phosphorylation was first identified in 1955 by 
Fischer and Krebs who were studying the interconversion of glycogen 
phosphorylase between its low and high activity states. Since then, this reversible 
protein modification has been implicated in the regulation of numerous cellular 
events such as glucose uptake and metabolism, muscle contraction, RNA 
processing, cell cycle progression, cell proliferation and differentiation, among 
others. Correspondingly, deregulated phosphorylation underlies a number of 
diseases such as various types of cancers, diabetes and neurological disorders.   
The reversible phosphorylation status of proteins is directed by the actions of 
kinases and phosphatases on three main residues: serine, threonine and tyrosine. 
Protein kinases catalyse the addition of the phosphate moiety to a protein while 
phosphatases hydrolyse the phosphoamino acid esters to release phosphate. 
Complicated cascades of signalling networks direct the specificity and subcellular 
localisation of kinases and phosphatases to effect different cellular outcomes in 
response to stimuli.  
Kinases and phosphatases make up about 2 to 4% of a typical eukaryotic 
genome (Manning et al., 2002a; Moorhead et al., 2009). In humans, there are about 
518 kinases compared with 150 phosphatases, while plants have double the number 
of kinases at 1055 to 127 plant protein phosphatases (Kerk et al., 2008; Moorhead et 
al., 2009). These ratios raise the interesting question of how the smaller number of 
phosphatases regulates the dephosphorylation of the many substrates generated by 
such a large number of kinases. While kinases have generally evolved to recognise 
amino acid sequences flanking the phosphorylated residue, protein phosphatases are 
aided in their substrate recognition and action by targeting proteins. These proteins 
target the phosphatases to different cellular locations, thereby bringing them closer 
to their substrates where they can then exert their dephosphorylating action. For 
example, the GM subunit of PP1 is responsible for targeting PP1 to glycogen in 
skeletal muscles where PP1 can then dephosphorylate and inactivate phosphorylase 
kinase and glycogen phosphorylase; and dephosphorylate and activate glycogen 
synthase, thereby modulating glycogen metabolism in these cells (Cohen, 1985; 
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Cohen, 1988). As well as targeting PP1, GM also mediates its regulation by protein 
kinases A and C, contributing to the regulation of glycogen metabolism by these 
kinases. The targeting subunits also influence substrate specificity by providing 
additional substrate binding surfaces, blocking substrate-binding channels and/or 
altering the conformation of the catalytic subunit (Bollen et al 2010). In these ways, 
the substrate repertoire of the smaller number of phosphatases, compared with 
kinases, can be increased by the regulatory proteins that allow for differential 
regulation of the same protein phosphatase catalytic subunit in different 
physiological contexts. 
1.2 Protein kinases 
Eukaryotic Protein Kinases (ePK) make up one of the largest superfamilies, 
containing 1 to 2% of human genes, sub-divided into eight families based on 
sequence similarity in the catalytic domains, the presence of accessory domains and 
by comparison of their modes of action (Hanks et al., 1995; Manning et al., 2002a) 
(Figure 1.1). These are the AGC (including protein kinases A, G and C), CAMK 
(calmodulin regulated kinases), CK1 family (casein kinase 1 and closely related 
kinases), the CMGC kinases (including the mitogen-activated protein kinases, 
glycogen synthase kinase and cyclin-dependent kinases), RGC family (receptor 
guanylate cyclases), STE kinases (including kinases functioning in MAP kinase 
cascades, the TK family (tyrosine kinases) and lastly, the TKL (tyrosine-like 
kinases, which are in fact serine/threonine kinases) (Manning et al., 2002a; Manning 
et al., 2002b; Miranda-Saavedra and Barton, 2007). The majority of the ePK family 
remained conserved throughout evolution from yeast to man (~51 subfamilies). A 
comparatively larger number of kinase subfamilies are shared among worms, flies 
and humans (~93), implying that most of these kinase subfamilies would have 
evolved after the divergence from the common ancestor with yeast (Manning et al., 
2002a).  
In addition to ePKs, there are also the atypical Protein Kinases (aPKs), which 
lack sequence similarity with the ePKs, although some aPKs share structural 
similarity to the ePK catalytic domains (Hanks et al., 1995). Strong experimental 
evidence of protein kinase activity has been shown for the aPK enzymes of the 
Alpha, RIO, PIKK and PHDK families (Miranda-Saavedra and Barton, 2007). 
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Figure 1.1: The eight ePK subfamilies of kinases classified according to their 
kinase domain similarity and modes of action (adapted from Manning et al., 
2005b) 
 
Miranda-Saavedra and Barton (2007) analysed 21 eukaryotic genomes and 
found that five ePK protein kinase families (AGC, CAMK, CK1, CMGC and STE) 
and two aPK protein kinase families (PIKK and RIO) were common to all of these 
genomes. Interestingly, they also found that while plants (namely Arabidopsis and 
rice) had almost double the number of kinases compared to human (see Table 1), 
there were markedly fewer TK-subfamily members in plants (7 in plants compared 
to 90 in humans) and many more TKL enzymes (1010 in plants compared to 55 in 
humans). Furthermore, plants had no RGC kinases at all, whereas humans expressed 
5 compared to 28 such kinases in the worm C. elegans.  As shown in Table 1.1, 
most of the other kinase families had more members in Arabidopsis compared to 
humans, especially in the CAMK, CMGC, STE and CK1 kinase families (Miranda-
Saavedra and Barton, 2007).  
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Table 1.1           
The protein kinase complement of eukaryotic organisms with the 8 ePK 
families and aPKs found in each organism 
Taxonomy and 
species  AGC CAMK CK1 CMGC RGC STE TK TKL 
Total 
ePKs 
Total 
aPKs 
Fungi           
S. cerevisiae 22 44 4 29 0 16 0 0 115 9 
           
Plants           
A. thaliana 67 158 28 149 0 104 2 776 1284 17 
O. sativa indica 54 93 15 97 0 55 6 1010 1330 8 
           
Animals           
C. elegans 35 65 92 56 28 36 94 20 426 10 
D. 
melanogaster 42 45 10 39 6 24 33 23 222 9 
H. sapiens 84 98 12 70 5 61 93 55 478 40 
           
(Compiled from: Manning et al., 2002b and Miranda-Saavedra and Barton, 2007) 
 
1.2.1 The human kinome 
The human kinome (Figure 1.2) contains 478 kinases from seven main ePKs 
families (the AGC, CAMK, CK1, CMGC, STE, TK and TKL families) and 40 
kinases from the aPKs families. Of these, Manning et al. (2002b) reported that 244 
kinases mapped to diseased loci or cancer-linked regions on chromosomes. This 
finding stresses the importance of understanding the different kinases and their 
regulation.  
Though some protein kinases also have docking sites distinct from their 
active sites, the substrate specificity of the different kinases in the kinome is 
conferred through the residues of the target protein lying in the catalytic groove of 
the kinase. For example, the CMGC kinase Erk1 and the closely related Erk2 share 
the substrate recognition consensus motif X-P-X-pS/T-P-X (with pS/T being 
phosphorylated by the Erk isoforms) (Davis, 1993; Ubersax and Ferrell Jr., 2007; 
Roskoski Jr., 2012). CK1, on the other hand, phosphorylates targets to create 
phosphorylated pS-x-x-S motifs (Ubersax and Ferrell Jr., 2007). Kinases control 
most cellular functions in the cell by regulating the phosphorylation status of 
proteins and are hence required to be highly specific in their functions.  
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1.2.2 AGC and CAMK subfamilies and their specificities 
The AGC and CAMK subfamilies are basophilic kinases, which are of 
particular interest to our group as most of the 14-3-3-interacting proteins that we 
have identified are phosphorylated by these enzymes. In contrast to many members 
of the CMGC family that require a proline at the +1 position relative to the 
phosphorylatable Ser/Thr residue, Zhu et al., (2005a) reported that proline at +1 
cannot form a critical amide linkage with the carbonyl group in the catalytic cleft of 
AGC/CAMK kinases, which thereby hinders their interactions with such substrates 
(Zhu et al., 2005a).  
Another feature of the substrate specificity of most AGC/CAMK family 
members is the requirement for an arginine residue at the -3 position. Interestingly, 
Zhu et al. (2005b) also reported that some of these kinases also displayed preference 
for arginine residues between -2 and -5 positions in their substrates. For example, 
PKA was the first shown to display preference for substrates having an Arg at the -3 
and -2 positions (Kemp et al., 1975; Kemp et al., 1977). 
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Figure 1.2: The human kinome (source: Manning et al., 2002b) 
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1.2.3 cAMP signalling and PKA regulation 
Cyclic adenosine monophosphate (also known as cAMP or 3',5'-cyclic 
adenosine monophosphate) was the first intracellular second messenger to be 
identified. Sutherland and his co-worker Rall discovered the molecule in 1958 while 
working on the effects of hormonal changes in glucose metabolism following 
stimulation with adrenaline (Sutherland and Rall, 1958a; Sutherland and Rall, 
1958b). While cAMP is in all mammalian tissues, its presence and whether cAMP 
acts as a second messenger molecule in plants is controversial (Gehring, 2010).  
cAMP gradients and localised cAMP pools in the cells are established by the 
opposing actions of adenylyl cyclases (ACs) that catalyse the formation of cAMP 
from ATP, and phosphodiesterases (PDEs) that hydrolyse cAMP. cAMP signalling 
is closely coupled with PKA signalling as this protein kinase is the major 
downstream effector of cAMP. Signalling through cAMP is also mediated by cyclic 
nucleotide gated (CNG) cation channels and guanine nucleotide exchange factors 
(GEFs) (discussed in section 1.2.3.4).  
1.2.3.1  Protein Kinase A  
Protein kinase A from the AGC kinase subfamily was the first kinase to have 
its crystal structure solved (Figure 1.3), the first protein reported to be myristylated 
and also the first kinase for which arginine residues at the -3 and -2 positions in its 
substrates were shown to be crucial (Kemp et al., 1975; Kemp et al., 1977; Carr et 
al., 1982; Knighton et al., 1991a; Knighton et al., 1991b).  
PKA exists in an inactive heterotetramer comprising two regulatory and two 
catalytic subunits. The regulatory subunits act as inhibitors, which restrict the 
indiscriminate action of PKA on its targets. There are three PKA catalytic subunits 
expressed from three genes, namely Cα, Cβ and Cγ. The C-subunits consist of the 
catalytic cores, and also N- and C-terminal tails that are thought to mediate protein-
protein interactions (Taylor et al., 2005). PKA activation involves its 
autophosphorylation at Thr197 in the activation loop, which induces conformational 
changes to bring the catalytic core residues into proximity, thereby converting the 
enzyme from an inactive to an active state (Steichen et al., 2010). Lys72 is one of 
the important residues, with equivalents in all protein kinases, and it interacts with 
the phosphate groups of ATP and also helps maintain the active conformation of the 
enzyme (Iyer et al., 2005; Taylor et al., 2005). It has also been shown that mutation 
of Lys72 to histidine suppresses the catalytic activity of PKA and restricts binding to 
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the R subunits; however, the phosphorylation of Thr197 by a heterologous kinase 
such as PDK1 is able to restore the interactions between the C subunit and the R 
subunits (Iyer et al., 2005). 
There are two types of regulatory subunits: RI (α and β) and RII (α and β). 
The R subunits have N-terminal dimerization/docking (D/D) domains and two C-
terminal cAMP-binding domains (Taylor et al., 2004). However, despite this 
conserved domain organisation, the R subunits are functionally non-redundant. They 
form homo- or heterodimers, which bind to the catalytic subunits of PKA, thereby 
generating different combinations with the three types of catalytic subunits, which in 
turn differentially influences substrate specificity in different cells and tissues 
(Tasken and Aandahl, 2004). These regulatory subunits also have an A-kinase 
anchoring protein (AKAP)-binding region, which allows them to further restrict the 
spatial action of PKA (discussed in section 1.2.3.3). PKA recognises and 
phosphorylates substrates with a consensus sequence ‘RRXS’. Other consensus 
sequences for this kinase have also been reported: RRXT, RKXS/T, KKXS/T, 
KRXS/T, RXXS and RXS (listed in decreasing order of PKA affinity) (Shabb, 
2001).  
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Figure 1.3: Crystal structure of the catalytic subunit of PKA 
The catalytic subunit of PKA is bound to ATP (red/pink balls and sticks, center) and 
Mn2+ ions (grey balls) in the active site (Structure 1ATP from www.rcsb.org). The 
phosphate group important for activation of PKA on Thr197 is adjacent to the active 
site (ball and stick model, centre right) (Zheng et al., 1993).  
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1.2.3.2 Adenylyl cyclase and PKA-dependent cAMP signalling 
Adenylyl cyclase, also known as adenylate cyclase and adenyl cyclase, was 
first identified as a transmembrane protein, which traverses the plasma membrane 
twelve times. Ten isoforms of AC have been reported in mammals, namely AC1-
AC10. AC1-AC9 are transmembrane cyclases (tmAC) while AC10 is soluble (sAC) 
(Kamenetsky et al., 2006). The tmACs are activated by G-proteins and forskolin, 
with the exception of AC9. In contrast, sAC is activated by bicarbonate and calcium 
ions and exhibits distinct catalytic and regulatory functions compared to its 
transmembrane counterparts (Kamenetsky et al., 2006). Structurally, tmACs have a 
variable N-terminal region, followed by transmembrane spanning helices (TM1), 
catalytic domain C1, a further six transmembrane helices (TM2) and the second 
catalytic region C2 (Kamenetsky et al., 2006). The N-terminal domain and the 
catalytic regions protrude on the cytosolic side of the plasma membrane. Upon 
activation of the enzyme, the C1 and C2 catalytic regions come into close proximity 
and form the active site (Figure 1.4). This site is also the binding region for the 
plant diterpene forskolin, which is an AC agonist.   
Activation of the G protein coupled receptors (GPCRs) by ligands such as 
adrenaline and glucagon activates heterotrimeric G proteins bound to the receptors. 
The G proteins consist of three subunits: Gα, Gβ and Gγ. Gβγ stay bound to each 
other, and in some cases also to the membrane, after activation of the receptor. Gα 
can be further sub-divided into four classes: Gαs, Gαi, Gαq and Gα12/13. Gαq binds to 
and activates members of the phospholipase C isoform β family while Gα12/13 
activates the RGS domain-containing Rho guanine exchange factors (Hewavitharana 
and Wededaertner, 2012). On the other hand, Gαs activates, whereas Gαi inhibits 
adenylyl cyclase. The activated GPCR receptor acts as a guanine exchange factor 
that converts Gαs–GDP to Gαs–GTP. This Gαs–GTP complex activates adenylyl 
cyclase to catalyse the conversion of ATP to cAMP, which in turn binds to the 
regulatory subunits of PKA. When two cAMP molecules bind cooperatively to each 
R subunit, the catalytic subunit of PKA is released to transmit the signal by 
phosphorylating its downstream targets (Figure 1.4).  
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1.2.3.3  Regulation of PKA activity: A-Kinase Anchoring proteins (AKAPs) 
The AKAPs endow PKA with specificity by acting as scaffolds that restrict 
its actions by targeting the enzyme to different substrates and cellular locations, and 
regulating the timing of its action. For example, AKAP79 directs the activity of 
PKA towards plasma membrane ion channels in response to activation of glutamate 
receptors in brain and β2-adrenergic receptors in cardiac cells (Tasken and Aandahl, 
2004). Further specificity is introduced by the association of AKAPs with different 
isoforms of adenylyl cyclases in different tissues (Edwards et al., 2011). As 
mentioned in section 1.2.3.2, AC has nine transmembrane isoforms that are mainly 
activated by G-proteins. Some of these AC isoforms have also been described to 
associate with AKAPs at particular cellular locations, where they enhance the 
specificity of PKA regulation. This in turn is proposed to create a PKA signalosome 
where all the components of the system (AC, AKAP, PKA and PDEs) are in close 
proximity to effect localised changes, which can also be regulated (Figure 1.4). For 
example, in rat brain extracts, AKAP79 has been shown to associate with AC5/6, 
where bound PKA phosphorylates and inhibits AC5/6 activity and also desensitises 
the bound β2-adrenergic receptor (β2-AR) through phosphorylation (Bauman et al., 
2006; Dessauer, 2009).  
To ensure timely control of PKA, it is critical to have an efficient system to 
clear cAMP. PKA can phosphorylate many proteins and unregulated PKA would be 
disastrous to the cell. There is growing evidence that phosphodiesterases associate 
with AKAPs. For example, the cardiac splice variant of muscle AKAP (mAKAPβ) 
is attached to the nuclear envelope where it interacts with PKA, PDE4D3 and AC5. 
In this system, when β2-AR-stimulated AC5 activates PKA, a feedback loop is also 
triggered whereby PKA phosphorylates and inhibits AC5 and at the same time 
activates PDE4D3, which lowers cAMP levels (Dessauer, 2009). In summary, by 
having the components and substrates for PKA activity and inhibition in close 
proximity, the actions of PKA can be tightly regulated spatially and temporally.  
1.2.3.4  PKA-independent cAMP signalling 
In addition to the well-established role of PKA in mediating responses to 
cAMP, other PKA-independent cAMP signalling networks have also been 
described. These include signalling through cyclic nucleotide-gated (CNG) channels 
and GEFs. CNG channels, such as the olfactory receptor, respond upon binding of 
cAMP and cGMP to control membrane potential and intracellular calcium levels 
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(Nakamura and Gold, 1987; Tasken and Aandahl, 2004). GEFs activate Ras-related 
proteins by stimulating their release of GDP and enhancing their binding of GTP 
(Bourne et al., 1990; Bourne et al., 1991). Two Rap-specific GEFs, namely Epac 1 
and 2 (Exchange protein activated by cAMP) have one and two cAMP-binding sites 
respectively, and are directly regulated by cAMP (De Rooij et al., 1998; Kawasaki et 
al., 1998; De Rooij et al., 2000). cAMP binding to these Epacs results in 
conformational changes that activate their GEF domain (Rehmann et al., 2003).  
 
1.3 Protein phosphatases 
The function and regulation of protein phosphatases (PPs) are relatively less 
defined compared to protein kinases. There are far fewer protein phosphatases (150 
in humans and 127 in Arabidopsis) compared to protein kinases (518 in humans and 
1055 in Arabidopsis) (Kerk et al., 2008; Moorhead et al., 2009).  How do such a 
comparatively small number of molecules control such a wide array of functions? 
Inside cells, protein phosphatases interact with many regulatory subunits, which 
define their function, substrate specificity and cellular localisation. In this way, 
relatively few catalytic subunits are directed to selectively control distinct processes 
inside a cell. 
1.3.1 Protein phosphatase gene families and their specificities 
Nine phosphorylated amino acids residues that have been reported to 
undergo dephosphorylation catalysed by PPs: serine, threonine, tyrosine, arginine, 
histidine, cysteine, lysine, glutamate and aspartate (Hunter, 2004), though 
phosphorylations of serine, threonine and tyrosine residues predominate in 
eukaryotic cells (Moorhead et al., 2009). Protein phosphatases can be divided into 
four main families (a) protein tyrosine phosphatases (PTP) (b) phospho-protein 
phosphatase (PPP), (c) metallo-dependent protein phosphatases (PPM) and (d) 
aspartate-dependent protein phosphatases (Moorhead et al., 2009). A summary of 
the catalytic site residues and signatures of the four protein phosphatase families are 
listed in Table 1.2.  
As the name suggests, the PTP family mainly catalyses dephosphorylation of 
tyrosine residues on proteins but certain of these enzymes can also dephosphorylate 
non-protein targets such as mRNA (Kenelly, 2003), glycogen (Cohen, 2002) and 
phosphoinositides (Tonks, 2006). PTP family members, such as PTEN, DUSPs, 
Cdc25, are defined by the P loop in their active sites, which contain a CX5R motif in 
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which phosphate from the substrate is temporarily transferred to the Cys residue 
during the dephosphorylation reaction (Tonks, 2006). The PPM family on the other 
hand dephosphorylate serine and threonine residues in a metal ion-dependent 
manner, more specifically, using Mn2+ or Mg2+. In contrast to the PPP family 
members, the PPM family, which include PP2C and pyruvate dehydrogenase 
phosphatase, do not have regulatory subunits and are also resistant to the common 
PPP inhibitors such as okadaic acid and microcystin (Moorhead et al., 2009). Instead 
of separate regulatory proteins, the PPM family members have evolved with 
additional domains that confer specificity to these phosphatases.  
The PPP family is defined structurally by the three signature motifs GDxHG, 
GDxVDRG and GNHE. This family comprises PP1, PP2, PP3 (also called PP2B), 
PP4, PP5, PP6, PP7 and PP1-like enzymes PPKL (PP1 and kelch-like) 
phosphatases. These enzymes are highly conserved across species, with the catalytic 
domain of mammalian PP1 sharing at least 76% similarity to plant and fungal PP1 
(Moorhead et al., 2009). Members of this family are potently inhibited by a 
chemically-diverse group of natural toxins including microcystin and okadaic acid 
(Takai et al., 1987; Bialojan et al., 1988; Bialojan and Takai, 1988; MacKintosh et 
al., 1994). PPP enzymes have metal ions in their active sites that take part in 
nucleophilic attack on the phosphate attached to the substrate. Members of this 
family have a core catalytic centre and have evolved to bind to regulatory subunits, 
which specify their function, localisation and substrate specificity.   
The eukaryotic aspartate-dependent protein phosphatases were discovered 
recently and relatively little is known about them. Their name comes from the use of 
an aspartate residue in their signature motif (DXDXT/V) to carry out their catalytic 
functions. Their specificity appears to be brought about by other domains, such as 
the BRCT domain, on the same polypeptides as their catalytic core, rather than by 
binding of separate regulatory subunits (Moorhead et al., 2009).    
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1.3.2 The PPP family of protein phosphatases and their regulatory subunits 
The members of the PPP family are distinct from other phosphatases in that 
they employ a variety of regulatory subunits to modulate their activity, specificity 
and localisation amongst other functions. The interaction between the catalytic 
subunit of a protein phosphatase and at least one of these regulatory subunits results 
in the formation of holoenzyme complexes which partake in a wide array of 
functions: control of cell cycle progression and regulation, protein synthesis, 
apoptosis, glycogen metabolism, muscle relaxation and contraction, and RNA 
processing among others. PP1 and PP2A are two of the most conserved enzymes 
known, with related enzymes also in prokaryotes (Moorhead et al., 2009). The 13 
members of the PPP family can be broadly clustered based on the similarities of the 
amino acids in their catalytic domain: PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7 in 
humans. Contrastingly, plants have a few different members compared to humans: 
they do not have any PP2B but have three distinct families including the PPKL 
family (Moorhead et al., 2009). Twelve PPP members are known in S. cerevisiae, 
while Drosophila has nineteen family members and Arabidopsis 26. A phylogenetic 
tree analysis of the catalytic domains of the PPP members in humans and 
Arabidopsis is shown in Figure 1.5. So far, there have been no reports indicating the 
existence of the free catalytic subunits of PP1, PP2A, PP2B, PP4 and PP6, implying 
that they are driven to function, and towards specificity, through the interaction with 
their respective regulatory subunits. 
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Figure 1.5: Phylogenetic tree analysis of the PPP family members in Homo 
sapiens and Arabidopsis 
The PPP members are clustered according to the amino acid similarity in their 
catalytic domains. (TOPP: Type One Protein Phosphatase is the name given to PP1 
in plants) (Source: Moorhead et al., 2009). 
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PP1, one of the most studied members of this family, was discovered to dock 
onto its regulatory subunits via the RVXF motif present on these subunits. 
Subsequently however, proteins that lacked the precise RVXF motif were found to 
bind to PP1. Then, bioinformatical analyses helped redefine the RVXF motif to the 
more degenerate [RK][VI]012[X][FW] (Egloff et al., 1997). Also, two additional 
signature motifs have recently been described: [GS]IL[RK] and MyPhoNE 
(Hendrickx et al., 2009). 
The PP1 catalytic isoforms in humans are expressed from three genes: 
PP1cα, PP1cβ and PP1cγ. PP1cγ also has two splice variants: PP1cγ1 and PP1cγ2. 
Although multiple isoforms have been reported in most mammals, S. cerevisiae has 
a single PP1c-encoding gene, Glc7, whose deletion is lethal. PP1 isoforms in plants 
are called TOPPs (Type One Protein Phosphatase). In humans, each PP1 isoform is 
fairly specific in their functions and the regulatory subunits to which they bind. For 
example, only PP1cβ binds to the muscle glycogen targeting subunit (GM) and the 
myosin phosphatase-targeting subunit 1 (MYPT1) (Moorhead et al., 1998; Toole 
and Cohen, 2007; Zagorska et al., 2010).  
Structural analyses of PP1 have shown that the enzyme has three binding 
grooves that are defined by their chemical (a hydrophobic cleft and an acidic 
groove) and structural (a C-terminal groove) properties respectively (Figure 1.6a). 
These three binding grooves form a Y-intersection, which radiates from the catalytic 
site. The active site contains two metal ions, which react with hydrated water 
molecules to initiate the nucleophilic attack during a dephosphorylation reaction. 
The β12-β13 loop, shown in green in Figure 1.6b, protrudes over the active site of 
PP1. This loop is important during substrate and inhibitor binding to PP1. For 
example, binding of microcystin to the PP1 active site has been shown to pull the 
loop inwards, thereby locking the PP1-microcystin complex tightly together. In 
contrast, regulatory subunits are thought to alter substrate selectivity of the enzyme, 
at least in part by altering the position of the β12-β13 loop. The three human PP1 
isoforms are around 89% identical in their amino acid sequences and share more 
than 97% homology in their catalytic site residues (Barker et al., 1994; Zhang et al., 
1997; Andreassen et al., 1998; Trinkle-Mulcahy et al., 2001). Despite this high 
similarity, it is thought that variations in the amino and carboxy termini of the PP1 
isoforms mediate selective binding to their regulatory proteins. For instance, in 
20 
 
humans, MYPT1 has been shown to interact selectively with the C-terminal domain 
of PP1β through its eight tandem ankyrin repeat domains (Terrak et al., 2004).   
 
 
a 
 
 
 
 
 
 
 
 
b 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The structure of PP1c, showing the catalytic site and different 
binding grooves  
(a) The active site contains two metal (Mn) atoms at its core. The substrate and 
inhibitor binding grooves (hydrophobic, acidic and C-terminal) form a Y-intersect 
over the active site. The site of interaction with the RVXF motifs present in the 
regulatory subunits is on the back end of the active site of the enzyme and cannot be 
seen in this view. (b) In this model, PP1c (blue ribbons) is complexed to MYPT1 
(red ribbons). The β12-β13 loop, which overhangs the active site is shown in light 
green while the RVXF-interacting region in darker green, indicated by the arrow on 
the right side of the structure (source: Terrak et al., 2004).    
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 The regulatory subunits of PP1 are important in specifying its activities. For 
example, the GM subunit of PP1 targets the enzyme to regulate enzymes on 
glycogen-protein particles in skeletal muscles (Strälfors et al., 1985; Tang et al., 
1991). MYPT1, on the other hand, targets PP1 to myosin light chains to regulate 
smooth muscle contraction and a more recent role of the MYPT-PP1 complex has 
been described in cell adhesion (Alessi et al., 1992; Chen et al., 1994; Shimizu et al., 
1994; Shirazi et al., 1994; Zagorska et al., 2010). PNUTS/p99 is another targeting 
subunit of PP1, which directs its phosphatase activity towards the transcription 
factor LCP1, the telomeric protein TRF2 and the γ-aminobutyric acid receptor (Rose 
et al., 2008; Kim et al., 2009; Lee et al., 2009). Some PP1-targetting proteins also 
direct the localisation of PP1 in the cell (Table 1.3). These binding subunits bring 
PP1 into closer proximity to its substrates by increasing the local pool of PP1. In 
addition to targeting PP1 to its substrates, some PP1-binding proteins can 
themselves be PP1 substrates. For instance, BRCA1 and CDC25C are activated 
when they are dephosphorylated by PP1. Furthermore, indiscriminate 
dephosphorylation by PP1 is prevented by proteins such as I-1. When 
phosphorylated by PKA, I-1 sequesters and inhibits PP1 upon the release of the 
latter from its associated subunits. In contrast, Inhibitor-2 (I-2) must be 
unphosphorylated to form an inactive complex with PP1 that was first identified as 
the Mg.ATP-dependent PP1 (Goris et al., 1979). This name comes from the fact that 
when I-2 is phosphorylated on Thr72 by glycogen synthase kinase 3 (GSK) in the 
presence of magnesium ions and ATP, the PP1 catalytic subunit is released and can 
bind its targeting subunits (Goris et al., 1979; Hemmings et al., 1981; Hemmings et 
al., 1982; Ballou et al., 1983; Cohen, 1989). PP1 has also been known to bind to an 
inhibitor/targeting subunit and a substrate at one time. For example, I-2 has been 
shown to bind to a PP1-neurabin I holoenzyme complex (Terry-Lorenzo et al., 2002) 
while I-1 has been shown bound to a PP1-GADD34 complex (Connor et al., 2001). 
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PP2/PP2A is distinct from PP1 in terms of binding to its regulatory subunits. 
The holoenzyme of PP2A consists of a catalytic core and a 65 kDa subunit termed 
the A subunit or PR65 subunit. A third variable subunit, called the B subunit 
completes the PP2A complex (Janssens and Gorris, 2001; Li and Virshup, 2002). 
There are at least 18 B subunits encoded by 14 genes in humans. In addition, there 
are two catalytic and two A subunits, which together with the B subunit, raise the 
potential number of different trimeric PP2A complexes to over 70. The subcellular 
localisations of these subunits vary, which could contribute to cell-type specific 
functions for these multiple holoenzymes.  
PP2A is more potently inhibited by okadaic acid compared to PP1. The 
differences in these affinities have been exploited to distinguish between these two 
phosphatases during purification processes. Similarly, microcystin is a more potent 
inhibitor of PP2A than it is of PP1 (MacKintosh et al., 1990). PP2A is involved in 
the regulation of a number of processes including, but not limited to, DNA and 
protein synthesis, cell cycle progression, apoptosis, metabolism and stress responses. 
PP2A has also been shown to act as a tumour suppressor by dephosphorylating c-
Myc, which leads to proteolytic degradation of the oncogenic c-Myc protein 
(Mumby, 2007).    
PP3/PP2B is differentiated by the other phosphatases through its dependence 
on Ca2+ and resistance to most PPP inhibitors including okadaic acid and 
microcystin (Armstrong, 1989; MacKintosh et al., 1990). Also known as 
calcineurin, the catalytic core of PP2B binds to its regulatory subunit, which confers 
the Ca2+ dependence to the enzyme. This results in further interaction with 
calmodulin, enabling the holoenzyme to regulate the calcium/ calmodulin reflux 
changes in the cell (Klee et al., 1998). PP2B is abundant in the brain where it 
regulates, through dephosphorylation, dopamine, DARPP32, G-protein coupled 
receptors (AMPA) and the ligand gated ion channels (NMDA). PP2B is inhibited by 
the immunosuppressant drugs cyclosporine and FK506, when the latter are bound to 
immunophilin proteins, cyclophilin A and FK506-binding protein (Hardie, 2003). 
Unfortunately, in the kidneys, PP2B activates the sodium/potassium ATPase ion 
transporter, which means that these drugs cause nephrotoxicity in organ transplant 
patients (Naessens et al., 2009). 
Like PP2A, PP4 forms both dimeric and trimeric holoenzyme complexes, 
although it has only three variable subunits, namely R3A, R3B and Gemin. The PP4 
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trimers comprise the catalytic core, one of the variable subunits and its R2 subunit. 
Dimeric structures are complexes of the catalytic subunit with its R1 subunit (Cohen 
et al., 2005). The functions of PP4 in the cell range from cellular signalling to 
spliceosome assembly and chromatin remodelling (Cohen et al., 2005).  
There is no evidence to suggest the presence of regulatory subunits for PP5. 
Instead, this enzyme is thought to interact with its substrates via the three 
tetratricopeptide repeats (TPR) in its amino terminal domain (Chinkers, 2001; Yang 
et al., 2005). PP5 has been shown to be involved in a number of cellular processes 
including transcription, apoptosis, DNA damage and stress responses, cell cycle 
arrest and regulation of signal transduction pathways.  
PP6, like PP4, forms dimeric and trimeric complexes (Stefansson et al., 
2008). PP6 has been shown to stabilise cyclin D1 during G1/S cell cycle progression 
in human cells (Stefansson and Brautigan, 2007). It is also involved in the regulation 
of TAK1-mediated stress response pathways (Kajino et al., 2006).  
PP7 is similar to PP2B in that it also depends on Ca2+ for its activity. A 
calmodulin-binding motif (distinct from the PP2B motif) in the amino terminal of 
PP7 mediates its interaction with calmodulin, while the EF hand-like sequences in 
the carboxy terminal of PP7 confer Ca2+ sensitivity (Andreeva and Kutuzov, 1999; 
Kutuzov et al., 2002). The functions of PP7 of mammals remain elusive (Andreeva 
and Kutuzov, 1999). The Drosophila PP7 homologue, rdgC, is involved in light 
sensing responses by dephosphorylating rhodopsin, resulting in its uncoupling from 
its G-protein receptor. However, mice deficient in PP7 exhibit normal rhodopsin 
phosphorylation and light responses, suggesting that the functions of PP7 might 
differ in mammals and flies (Ramulu et al., 2001).  
1.3.3 Use of toxins to inhibit and purify protein phosphatases 
To investigate the structures and functions of phosphatases, small-molecule 
inhibitors became in demand. When a phosphatase is inhibited, the levels of 
phosphorylated proteins in that particular cell increases, provided the relevant 
protein kinases are at least slightly active. The resulting cellular effects can give 
clues about how processes are affected by phosphorylation. Several natural protein 
phosphatase inhibitors have been discovered, namely microcystin-LR, okadaic acid, 
calyculin A, cantharidin, foestricin, tautomycin and nodularin. With the exception of 
cantharidin, these toxins mostly bind phosphatases at subnanomolar and nanomolar 
ranges (MacKintosh and Diplexcito, 2003). The first phosphatase inhibitor used, 
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okadaic acid, is a polyether fatty acid produced by marine microalgae (Dawson and 
Holmes, 1999). Although okadaic inhibits most PPP members, its potency is highest 
against PP2A and PP4, followed by PP1; PP5 is also inhibited by okadaic acid 
(reviewed in Cohen, 2010). Microcystin is a potent inhibitor of a wider range of 
PPPs: PP1, PP2A, PP4, PP5 and PP6 (reviewed in Cohen, 2010). Interestingly, none 
of these toxins are effective towards PP2B.  
The microcystin (MC) cyclic peptides are potent hepatotoxins produced by 
cyanobacteria in fresh waters. Over 80 variants of MC have been identified, 
including amino acid variations and modifications (Feurstein et al., 2009), with the 
most common being MC-LR, MC-RR and MC-YR (L-Leucine, R-Arginine and Y-
Tyrosine in the variable positions) (Puerto et al., 2009). The general structure of a 
microcystin, depicted in Figure 1.7, is cyclo-(D-Ala-X2-D-MeAsp3-Z4-Adda5-D-
Glu6-Mdha7), where X and Z are variable amino acids such as L, R or Y, D-MeAsp 
represents D-erythro-β-methylaspartic acid, Mdha is N-methyldehydroalanine and 
Adda is the unusual amino acid (2S, 3S, 8S, 9S)-3-amino-9-methoxy-2,6,8-
trimethyl-10-phenyldeca-4,6,dienoic acid (van Appledoorn et al., 2007). This Adda 
amino acid is critical for the toxicity of MC, and its oxidisation and isomerisation 
have been reported to reduce the potency of MC as a toxin (Tsuji et al., 1994; Song 
et al., 2006). While MCs have also been reported to either increase or decrease the 
activities of other proteins in vivo, these effects are probably mediated via inhibition 
of PPP enzymes. For example, MC has been shown to decrease the activity of DNA-
PK during DNA repair in cell extracts (Ariza et al., 1996; Douglas et al., 2001). MC 
increases the gene and protein expression of p53, which is a well-known tumour 
suppressor, in vivo, in liver tissues, primary hepatocytes and HepG2 cell lines (Fu et 
al., 2005; Xing et al., 2008; Zegura et al., 2008). Furthermore, exposing liver tissues 
to MC in vivo has also been shown to increase the protein expression of Bax and 
JNK, thereby affecting apoptosis and MAPK signalling respectively (Weng et al., 
2007; Wei et al., 2008).   
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Figure 1.7: General structure of microcystin 
Microcystin, a potent inhibitor of PPP family members (except PP3), is a cyclic 
peptide with the unusual ADDA moiety. (1) D-Ala is D-alanine; (2) X and (4) Z 
represent the L-amino acid variations for the many microcystin variants; (3) D-
MeAsp is D-erythro-β-methylaspartic acid; (5) Adda is the unusual amino acid 
(2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid; 
(6) Mdha is N-methyldehydroalanine (Source: Campos and Vasconcelos, 2010). 
 
Microcystin and okadaic acid have similar 3-dimensional tadpole shapes and 
both interact with PP1 in a similar ways, at three points within the active site: the 
hydrophobic groove, the C-terminal groove and the β12-β13 loop above the catalytic 
site (Figure 1.6). Upon binding, MC-LR interacts with the two hydrated catalytic 
metal ions of the substrate-binding pocket of the phosphatase. The long hydrophobic 
tail comprising the Adda residue lies within the hydrophobic groove of PP1, which 
projects from the active site. The third point of contact is the β12-β13 loop, which 
overhangs the active site. MC-LR binding pulls this loop into the catalytic groove 
through a covalent bond formed between the dehydroalanine of MC-LR and Cys273 
in the β12-β13 loop (MacKintosh et al., 1995). Mutating the adjacent Tyr272 in 
recombinantly expressed PP1 enzymes from E.coli decreases the sensitivity of PP1 
to MC-LR, without affecting the enzymatic activity of PP1 per se (Zhang et al., 
1996; Connor et al., 1998; Watanabe et al., 2001). However, PP1 purified from 
insect Sf9 cells showed decreased phosphatase activity when Tyr272 was mutated 
(Watanabe et al., 2001). 
To study the properties of PPs, their purification from cell extracts was of 
essence, inspiring the design of microcystin affinity chromatography. Because the 
covalent bond between the dehydroalanine of MC-LR and Cys273 of PP1 is not 
essential for inhibition, the dedydroalanine could be adopted for immobilising the 
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toxin. Using Michael chemistry, the dehydroalanine residue can be reacted with 
small reactive thiols that also carry an amine group. The amine is in turn linked to 
N-hydroxy-succinamide activated Sepharose, biotins and other such compounds 
(Moorhead et al., 1994; Campos et al., 1996). The resulting microcystin-Sepharose 
beads allow the affinity purification of phosphatases and their regulatory subunits 
from cell extracts. In the case of PP1, the regulatory subunits can be displaced from 
the phosphatases bound to MC-LR on the column by competitive elution with a 
synthetic peptide containing the RVXF motif (Moorhead et al., 2008). The 
phosphatase catalytic subunits can be released using a chaotropic salt such as 
sodium thiocyanate in the case of PP1, while denaturing buffers are required to 
release PP2A from the microcystin columns (Moorhead et al., 1994).   
1.3.4 Outstanding questions about the acute regulation of protein phosphatases 
Protein phosphatases of the PPP family are involved in many signalling 
pathways. For example, PP2A has been heavily implicated in the regulation of the 
insulin- and Erk-signalling pathways by dephosphorylating and inactivating key 
kinases involved in these pathways (Millward et al., 1999). For instance, PP2A has 
been shown to dephosphorylate Akt in vitro, and this dephosphorylation is prevented 
upon okadaic acid treatment (Andjelkovic et al., 1996). Moreover, the p70S6K has 
also been shown to be dephosphorylated in vivo by PP2A and also stably associates 
with this phosphatase in vivo (Ballou et al., 1988; Westphal et al., 1999). PP2A has 
also been shown to dephosphorylate PKCα and Erk, thereby inactivating them 
(Hansra et al., 1996; Alessi et al., 1999; Gomez and Cohen, 1991; Anderson et al., 
1990). However, little is known about the acute regulation of the PPPs by external 
stimuli.  
In skeletal muscle, protein phosphatase 1 was reported in the mid to late 
1980s to be regulated in vitro by cAMP-dependent protein kinase (PKA) (Caudwell 
et al., 1986) and in vivo by the hormone adrenaline (mediated by PKA) 
(MacKintosh et al., 1988). This regulation of PP1 was via its glycogen-binding GM 
subunit. Upon phosphorylation of GM by PKA, PP1 is released from the glycogen 
granules into the cytosol where it is sequestered by I-1 (Strålfors et al., 1985; 
MacKintosh et al., 1988). In common with many other targeting subunits of PP1, the 
GM subunit has the degenerate RVXF motif that binds to the hydrophobic cleft of 
PP1 distal from the active site (Caudwell et al., 1986; Dent et al., 1990; Egloff et al., 
1997; Wakula et al., 2003). This serine (SRRVS67FAD) within the PP1-binding site 
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of GM was identified to be one of the two sites whose phosphorylation by PKA 
disrupts the PP1.GM complex in response to adrenaline (MacKintosh et al., 1988 
Dent et al., 1990). The other PKA-phosphorylated site, Ser48 (PSRRGS48GSSED), 
was shown to be important for the dissociation of PP1 from the GM subunit, thereby 
enhancing the phosphorylation, and inhibition of glycogen synthase by PKA; this 
site has also been shown to be phosphorylated by p90RSK (Hiraga and Cohen, 
1986; MacKintosh et al., 1988; Dent et al., 1990; Lavoinne et al., 1991). This 
remains until now the most lucid example of PP1 regulation through cAMP–PKA 
signalling by an external stimulus, in this case adrenaline.  
PP1 is also regulated by I-1 and the related DARPP32 (Dopamine- and 
cAMP-regulated phosphoprotein of apparent Mr 32,000) in the brain via cAMP–
PKA signalling (Aitken et al., 1982; Endo et al., 1996). Similar to I-1, DARPP32 
inhibits PP1 in neurons upon phosphorylation of its Thr34 by PKA. At basal levels, 
DARPP32 is phosphorylated by Cdk5 at Thr75, which blocks the PKA-mediated 
phosphorylation of DARPP32 at Thr34 (Bibb et al., 1999). Interestingly, upon 
forskolin stimulation in neurons, PKA phosphorylates the B56δ subunit of the PP2A 
complex, which in turn dephosphorylates Thr75 of DARPP32, thereby enhancing 
parallel phosphorylation of Thr34 by PKA (Ahn et al., 2007). This coordinated 
regulation of PP1, involving PP2A and DARPP32 is interesting, and raises questions 
about whether there are other regulatory/inhibitory proteins that work in 
synchronised systems to regulate these dephosphorylating enzymes.  
Other than these examples, very little is known about how protein 
phosphatases are regulated. Since most of these proteins seem to regulate PPs upon 
PKA activation, it would seem logical that there would be other proteins regulating 
under similar conditions. Following this thought, we were interested to investigate 
whether there were other proteins we could find which might be possibly involved 
in the acute regulation of protein phosphatase 1 in particular (see Chapter three).  
 
1.4 Protein phosphorylation can create sites for binding to specific domains and 
proteins 
The phosphorylation of proteins on serine, threonine and tyrosine residues 
can result in conformation changes that, for example, activate or inhibit the target 
protein. However, some phosphorylations have no direct effect on the isolated 
target, but rather inhibit or promote its interaction with other proteins. For example, 
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the PTB (phosphotyrosine binding) and SH2 (Src-2 homology) domain-containing 
proteins are known to bind phosphorylated tyrosine residues: the SH2-domain of 
APS binds to two phosphotyrosine residues in the activation loop of the insulin 
receptor kinase (Seet et al., 2006). Domains such as WW, WD40, FHA and BRCT 
can also mediate binding to their targets via phosphorylated serine/threonine 
residues (Seet et al., 2006). 14-3-3s are one such group of proteins that mainly bind 
to phosphorylated serine/threonine residues on their targets. However, in contrast to 
the other domains mentioned, which are domains within larger proteins, the 14-3-3s 
are ‘stand-alone’ dimers.  
 
1.5 14-3-3 proteins 
14-3-3s are becoming increasingly important in understanding signalling 
pathways and their regulation. 14-3-3 proteins were first identified from bovine 
brain extracts by Moore and Perez in 1967. The importance of 14-3-3s was first 
understood when they were shown to bind, and activate, phosphorylated tryptophan 
and tyrosine hydroxylases (Ichimura et al., 1987; Furukawa et al., 1993). The rather 
unusual name of this family is derived from their elution and migration pattern: the 
protein was found in the 14th fraction on DEAE-cellulose chromatography and in 
spot cluster 3.3 upon starch gel separation of a brain extract (Moore and Perez, 
1967).  14-3-3s consist of a group of acidic proteins ranging from 28-30 kDa, which 
exist as dimers; they are highly conserved both within and across eukaryotic species 
(Aitken, 2006). Although 14-3-3s are quite varied in terms of cellular distributions, 
they are in particularly high abundance in the brain (~1% of total soluble brain 
protein) (Boston et al., 1982) and the implications of this are only now being 
understood. For instance, mutations in 14-3-3-binding (phospho)proteins such as 
Ndl1 and the Reep family are implicated in brain disorders (Burdick et al., 2008; 
Argasinska et al., 2009; Nicodemus et al., 2010; Park et al., 2010; McCorquodale III 
et al., 2011). Understanding the binding of 14-3-3s to their targets and elucidating 
the outcomes of such interactions is a priority, considering the vast number of 
disorders that involve 14-3-3s and their binding partners (Tinti et al., 2012).   
1.5.1 Isoforms and structure of 14-3-3 proteins 
In most eukaryotic species studied, 14-3-3s have been observed to have 
multiple isoforms: Arabidopsis is reported to have at least 12 isoforms; humans have 
7 while yeast has two isoforms, BMH1 and BMH2. The 14-3-3 family in humans 
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are encoded by seven genes, giving rise to nine isoforms: α/β, γ, ζ/δ, ε, η, θ and σ 
(where α and δ are the phosphoforms of β and ζ respectively) (Aitken 2006; Aitken, 
2011). A tenth isoform has recently been reported as the splice variant of 14-3-3 ε, 
known as 14-3-3 epsilon sv (Aitken 2011). In humans, 14-3-3ε was reported to be 
the oldest member (meaning most similar to the 14-3-3 isoforms from yeast and 
plants) while 14-3-3σ was thought to be the last evolved member (Rosenquist et al., 
2000). However, the evolution of the 14-3-3 proteins should, perhaps, be revisited in 
view of recent discoveries about how their interacting phosphoproteins evolved at 
the evolutionary transition from invertebrates to vertebrate animals (Tinti et al., 
2012). These evolutionary studies were ongoing during the latter part of my PhD 
studies and are discussed further in Chapter 5. 
The high degree of conservation of 14-3-3 isotypes within and across 
eukaryotic species suggests that these proteins have evolved from early eukaryotes 
and play important roles in cells. Indeed, knocking out both 14-3-3 isoforms in S. 
cerevisiae was shown to be lethal; complementation with plant isoforms of 14-3-3 
was able to rescue the phenotype (Gelperin et al., 1995). Thus far, no 14-3-3 or 14-
3-3-like proteins have been found in prokaryotes (Bridges and Moorhead, 2005). 14-
3-3 isoforms have been found to preferentially exist as dimers (homodimers and 
heterodimers) as monomeric 14-3-3 isoforms are thermodynamically unstable 
(Aitken, 2006). Since 14-3-3s are quite widely distributed in cells and differ in cell 
types, the occurrence of a particular heterodimer would then depend on the isoform 
distribution in that cell. For example, while most 14-3-3 isoforms are widely 
expressed, 14-3-3θ is predominant in T cells while epithelial cells express 14-3-3σ 
(Aitken, 2006). These cell types would then mainly have homodimers of the 
respective isoforms. Moreover, 14-3-3σ is evolutionarily distant from the other 
isoforms: it preferentially homodimerises and displays a unique binding affinity for 
its target protein (Wilker et al., 2005; Bridges and Moorhead, 2005).  
Crystal structures have shown 14-3-3s to be highly helical: each monomer 
consists of nine antiparallel α-helices, forming a cup shaped dimer with a central 
amphipathic groove. This groove forms the interaction site with the target protein 
and consists of the most highly conserved residues in all the 14-3-3 isoforms in 
eukaryotes. The four residues Lys49, Arg56, Arg127 and Tyr128, which are 
involved in binding the phosphate group of the target protein lie in this region and 
are fully conserved across all species (residues labelled according to their positions 
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in 14-3-3ζ) (Yaffe et al., 1997; Petosa et al., 1998; Rittinger et al., 1999; Obsil et al., 
2001; Wurtele et al., 2003). The N- and C-termini are less conserved and may be 
useful to ensure specificity of interactions with their target proteins. The amino 
terminal is responsible for the dimerization of the protein, while the carboxy tail of 
the protein is able to change its conformation upon getting phosphorylated, and upon 
a ligand binding into the groove. The overall structure of the 14-3-3 dimer is 
otherwise reported to be very rigid, acting as a backbone for binding its targets, 
which are able to modify their conformations to fit into the dimer (Figure 1.8). Each 
monomer of the 14-3-3 is able to bind a phosphate moiety from a single or two 
phosphorylated proteins; these phosphate groups have been observed to be 
approximately 34 Ångströms apart when bound to the 14-3-3-dimer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Structural representation of a 14-3-3β homodimer 
One 14-3-3β monomer is in blue and the other in red (source: Yang et al., 2006). 
 
1.5.2 Specificity and regulation of 14-3-3s 
14-3-3s are involved in a wide array of functions in the cell, including cell 
cycle control, DNA and RNA binding, protein synthesis, apoptosis, cell signalling, 
and metabolism. It follows that there must be some kind of regulation and specificity 
in place to ensure that only the required 14-3-3 and target(s) are activated under a 
given stimulus. This specificity is brought about at different levels in 14-3-3-
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signalling. These adapter molecules have been shown to bind phosphorylated 
targets: the target must have undergone a previous phosphorylation event by an 
upstream kinase to enable its interaction with 14-3-3s. This already confers some 
specificity as only a kinase activated by a particular signalling pathway would be 
able to phosphorylate its target, which would consequently bind to a 14-3-3 dimer. 
Members of the CAMK and AGC families are the major kinases known to 
phosphorylate 14-3-3-binding proteins. It is also inferred that the amount and 
distribution of 14-3-3s in the cell will greatly influence the type of interaction. The 
different heterodimers that are present would also reflect on the type of interactions 
occurring upon activation of a particular signalling pathway. 14-3-3 isoforms may 
bind to certain phosphorylated binding partners with stronger affinities than others. 
Thus 14-3-3s could be described as signal integrators, which amplify stronger 
signals in the cell while filtering out weaker interactions, to generate a meaningful 
physiological outcome, such as apoptosis.   
Another level of specificity in the mode of action of 14-3-3s is conferred by 
their strong specificity for the residues flanking the phosphorylated sites.  
Phosphopeptide library and literature searches identified two major consensus 
motifs in the binding targets: mode I RSX(pS)XP and mode II RX(F/Y)X(pS)XP 
(Yaffe et al., 1997).  Interestingly, proline at the +2 occurs in approximately only 
50% of 14-3-3-binding phosphoproteins identified so far (Johnson et al., 2010).  A 
proline at this position induces a twist by directing the residues lying at the carboxy-
end of the phosphorylated sites outwards from the amphipathic groove. Yaffe et al 
(1997) observed that the binding affinity of a doubly phosphorylated peptide is 30-
fold higher compared with a singly phosphorylated peptide, implying that binding of 
the target to a 14-3-3 dimer can be cooperative. This becomes important in a 
physiological context where a protein that displays two weak 14-3-3-binding sites in 
tandem can bind with a stronger affinity. A third consensus motif located at the 
extreme carboxy termini of proteins, (pS/T)X1-2 (mode III) has also been reported in 
the literature, although its occurrence is less frequent in the known 14-3-3-binding 
targets. In mammalian cells, few proteins have been reported to bind 14-3-3s 
through mode III, but the evidence is not very strong. The plant proton ATPase 
protein located at the plasma membrane is the best understood example of a mode 
III 14-3-3-binding target. In this case, three 14-3-3 dimers bind six adjacent 
phosphorylated ATPase proton pumps at the carboxy terminus, thereby stabilising 
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the oligomerisation of the proton pump to enable its function at the cell surface level 
(Ottmann et al., 2007).  
Most of the interactions of 14-3-3s are described to be phosphorylation-
dependent. However, there are a few reported cases of phosphorylation-independent 
14-3-3-binding proteins. For example, the Exoenzyme S (ExoS) ADP-
ribosyltransferase toxin of Pseudomonas aeruginosa requires 14-3-3-binding to 
activate its ADP-ribosyltransferase activity (Ottmann et al., 2007b). However, there 
are no known 14-3-3s in prokaryotes and since this interaction only occurs in 
infected host cells, this represents a case of opportunistic pathological interaction, as 
opposed to a true physiological interaction. The synthetic R18 peptide 
(PHCVPRDLSWLDLEANMCLP), used to bind 14-3-3s in competition with its 
phosphoprotein targets, is another example of phosphorylation-independent 14-3-3-
binding: this peptide binds with high affinity to the amphipathic groove of 14-3-3s, 
in a similar fashion to phosphorylated targets (Wang et al., 1999; Jin et al., 2004).  
It should be noted that 14-3-3s are themselves also subjected to 
phosphorylation as a regulatory mechanism, although the physiological relevance of 
this is still not very well understood. Phosphorylation of Ser58 on 14-3-3ζ has been 
shown to promote the formation of 14-3-3ζ monomers as opposed to the naturally 
occurring dimers, which would clearly affect the interaction of dimers involving 14-
3-3ζ and their interacting partners (Powell et al., 2002; Woodcock et al., 2003). 
Another site, Ser233, in this isoform has been reported to negatively regulate 
interactions between 14-3-3 and its binding proteins by sitting in the phosphopeptide 
binding region of the 14-3-3 dimer, thereby competing with actual binding partners 
(Dubois et al., 1997; Aitken et al., 2002; Dumaz et al., 2003; Obsilova et al., 2004). 
Additionally, phosphorylation of Ser184 has been shown to decrease the interaction 
between 14-3-3 and its targets (Tsuruta et al., 2004; Yoshida et al., 2005). However, 
none of these sites are conserved in the human 14-3-3 isoforms, suggesting that 
these regulatory mechanisms may be applicable only under certain conditions, and 
only for certain isoforms, stressing the importance of phosphorylation in the 
heterodimerisation of the 14-3-3 proteins, and consequent binding to their targets.   
1.5.3 14-3-3 phosphoproteomics show a link between AGC and CAMK kinases 
and 14-3-3-binding proteins 
Many phosphorylated proteins bind to the 14-3-3s. Generally, a 14-3-3 dimer 
engages with a pair of tandem phosphorylated sites within disordered regions and/or 
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straddling either side of a functional domain (Johnson et al., 2010). Analyses of the 
14-3-3-binding sites show that they fall into distinct subtypes that overlap with the 
specificities of basophilic protein kinases in the CAMK and AGC families, 
including PIMs, PKA, PKCs, PKB, p90RSK and AMPK (Johnson et al., 2010). 
Previously, members of the group have exploited the specificities of 14-3-3s to 
identify many new downstream targets of the CAMK and AGC kinases and their 
associated pathways: the PI 3-kinase–PKB, the (PKC)–Erk–p90RSK and AMPK 
pathways (Pozuelo Rubio et al., 2004; Dubois et al., 2009; Olsson, Synowsky and 
MacKintosh, unpublished results).  
1.5.4 Initial focus of 14-3-3-binding phosphoproteome centred on the PI 3-
kinase–PKB pathway 
Proteomics coupled with the dimethyl labeling method (Boersema et al., 2008) 
were used to study the quantitative changes in the sets of proteins that are 
phosphorylated when the insulin–PI 3-kinase–PKB signaling pathways are activated 
in cells (Dubois et al., 2009). 14-3-3 affinity capture and release methods have been 
successfully developed to purify 14-3-3-binding proteins from lysates of 
differentially treated cells with agonists and/or inhibitors. Phosphoproteins that bind 
specifically to 14-3-3-Sepharose are competitively eluted using a synthetic 
phosphopeptide. The proteins thus captured are separated on a one-dimensional 
SDS-PAGE gel and the resulting bands are digested with trypsin. Thereafter, the 
tryptic digests are reacted with different isotopic combinations of formaldehyde and 
sodium cyanoborohydride (Figure 1.9), with the aim of dimethylating every primary 
amine. The different combinations of stable isotope labelling generate three stably 
‘labelled’ sets of peptides: ‘light’, ‘intermediate’ and ‘heavy’, which each differ by 4 
mass units for each amine group modified. The peptides are then identified using 
mass spectrometry and quantified to determine the ratios for each of the labelled 
peptides in the three conditions, thereby enabling the distinction between proteins 
whose peptides are highly enriched in one set of treatment, for example insulin-
stimulated compared with inhibitor-treated cells or unstimulated cells. This method 
was successfully used to identify novel targets of the insulin–PI 3-kinase–PKB 
signalling pathway in cultured human cells (Dubois et al., 2009). In addition to 
known targets of PKB-phosphorylated 14-3-3-binding proteins including, PRAS40, 
TBC1D1 and FOXO1, further novel targets were also validated as insulin-regulated 
proteins in this study. For example, one of the novel targets, the E3 ubiquitin ligase 
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ZNRF2, was later discovered to mediate the regulation of ion pumps in response to 
multiple stimuli including insulin and IGF1 (Hoxhaj et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The dimethyl labelling method using stable isotopes 
Different combinations of labelled isotopes of hydrogen and carbon atoms in 
formaldehyde and sodium cyanoborohydride are used to generate differentially 
‘labelled’ amines in peptides (Source: Boersema et al., 2008).  
 
1.5.5 PKB targets display differing responses to other stimuli, including cAMP 
elevating agents 
In our studies, it soon became clear that few proteins are selectively induced 
to bind 14-3-3s by insulin–PI 3-kinase only. One exception is coiled-coil domain 6 
(CCDC6) (Dubois et al., 2009), which was recently implicated in regulation of 
genome stability and S-phase of the cell cycle (Thanasopoulou et al., 2012). Binding 
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of CCDC6 to 14-3-3s needs phosphorylation of Ser240 by PKB, and this site is not a 
good substrate for any other kinases tested (MacKintosh group, unpublished results). 
In contrast, other proteins that were first identified to bind to 14-3-3s 
downstream of insulin–PI 3-kinase signalling were subsequently also discovered to 
bind to 14-3-3s when other signalling pathways were activated. In other words, 
many proteins are convergence points whose 14-3-3 binding is promoted by 
multiple kinases.  
One finding is that several proteins that bind to 14-3-3s in response to PKB 
activation also bind to 14-3-3s in response to cAMP-elevating agents, such as the 
adenylate cyclase activator forskolin, probably due to phosphorylation by PKA. 
These include the E3 ubiquitin ligases BRCA1 and ZNRF2, and PANK2 in the 
coenzyme A synthesis pathway (MacKintosh group, unpublished results). However, 
it seems surprising to find that the PI 3-kinase–PKB pathways and cAMP–PKA 
pathways have so many substrates in common because in many different 
physiological contexts these two signalling pathways have opposite outcomes, for 
instance, insulin stimulates glycogen synthesis in skeletal muscle, whereas 
adrenaline activates PKA that stimulates glycogen breakdown to provide energy for 
muscle action (discussed further in section 1.5.5.1). 
1.5.5.1 Physiological opposing regulation of cellular processes by PKA and PKB 
Under most conditions, PKA and PKB have distinct activating and signalling 
mechanisms. PKA signalling mainly occurs through ligand binding at the G-protein 
coupled receptors (GPCRs) in the plasma membrane, whereas PKB can be activated 
through ligand binding at receptor tyrosine kinases (RTKs) such as insulin receptor 
(IR), platelet-derived growth factor receptor (PDGF-R), epidermal growth factor 
(EGF), insulin-like growth factor (IGF1) and basic fibroblast growth factor (bFGF) 
(Hanada et al., 2004). In a number of cell types an increase in cellular cAMP levels 
is associated with cell differentiation and decreased proliferation, thereby 
antagonising the action of growth factors. On the other hand, PI 3-kinase–PKB 
signalling has generally been associated with the amplification of signals generated 
from growth factors and other stimuli to promote cell survival, growth and 
proliferation.  
Upon ligand binding to any of the above-mentioned receptors involved in 
PKB signalling, phosphatidyl inositol-3-kinase (PI 3-kinase) is activated which in 
turn converts phosphatidyl inositol-3,4-phosphate (PIP2) into phosphatidyl inositol-
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3,4,5-triphosphate (PIP3). PIP3 next recruits PDK1 and PKB to the membrane, 
enabling PDK1 in turn to phosphorylate PKB at Thr308. The second site, Ser473, 
required for PKB activation, is phosphorylated by the upstream kinase mTORC2. 
Once both these sites are activated, PKB is released from the membrane and in turn 
propagates the signal to its downstream targets, which include GSK3, BAD, FOXO1 
and AS160 among others (Burgering and Coffer, 1995; del Peso et al., 1997; Datta 
et al., 1997; Rena et al., 1999; Sano et al., 2003; Geraghty et al., 2007).  
One of the first-described opposing physiological actions of PKB and PKA 
was the synthesis (PKB) and breakdown (PKA) of glycogen in animal tissues. In 
skeletal muscles, stimulation of the beta-adrenergic GPCR by adrenaline, results in 
PKA activation. In turn, PKA activates phosphorylase kinase, which phosphorylates 
glycogen phosphorylase, with the end result being glycogen breakdown. In contrast, 
when the PI 3-kinase pathway is triggered by insulin, PKB is activated. This 
activation results in glucose uptake by cells due to downstream phosphorylation and 
inhibition of GSK3 and simultaneous activation of glycogen synthase, resulting in a 
net increase in glycogen synthesis.  
In another example, Monfar and colleagues reported that Interleukin-2 (IL-2) 
could activate p70S6K through PI 3-kinase to promote the transition from G1-S in T 
cells. Interestingly, they went on to show that elevated cAMP levels in these cells 
could block this activation, thus inhibiting the G1-S transition in T cells (Monfar et 
al., 1995). These studies indicate effects of PKB and PKA that are mutually 
antagonistic in controlling glucose homeostasis and T cell proliferation.  
In addition to the above-mentioned examples of crosstalk between PKA and 
PKB, a number of other proteins have also been observed to have consensus 
phosphorylation sites for both of these AGC kinases, e.g. GSK3, CREB and ZNRF2. 
However, not all physiological contexts involving these two AGC kinases are 
clearly defined. Also, it seems to be commonly stated in the literature that activation 
of PKA also has a contributory effect activating PKB and/or enhancing the effect of 
PKB in particular physiological circumstances. Examples detailing some of the 
proposed scenarios are outlined below.  
1.5.5.1.1 cAMP–PKA pathway antagonises the PI 3-kinase–PKB signalling 
pathway 
When PKB phosphorylates and inhibits GSK3, this relieves the inhibitory 
phosphorylation of GSK3 on glycogen synthase, with the result that glycogen 
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synthesis is activated. It has also been shown that in rat hepatocytes, acute activation 
of PKB leads to inactivation of glycogen phosphorylase in a mechanism 
independent of the phosphorylation and inhibition of GSK3 (Aiston et al., 2006). 
This precise regulation of glycogen metabolism is crucial in maintaining glucose 
homeostasis in cells following a meal and during and after periods of strenuous 
exercise. In brown adipocytes, stimulation of the β3-adrenergic receptors was found 
to counteract the insulin signalling pathway by inhibiting glucose uptake in these 
cells (Klein et al., 1999). In these adipocytes, treatment with insulin alone triggered 
activation of the PI 3-kinase–PKB signalling pathway leading to glucose uptake 
from the blood.  On the other hand, pre-treating with a β3-adrenergic agonist 
(CL316243) prior to insulin stimulation in these cells led to a significant decrease in 
PI 3-kinase activity and PKB activation. Although the precise mechanism remains 
unclear, the β3-adrenergic agonist, and other cAMP analogues tested in these brown 
adipocytes cells, mediated the activation of PKA, which in turn was reported to 
inhibit PKB phosphorylation.  Importantly, non-specific PKA inhibitors such as H-
89 and PKC inhibitors reversed the effect observed upon pre-treatment with β3-
adrenergic agonists, suggesting crosstalks in these cells not only between PKA and 
PKB signalling, but also with some components of the PKC pathway.  This might be 
a representative of glucose metabolism in brown adipocytes and might be important 
in understanding insulin resistance in states of adrenergic overactivity (Klein et al., 
1999). However, better reagents are needed to dissect these events properly. 
The PI 3-kinase signalling pathway has been implicated in promoting 
cellular proliferation by mediating the transmission of signals derived from growth 
factors and other mitogenic agents in cells. Lymphoid T cells have been reported to 
activate the PI 3-kinase signalling pathway via IL-2. This activation leads to the 
phosphorylation of p70S6 kinase, which through a series of downstream 
phosphorylation events promotes the transition of these T cells from the G1 phase to 
the S phase. Elevating cAMP levels in these cells were shown to be inhibitory 
towards the activation of both PI 3-kinase and towards the phosphorylation of p70S6 
kinase. PDK1 is the upstream kinase required for phosphorylation and activation of 
PKB. Upon ligand binding on the receptor tyrosine kinase (RTK), a series of auto-
phosphorylation of the RTK leads to the phosphorylation of PI 3-kinase and 
generation of PIP3 from PIP2.  PIP3 in turn recruits both PDK1 and PKB to the 
plasma membrane to aid phosphorylation of PKB by PDK1 at Thr308. A second 
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phosphorylation site, Ser473, is also required for complete PKB activation and this 
phosphorylation is mediated by mTORC2 in response to growth factors, though 
other kinases including DNA-PK can also phosphorylate this site in response to 
DNA-damage (Bozulic et al., 2008).  An elevation of cAMP in the cells has been 
reported to account for the reduced and/or loss of PKB activity. The high cAMP 
levels (a) reduces the lipid kinase activity of PI 3-kinase, thereby reducing its ability 
to phosphorylate PIP2 into PIP3, and (b) decrease the translocation of PDK1 from the 
cytosol to the plasma membrane which is required for PKB phosphorylation, with 
no loss of PDK1 activity as such (Kim et al., 2001).   
The fasting hormone glucagon which signals through cyclic AMP is also 
well known to antagonise the actions of insulin in the liver to regulate 
gluconeogenesis. Glucose levels in the blood is maintained within a narrow range by 
a fine balance between glycogen synthesis, glycolysis and gluconeogenesis. 
Gluconeogenesis occurs primarily in the liver to generate glucose from new sources, 
including fatty acids, arginine and methionine and occurs during prolonged periods 
of fasting when blood glucose levels are low and the process is triggered by 
glucagon. Glucagon regulates the transcription of gluconeogenic genes such as 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). 
These genes are activated by FOXO transcription factors such as FoxO1, which are 
in turn activated by glucagon via cAMP—PKA signalling. Contrastingly, insulin-
dependent PKB phosphorylation of Foxo1a has been shown to lead to its exclusion 
from the nucleus and 14-3-3-binding, which in turn affects its transcriptional 
activities (Rena et al., 1999; Rena et al., 2001; Rena et al., 2002). Furthermore, 
glycogen synthase kinase-3 (GSK3) has also been shown to regulate blood glucose 
levels by modulating the activities of G6Pase and PEPCK in the liver (Lochhead et 
al., 2001, Lipina et al., 2005).  PKB phosphorylation of GSK3 inhibits its activity 
and this is promoted by insulin signalling (Sutherland et al., 1998; Cross et al., 
1995).      
Another example where insulin and cAMP agonists display opposing 
physiological effects concern leptin and resistin regulation in adipocytes. Leptin and 
resistin are two adipokines, which are important for regulation of energy 
homeostasis in the adipose tissues and have been implicated in metabolic disorders. 
Although both adipokines share some similarities in terms of inhibiting adipocyte 
differentiation and adipose development, they also play important opposing 
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physiological roles. Leptin increases insulin sensitivity and reduces 
gluconeogenesis. Resistin, on the other hand, suppresses insulin sensitivity and 
promotes gluconeogenesis (Rosetti et al., 1997; Ogawa et al., 1999; Steppan et al., 
2001; Chepurny et al., 2010). Accordingly, insulin signalling increases the leptin-
vesicle trafficking and promotes leptin secretion from these vesicles; insulin 
signalling also suppresses resistin-vesicle trafficking and secretion (Ye et al., 2010).  
cAMP–PKA signalling agonists such as forskolin, on the other hand, were reported 
to promote resistin-vesicle trafficking and secretion, while suppressing leptin 
trafficking and secretion in these adipocyte tissues (Ye et al., 2010).  
1.5.5.1.2 Does cAMP activate Erk via PKA, or not, in melanocytes?  
One caution about the above-mentioned interactions between cAMP–PKA 
signalling and the PI 3-kinase–PKB pathway is that mechanisms to explain the 
observed phenomena are lacking, and some of the data rely on non-specific 
inhibitors such as H-89. Further caution also comes from studies of the effects of the 
alpha-melanocyte stimulating hormone (αMSH) on melanocytes.  
Several papers reported crosstalks between the cAMP–PKA and the Erk 
signalling pathways. Melanocortins such as αMSH have long been associated with 
activation of the cAMP cascade leading to melanogenic differentiation (Buscà and 
Ballotti, 2000; Buscà et al., 2000). For instance, it was reported that activation of the 
Melanocortin 1 receptor (MC1R) by α-MSH occurs through a cAMP-dependent 
pathway, which activates Erk1/2 in rat melanoma cells (Englaro et al., 1995; Buscà 
et al., 2000). Furthermore, cAMP was said to activate Erk in cystic epithelial cells 
from polycystic kidneys through the sequential phosphorylation of PKA, B-Raf and 
Erk, leading to the proliferation of autosomal dominant polycystic kidney disease 
(ADPKD) epithelial cells; this is however not observed in normal kidney cortex 
cells (Yamaguchi et al., 2003). The activation of Erk from cAMP via PKA has been 
proposed to be mediated by B-Raf; consequently, activation of B-Raf, but not C-
Raf, by PKA enables B-Raf to signal to MEK, which in turn activates Erk leading to 
cellular proliferation (Stork and Schmitt, 2002; Yamaguchi et al., 2003). In contrast, 
PKA phosphorylation of C-Raf/Raf-1 leads to 14-3-3 binding, which prevents 
interaction with Ras, and hence prevents its activation (Dumaz and Marais 2003).  
Therefore, the role of PKA in regulating Raf isoforms as a whole is not clear. 
Moreover, rather than cAMP–PKA signalling causing activation of Erk as 
has been reported in rat melanocytes (Englaro et al., 1995; Buscà et al., 2000;Amsen 
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et al., 2006), recent research in human melanocytes points to a cAMP–PKA-
independent mechanism of Erk activation by αMSH. Rather, Erk activation by 
αMSH in normal human melanocytes and melanoma cells was discovered to involve 
transactivation of the cKIT tyrosine kinase receptor, most likely via Src (Herraiz et 
al., 2011). The potent cAMP-agonist forskolin has never been successfully shown to 
activate Erk in normal human melanocytes (Tada et al., 2002). Furthermore, a 
naturally-occurring E92K mutation in the MC1R receptor results in an increased 
constitutive activity for MC1R; the E92K mutation also abolishes the ability of the 
receptor to be stimulated by αMSH (Lu et al., 1998; Ling et al., 2003). Interestingly, 
cells with this mutation have been shown to have elevated cAMP, but not Erk 
activation, consistent with stimulation and activation of Erk by αMSH occuring 
independently of cAMP (Benned-Jensen et al., 2011). From these studies, it is 
apparent that crosstalks between signalling pathways are commonly misunderstood, 
and suggest that detailed analyses are required to delineate potential ambiguities 
between signalling pathways.  
1.5.6 Outstanding questions about the acute regulation of 14-3-3s with their 
targets involving PKA 
There is considerable information currently available on the acute regulation 
of phosphorylation and 14-3-3 binding to many target proteins upon activation of the 
insulin–PI 3-kinase–PKB signalling pathway. It would be interesting however, to 
define the 14-3-3-binding phosphoproteome involving PKA activation in cells. As 
discussed in section 1.2.3, PKA plays a major role in regulating a number of 
functions in the cell, including glycogen breakdown in hepatocytes and skeletal 
muscles, lipolysis in adipocytes and vasodilation. Numerous reports show that some 
14-3-3-binding proteins seem to have preferential regulation under cAMP–PKA 
activation. It is also clear that another subset of 14-3-3-binding proteins may be 
phosphorylated by both PKA and PKB, presumably under differing physiological 
conditions/ stimulus to generate different outcomes. As discussed in section 1.4.5.1, 
PKA and PKB engage in crosstalk during their respective signalling activities at 
different levels, depending on the cell type and stimulus triggering the pathway. 
However, there is much in the literature that is contradictory. The field seems to be 
divided between those who argue for a crosstalk and those against a crosstalk 
between PKA and PKB. In order then to delineate the ambiguity, it would be helpful 
to perform a proteomics screen to identify proteins whose binding to 14-3-3 is 
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promoted via PKA-phosphorylated sites, but not via PKB, and vice versa.  Such 
downstream target sites would be very useful for helping to delineate the 
intracellular processes regulated by each pathway, and help to disentangle some of 
the confusion about levels of crosstalk between the two pathways. One starting point 
could be 14-3-3-affinity capture of proteins from cells stimulated with cAMP-
elevating agents, similar to the work undertaken previously to identify PKB-
phosphorylated 14-3-3-binding proteins (Dubois et al., 2009).   
 
1.6 Technical rationale and aims of this thesis 
The few cases where PP enzymes have been linked to specific signalling 
pathways mainly involve the phosphorylation of their regulatory, and inhibitor, 
subunits via the cAMP–PKA pathway. So, we set out to try and identify how cAMP-
elevating agents regulate the PPP family of protein serine/threonine phosphatases. 
This involved trialling a new approach to monitor how protein serine/threonine 
phosphatases of the PPP family are regulated in response to extracellular stimuli, 
such as the cAMP-elevating agent forskolin (Chapter three). Our group has 
exploited the specificity of 14-3-3s to identify many new downstream targets of the 
PI 3-kinase–PKB, PKC–Erk–p90RSK and AMPK pathways. PI 3-kinase–PKB and 
PKC–Erk–p90RSK are activated by insulin and growth factors, while AMPK is 
activated in cellular responses to energy stress. Identifying the substrates of these 
pathways, and the interplay between them, is particularly important because PI 3-
kinase–PKB and PKC–Erk–p90RSK are deregulated in diabetes and cancers, while 
activating AMPK by exercise and drugs seems to have beneficial effects in these 
diseases. 14-3-3-binding sites fall into distinct subtypes that overlap with the 
specificities of basophilic protein kinases in the CAMK and AGC families, 
including PIMs, PKA, PKCs, PKB, p90RSK and AMPK (Johnson et al., 2010). 
Since there was little knowledge about the acute regulation of 14-3-3s upon PKA 
activation, we decided to investigate the sets of proteins that bind to 14-3-3s when 
intracellular cAMP levels are elevated (Chapter four). Several candidate proteins 
were identified in this screen and I started characterising a few of these as potential 
14-3-3-binding targets: the DENND4 family (section 4.2), EML3 (section 4.3) and 
ATG9A (section 4.4). Initial studies suggest that the DENND4 family might 
possibly be one of the newly described 2-R ohnologue families of proteins, which 
bind 14-3-3s (Tinti et al., 2012). Preliminary studies with ATG9 also hint at a 
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potential new role of 14-3-3s in autophagy.  Since many reports suggested crosstalks 
between PKA and PKB, I also wanted to compare the PKA data obtained with 
existing data on the proteins that bind to 14-3-3s when the PI 3-kinase–PKB 
pathway is activated.  
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2.1  Materials 
2.1.1 General materials and equipment 
Digoxygenin-O-methylcarbonyl-ε-aminocaproic-acid-N-hydroxysuccinimide 
(DIG) ester, anti-DIG HRP secondary antibody and ‘complete' protease inhibitor 
cocktail tablets were from Boehringer Ingelheim/Roche (Lewes, UK). Coomassie 
protein assay reagent (Bradford reagent) was from Pierce (Chester, UK). Ponceau S, 
dimethyl sulphoxide (DMSO), cell culture trypsin solution and bovine serum 
albumin (BSA) were from Sigma-Aldrich (Poole, UK). Glutathione-Sepharose, 
protein G-Sepharose, enhanced chemilluminescence (ECL) immunoblotting kit were 
from Amersham International (Bucks, UK). Ni-NTA agarose and HiSpeed Plasmid 
Maxi Kit were from Qiagen (West Sussex, UK). Microcystin-LR was purchased 
from Dr Linda Lawton, Robert Gordon University, and Aberdeen, UK. Dialysis 
tubing (12-14 kDa molecular mass cut-off) was from Medicell International 
(London, UK). Pre-cast NuPAGE Bis-Tris and Tris-Acetate gels, NuPAGE MOPS 
and Tris-Acetate running buffers, Novex X-cell II electrophoresis tanks and X-cell II 
blot modules were from Invitrogen (Groningen, Netherlands). Vivaspin centrifugal 
concentration/filtration devices were from Vivascience (Lincoln, UK). Econopac 
column holders were from BioRad (Hemel Hempstead, UK). Centrifuges and rotors 
were from Beckman Instruments Inc. (Palo Alto, CA, USA). Leec CO2 incubators 
were from Mackay and Lynn (Dundee, UK). Bradford reagent was from Pierce 
(Chester, UK). X-ray film was from Konica (Tokyo, Japan) and autoradiography 
cassettes, photographic fixative, and photographic developer solution from Kodak 
(Rochester, NY, USA). The Odyssey™ Infrared scanner was from Li-Cor 
Biosciences UK Ltd. The pH meters and electrodes were from Horiba (Kyoto, 
Japan). Plastic cell culture dishes were from Nunclon (Denmark) and cell scrapers 
from Costar (Cambridge, MA, USA). Dulbecco's Modified Eagle's Medium 
(DMEM), antibiotic/antimycotic solution, foetal bovine serum (FBS) and 
trypsin/EDTA (ethylenediaminetetraacetic acid) were from Invitrogen/Life 
Technologies (Paisley, UK). Skimmed milk powder (Marvel) was from Premier 
Beverages (Stafford, UK). Cellulose filters (0.22 μm) and nitrocellulose membranes 
were from Millipore Ltd. (Norwich, UK). HEK293 and HEK293 Flp-In T-REx cell 
lines were from the European Collection of Cell Cultures (http://www.ecacc.org.uk/) 
and were maintained by Kirsten McLeod and Janis Stark. Forskolin at >98 % purity 
was obtained from Sigma Aldrich. H-89, A23187 and Calyculin A were from Cell 
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Signaling (MA, USA). Other chemicals and reagents were from Sigma or 
Merck/BDH. 
 
2.1.2 Synthetic peptides 
Peptides were synthesised by Graham Bloomberg (University of Bristol) 
using N-9-fluorenylmethoxycarbonyl chemistry on an Applied Biosystems 430A 
peptide synthesizer and reagents supplied by the manufacturers. Phosphoserine 
residues were incorporated using FMOC (9-Fluorenylmethyloxycarbonyl)-
phosphoserine (Novobiochem). Peptides were purified by reverse phase HPLC 
(High-performance liquid chromatography), their structures were verified by mass 
spectrometry, and peptide concentrations were determined by amino acid analysis.  
 
2.1.3 Antibodies and antisera 
The primary antibodies used for immunoblotting and immunopreciptation 
are listed in Table 2.1. Horseradish peroxidase-conjugated secondary antibodies, 
rabbit anti-sheep IgG was from Pierce, donkey anti-rabbit IgG, HRP anti-mouse IgG 
and donkey anti-goat IgG were from Promega (Tattenhall, Cheshire, UK). 
Alexafluor secondary antibodies for the Odyssey were from Rockland and Pierce. 
Some antibodies were raised against peptides and purified by staff in the Division of 
Signal Transduction Therapy, University of Dundee (DSTT) (see Table 2.1). The 
peptides were conjugated to bovine serum albumin and keyhole limpet 
haemocyanin, mixed and injected into sheep at Diagnostics Scotland (Penicuik, 
UK). The antibodies were affinity-purified by DSTT staff first by binding to the 
peptides coupled to NHS-activated CH-Sepharose (for coupling via lysine) or 
Iodoacetyl-activated UltraLink Support (for coupling via cysteine). Anti-TOPP 
antibodies were kindly provided by Dr Greg Moorhead (University of Alberta, 
Canada).  
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Table 2.1 Antibodies used in this thesis 
Antibody Immunogen Host Source Usage 
GFP Full length GFP Rabbit Santa Cruz 1/1000 
14-3-3(K-
19) 
Amino-terminus of human 
14-3-3 β  
Rabbit Santa Cruz 1/1000 
HA YPYDVPDYA (influenza 
haemaglutinin-HA epitope) 
Mouse DSTT 
(12CA5) 
0.1 μg/ 
ml 
AMPK 
(pThr172) 
Phospho-AMPK alpha 
(pThr172) 
Rabbit Cell Signaling 1/1000 
ERK Total ERK Rabbit Cell Signaling 1/1000 
ERK 
(pT202/ 
pY204) 
Phospho-p44/42 MAPK 
(pThr202/ pY204) 
Rabbit Cell Signaling 1/1000 
PKB Total PKBα Rabbit Cell Signaling 1/1000 
PKB 
(S473) 
Phosphopeptide containing 
phosphorylated S473 of 
PKB 
Rabbit Cell Signaling 1/1000 
VASP Total VASP Mouse Abcam 1/10000
VASP 
(pS157) 
VASP phosphopeptide 
containing phosphorylated 
S157 
Mouse Abcam 1/5000 
ATG9 Total ATG9 Rabbit Abcam 1/1000 
DENND4A Recognises internal region 
of DENND4A 
Goat Santa Cruz 1/5000 
DENND4C Recognises an internal 
region of DENND4C 
Goat Santa Cruz 1/5000 
RBM15 Recognises an internal 
region of RBM15  
Rabbit Santa Cruz 1/1000 
FPA Raised against residues 
441-901 of FPA 
Rabbit Dr G. Simpson 1/1000 
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2.2 Methods 
2.2.1 General methods 
2.2.1.1 Buffers and solutions 
The lysis buffer contained Triton X-100 to solubilise the membranes, PMSF 
(phenylmethanesulphonyl fluoride) and benzamidine to inhibit serine and trypsin-
like serine proteases, respectively.  EDTA was added to chelate Mg2+ ions which are 
essential cofactors required by protein kinases. The reducing agent, β-
mercaptoethanol was also added to the buffer to mimic the reducing cytosolic 
environment of the cell. Sodium fluoride, sodium β-glycerophosphate, sodium 
pyrophosphate and microcystin-LR were included to inhibit serine/threonine protein 
phosphatases. Sodium orthovanadate (Na3VO4) was used to inhibit protein tyrosine 
phosphatases. These ensured that the phosphorylation status of proteins in the 
extracts was fixed at the levels present in vivo at the time of lysis. The mammalian 
cell lysis buffer also contained a cocktail of inhibitors of metallo, aspartyl, cysteinyl, 
and seryl proteinases. A 200	 mM solution of Na3VO4 was prepared by several 
successive rounds of boiling, cooling to room temperature on ice and adjusting to 
pH 10. This procedure was repeated until the pH remained stable at 10 after boiling 
and the solution became colourless. This procedure ensures that the majority of the 
Na3VO4 is in the depolymerised state that most favours tyrosine phosphatase 
inhibition. The solution was stored at 4oC. The pH of Tris buffers changes 
significantly with temperature and so in this thesis, the temperature will be stated. 
Other commonly-used buffers during this thesis are listed in Table 2.2. 
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Table 2.2 Buffers used frequently used in this thesis 
Mammalian cell lysis 
buffer 
50 mM Tris-HCl pH 7.5 (4⁰C), 1 mM EDTA, 1 mM 
EGTA, 0.1% (v/v) Triton X-100, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 0.27 M sucrose. Added fresh prior to 
use: 0.1 % (v/v) 2-mercaptoethanol, 1 mM benzamidine, 
1 mM PMSF and 1 tablet/50 ml Complete protease 
inhibitor cocktail. 
Note: 1 μM microcystin-LR was added fresh prior to 
use to the above lysis buffer for all experiments in 
Chapter 4. 
Dulbecco’s PBS 
(Phosphate buffered 
saline, Gibco/ 
BioWhittaker) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 
mM KH2PO4 
TBS (Tris-buffered 
saline) 
50 mM Tris-HCl pH 7.5 (room temp.), 500 mM NaCl 
TBST (Tris-buffered 
saline-Tween) 
50 mM Tris-HCl pH 7.5 (room temp.), 500 mM NaCl, 
0.1% (v/v) Tween-20. 
High salt wash buffer 0.5 M NaCl, 50 mM Tris-HCl pH 7.5 (room temp.) 
Low salt wash buffer 50 mM Tris-HCl pH 7.5 (room temp.), 1 mM EDTA, 
0.1% 2-mercaptoethanol 
 
2.2.2  Mammalian cell culture 
2.2.2.1 Maintenance of cells 
 Human Embryonic Kidney (HEK) 293 cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) FBS (foetal bovine 
serum) (complete DMEM). Flp-In TREx cells stably expressing proteins of interest 
were cultured in DMEM supplemented with 10% FBS, hygromycin (100 μg/ml) 
and blasticidin (up to a final concentration of 15 μg/ml) (complete DMEM + H + B).  
The cells were grown at 37⁰C in a 95% air/5% CO2 water-saturated incubator. Cells 
were rinsed with warm PBS, trypsinised into fresh medium and allowed to reach 
confluence prior to splitting or cell treatment.  
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2.2.2.2 Transfection of cells using PEI 
 Cells growing in DMEM supplemented with 10% FBS were seeded at 10 to 
20% confluency in 10 cm-diameter dishes with 10 ml of media. After 8 to 24 h, cells 
were transfected with 30 μg polyethylenimine (PEI) and 10 μg of DNA. This mix 
was made up to 1 ml using DMEM, vortexed for 10 sec and allowed to stand at 
room temperature for 20 min. After this incubation period, the transfection mix was 
added slowly to the cells by dropping gently and evenly into the media, and dishes 
returned to the 37⁰C incubator for 16 to 24 h. 
2.2.2.3 Generation of Flp-In T-REx stable cell lines 
 Flp-In T-REx system (Invitrogen) was used for the generation of stable cell 
lines enabling tetracycline-inducible expression of GFP-TAP-tagged proteins. Flp-In 
T-REx 293 host cells contain an integrated FRT recombination sequence and stably 
express the Tet repressor. These cells were co–transfected with the pOG44 plasmid 
(which constitutively expresses the Flp recombinase) and with pcDNA5/FRT/TO 
vector containing a hygromycin resistance gene for selection and the gene of interest 
under the control of a tetracycline-regulated promoter. The result of co-transfection 
is a homologous recombination event between the FRT sites such that the FRT site 
on pcDNA5/FRT/TO construct is inserted into the FRT site integrated into the 
genome. The stable Flp-In T-REx cell lines were selected for hygromycin (gene of 
interest selection marker) and blasticidin (Flp-In T-REx host cell line selection 
marker) resistance. When the pcDNA5/FRT/TO vector is integrated into the genome 
at the FRT site, expression of the recombinant protein of interest can be induced by 
the addition of tetracycline. HEK293 Flp-In T-REx host cells were split in to T75 
flasks and transfected at approximately 40% confluency with 10 μg DNA (1 μg 
pcDNA5/FRT/TO plasmid to express GFP-tagged protein of interest and 9 μg 
pOG44 plasmid). The cells were selected for hygromycin and blasticidin resistance 
three days after transfection by adding new medium that contains hygromycin (100 
μg/ml) and blasticidin (7.5 μg/ml). After 2 weeks of selection the colonies were 
dissociated with trypsin and expanded. Expression of the protein was verified by 
inducing the cells with tetracycline at least 24 h before lysis and performing SDS-
PAGE and Western blotting on the lysates.     
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2.2.2.4 Stimulation of cells 
 Cells were serum starved with DMEM for 6 to 12 h prior to stimulation. 
Cells were treated with activators for the indicated time in the figure legends; where 
indicated, cells were pre-treated with inhibitors prior to addition of the agonists.  
2.2.2.5 Mammalian cell lysis 
 When cells reached about 90% confluence, they were lysed. The dishes were 
placed on ice, the medium aspirated and the cells were washed in ice-cold PBS. 
Lysis buffer was added (300 µm per 10 cm-diameter dish; 500 μl per 15 cm dish) 
and cells harvested by scraping. The lysates were transferred to labelled, pre-cooled 
Eppendorf tubes and kept on ice for 15 min. Lysates were spun at 13000 rpm for 20 
min at 4⁰C and supernatants transferred to fresh tubes, snap frozen in liquid nitrogen 
and stored at -80⁰C.  
 
2.2.3  Determination of protein concentration 
 The protein content of cell lysates was determined by using a Coomassie 
Protein Assay Reagent (Pierce, Rockford, IL, USA), based on the method of 
Bradford (1976). A standard curve was made using the microplate procedure in the 
manufacturer’s protocol. Stock dilutions of BSA (5 μl of 25 to 2000 μg/ml) in water 
were added to 200 μl of Bradford reagent in a 96 well plate, using 5 μl of water in 
200 μl of Bradford reagent as a blank. After mixing on a plate shaker for 1 min, the 
samples were stood at room temperature for 10 min. The absorbance at 595 nm was 
measured using a 96 well plate reader and plotted against the concentration of BSA 
in the sample. A new standard curve was prepared for each sample analysis. To 
determine the protein concentration of clarified lysates or purified proteins, a 1/10 
dilution of the sample in water was prepared, and 5 μl added to 200 μl of Bradford 
reagent. The absorbance of the samples was measured as above. Protein 
concentration was extrapolated from the best-fit line of the standard curve. 
 
2.2.4  Immunoprecipitation  
2.2.4.1 Immunoprecipitation using non-covalently coupled antibodies 
 Lysates were pre-cleared prior to immunoprecipitation by incubating with 
PBS-washed protein G-Sepharose for 30 min at 4⁰C on an IP shaker. The 
supernatants of these lysates were recovered by spinning in a refrigerated bench top 
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centrifuge at 5000 rpm for 1 min. The pre-cleared lysates were then transferred to 
fresh tubes containing the appropriate antibody-coupled protein G-Sepharose beads 
and incubated for 1 to 2 h at 4⁰C. After this period, the tubes were centrifuged at 
5000 rpm at 4⁰C and the supernatant discarded. The proteins bound to the beads 
were washed twice in a high salt buffer followed by two no salt buffer washes. The 
beads were spun down briefly between washes at 5000 rpm at 4⁰C and each wash 
discarded. Proteins bound to the beads were eluted by heating in 2 x SDS sample 
buffer at 70⁰C for 10 min. The beads were spun down at 13000 rpm for 5 min to 
recover the denatured proteins (in the supernatant). The supernatant was stored at -
20⁰C or loaded onto gels for SDS-PAGE.  
2.2.4.2 GFP-Trap® pull downs 
 Lysates were pre-cleared as described in section 2.2.4.1. GFP-Trap® beads 
bind the proteins with high capacity and so, a little amount of the beads (~5 μl) is 
usually sufficient for 2-5 mg pull downs. The GFP-Trap® beads were mixed in a 
ratio of 1:5 with Sepharose-6B to increase the volume for easier handling. The pre-
cleared lysates (2-5 mg) were incubated with 20 μl of the GFP-Trap®/Sepharose-6B 
mix for 1 h at 4⁰C on an IP shaker. The beads were recovered by spinning at 5000 
rpm for 1 min in a refrigerated centrifuge at 4⁰C. The supernatant was discarded and 
the pellet washed twice in high salt buffer, followed by two no-salt buffer washes, 
spinning the tubes at 5000 rpm for 30 s between the washes and discarding the used 
wash buffer. The proteins were denatured by heating in 2 x SDS sample buffer at 
70⁰C for 10 min, centrifuged briefly and loaded onto SDS-PAGE gels or stored at -
20⁰C until loading. 
 
2.2.5  Dialysis tubing preparation 
 Dialysis tubing (cut-off mass 12-14 kDa) was boiled in a solution of 10 mM 
EDTA and 100 mM sodium acetate and then washed extensively with distilled water 
prior to use.  
 
2.2.6  Preparation of self-cast ATTO gels 
 Self-cast gels were prepared by making a separating gel containing 375 mM 
Tris- HCl, 0.1% SDS, 0.05% APS and 0.05% TEMED at pH 8.6 and adjusting the 
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amount of acrylamide to 8, 10 or 12%. The stacking gel was made with 125 mM 
Tris-HCl, 0.1% SDS, 5% acrylamide, 0.1% APS and 0.1% TEMED at pH 6.8. 
 
2.2.7 Protein separation using SDS-PAGE 
 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
separates proteins in a complex mixture by allowing the migration of proteins 
relative to their size, which is proportional to molecular weight because the SDS 
imparts a constant distribution of negative charge around the linearized proteins. 
Smaller proteins move faster through the gel than larger proteins. The protein mix in 
cell lysates and immunoprecipitates are first denatured by heating with 2 x SDS 
sample buffer at 70⁰C for 10 min, in the presence of 1% DTT. The Precision Plus 
markers from Bio-Rad with molecular markers at 250, 150, 100, 75, 50, 37, 25, 20, 
15 and 10 kDa were used as standards. The marker and samples were loaded onto 
either self-cast gels (10% polyacrylamide Tris-glycine gels) and run in Atto tanks 
with Tris-glycine SDS running buffer for ~100 min at 150 V, or onto Novex pre-cast 
gels (4-12% polyacrylamide Bis-Tris gels) and run with MOPS running buffer in an 
Xcell SureLockTM Mini-Cell tank for 1 h at 200 V.   
 
2.2.8  Coomassie Blue staining of gels for visualisation and mass spectrometry 
 The Colloidal Blue staining kit (Invitrogen) was used to stain protein gels for 
visualisation of the bands and general mass spectrometry. Gels were first fixed in 
40% (v/v) Milli Q water, 10% (v/v) acetic acid and 50% (v/v) methanol for 10 min 
by shaking gently on a rocking platform. The gel was then rinsed in Milli Q water 
and incubated for 10 min with the staining solution mix: 55% (v/v) Milli Q water, 
20% (v/v) methanol and 20% (v/v) stainer A. After 10 min, 5% (v/v) stainer B 
solution was added to the previous solution on the gel and left to stain for 3 to 12 h 
at room temperature. The background staining was removed by several washes in 
Milli Q water for at least 3 h.  
 
2.2.9  Transfer of proteins from gels to nitrocellulose membranes  
 Gels were transferred onto nitrocellulose membranes for Western blotting 
using the Novex X-cell transfer modules from Invitrogen, according to the 
marnufacturer’s protocol. Sponges, nitrocellulose membranes and Whatmann 3MM 
filter papers were pre-soaked in transfer buffer. A sponge was placed on the cathode 
54 
 
of the transfer cassette and the gel-membrane sandwich was built in the following 
way. A piece of wet Whatmann 3MM paper was placed on the sponge, followed by 
the gel (with wells and dye front removed), topped with the nitrocellulose membrane 
and then another piece of filter paper. The cassette was filled with sponges and 
placed in a Novex tank for transfer. The transfer cassette was filled with transfer 
buffer while the cooling chambers were filled with water. The gel was transferred 
for 2 to 3 h at 30 V, depending on the molecular weight of the protein. 
 
2.2.10 Western Blotting and enhanced chemilluminescence or Odyssey 
detection 
 After the transfer, the nitrocellulose membranes were blocked in TBS 
containing 0.1% (w/v) Tween-20 (TBST) and 5% dried skimmed milk powder for 1 
h at room temperature or at 4⁰C overnight. The membrane was rinsed twice in TBST 
before incubating with the primary antibody at 4⁰C overnight. The membrane was 
washed by fast shaking at least four times with TBST, each wash for approximately 
10 min. The membrane was next incubated with the secondary antibody for 1 h at 
room temperature. The primary and secondary antibodies were diluted in TBST 
containing either 5% (w/v) milk powder or 5% BSA. The membrane was then 
washed as before and the antibody detected using the enhanced chemilluminescence 
(ECL) system. The blot was exposed to X-Ray film which was developed and fixed 
in an automatic processor. In some cases, the antibodies were stripped from the 
membrane by stripping the membrane in the ’10 x strong Re-Blot’ stripping solution 
(Millipore). The stock stripping solution was diluted 1 in 10 in Milli Q water and 5 
ml of this diluted solution was enough for a blot. The blot was incubated with the 
stripping solution for 15 min at room temperature, washed briefly with TBST, and 
then blocked as described before with TBST-milk or TBST-BSA. The blot was then 
incubated with another primary antibody and the process repeated. Western blotting 
signals were also sometimes visualised using the OdysseyTM Infrared Imaging 
System instead of the ECL. The procedure was the same until the addition of the 
secondary antibody. The blot was incubated for 1 h at room temperature with 
secondary antibodies labelled with either IRD800 (Rockland) or Alexa680 
(Molecular Probes) dyes. The membrane was washed and the signal captured with 
an Odyssey Infrared Imaging system.  
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2.2.11 In vitro dephosphorylation of immunoprecipitated proteins with lambda 
phosphatase 
 GFP-pull downs of the protein were performed in triplicate and washed as 
described in section 2.2.4.2. The immunoprecipitated protein (~3 mg cell lysate) was 
subjected to in vitro dephosphorylation using lambda phosphatase purified by the 
DSTT. Reactions were performed in a final volume of 100 μl no salt buffer (50 mM 
Tris-HCl pH 7.5 (room temperature) and 0.1% β-mercaptoethanol) containing 50 
mU/ml lambda phosphatase with MnCl2 and 1mM EDTA as indicated in the figure 
legends. The reactions were performed at 30oC for 30 min by shaking in a 
Thermomixer.  The reactions were stopped by adding 2 x SDS-sample buffer. When 
EDTA was used, the MnCl2 and EDTA were mixed first to allow chelation prior to 
addition of the phosphatase to the tubes.  
 
2.2.12   General molecular biology 
2.2.12.1    Competent cell preparation and plasmid transformation of 
Escherichia coli 
 In general, the DH5α or the XL1-Blue strain of Escherichia coli (E. coli) was 
used to amplify for DNA plasmid whereas the BL21 strain was used to express 
recombinant proteins, except that the DH5α strain was used to express 6-His-tagged 
BMH1 and BMH2 proteins (the two 14-3-3 isoforms from Saccharomyces 
cerevisiae). The bacterial cells to be made competent for transformation were 
collected from a culture by centrifugation at 8000 rpm for 2 min in a Biofuge. The 
DH5α pellet was resuspended in 20 ml of cold, sterile 0.1 M CaCl2 solution, and 
incubated on ice for 30 min. The cells were sedimented and resuspended again in 4 
ml of cold, sterile 0.1 M CaCl2 solution. This cell suspension was stored at 4
oC for 
up to 2 weeks or at –80oC, and used as a source of competent cells for 
transformation. A 50 μl aliquot of chemically competent E. coli (usually DH5α 
strain) was removed from -80oC and thawed on ice. Plasmid DNA (typically 2 μg) 
was added to the bacteria and the tube flicked gently to mix. The DNA and bacteria 
mix were kept on ice for 30 min. The tube was transferred to a 42oC water bath for 1 
min. The ‘heat-shocked’ cells were returned to ice for 5 min, at which point 500 μl 
of LB broth was added and the cells allowed recovering at 37oC for at least 30 min. 
The cell suspension was centrifuged at 13000 rpm for 1 min in a benchtop 
microfuge. The supernatant was discarded and the pellet resuspended in 250 μl of 
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LB broth. Aliquots (50 μl) were spread onto agar plate containing 50 μg/ml of the 
relevant antibiotic (typically Ampicillin) and the cells were grown overnight at 
37oC. Single colonies were picked and transferred to 5 ml LB broth with the 
appropriate selection antibiotic and grown overnight at 37oC in a shaking incubator. 
2.2.12.2 DNA sequencing 
 DNA sequencing was performed by the Sequencing Service 
(http://www.dnaseq.co.uk/; College of Life Services, University of Dundee) on 
Applied Biosystems automated DNA sequencers. The sequencer results were 
viewed using the Editview software package and DNA alignments and other 
comparisons were made using the DNA Strider package. 
2.2.12.3 Plasmid constructs 
 The following expression plasmids were used in this thesis. All the 
subcloning and PCR involved in their generation were carried out by Dr Rachel 
Toth in the DSTT (Table 2.3). The mammalian vector pCMV5 allows expression of 
proteins with an N-terminal HA-tag under control of the cytomegalovirus promoter. 
The pcDNA5 FRT/TO vector backbone was purchased from Invitrogen and 
modified by Dr Rachel Toth to express proteins with an N-terminal green 
fluorescent protein (GFP) or GFP-TAP (tandem affinity purification) tag under a 
tetracycline inducible promoter.  
Table 2.3. Plasmids used in this thesis 
pcDNA3.1 ATG9-CRL  DU36917  
pcDNA5 FRT/TO GFP ATG9  DU36887  
pcDNA5 FRT/TO GFP DENND4B  DU36735  
pcDNA5 FRT/TO GFP DENND4B P1078-end  DU40009  
pcDNA5 FRT/TO GFP DENND4B M1-P1078  DU40052  
pcDNA5 FRT/TO GFP DENND4B M1-Q899  DU40051  
pcDNA5 FRT/TO GFP DENND4B M1-Q899 S343A  DU40007  
pcDNA5 FRT/TO GFP DENND4B M1-Q899 S343A S732A  DU40024  
pcDNA5 FRT/TO GFP DENND4B Q900-P1078  DU40008  
pcDNA5 FRT/TO GFP DENND4B S343A  DU36830  
pcDNA5 FRT/TO GFP DENND4B S732A  DU36831  
pcDNA5 FRT/TO GFP DENND4B S961A  DU36832  
pcDNA5 FRT/TO GFP-DENND4B M1-P1078 S343A  DU40026  
pcDNA5 FRT/TO GFP-DENND4B M1-P1078 S343A S732A S961A  DU40025  
pcDNA5 FRT/TO GFP-DENND4B S343A S732A  DU36993  
pcDNA5 FRT/TO GFP-DENND4B S343A S732A S961A  DU36994  
pcDNA5 FRT/TO GFP DENND4C 1017-1316  DU36836  
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pcDNA5 FRT/TO GFP DENND4C 1017-1316 S1042A  DU36850  
pcDNA5 FRT/TO GFP DENND4C 1017-end S1042A  DU36833  
pcDNA5 FRT/TO GFP DENND4C 1017-end S1404A  DU36834  
pcDNA5 FRT/TO GFP DENND4C 1017-end S1426A  DU36835  
pcDNA5 FRT/TO GFP DENND4C 1017-end S1608A  DU36846  
pcDNA5 FRT/TO GFP DENND4C M1017-end  DU36745  
pcDNA5 FRT/TO GFP DENND4C T1316-end  DU36827  
pcDNA5 FRT/TO GFP DENND4C T1316-end S1404A  DU36851  
pcDNA5 FRT/TO GFP DENND4C T1316-end S1426A  DU36852  
pcDNA5 FRT/TO GFP DENND4C T1316-end S1608A  DU36881  
pcDNA5 FRT/TO GFP FPA  DU16955  
pcDNA5 FRT/TO GFP FPA F163A  DU16927  
pcDNA5 FRT/TO GFP FPA V161A  DU16926  
pcDNA5 FRT/TO GFP FPA V161A/F163A  DU16928  
pcDNA5 FRT/TO GFP IRLB  DU36829  
pcDNA5 FRT/TO GFP IRLB S1151A  DU36886  
pcDNA5 FRT/TO GFP IRLB S1251A  DU36865  
pcDNA5 FRT/TO GFP IRLB S1589A  DU36946  
pcDNA5 FRT/TO GFP IRLB S1609A  DU36866  
pcDNA5 FRT/TO GFP IRLB S1798A  DU36879  
pcDNA5 FRT/TO GFP IRLB S338A  DU36868  
pcDNA5 FRT/TO GFP IRLB S755A  DU36869  
pcDNA5 FRT/TO GFP DENND4A DU36708  
pcDNA5 FRT/TO GFPTAP PP1 alpha  DU31245  
pACT2.6 PP1 alpha  DU31264  
pAS2.6 PP1 alpha  DU31246  
pcDNA5 FRT/TO GFPTAP PP1 beta  DU31213  
pACT2.6 PP1 beta  DU31254  
pAS2.6 PP1 beta  DU31212  
pcDNA5 FRT/TO GFPTAP PP1 gamma  DU31199  
pACT2.6 PP1 gamma  DU31187  
pAS2.6 PP1 gamma  DU31181  
pcDNA5 FRT/TO GFP RBM15  DU16753  
pcDNA5 FRT/TO GFP RBM15 F526A  DU16755  
pcDNA5 FRT/TO GFP RBM15 L300-T600  DU31344  
pcDNA5 FRT/TO GFP RBM15 M1-K720  DU31339  
pcDNA5 FRT/TO GFP RBM15 M1-L300  DU31337  
pcDNA5 FRT/TO GFP RBM15 M1-T600  DU31338  
pcDNA5 FRT/TO GFP RBM15 S294A  DU31313  
pcDNA5 FRT/TO GFP RBM15 S700A  DU31312  
pcDNA5 FRT/TO GFP RBM15 T568A  DU31311  
pcDNA5 FRT/TO GFP RBM15 T600-A900  DU31345  
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pcDNA5 FRT/TO GFP RBM15 V524A  DU16754  
pcDNA5 FRT/TO GFP RBM15 V524A F526A  DU16756  
pcDNA5 FRT/TO GFPTAP RBM15  DU16757  
pcDNA5 FRT/TO GFPTAP RBM15  DU31117  
pcDNA5 FRT/TO GFPTAP RBM15 F526A  DU16759  
pcDNA5 FRT/TO GFPTAP RBM15 S294A  DU31315  
pcDNA5 FRT/TO GFPTAP RBM15 S700A  DU31314  
pcDNA5 FRT/TO GFPTAP RBM15 T568A  DU31316  
pcDNA5 FRT/TO GFPTAP RBM15 V524A  DU16758  
pcDNA5 FRT/TO GFPTAP RBM15 V524A F526A  DU16760  
pCMV5.HA RBM15  DU16553  
pCMV5.HA RBM15 F526A  DU16555  
pCMV5.HA RBM15 V524A  DU16554  
pCMV5.HA RBM15 V524A/F526A  DU16556  
pACT2.6 RBM15  DU31183  
pAS2.6 RBM15  DU31163  
pcDNA5 FRT/TO GFP RBM15B  DU16795  
pcDNA5 FRT/TO GFP RBM15B F489A  DU16837  
pcDNA5 FRT/TO GFP RBM15B V487A  DU16828  
pcDNA5 FRT/TO GFP RBM15B V487A F489A  DU16840  
pcDNA5 FRT/TO GFPTAP RBM15B  DU31127  
pcDNA5 FRT/TO GFPTAP RBM15B F489A  DU31203  
pcDNA5 FRT/TO GFPTAP RBM15B V487A  DU31202  
pcDNA5 FRT/TO GFPTAP RBM15B V487A F489A  DU31204  
pCMV5.HA RBM15B  DU16557  
pCMV5.HA RBM15B F489A  DU16563  
pCMV5.HA RBM15B V487A  DU16562  
pCMV5.HA RBM15B V487A/F489A  DU16564  
pACT2.6 RBM15B  DU31188  
 
2.2.12.4 Purification of plasmid DNA 
 Plasmid minipreps were performed by staff in the DSTT. To prepare 
microgram quantities of plasmid DNA, an individual colony of plasmid-transformed 
bacteria was transferred into ~5 ml of LB broth containing 100 μg/ml ampicillin and 
grown overnight (approximately 16 h) at 37oC in a shaking incubator. The culture 
was then spun at 3000 rpm for 15 min in a Beckman Allegra benchtop centrifuge. 
The DNA was purified from the bacterial pellet using the Qiagen Mini-Prep system, 
by the College of Life Sciences Sequencing service (University of Dundee) using an 
automated Qiagen 9600 Bio-robot. 
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To prepare milligram quantities of DNA, an individual colony of plasmid 
transformed bacteria was transferred into 5 ml of LB broth, containing 100 μg/ml 
ampicillin or 50 μg/ml kanamycin and grown at 37oC for 6 to 8 h in a shaking 
incubator. The 5 ml culture was used to seed 500 ml LB broth (also containing the 
relevant antibiotic), which was grown overnight at 37oC in a shaking incubator. The 
following day, the culture was centrifuged at 3000 rpm in a Beckman J6 rotor for 15 
min at 4oC to pellet the bacteria. The DNA was purified from the bacterial pellet 
using the Qiagen Mega-Prep kit, according to the manufacturer’s instructions. The 
resulting DNA was solubilised in Milli Q water and stored at -20oC. 
2.2.12.5 Determination of DNA concentration 
 The absorbance of DNA in aqueous solutions was measured in a NanoDrop 
(ThermoFisher) at 260 nm. Briefly, 2 μl of water was used to blank the machine, and 
2 μl of each DNA sample was placed on the nanodrop counter according to the 
manufacturer’s instructions. The counter was wiped clean in between each sample 
measurement. The purity of the sample was calculated by looking at the ratio of the 
absorbance at 260 nm and 280 nm. A ratio of 1.6 or greater was indicative of a 
highly purified sample of DNA.  
 
2.2.13  14-3-3-affinity chromatography and 14-3-3-overlays 
2.2.13.1    Expression of the Saccharomyces cerevisiae 14-3-3 isoforms Bmh1 
and Bmh2 
 Two 2 L flasks each containing 500 ml LB-Amp medium (LB broth plus 100 
μg/ml ampicillin) were inoculated with E. coli DH5α cells expressing the Bmh1 or 
Bmh2 14-3-3 isoforms from S. cerevisiae, each with an N-terminal 6-His-tag (a gift 
from Dr Marie Scarabel and Professor Alistair Aitken, University of Edinburgh). 
Starter cultures were grown overnight at 37oC, with shaking at 250 rpm, and used to 
inoculate 25 L LB-Amp in a fermenter with 1 ml antifoam. The culture was grown 
aerobically with stirring at 37oC until mid-log phase (optical density at 600 nm = 0.6 
to 0.7). Expression of the 14-3-3 constructs was induced by adding 0.5 mM IPTG 
for 3 h. The bacteria were harvested by centrifugation for 20 min at 4200 rpm (or 
~2100 x g using a Beckman J6-MI rotor), snap-frozen and stored at -80oC.  
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2.2.13.2 Purification of 6-His-tagged Bmh1 and Bmh2 from Escherichia 
coli 
 Recombinant 6-His-tagged S. cerevisiae 14-3-3 isoforms, Bmh1 and Bmh2 
were supplied by Dr Jean Harthill in this laboratory or prepared using the following 
method by members of the DSTT. The frozen bacterial pellet from a 500 ml culture 
was thawed on ice in bacterial lysis buffer (50 mM Tris-HCl pH 7.5 (4oC), 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% (v/v) Triton-X100, 0.07% (v/v) 2-
mercaptoethanol, 1 mM benzamidine, 0.2 mM PMSF) and vortexed vigorously. The 
cells were lysed using a French press. The lysate was centrifuged at 15000 rpm for 
30 min at 4oC in a Beckman JLA 16.25 rotor. The supernatant was removed and 
incubated for 45 min at 4oC with 2.4 ml pre-equilibrated nickel-NTA agarose 
(washed several times in equilibration buffer consisting of 50 mM Tris-HCl pH 7.5 
(room temp), 0.5 M NaCl and 1 mM PMSF). The agarose was centrifuged at 3000 
rpm for 10 min at 4oC in a Beckman J6 rotor and the supernatant discarded. The 
pellet was resuspended in high salt wash buffer (50 mM Tris-HCl pH 7.5 (room 
temp), 0.5 M NaCl and 10 mM imidazole), poured into a Bio-Rad disposable 
Econopac column, and the column washed with at least 20 column volumes of high 
salt buffer, followed by 20 column volumes of low salt buffer (50 mM Tris-HCl pH 
7.5 (room temp), 150 mM NaCl and 10 mM imidazole). When protein could no 
longer be detected in the eluate, protein bound to the resin was eluted with 50 mM 
nickel (II) sulphate in equilibration buffer. Twelve fractions of 1 ml were collected. 
The protein concentration of each fraction was measured and peak fractions were 
pooled, dialysed overnight at 4oC in 15 ml Slide-a-Lyser cassette, against 25 mM 
HEPES pH 7.5, 1mM DTT, 50% glycerol and stored at -20oC. An aliquot of the 
dialysed sample was subjected to SDS-PAGE, and the gel stained with colloidal 
Coomassie blue or immunoblotted to allow the purity and amount of protein to be 
checked. 
2.2.13.3 Coupling Bmh1 and Bmh2 to activated CH-Sepharose 4B 
 Activated CH Sepharose 4B is actually NHS-activated Sepharose, which 
forms covalent bonds with lysine residues and other primary amine groups. Dry 
matrix (2 g, which swells to 6 ml) was poured onto the glass sinter of a filtering 
system and swelled in 500 ml of cold 1 mM HCl (43 μl concentrated HCl/500 ml). 
The solution was removed by vacuum suction, being careful not to let the matrix dry 
out. The matrix was washed with 200 to 300 ml coupling buffer (200 ml of 0.1 M 
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NaHCO3, 0.5 M NaCl pH 8.0), and the appropriate amount (2 mg/ml) of 14-3-3 
ligand was added and left to crosslink for 2 h at room temperature, or 4 h at 4oC. The 
matrix was centrifuged at 3000 rpm at 4oC for 5 min and the supernatant was 
removed. A 5 μl sample of the supernatant was used for a Bradford assay to assess 
the efficiency of protein coupling to the matrix. Any remaining reactive groups of 
the matrix were blocked in 0.1 M Tris-HCl pH 8.0 at room temperature for 1 h. The 
matrix was washed by pouring onto a glass sinter, which was drained to dampness 
under vacuum suction and washed alternately with 0.05 M Tris-HCl pH 8.0 (room 
temp), 0.5 M NaCl followed by 0.05 M sodium acetate, 0.5 M NaCl pH 4.0 for a 
total of 5 x 50 ml washes for each buffer. The 14-3-3 Sepharose was stored in 50 
mM Tris-HCl pH 7.5 (room temp) and 0.05 % sodium azide at 4oC until use. 
2.2.13.4 14-3-3-Sepharose affinity chromatography and purification 
 Cells were cultured, stimulated and lysed as indicated previously in section 
2.2.2. The broken cells were centrifuged at 15000 g for 30 min and the supernatant 
collected. The clarified solution was mixed end-over-end for 2 h at 4oC with 10 ml 
14-3-3-Sepharose (for 100 dishes of cells). The mixture was poured onto an 
Econopac column, the flow through collected, and the column washed with 500 ml 
of 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM DTT (buffer A). Proteins bound 
to the phosphopeptide binding site of 14-3-3s were eluted with 12 ml of 2 mM 
ARAApSAPA phosphopeptide in buffer A. Two elutions with the competitive 
phosphopeptide were performed. These eluates were pooled and concentrated in 
Vivaspin columns.  
2.2.13.5 Preparation of the DIG-labelled 14-3-3 probe for 14-3-3-overlays 
 14-3-3 protein (50 μg each of the 6-His-tagged Bmh1 and Bmh2 isoforms) as 
incubated for 2 h at room temperature with 8 μg digoxygenin-O-methylcarbonyl-ε-
aminocaproic acid-N-hydroxysuccinimide (DIG-NHS) ester, added from a 2 mg/ml 
stock solution in dimethyl sulphoxide, and 400 μl PBS, pH 8.5, with occasional 
mixing. The mixture was dialysed extensively in PBS pH 7.2 at 4oC to remove 
unreacted DIG ester, then aliquoted and stored at -20°C. For the 14-3-3 probe, 
aliquots of DIG-14-3-3 were diluted to a final protein concentration of 1 μg/ml in 25 
mM Tris-HCl pH 7.5 (room temp), 500 mM NaCl, 1% non-fat milk powder. The 
resulting DIG-14-3-3 probe was stored at 4oC with 0.05% sodium azide. It was 
found that the probe could be reused many times.  
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2.2.13.6 DIG-14-3-3 overlay 
 To identify proteins that can bind directly to 14-3-3, a Far-Western overlay 
procedure was used. Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose. The membrane was blocked with 5% non-fat milk in TBST as for 
Western blotting, then incubated with DIG-labelled 14-3-3 probe overnight at 4°C. 
The membrane was washed 6 x 10 min in TBST. HRP-conjugated anti-DIG 
antibody, diluted 1:2500 in TBST containing 1% non-fat milk powder, was applied 
for 1 h. The membrane was washed in TBST as before, and the overlay was 
developed with ECL reagent as described in the manufacturer’s instructions. 
 
2.2.14  Purification of protein phosphatases 
2.2.14.1  Preparation of Microcystin-Sepharose beads  
 The aminoethanethiol-MC-LR-Sepharose beads were prepared by Carol 
MacKintosh and the DSTT staff using the following protocol. DMSO, 
aminoethanethiol and 5 M NaOH were purged separately with nitrogen gas. 1 vol. 
MC-LR (1-5 mg/ml in methanol) was then added to a solution comprising 1.5 vol. 
water, 2 vol. DMSO, 0.67 vol. 5 N NaOH and 1 vol. aminoethanethiol 
hydrochloride (1 g/ml). After incubation for 30 min at 50°C under N2 gas, the 
solution was cooled, mixed with an equal volume of glacial acetic acid, then diluted 
5-fold with 0.1% (v/v) TFA and the pH reduced to 1.5 by dropwise addition of 
100% (v/v) TFA. The sample was applied to a Waters C18 Sep-Pak cartridge 
equilibrated in HPLC grade methanol and washed with 0.1% (v/v) TFA in 10% (v/v) 
acetonitrile. The aminoethanethiol-MC-LR was eluted from the cartridge with 0.1% 
(v/v) TFA/100% (v/v) acetonitrile, dried by rotary evaporation and dissolved in 0.02 
ml of methanol. Chromatography of an aliquot on a Vydac C18 column developed 
with a gradient of water/acetonitrile in 0.1% TFA showed that >95% of the MC-LR 
had been converted to the aminoethanethiol derivative which was eluted at 33.7% 
acetonitrile, compared with 35.6% acetonitrile for unmodified MC-LR. 
Aminoethanethiol-MC-LR (1 mg) was reacted for 4 h at room temperature with 6 ml 
of swollen N-hydroxysuccinimide-activated CH-Sepharose 4B in 50 mM sodium 
bicarbonate, pH 8.0 with end-end rotation. The columns were washed alternately 
with 100 ml each of 50 mM sodium acetate pH 4.0 plus 0.5 M NaCl, and 50 mM 
Tris-HCl pH 8.0 plus 0.5 M NaCl (five times with each buffer).  The beads were 
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finally washed and stored in 50 mM Tris-HCl pH 7.5 with a pinch (0.02%) of 
sodium azide.     
2.2.14.2 Microcystin-affinity chromatography for the purification of 
protein phosphatases from cauliflower 
 The following protocol was carried out at 4⁰C. The outer florets of a 
cauliflower were shaved off and homogenised in a blender in two volumes of ice-
cold buffer A (50 mM triethanolamine-HCl pH 7.5, 0.1 mM EGTA, 5% (v/v) 
glycerol, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine and 1 mM PMSF. The 
homogenate was clarified by centrifugation at 7000 rpm for 20 min and filtered 
through two layers of miracloth. The supernatant was then fractionated from 0-17 % 
poly(ethylene glycol) (PEG)  by addition of 50% PEG6000 in buffer A. The sample 
was gently stirred for 30 min before centrifuging at 7000 rpm for 20 min.  The pellet 
was resuspended to a total volume to 200 ml with buffer A and centrifuged again at 
7000 rpm for 20 min. The supernatant was mixed end-over-end with 1 ml MC-
Sepharose for 1 h. The mix was then poured onto Econopac columns and the flow 
through collected, ensuring the column did not run dry throughout the rest of the 
procedure. The column was washed with 100 ml of buffer A plus 300 mM NaCl, 
followed by another 100 ml wash with buffer A containing 500 mM KCl. The flow-
throughs were collected and Bradford assays of the wash fractions, confirmed that 
the last wash contained less than 0.005 mg/ml protein.  Two elutions with the RVDF 
competitive peptide (that binds to PP1 catalytic subunit in competition with 
regulatory subunits) in buffer A were performed, one at 0.5 mM followed by a 2 
mM elution, with the peptide being mixed end-over-end for 30 min at each 
concentration, and eluates were pooled for concentration in Vivaspin columns. The 
protein phosphatases that remained bound to the beads were then eluted by mixing 
end-over-end with ~3 ml buffer A containing 3 M NaSCN. This step was repeated 
and the two fractions pooled and dialysed extensively with buffer A, with at least 
two changes of the dialysis buffer. The sample was then concentrated in Vivaspin 
columns and analysed using SDS-PAGE.     
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2.2.14.3 Microcystin-affinity chromatography for the purification of 
protein phosphatases from HEK293 cells 
 The following protocol was mostly carried out at 4⁰C. HEK293 cells were 
harvested in ice-cold lysis buffer and the lysates centrifuged at 13000 rpm for 15 
min. The supernatant was mixed end-over-end with 1 ml MC-Sepharose for 1 h. The 
mix was then poured onto Econopac columns and the flow through collected, 
ensuring the column did not run dry throughout the rest of the procedure. The 
column was washed with 250 ml of buffer A plus 300 mM NaCl. Two 1 ml elutions 
with the RVDF competitive peptide in buffer A were performed, one at 0.5 mM 
followed by a 2 mM elution, with the peptide being mixed end-over-end for 30 
minutes at each concentration. The column was washed with 5 ml of buffer A 
containing 300 mM NaCl and this wash and the peptide elutions were pooled for 
concentration in Vivaspin columns. The protein phosphatases bound to the beads 
were then eluted by mixing end-over-end with ~3 ml buffer A containing 3 M 
NaSCN. This step was repeated and the two fractions pooled and dialysed 
extensively with buffer A, with at least two changes of the dialysis buffer. The 
sample was then concentrated in Vivaspin columns and analysed using SDS-PAGE.     
2.2.14.4 GFP-Trap® pull downs for the purification of protein 
phosphatase 1 complexes from cells stably expressing the three human isoforms 
of PP1  
 Flp-In T-REx cells stably expressing the 3 isoforms of PP1, namely PP1α, 
PP1β and PP1γ were grown, tet-induced and lysed as described in sections 2.2.2.1, 
2.2.2.3 and 2.2.2.5. Since these proteins were GFP-tagged, they were 
immunoprecipitated using GFP-Trap® beads as described in section 2.2.4.2. 
 
2.2.15  Protein chemistry for the analysis of peptides and 
phosphopeptides 
2.2.15.1 Proteolytic digestion of proteins ‘in gel’ 
 Proteins were reduced and alkylated in the lysates by adding 10 mM DTT in 
0.1 M ammonium bicarbonate for 45 min at 65°C followed by 50 mM 
iodoacetamide in 0.1 M ammonium bicarbonate for 20 min at room temperature. 
The gels were stained with colloidal Coomassie blue. Protein bands were excised 
with a razor blade and cut into small pieces (~1 mm3) and placed in 1.5 ml 
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Eppendorf tube. The gel pieces were rinsed in turn sequentially for 15 min on a 
vibrating platform with 1 ml of the following: water, a 1:1 mixture of water and 
acetonitrile, 0.1 M ammonium bicarbonate, a 1:1 mixture of 0.2 M ammonium 
bicarbonate and acetonitrile. Gel pieces were shrunk in acetonitrile and dried by 
rotary evaporation, then incubated with 5 μg/ml trypsin in 25 mM 
triethylammonium bicarbonate for 16 h. An equal volume of acetonitrile was added 
and the mixture incubated on a shaking platform for 15 min. The supernatant was 
removed and dried by Speed-Vac and the gel pieces were further washed with 100 
μl 50% acetonitrile/2.5% formic acid for 10 min. This supernatant was added to the 
first extract and dried. 
2.2.15.2 N-dimethylation reaction for protein quantification 
 After the overnight trypsin digestion as described in section 2.2.15.1, the 
peptides were transferred to fresh tubes. Up to 100 μl of 100 mM TEAB buffer was 
added to the gel pieces, which were shaken for a further 15 min, and the supernatant 
was combined with the first extract. One third of the combined sample was used for 
N-dimethyl labelling in the following way. All of the dimethyl labelling procedure 
and analysis (Chapter 3) were performed with the help of Dr Silvia Synowsky 
(College of Life Sciences, University of Dundee), using the procedure described by 
Boersema et al. (2008). Briefly, 4 μl of 4% formaldehyde (CH2O) (‘light’) or 4% 
deuterated-formaldehyde (CD2O) (‘intermediate’) or 4% 
13C-labelled deuterated 
formaldehyde (13CD2O)(‘heavy’) was added to the respective peptides. Then, 4 μl of 
600 mM NaBH3CN (light and intermediate) or 4 μl of 600 mM NaBD3CN (heavy) 
were added, respectively. The mixtures were incubated for 1 h at room temperature 
on a shaking platform. The reaction was quenched with 16 μl of 1% ammonia. 
Finally, 8 μl formic acid was added and desalted using C18 ZipTip (Millipore), 
filled with extra Reprosil (5 µm, Dr. Maisch GmbH, Germany) beads. Prior to mass 
spectrometric analyses the three differentially-labelled samples were pooled. 
2.2.15.3  Mass spectrometry analysis for protein identification  
 All the mass spectrometric (MS) analyses reported in Chapter 3 result 
section 3.4 were performed by Dr. David Campbell, Robert Gourlay and Sanjay 
Kothiya (College of Life Science, University of Dundee). Mass spectrometric 
analysis of proteins digested with proteases (as described in section 2.2.15.1) was 
performed to identify proteins and phosphorylated residues in proteins. For protein 
fingerprinting, samples were analysed by Liquid Chromatography-Mass 
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Spectrometry (LC-MS) on a Thermo LTQ-Orbitrap system. The generated MS data 
was analysed through the Mascot search engine (www.matrixscience.com) against 
appropriate databases.  
2.2.15.4  Phosphopeptide enrichment using titanium dioxide  
 The columns were made using C8-Empore Extraction Disks and adding TiO2 
beads previously resuspended in acetonitrile (ACN). The columns were first washed 
with acetonitrile and then equilibrated with 0.2% TFA. The peptide samples were 
adjusted to 70% ACN/ 3% TFA/ 250 mM lactic acid, loaded onto the columns and 
washed sequentially with 70% ACN/ 3% TFA/ 250 mM lactic acid, 70% ACN/ 3% 
TFA and 0.1% TFA. Peptides were eluted using 1% ammonium hydroxide into 
tubes containing 50% TFA (5% of the total volume) and loaded onto the Orbitrap 
for analysis. 
2.2.15.5 LTQ-orbitrap analysis for protein quantification  
 All the mass spectrometric analyses in Chapter 3 and Chapter 4 were 
performed by Dr Silvia Synowsky (College of Life Sciences, University of Dundee). 
Samples were analyzed by nano-ESI-MS/MS on an LTQ-Orbitrap mass 
spectrometer coupled with a Proxeon Easy nLC HPLC system. HPLC separation 
was on a C18 reverse phase column (pepmap75μm ID, 15cm cat no 160321) with a 
linear gradient of buffer A (0.1% formic acid, 2% acetonitrile) from 5 to 40% buffer 
B (90% acetonitrile, 0.08% formic acid) over 80 min. The HPLC column was 
flushed with 80% buffer B for 10 min and re-equilibrated with 5% buffer B for 10 
min. A Fourier Transform (FT) scan on mass range 300 to 1820 amu was acquired at 
a resolution of 60000 with an internal calibration by a single lockmass (445.120020) 
reference. Each FT scan led to 5 MS/MS (LTQ) with multistage activation (MSA) 
on the top five most intense detected ions. Raw data were converted to Mascot 
generic files using raw2msm software (gift from Matthias Mann) in order to search 
with an in house Mascot 2.2 server against the Swiss-Prot database. Mass tolerances 
were 10 ppm for precursor mass and 0.8 Da for fragment mass. Carbamidomethyl-
cysteine was a fixed modification; dimethylated N-terminus and lysine for the three 
different conditions and oxidized methionine were variable modifications. The 
quantification of proteins was performed using a modified version of MSQuant, 
which allows for the quantification of triply-labelled peptides. 
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3.1 Regulation of protein phosphatases 
 Many effects of protein phosphatases in cellular events have been identified 
by studies using genetic mutants, pharmacological inhibitors and biochemical 
studies (Dombradi et al., 1990; Alessi et al., 1992; Wek et al., 1992; Hubbard and 
Cohen, 1993; Ceulemans and Bollen, 1994; Depaoli-Roach et al., 1994; Stark et al., 
1994; Luke et al., 1996; Smith and Walker, 1996; Baskin and Wilson, 1997; Helps 
et al., 1998; Evans et al., 1999; Lizotte et al., 1999; Evans and Hemmings, 2000). 
However, the number of protein phosphatases (150) compared to kinases (500) in 
humans is strikingly low, raising the question of how such a small number of 
phosphatases counterbalance the effects of the larger number of kinases (Moorhead 
et al., 2009). The emerging answer is that the actions of phosphatases are largely 
dependent on their regulatory subunits, which specify their function(s). Although the 
regulation of the PPs through their regulatory subunits are somewhat understood 
(section 1.5.4), there are relatively few cases where the mechanisms of regulation of 
the protein phosphatases in response to extracellular stimuli have been defined.  
The studies in this Chapter stemmed from an investigation into whether three 
RNA-binding Spen (Split-end) proteins, namely Arabidopsis FPA, and human 
RBM15 and RBM15B, might be novel PP1 interacting proteins, and these 
experiments are described in the last sections of this Chapter. However, while the 
primary goal was to test for interactions of PP1 with FPA, RBM15 and RBM15B, 
we also extended the scope of the experiments by aiming to identify further protein 
phosphatase interacting proteins. In addition, the MacKintosh group has been using 
differential quantitative proteomics to identify proteins whose binding to 14-3-3 
proteins is regulated by different extracellular stimuli and inhibitors of signalling 
pathways. We were therefore curious to know whether we could adopt analogous 
procedures to screen for cases where the interactions between regulatory proteins 
and protein phosphatase catalytic subunits are acutely regulated by extracellular 
stimuli.  
3.1.1 Microcystin as a useful and potent inhibitor for purifying protein 
phosphatases from cellular extracts 
 Even though phosphatases were identified quite early, their structures and 
regulation were not well understood. The roles of phosphatases became clearer with 
the development of tools such as the microcystin-affinity chromatography. This 
method is based on the binding and inhibitory property of microcystin towards 
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several members of the serine/threonine protein phosphatase family, PPP, including 
PP1, PP2A, PP4, PP5 and PP6. Although other inhibitors are effective towards these 
phosphatases, the ability to couple a modified microcystin-LR to Sepharose provides 
an easy method of purifying phosphatases from cellular extracts. Briefly, the 
dehydroalanine residue of microcystin-LR is modified by reacting it via Michael 
addition to small reactive thiols, which carries an amine group that in turn is coupled 
to N-hydroxy-succinamide-activated Sepharose (section 1.3.3). While the 
dehydroalanine in the native toxin forms a covalent bond with a cysteine residue in 
the β12-13 loop of the protein phosphatases, this bond is not essential for tight 
binding of the toxin to the enzyme. This modification therefore allows the 
phosphatase catalytic subunits to bind non-convalently to the microcystin-Sepharose 
beads, and these interactions can be disrupted using a chaotropic salt such as sodium 
thiocyanate (Moorhead et al., 1994). This method enabled the purification of 
different plant and mammalian members of the PPP family of phosphatases and their 
different interacting proteins (Moorhead et al., 1994; Moorhead et al, 1995; Meek et 
al., 1999). In a further modified version of this technology, Moorhead et al (2008) 
added a further step using PP1-targetted peptides to elute the regulatory subunits 
specific to this phosphatase. A short synthetic peptide (GKKRVRWADLE) 
containing a variation of the RVXF motif (known to direct the interaction between 
PP1 and its interacting proteins) can first be used to elute the binding partners off the 
column, followed by the chaotropic salt wash to elute the phosphatases.  
3.1.2 Using the cAMP-agonist forskolin to find potential novel targets of 
protein phosphatases 
Cases are known where protein phosphatase interactions with their 
regulatory subunits are regulated via PKA-phosphorylation. For example, the 
regulation of PP1 in skeletal muscles occurs through its glycogen-bound regulatory 
subunit, GM. When the PP1.GM subunit is phosphorylated by PKA at Ser67, PP1 is 
released into the cytosol from the glycogen granules (MacKintosh et al., 1988).  This 
is because Ser67 is the residue X within the RVXF motif of the GM subunit, which 
means that its phosphorylation directly disrupts the interaction (Hubbard and Cohen, 
1989). A simultaneous phosphorylation of Inhibitor-1 by PKA at Thr34 sequesters 
the PP1 into an inactive cytosolic form, PP1-I (Stralfors et al., 1985). DARRP32, the 
brain homologue of I-1 is also known to exert an inhibitory regulation of PP1 in 
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brain cells upon activation by PKA (Desdouits et al., 1995; Endo et al., 1996; Huang 
et al., 1999).  
Because of these precedents and because the group have an interest in PKA 
signalling (sections 1.3.4 and 1.5.6), testing the effects of modulating PKA activity 
on phosphatase–regulatory subunit interactions seemed a good place to start in 
trialling the use of microcystin affinity chromatography to search for further acutely-
regulated interactions of protein phosphatases with their regulatory subunits. For this 
purpose, we used the adenylate cyclase agonist forskolin to activate the cAMP–PKA 
pathway in HEK293 cells, with the non-specific PKA inhibitor H-89 as the negative 
control. A further batch of cells was left unstimulated and used later for 
normalisation of the quantified data.  Lysates of cells from these three conditions 
were passed through microcystin affinity columns (section 3.1.1) and bound 
proteins were eluted with a chaotropic salt, separated by SDS-PAGE and identified 
by mass spectrometry. The tryptic peptides were also labelled by reacting with 
borohydride and formaldehyde to dimethyl primary amines. The chemicals for each 
preparation contained different amounts of the stable isotopes 2H and 13C, which 
meant that the relative amounts of any given peptide in each of the three 
preparations could be determined by differential mass spectrometry (as described in 
sections 2.2.15 and 3.1; Boersema et al., 2008). These analyses allow the 
comparison on the enrichment of the different proteins under the various treatment 
conditions. I performed these experiments to test the effect(s) of cAMP–PKA 
activation on the acute regulation of interactions of proteins with protein 
phosphatases (PPP family) in general (section 3.1.3) and PP1β specifically (section 
3.1.4). Furthermore, I wanted to explore the isoform specifities of protein 
phosphatase 1 and used HEK293 cells stably-expressing the three isoforms of PP1 to 
further analyse proteins that potentially displayed isoform preference for the PP1 
catalytic subunits (section 3.2).  
3.1.3 Results 
 Analysis of the mass spectrometry data from the MC-affinity 
chromatography eluates (Figure 3.1) identified a total of around 380 proteins 
(Appendix I) including expected protein phosphatases. The MC-Sepharose affinity 
chromatography purification of protein phosphatases and their respective regulatory 
subunits provide a closer look into the regulation of the endogenous proteins. The 
phosphorylation of the PKA substrate VASP (vasodilator-stimulated 
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phosphoprotein) at Ser157 was used as a control for the treatments with forskolin 
and H-89 (Figure 3.2). Several known regulatory subunits of protein phosphatases 
were isolated in this procedure, giving confidence in the methodology. Some of the 
protein phosphatases and their respective subunits identified in this screen were (the 
complete list can be found in Appendix I): PPP1C and its regulatory subunits 
NIPP1, p53BP2, MYPT1; PPP2C and its regulatory subunits PPP2R1A, PPP2R1B, 
PPP2R2A, PPP2R2D, PPP2R5D, PPP2R5E; PPP4C and its regulatory subunits 
PPP4R1, PPP4R2, SMEK1 and SMEK2, PPP4R4; PPP5C, PPP6C and its regulatory 
subunits SAPS1, SAPS2 and SAPS3, among others (Alessi et al., 1992; Helps et al., 
1995; Van Eynde et al., 1995; Csortos et al., 1996; Zolnierowicz et al., 1996; 
Trinkle-Mulcahy et al., 1999; Cohen et al., 2005; Stefansson et al., 2008). However, 
we could not identify any protein which seemed to be highly enriched or decreased 
in amount in the preparation from forskolin-treated cells. Such changes would have 
indicated regulation of interactions of regulatory proteins with catalytic subunits of 
protein phosphatases that was mediated by cAMP-signalling, possibly via PKA. As 
can be seen from the correlation value (R2) in Figure 3.3, the two different treatment 
conditions (forskolin only versus H-89 and forskolin, with both normalised to the 
serum starved condition) do not seem to have any major quantitative effect on the 
proteins that were affinity-purified from the microcystin-Sepharose column in this 
experiment.  
Proteins identified in this screen (total of 384) were classified into two 
groups: cellular localisation (Figure 3.4) and functional classification (Figure 3.5) 
(based on associated gene ontology (GO) terms from the Swiss-Prot database). As 
described in section 1.5.2, although PP1 is widely distributed throughout the cell, it 
is targeted to different cellular structures by associating with its subunits. For 
example, GM proteins target PP1 to glycogen particles in skeletal muscles, Repo-
Man recruits PP1 onto mitotic chromatin, URI localises PP1 to the mitochondria, 
and GADD34 targets PP1 to the endoplasmic reticulum (Hubbard and Cohen, 1993; 
Connor et al., 2001; Novoa et al., 2001; Djouder et al., 2003; Trinkle-Mulcahy et al., 
2006; Theurillat et al., 2011). The classification of the different proteins that were 
identified in this screen suggests that there are many more examples of protein 
phosphatase regulatory subunits yet to be characterised. The cellular distribution of 
protein phosphatases and their regulatory subunits identified in this screen are in 
agreement with previous studies on their localisation in the cell (Luke et al., 1996; 
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Janssens and Goris, 2001; Carnegie et al., 2003; Trinkle-Mulcahy et al., 2006a). 
Since most, if not all, of the protein phosphatases identified here have been 
implicated in DNA-damage repair pathways, transcription, mitosis and cell cycle 
progression, it is reassuring to find a high proportion of the proteins are linked to 
nuclear functions. In agreement with the effects of protein phosphatases on protein 
synthesis and intracellular trafficking (Peters et al, 1999; Janssens and Goris, 2001; 
Cohen, 2002; Cohen et al., 2005) a considerable fraction of the proteins identified 
here are also found on the ribosomes and cytoplasmic face of the endoplasmic 
reticulum. Similarly, the functional classification of the proteins (Figure 3.5) is in 
line with most of the functions with which microcystin-inhibited protein 
phosphatases have been associated. For example, some functions of these protein 
phosphatases include, but are not limited to: PP1 in glycogen metabolism, cell 
adhesion, cell cycle progression, spliceosome assembly and differentiation (Cohen, 
2002); PP2A in cell cycle regulation, protein synthesis and apoptosis (Janssens and 
Goris, 2001); PP4 in protein synthesis, mitosis, cell cycle progression and DNA 
repair (Cohen et al., 2005); PP5 in the regulation of DNA-damage pathways and 
transcription (Ali et al., 2004; Ikeda et al., 2004); PP6 in mitosis and DNA-damage 
repair (Stefansson and Brautigan, 2007).  
Overall therefore, several protein phosphatases and their respective 
regulatory subunits were identified using this technique. However, the list of 
proteins generated is not robust enough to confidently suggest proteins that might be 
cAMP-regulated in this screen. For instance, having at least two more biological 
replicates for this screen would induce more confidence in the prediction of 
cAMP—PKA-dependent regulation of protein phosphatases and their subunits. 
Furthermore, different PKA inhibitors could also be used to check whether these 
proteins are indeed PKA-regulated or rather due to the non-specific nature of H-89. 
Nonetheless, the data generated from this screen could be used as a rough guide for 
further experiments into the regulation of protein phosphatases regulated by the 
cAMP—PKA signalling pathway.   
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Figure 3.1: Coomassie-stained SDS-polyacrylamide gel of proteins that have 
been eluted from the microcystin-Sepharose columns 
HEK293 cells were deprived of serum for 8 h. The serum-starved cells were kept in 
either serum-free medium, treated with forskolin (20 µM) for 30 min, or pre-treated 
with H-89 (30 μM) for 30 min before the addition of forskolin. Proteins in cell 
lysates were captured on microcystin-Sepharose and bound proteins phosphatases 
and their regulatory subunits were eluted with the chaotropic salt sodium 
thiocyanate. The column eluates (75% of each) were loaded onto each lane of an 
SDS-polyacrylamide gel, which was stained with colloidal Coomassie blue for 
protein visualisation. The lines and numbers represent the sections that were cut for 
further processing by the methods outlined in section 2.2.15. 
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Figure 3.2: Western blots of phospho-VASP Ser157 and total VASP from the 
cell lysates used for the experiment in Figure 3.1 
HEK293 cells were serum starved for 8 h. Serum starved cells were kept either in 
serum free medium, treated with forskolin (20 µM) for 30 min, or pre-treated with 
H-89 (30 μM) before adding forskolin (20 µM) for 30 min. Immnunoblots were 
performed with 40 μg of cell lysates run on SDS-PAGE and Western blotted with 
anti-phosphoSer157-VASP and anti-VASP.   
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Figure 3.3: Comparison of the proteins that were affinity-purified on 
microcystin-Sepharose columns after treatment with forskolin (FSK) only or 
H-89 and forskolin  
Proteins that were identified in the screen with at least two peptides were plotted on 
a scatter graph. The catalytic subunits of protein phosphatase 1, 2A, 4, 5 and 6 are in 
red while their known regulatory subunits are in blue. The quantification values in 
the two treatment conditions were normalised to the serum-starved (SS) condition. 
The correlation value (r) between the two treatments is shown on the graph. 
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Figure 3.4: Subcellular distribution of the different proteins that were isolated 
with microcystin-Sepharose affinity chromatography 
Protein phosphatases are found in the cytoplasm and nucleus, but can also be 
targeted to specific sub-cellular structures by association with regulatory subunits 
that contain motifs and domains for targeting to particular proteins and locations 
(section 1.5.2). The 384 proteins identified in this screen have been categorized 
according to subcellular locations according to the Gene Ontology terms in the 
Swiss-Prot database, though these should be regarded as loose assignments because 
proteins can be found in more than one location.  
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Figure 3.5: Functional distribution of the proteins that were affinity purified 
and identified from the microcystin-Sepharose affinity chromatography  
Microcystin-Sepharose has been successfully used to enrich in protein phosphatases 
PP1, PP2A, PP4, PP5 and PP6. The protein hits identified in this screen (384 
proteins) have been classified according to the different cellular processes that 
protein phosphatases and their regulatory subunits have been reported to be involved 
in according to the Gene Ontology terms in the Swiss-Prot database. 
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3.1.4 GFP-Trap pull-down to find potential PKA-mediated PP1 beta 
regulation events 
 In another approach to identify PP1-binding proteins that were potentially 
regulated by cAMP–PKA activation, we used HEK293 cells stably expressing PP1β 
with a GFP tag. These cells were expressed, treated with or without forskolin in the 
presence or absence of H-89 and purified on GFP-Trap® agarose beads. The 
proteins were run on an SDS-polyacryamide gel (Figure 3.5), digested with trypsin, 
differentially dimethyl-labelled with stable isotope and identified by mass 
spectrometry, as described in section 2.2.15. Control blots for cell lysates measured 
VASP phosphorylation at Ser157 to check PKA inhibition and activation following 
treatments with H-89 and forskolin respectively (Figure 3.6). Around 140 proteins 
(Appendix II) were identified in this screen and these have been classified based on 
their cellular localisations (Figure 3.7) and functions (Figure 3.8). A few known 
PP1 regulatory subunits were identified, including MYPT1, URI, Staufen, NIPP1, 
WDR82, Sds22, Mbs85, Inhibitor-2 and p53BP2 (Huang and Glinsmann, 1976; 
Allen et al., 1998; Alessi et al., 1992; Helps et al., 1995; Van Eynde et al., 1995; 
Kreivi et al., 1997; Trinkle-Mulcahy et al., 1999; Ceulemans et al., 2002; Tan et al., 
2002; Monshausen et al., 2003; Trinkle-Mulcahy et al., 2006; Djouder et al., 2007; 
Theurillat et al., 2011). Interestingly, a few of these were seen to be slightly more 
enriched in forskolin-treated cells, though not strikingly so (Table 3.1).  
However, one group of glycogen-related proteins (Figure 3.9) were highly 
enriched in the preparation from cells stimulated with forskolin in the presence of H-
89 (Table 3.2). These proteins comprised PPP1R6 (also known as R6), glycogenin 
and glycogen synthase. PPP1R6 is one of a family of glycogen-targeting subunits of 
PP1 (Armstrong et al., 1997). Although little is known about its function, R6 has 
been shown to co-purify with glycogen granules, has a wide tissue distribution, but 
it has no apparent consensus sequence for PKA phosphorylation (Armstrong et al., 
1997). Glycogenin was first described as the 44 kDa subunit of glycogen synthase 
(Nimmo et al., 1976) and in 1985, was isolated as the covalently bound protein part 
of muscle glycogen (Rodriguez and Whelan, 1985). A decade later, glycogenin was 
reported as the 38 kDa subunit of glycogen synthase required to initiate glycogen 
synthesis (Pitcher et al., 1987). Glycogenin binds to a glucose residue via its Tyr194 
which triggers its glucosyltransferase activity, thereby catalysing the transfer of 
glucose molecules from the donor UDP-glucose to itself until the nascent 
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oligosaccharide chain is approximately eight glucose units long (Lomako et al., 
1988; Pitcher et al, 1988; Cao et al., 1993). Glycogen synthase elongates the 
glycogen moiety started by glycogenin by linking glucose molecules through the α1-
4 and α1-6 linkages. It was also reported that the ability of glycogen synthase to 
glucosylate glycogenin depends on the correct glucosylation state of glycogenin 
(Skurat et al., 1993). Glycogen synthase is also activated through dephosphorylation 
by PP1 (Brady et al., 1997). This suggests a very intricate role of glycogenin and 
glycogen synthase in regulating blood glucose levels.  
Taken together, the increased amount of glycogenin and glycogen synthase 
associated with PP1 with H-89 and forskolin treatment might be linked to the 
enrichment of the R6 glycogen-targeting subunit of PP1 under the same condition. 
The coordinated behaviour of the three proteins in this experiment might indicate a 
role for R6 in targeting PP1 to actively lower blood glucose levels by promoting 
glycogen synthase activation. The cAMP cascade normally inhibits glycogen 
synthesis in the liver when blood glucose levels are low; PKA phosphorylates and 
inactivates glycogen synthase, while simultaneously phosphorylating glycogen 
phosphorylase through phosphorylase kinase leading to glycogen catabolism 
(Soderling et al., 1970; Cohen et al., 1978). Forskolin triggers the cAMP cascade 
and H-89 is known to block this activation: the observations in this experiment 
suggest that the enrichment of glycogen synthase, glycogenin and R6 are 
independent of PKA activation. Further experiments are required to check the 
correlation between R6 and the enzymes of glycogen synthesis and to delineate the 
reason underlying these observations. 
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Figure 3.6: Coomassie-stained SDS-polyacrylamide gel of proteins that were 
captured with GFP-Trap® from lysates of cells expressing GFP-PP1β 
Flp-In T-REx 293 cells were stably transfected to express GFP-TAP-PP1β in a 
tetracycline-inducible manner. Protein expression was induced with 1 mg/ml of 
tetracycline for 24 h. These cells were then serum starved for 8 h. Serum starved 
cells were either kept in serum free medium, treated with forskolin (20 µM) for 30 
min, or pre-treated with H-89 (30 μM) for 30 min before the addition of forskolin. 
Proteins that co-immunoprecipitated with GFP-TAP-PP1β were captured on GFP-
Trap® beads. Bound proteins were eluted by boiling the beads with 4 x SDS-loading 
buffer. Column eluates (75%) were loaded in each lane of an SDS-polyacrylamide 
gel that was then stained with colloidal Coomassie blue for protein visualization. 
The lines and numbers represent the sections that were cut for further processing by 
the methods outlined in section 2.2.15. 
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Figure 3.7: Western blots of phospho-Ser157-VASP and total VASP from the 
cell lysates used for the experiment in Figure 3.5 
Flp-In T-REx 293 cells were stably transfected to express GFP-PP1β and induced to 
express the protein using 1 mg/ml tetracycline for 24 h. These cells were then serum 
starved for 8 h. Serum starved cells were either kept in serum free medium, treated 
with forskolin (20 µM) for 30 min, or pre-treated with H-89 (30 μM) for 30 min 
before the addition of forskolin. Immunoblottings were performed with 40 μg of cell 
lysates run on SDS-PAGE and Western blotted with anti-phospho- Ser157-VASP 
and anti-VASP.   
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Figure 3.8: Subcellular distribution of the different PP1β-interacting proteins 
that were pulled down with the GFP-Trap® technology 
Proteins (total 140) that were captured with PP1β on the GFP-Trap® beads have 
been grouped according to their cellular localisations. The relevant information was 
retrieved from the assigned GO terms for the relevant proteins from the Swiss-Prot 
database.  
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Figure 3.9: Functional classification of the different PP1β-interacting proteins 
identified in this screen 
Proteins (total 140) that were captured with PP1β on the GFP-Trap® beads have 
been grouped according to their functional classifications based on the relevant 
information retrieved from the assigned GO terms in the Swiss-Prot database.  
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Figure 3.10: Comparison of the effects of forskolin (FSK) versus H-89 followed 
by forskolin treatments on PP1-beta expressing stable cell lines.  
Proteins that were identified in the screen with at least two peptides were plotted on 
a scatter graph. The known regulatory subunits of protein phosphatase 1 are in red. 
The quantification values in the two treatment conditions were normalised to the 
serum-starved condition. The correlation value (r) between the two treatments is 
shown on the graph. 
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3.2 Comparison of the isoform specificity of PP1-binding proteins using 
GFP-Trap® capture of GFP-TAP-tagged proteins 
 Protein phosphatase 1, one of the most conserved eukaryotic proteins, is a 
serine/threonine protein phosphatase which has been implicated in a number of 
cellular processes, e.g., glycogen targeting to muscles, smooth muscle contraction, 
splicing, apoptosis etc. In humans, PP1 has three major catalytic isoforms-alpha, 
beta/delta and gamma, which are more than 89% identical to each other in their 
amino acid sequences. The major differences among these isoforms occur at their 
variable amino and carboxy terminals.  The catalytic forms of PP1 do not exist 
freely in cells; rather, they associate with regulatory subunits which either inhibit, 
target or modulate the activity of PP1. Most of these regulatory subunits have been 
observed to bind non-specifically to all three isoforms of PP1, generally through a 
degenerate RVXF motif (section 1.5.2). However, some regulatory subunits are 
more selective: MYPT1 binds preferentially to PP1β while Repo-Man selectively 
recruits PP1γ (Alessi et al., 1992; Trinkle-Mulcahy et al., 2006; Zagorska et al., 
2010). With the high degree of similarity (almost 90% amino acid sequence 
similarity) among the three PP1 isoforms, it seems reasonable to assume that a large 
proportion of these regulatory subunits would be shared among the catalytic 
subunits. Interestingly though, the different cellular expression patterns of these 
isoforms imply a higher degree of specificity than would have been originally 
thought. For instance, PP1α and PP1β have a rather diffused localisation throughout 
the cell whereas PP1γ has been observed to be concentrated in the nucleoli 
(Andreassen et al., 1998; Trinkle-Mulcahy et al., 2001; Trinkle-Mulcahy et al., 
2006). Subcellular fractionation studies of the brain have revealed distinct 
associations of PP1β with microtubules, whereas PP1γ associates more with the 
actin cytoskeleton (Strack et al., 1999). Furthermore, some interacting proteins also 
target PP1c to different cellular structures, for example, MYPT1 targets PP1β to 
myosin chains in smooth muscles, p99/PNUTS targets PP1α to the nucleus, while 
the GM targets PP1 to glycogen particles in skeletal muscles (Alessi et al., 1992; 
Hubbard and Cohen, 1993; Allen et al., 1998). 
 We generated stable cell lines expressing the three PP1 catalytic subunits 
tagged to GFP-TAP. The proteins were expressed, immunoprecipitated using the 
GFP-Trap® beads and the protein partners analysed and quantified by mass 
spectrometry (section 2.2.15). As can be seen from Figure 3.10, all three catalytic 
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PP1 isoforms were successfully expressed and identified as the major bands in the 
respective lanes. Many of the known regulatory subunits of PP1 were identified, 
giving confidence in the screen. The co-immunoprecipitated proteins (Appendix 
III) were quantified and the values converted to log 2 and used as a measure of 
enrichment for each protein with that particular PP1 isoform. The identified proteins 
have been recorded on a graph on Figure 3.11, which shows the different log 2 
ratios for each protein when comparing gamma to alpha. A more exhaustive 
comparison of the three isoforms has been included in Appendix IV. We could not 
find any pattern which would indicate a preference for any of the PP1 isoform 
relative to the other two in this screen.  
Using the dimethyl labelling approach meant that only two sets of pull-
downs could be compared side-by-side and so all the data were normalised to the 
values in the PP1α preparation for the following part of the analysis. Since not much 
has been published in terms of isoform selectivity for PP1, we could not verify all of 
the data. Nonetheless, some of the data obtained were in agreement with the 
information that was available (Table 3.3). For instance, MYPT had a higher 
enrichment value with PP1β (8.7) compared to PP1γ (1.7), suggesting that MYPT1 
might have a higher affinity for PP1β compared to PP1γ, as previously described by 
Zagorska and colleagues (2010). In addition, NIPP1 was preferentially isolated with 
PP1β (46.6) compared to PP1γ (6.9). Known regulatory subunits of PP1 that were 
identified in this screen are listed in Table 3.3 along with the different enrichment 
values for the specific isoforms. Some regulatory subunits such as Tra2-beta and 
SDS22 did not show any isoform specificity under these conditions. Although Repo-
Man has been widely cited as preferentially binding to PP1γ, overexpression of 
Repo-Man has also led to binding to PP1α (Trinkle-Mulcahy et al., 2006). This 
suggests that although the regulatory subunits exhibit some degree of specificity for 
isoform selectivity, there can still be some degree of overlap. The data from this 
experiment suggests that the isoform preferences of the regulatory subunits of PP1 
are not as striking as initially thought. Previous experiments using bacterially-
expressed protein phosphatases could have been affected by the fact that the 
bacterially-expressed protein, albeit active, does not appear to fold up correctly and 
have different properties from the native enzymes isolated from eukaryotic cells and 
tissues (MacKintosh et al., 1996).  This would likely contribute to bias in readouts, 
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similar to the data shown about overexpression of the targeting subunits leading to 
isoform bias (Trinkle-Mulcahy et al., 1999; Trinkle-Mulcahy et al., 2006).   
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Coomassie-stained SDS-polyacrylamide gel of PPP1C isoforms 
alpha, beta and gamma and their respective interacting proteins that have been 
eluted from GFP-Trap® immunoprecipitates 
Stably transfected Flp-In T-REx 293 cells were treated with tetracycline for 24 h to 
stably express the GFP-TAP-tagged versions of the three catalytic isoforms of PP1, 
namely PP1α, PP1β and PP1γ. Proteins that co-immunoprecipitated with the three 
catalytic PP1 isoforms were captured on GFP-Trap® beads. Bound proteins were 
eluted by boiling the beads with 4 x SDS-loading buffer. Column eluates (75%) 
were loaded onto each lane of an SDS-polyacrylamide gel that was then stained with 
colloidal Coomassie blue for protein visualisation. Each lane was then cut into eight 
gel pieces, digested with trypsin, labelled with the dimethyl approach as outlined in 
section 2.2.15 and analysed by mass spectrometry. 
 
 
 
 
90 
 
 
 
Figure 3.12: Ratio of PP1-interacting proteins from PP1γ and PP1α 
Enrichment values from PP1α and PP1γ were converted to log 2 values and plotted 
as a ratio of their abundance in the preparations, with PP1γ:PP1α respectively.  
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3.2.1 Bioinformatic analysis of novel PP1-binding motifs 
 Most PP1-interactors were previously defined by their ubiquitous 
[RK][VI]012[X][FW] (commonly referred to as the RVXF signature) motif, through 
which interaction with PP1 was mediated. It is now becoming increasingly clear that 
other motifs exist which are also able to mediate interaction with PP1. For example, 
the recently described MyPhoNE and [GS]IL[RK] (commonly referred to as SILK) 
motifs, although not very common, are also able to mediate interaction with PP1 to 
effect a specific cellular function (Hendrickx et al., 2009; Roy and Cyert, 2009). 
Inhibitor-1, although not identified in this screen, was one of the first PP1-regulatory 
subunits reported to interact and inhibit PP1 through its SILK motif (Huang et al., 
1999; Wakula et al., 2003). The SILK motif can functionally replace the RVXF 
motif as demonstrated with NIPP1 (Wakula et al., 2003). MYPT1 has a MyPhone 
motif which mediates its interaction with PP1beta to effect muscular contractions 
and cell adhesion (Zagorska et al., 2010). In order to analyse whether other proteins 
have these two new motifs, a bioinformatics approach was undertaken. Protein 
interactors of three different isoforms of PP1 that were identified in the GFP-Trap 
immunoprecipitates were analysed and classified into three broad groups: RVXF, 
SILK and MyPhoNE. Of the 234 proteins isolated, 15 were found to have the 
SILK/GILK motif and 4 proteins had the MyPhoNE motif (Table 3.4). Of the 15 
SILK/GILK motif-containing proteins identified here, 2 have been cited in other 
studies to putatively interact with PP1, namely NUP153 and RMP (Djouder et al., 
2007; Moorhead et al., 2009). Three out of the four proteins containing the 
MyPhoNE motif belong to the MYPT family: PPP1R12A, PPP1R12B and 
PPP1R12C. The only other protein seen in this experiment that has such a motif is 
SH2D4A, which is a cytoplasmic protein involved in the development of T-cells and 
also in the inhibition of oestrogen-induced cellular proliferation (Lapinski et al., 
2008; Li et al., 2009).  
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Table 3.4: PP1-binding proteins displaying the SILK and MyPhoNE motifs 
identified in HEK293 cells stably expressing GFP-TAP-PP1 
 
Accession # Description Motif References 
SILK/GILK 
P49790 Nuclear pore complex protein Nup153  NUP153  246-250 SILK Moorhead et al., 2009 
P07814 Bifunctional aminoacyl-tRNA synthetase   EPRS  52-56 SILR ‐ 
Q14160 Protein LAP4  SCRIB  268-272 SILK ‐ 
P49327 Fatty acid synthase  FASN  518-522 SILR ‐ 
O94763 Unconventional prefoldin RPB5 interactor   RMP  407-411 SILK Djouder et al., 2007 
P50991 T-complex protein 1 subunit delta  CCT4        
302-306
 SILR, 
 
527-531
 SILK ‐ 
P06733 Alpha-enolase  ENO1  1-5 SILK ‐ 
P12004 Proliferating cell nuclear antigen  PCNA        9-13 SILK ‐ 
Q00610 Clathrin heavy chain 1  CLTC  389-393 GILR ‐ 
O94822 RING finger protein 160  RNF160  1187-1191 GILK ‐ 
Q9P2J5 Leucyl-tRNA synthetase, cytoplasmic  LARS        762-766 GILR ‐ 
P11021 78 kDa glucose-regulated protein  HSPA5        506-510 GILR ‐ 
P49411 Elongation factor Tu, mitochondrial  TUFM        281-285 GILK ‐ 
Q06830 Peroxiredoxin-1  PRDX1  136-140 GILR ‐ 
Q6NXS1 
Putative protein phosphatase inhibitor 2-like protein 3 
PPP1R2P3  
12-16
 GILK ‐ 
        
MyPhoNE 
O14974 
Protein phosphatase 1 regulatory subunit 12A 
PPP1R12A   
9-17
  RNEQLKRW 
Alessi et al., 
1992 
O60237 
Protein phosphatase 1 regulatory subunit 12B 
PPP1R12B  
18-26
 RAEQLRRW Fujioka et al., 1998 
Q9BZL4 
Protein phosphatase 1 regulatory subunit 12C 
PPP1R12C  
21-29
 RREQLRQW Tan et al., 2001 
Q9H788 SH2 domain-containing protein 4A SH2D4A   31-39 REEQIRRW 
Hendrickx 
et al., 2009;  
Roy and 
Cyert, 2009 
        
The numbers in superscript next to the motif sequences denote the positions of those 
amino acids in the protein sequences. The proteins whose interaction with PP1 have 
been tested and validated are given in the papers cited.  
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3.3 Do the RVDF-containing SPEN proteins FPA and RBM15 interact with 
Protein Phosphatase 1? 
 The RVXF motif has long been recognised as the major motif-determinant 
for specifying PP1 interaction with its targeting subunits. This motif was first 
identified in studies of the myosin-targeting subunit M110 and the glycogen-targeting 
subunits GM and GL of PP1. Thereafter, it was found to mediate the interaction with 
a number of PP1-targeting subunits, such as PNUTS/p99, NIPP1, I-1 and p53BP2 
among others. In 2008, Novoyatleva et al. described the novel interaction between 
PP1 and the splicing factor transformer-2 beta-1 (Tra2-beta-1). This proved 
interesting as this interaction was mediated through the RVDF motif of Tra2-beta-1; 
furthermore, this motif was present in the beta-4 strand of the RNA-recognition 
motif (RRM) domain of the protein (Novoyatleva et al., 2008). The authors 
proposed a novel functional role of PP1 in alternative splicing events by PP1 
binding to splicing factors such as Tra2-beta-1, SF2/ASF and SRp30c. Tra2-beta-1 
is a serine arginine (SR)-like protein involved in regulating splice site selection on 
RNA substrates; it has an RRM domain flanked by an SR-rich domain on either 
side. Eight other SR proteins including SF2/ASF also have the RVDF motif in the 
beta-4 strand of their respective RRMs which may be used to bind PP1, suggesting a 
new role for RRMs as binding partners of PP1 (Novoyatleva et al., 2008). 
Bioinformatical analysis of FPA, a protein being studied in the laboratory of 
Dr Gordon Simpson, showed that FPA also had an RVDF motif in its beta 4 strand 
of its third RRM domain. FPA is a Spen (Split-end) protein involved in flowering 
control and more recently shown to be involved in mediating polyadenylation events 
in Arabidopsis (Hornyik et al., 2010). Spen proteins were first identified in 
Drosophila where mutations of the protein led to lethal developmental defects in the 
embryo and they have now been implicated in cell-fate determination and 
transcriptional repression (Ariyoshi and Schwabe, 2003). A reciprocal BLAST search 
of FPA against the human database suggested two other Spen proteins, RBM15 and 
RBM15B, as the human homologues of FPA. Analyses of the sequences of these 
human proteins showed that they also have an RVDF motif within their respective 
RRM domains. We thus set out to verify whether these three Spen proteins, FPA, 
RBM15 and RBM15B, could be novel PP1 interacting proteins (sections 3.2.4.1 and 
3.2.4.2 respectively).  
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3.3.1 Is FPA a novel PP1-interacting protein in Arabidopsis thaliana? 
 Different pathways control the floral transition in plants including the 
autonomous pathway (AP), the photoperiod pathway (PP) and the gibberillic acid 
pathway (GA).  Genes in the PP and GA pathways act mainly by promoting the 
upregulation of the floral meristem idendity (FMI) genes. FPA is a gene in the 
autonomous pathway which affects flowering independent of day-length (Lorkovic 
and Barta, 2002). FPA has been shown to control the expression of Flowering Locus 
C (FLC); FLC in turn regulated FMI genes. The FMI in turn controls the switch 
from the vegetative state to the reproductive state in a plant (Simpson et al., 1999).  
fpa mutants exhibit late-flowering phenotypes due to mis-regulation of FLC, 
whereas double mutant fpa flc plants flowered as early as single flc-3 mutants, which 
indicates that a functional FLC gene is required to repress flowering (Veley and 
Michaels, 2008). While FLC is not very conserved, FPA is highly conserved 
amongst plant species, suggesting that FPA plays a significant role in plants other 
than just controlling flower development, consistent with its expression in other 
plant tissues (Schomburg et al., 2010). FPA also has the highest expression in young 
and actively growing tissues (Schomburg et al., 2001). Subsequently, FPA has been 
implicated in RNA-mediated chromatin silencing (Baurle et al. 2007) and reported 
to regulate 3’end formation through alternative polyadenylation (Hornyik et al., 
2010). The initial studies on FPA localisation using the GUS promoter fused to the 
FPA gene showed that this protein was expressed throughout the life cycle of the 
plant, with the highest expression being in young developing tissues. This indicated 
that expression of FPA is not triggered or restricted by floral induction but suggested 
that FPA may be involved in more fundamental aspects of plant development, hence 
its high expression in developing tissues. Characteristic of the SPEN family, FPA 
has three RNA-Recognition motifs (RRMs) in the N-terminal region, which are 
involved in RNA-binding, and a SPEN Paralogue and Orthologue C-terminal 
(SPOC) domain (Figure 3.12), which is used for protein-protein interactions 
(Schomburg et al., 2001). FPA has the RVDF motif in its third RRM; the RVDF 
motif has been found in most regulatory subunits of PP1. We therefore set out to 
investigate whether FPA interacts with PP1 through its RVDF motif.  
Working with Arabidopsis confers many advantages, but one of the many 
limitations of this model organism is its tiny size, which restricts the amount of 
starting material for any experiment. To circumvent this, we decided to use 
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cauliflower as a source material to work with FPA for this purpose. Arabidopsis and 
cauliflower are closely related to each other in the Brassicacae (mustard plants). The 
endogenous levels of FPA in Arabidopsis (Col-0) are relatively low as can be seen 
by the Western blot detection (Figure 3.13). The fpa-7 mutant does not show any 
signal as expected, indicating that the antibody is highly specific to the protein. 
Moreover, the results showed that the purified FPA antibody is able to recognise the 
FPA protein expressed in cauliflower (Figure 3.14) and can hence be used to detect 
this protein during its purification from cauliflower. Total cell extract from 
cauliflower inflorescence was used as a starting material to extract FPA-interacting 
partners. The cauliflower extracts were subjected to the microcystin-Sepharose 
affinity chromatography, to enrich for protein phosphatases, including PP1 (section 
1.3.3). We used the synthetic peptides described by Moorhead et al. (2009) to 
specifically elute PP1-binding proteins displaying the RVXF motif. The anti-FPA 
antibody was used to track the FPA protein through the procedure; anti-TOPP1 
antibody was also used to blot for the PP1 protein (the plant PP1 catalytic subunits 
are named TOPPs for Type One Protein Phosphatases). Although FPA could be 
tracked through all steps prior to the elution, there was relatively less FPA in these 
fractions, which were loaded onto the microcystin column, compared to a parallel 
preparation that started with a urea extraction (Figure 3.14). The results indicate that 
the FPA did not solubilise properly under the extraction conditions used in this 
procedure. Lanes 1-6 are the sequential samples during the homogenisation steps: 
lane 1 has the whole tissue extract, lane 2 is the first pellet after filtering the 
homogenate through miracloth, lane 3 is the corresponding supernatant (SP), lane 4 
is the supernatant after the centrifugation of the supernatant from lane 3, lane 5 is the 
corresponding pellet, lane 6 is the supernatant after filtering the supernatant from 
lane 4 through miracloth. Lane 7 is the fraction that was incubated with microcystin-
Sepharose and lane 8 is the flow through, which runs through the column after this 
incubation but prior to any washing. The washes of the column after step 8 did not 
show any bands except in lane 9. Lane 9, on the other hand, is the sample collected 
at the washes after the peptide elution steps. The samples after elution with the 
peptides did not appear to have any FPA on the blot either (data not shown). The 
sample in lane 9 was the last step where the FPA protein was detected, suggesting 
that a small fraction of FPA might have been on the column and was eluted by the 
peptide washes. In contrast, TOPP1 was detected only in lane 5 (lower band ~35 
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kDa) and lane 8 (upper band ~37 kDa). This meant that the protein in the 35 kDa 
band was not in the soluble fraction and was pelleted during the centrifugation step. 
The ~37 kDa forms of TOPP1 though, were detected up to lane 8, which is the 
eluate after incubation with the microcystin-Sepharose beads. This suggests that the 
TOPP1 isoform of 37 kDa did not bind to the microcystin-Sepharose beads as 
expected. Neither protein was detected in the subsequent steps whereby the proteins 
were displaced by the synthetic peptide until the wash following peptide elution. 
The FPA and TOPP1 proteins were not detected in the control column either, 
suggesting that most of the proteins could have been degraded during the process 
and this might explain why there was no indication of the proteins on either column 
following the incubation with microcystin-Sepharose beads. However, FPA was 
readily detected in urea extracts of cauliflower, showing that the protein was present 
in this tissue. However, urea cannot be used in experiments that aim to maintain 
protein:protein interactions. These results suggest that FPA was not solubilised 
properly under the native extraction conditions used, and for this technical reason it 
was not possible to determine whether or not the protein could be co-
immunoprecipitated with PP1. 
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Figure 3.13: Structural representation of the protein FPA 
FPA is a Spen protein containing three RNA-recognition motifs (RRM) and a Spen 
Paralogue and Orthologue C-terminal (SPOC) domain.  FPA also has an RVDF 
motif in its third RRM domain.  
 
 
 
 
 
 
 
 
 
Figure 3.14: Detection of FPA protein in Arabidopsis and cauliflower using the 
anti-FPA antibody 
A wild type plant (Col-0), a fpa-7 mutant, a plant over-expressing FPA tagged to the 
YFP protein (35S::FPA:YFP) and cauliflower.   
 
 
 
 
 
 
 
 
Figure 3.15: Purification of FPA and TOPP1 from cauliflower extract 
Lanes 1-9 show the different steps during the purification. The lane labelled 
‘cauliflower’ represents a urea extract of cauliflower and 35S::FPA:YFP is the over-
expressed FPA protein from Arabidopsis protein: both were loaded as positive 
controls. These samples represent the steps where a positive signal was observed for 
the respective proteins blotted for. The same lysates for each step were used to blot 
for the FPA and TOPP1 proteins using anti-FPA and anti-TOPP1 respectively. 
Lanes 1-6 are samples taken during the homogenisation steps; lane 7 is the sample 
prior to loading onto the microcystin-Sepharose beads; lane 8 is the eluate after 
incubation with microcystin-Sepharose beads; lane 9 is the sample after the peptide 
elution from microcystin-Sepharose beads.   
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3.3.2 Do RBM15 and RBM15B interact with PP1 via their RVDF motifs?  
 
 RBM15 (RNA-binding protein motif 15, also known as OTT1-One twenty 
two protein 1), and RBM15B (RNA-binding protein motif 15B also known as 
OTT3-One twenty two protein 3) are Spen (Split End) proteins, which have been 
widely implicated in development (Mercher et al., 2001; Ariyoshi and Schwabe, 
2003). RBM15 was initially characterised as the genetic aberration involved in 
infant acute megakaryocytic leukaemia, where it was described as being possibly 
involved in chromatin modulation through its translocation fusion to the 
Megakaryocytic Acute Leukemia (MAL) gene (Li et al., 2001; Mercher et al., 
2001). Both RBM15 and RBM15B have three RRM domains and a SPOC (Spen 
Paralogue and Orthologue C-terminal domain) (Figure 3.15). RBM15 and RBM15B 
interestingly have this consensus RVDF motif in their RRM domains. Given the 
structural relationship between FPA, RBM15 and RBM15B we were interested to 
know whether RBM15 and RBM15B are able to bind to PP1 through this motif. For 
simplicity, only the RBM15 results will be shown and discussed here; both RBM15 
and RBM15B gave similar results in these experiments. To test the potential 
RBM15-PP1 interaction, we used HEK293 cells transiently and stably expressing 
GFP-tagged RBM15. In both cases, the cells were lysed, GFP proteins 
immunoprecipitated using the GFP-Trap beads, separated on SDS-polyacrylamide 
gels, digested with trypsin and the peptides analysed by mass spectrometry.  
 Analysis of the mass spectrometry data from the peptides showed that 
RBM15 was successfully expressed and purified from the cells as the major band on 
the gel (Figure 3.16). Moreover, NXF1 was also pulled down in this experiment, 
albeit with a low Mascot score. NXF1 is a nuclear export factor protein reported in a 
study of the NXF1 export pathway to interact with RBM15 to promote RTE-
containing retrotransposon mRNA transcripts out of the nucleus (Lindtner et al., 
2006). On the other hand, PP1 was co-immunoprecipitated with a very low Mascot 
score, and not any more enriched than in the GFP control where it was also 
identified as a low-scoring protein. This suggests that trace amounts of PP1 were 
being isolated via the GFP-tag in the GFP-RBM15 expressing cells. However, 
reciprocal GFP-PP1 pull-down experiments did not identify RBM15 as a PP1 
interactor (Appendices II and III). Interestingly, the protein identified by 
Novoyatleva et al (2008), Tra2-beta-1 was identified in the PP1-GFP 
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immunoprecipitates (Figure 3.17). These experiments suggest that PP1 and RBM15 
(RBM15B) do not interact with each other, at least under the experimental 
conditions used here. Nonetheless, it could be possible that RBM15 and PP1 interact 
transiently and/or under different conditions, which have not been explored in this 
thesis.  
 
 
Figure 3.16: Structural representation of RBM15 and RBM15B 
RBM15 and RBM15B are members of the Spen family of proteins in humans. Both 
RBM15 and RBM15B have three RRM domains and a SPOC domain, characteristic 
of Spen proteins. RBM15 has the RVDF motif in its third RRM domain, while 
RBM15B has the RVDF motif in its second RRM domain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Coomassie-stained SDS polyacrylamide gel of GFP-RBM15 
immunoprecipitated using GFP-Trap® from lysates of transfected HEK293 
cells, and the identified proteins  
Proteins were isolated from GFP-RBM15-expressing HEK293 cells using the GFP-
Trap technology to identify the protein interacting partners of RBM15. RBM15 was 
identified as the major protein band on the gel, as were a number of RNA-binding 
proteins. A known interactor of RBM15, namely NXF1, was also identified.  
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Figure 3.18: Coomassie-stained SDS polyacrylamide gel of GFP-PP1  
Proteins were isolated from HEK293 cells stably expressing GFP-PP1 using the 
GFP-Trap® technology and run on an SDS-PAGE gel. Peptides were extracted from 
the gel by trypsin digestion and identified using mass spectrometry to identify the 
protein interacting partners of PP1. Tra-2 beta-1 was identified as a PP1-interactor 
but not RBM15. 
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3.3 Discussion 
 For many years, the importance of protein phosphatases has been highlighted 
for their roles in regulating cellular events, including DNA synthesis, mitosis, cell 
cycle control, glycogen metabolism, muscle contraction and regulation of RNA 
splicing. Regulation of protein phosphatases is thus critical to maintain the balance 
in the cellular processes controlled by these enzymes. Most of the protein 
phosphatases are controlled through interactions with their regulatory subunits, 
which either target them to their substrates and/or different cellular localisations, or 
inhibit their activities. The usage of naturally-occurring toxins such as microcystin 
and okadaic acid for the study of protein phosphatases has proven beneficial as it 
helped identify their regulatory subunits. As described in section 3.1.1, modifying 
microcystin-LR and coupling it to Sepharose beads has been successfully employed 
to study protein phosphatases at endogenous levels. Most of the knowledge about 
the acute regulation of serine/threonine protein phosphatases involves regulation 
through the cAMP-dependent protein kinase. Using forskolin as a cAMP-elevating 
agent (section 3.1.2), we tried to identify novel targets of protein phosphatases that 
might be PKA-regulated. The dimethyl labelling approach (Boersema et al., 2008) 
allows the quantification of peptides; although around 99% of the peptides are 
labelled, the quantification values only provide an indication on the enrichment 
ratios of the different peptides, and are not absolute values. For instance, the 
treatment with forskolin on the lysates in section 3.2 shows no enrichment when 
compared to the lysates pre-treated with H-89 prior to the addition of forskolin 
(Figure 3.3). No proteins were found to have a high enrichment ratio, which does 
not necessarily indicate that none of these proteins are actually PKA-regulated, since 
these values mostly represent enrichment fractions, and not absolute expression 
values. Other labelling methods such as SILAC (stable isotope labelling by amino 
acids in cell culture) have been shown to more accurately represent expression 
values of proteins through their quantitative analysis. The dimethyl labelling method 
used here was a cheaper and easier alternative to SILAC, and nonetheless provided a 
good indication on the differential enrichment of PP-interacting proteins. 
Furthermore, if more positive results had been obtained with the plant studies, the 
differential dimethyl labelling procedures could have been useful for determining 
how interactions of the plant protein(s) with PP1 are regulated under different 
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conditions. SILAC is not possible with plants, though it is being adapted for work 
with plant cell cultures (Gruhler et al., 2005; Schütz et al., 2011). 
The catalytic and regulatory subunits of several PPs (section 3.1.3) were 
successfully identified, adding confidence to the microcystin-Sepharose 
methodology. A similar approach was undertaken to identify regulatory subunits 
that bound PP1β upon forskolin treatment (section 3.1.4). Regulatory subunits of 
PP1 were identified in this screen and these comprised the highest scoring peptides 
during the mass spectrometry identifications. Interestingly, a subset of proteins was 
seen to be enriched in the cells treated with H-89 and forskolin. These differentially 
enriched proteins, namely R6, glycogenin and glycogen synthase, are all involved in 
glycogen metabolism. Forskolin acts as a cAMP-agonist to activate PKA; elevated 
cAMP levels are usually associated with glycogen breakdown in skeletal muscle 
cells. Although H-89 has been shown to antagonise the action of forskolin, it is 
nonetheless a non-specific PKA inhibitor. It might be possible that treatment with 
H-89 and forskolin in these cells result in additional inhibition/activation of 
undefined targets, which are in turn responsible for the enrichment of these 
regulatory proteins of glycogen metabolism. Further experiments are needed to 
define the roles of these proteins in cells treated with H-89 and forskolin.        
 Protein phosphatase 1 is one of the most conserved eukaryotic proteins. In 
humans, there are three catalytic subunits of PP1 expressed from three genes: alpha, 
beta/delta and gamma. The beta and delta isoforms are alternative splicing products 
of the same PP1 gene. The three PP1 isoforms are more than 89% identical in amino 
acid sequence and only vary at their carboxy and amino-terminals (Barker et al., 
1994; Andreassen et al., 1998; Trinkle-Mulcahy et al., 2001). The catalytic residues 
of the PP1 isoforms share at least 97% homology and have been shown to perform 
similar activities in vitro (Zhang et al., 1997). The regulatory subunits have mostly 
been defined by the RVXF motif, which mediates binding to PP1. Most of the 
regulatory subunits of PP1 are known to bind non-specifically to all three isoforms, 
which is expected with such a high degree of identity. Additional interactions with 
the terminal domains of the different PP1 isoforms provide specificity in terms of 
isoform preference. For example, MYPT1 has been shown to bind preferentially to 
the C-terminus of the beta isoform through its eight ankyrin repeats (Terrak et al., 
2004). Section 3.2 describes how ectopic expression of the three forms of PP1 was 
used to identify proteins that display differential enrichments in terms of their 
104 
 
binding to each isoform, as a potential measure of isoform preference. These data 
provide an indication on the preference of the different regulatory subunits of PP1 
for the different isoforms. However, we found no evidence to suggest a specific 
preference of a particular PP1 isoform for any given protein. Most of the evidence of 
isoform preference for PP1 isoforms stem from their differential cellular 
localisations, which indicate binding to proteins found in those particular organelles. 
However, Trinkle-Mulcahy and colleagues (1999) showed how overexpression of 
targeting subunits leads to the re-distribution of PP1 isoforms in the cell (Trinkle-
Mulcahy et al., 1999). Since most of the reports on isoform preference could 
possibly be biased in terms of PP1-interacting protein overexpression, it is likely 
that the isoform preference observed in these conditions are simply reflective of an 
artefact generated through the overexpression of a particular protein in the cell. 
Nonetheless, a handful of proteins could very well bind specifically to one particular 
isoform, especially if the interaction between PP1 and its subunit occurs at the C- or 
N-terminal of PP1. For instance, the binding of MYPT1 to PP1 has been well-
characterised and shows how the interaction of MYPT1, through its eight tandem 
ankyrin repeat domains, occurs with the C-terminal domain of PP1β (Terrak et al., 
2004). Although isoform preference is possible, it is most likely restricted to only a 
handful of PP1-interacting proteins. Consequently, it is becoming increasingly clear 
that the RVXF motif which was long thought to be the major mediator of PP1-
interaction with its subunits is not the only PP1-binding motif. Two novel motifs 
mediating PP1-binding were recently reported: the SILK and MyPhoNE motifs 
(Hendrickx et al., 2009; Roy and Cyert, 2009). A motif-based bioinformatics 
analysis of the different proteins identified in this screen showed that 15 proteins, 
including previously reported PP1-interactors, NUP153 and RMP, as having the 
SILK motif while 4 proteins including MYPT1 and MBS85 had the MyPhoNE 
motif (Alessi et al., 1992; Tan et al., 2002; Trinkle-Mulcahy et al., 2006; Djouder et 
al., 2007; Zagorska et al., 2010; Theurillat et al., 2011). Further biochemical and 
mutational analyses are required to verify whether these motifs are required to 
mediate PP1 binding and modulate the actions of PP1.  
 A report suggested binding of PP1 to the RRM domains of splicing factors 
such as tra-2 beta and ASF/SF2 as a novel function of the PP1 in splicing-mediated 
events (Novoyatleva et al., 2008). Tra-2 beta was found to have the RVDF motif in 
the fourth beta sheet of its RRM domain, only one of eight such human proteins 
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(Novoyatleva et al., 2008). The Spen proteins FPA, RBM15 and RBM15B were also 
found to have the RVDF motifs in their RRM domains. As described in section 
3.3.1, the extraction conditions of FPA were not optimal to test a potential PP1-FPA 
interaction. In section 3.3.2, it was shown that PP1 did not bind to the human Spen 
proteins RBM15 and RBM15B, at least not under the experimental conditions used. 
Although the RVXF motif is present in most PP1-interacting proteins, this motif is 
also present in about a quarter of all eukaryotic proteins (Ceulemans and Bollen, 
2006). Only a small proportion of these are actual PP1-interacting proteins, 
suggesting that the presence of an RVXF motif by itself is not sufficient to classify a 
protein as a putative PP1 interactor, as demonstrated by FPA and RBM15. More 
recently, the RVXF motif has been suggested to act more as a ‘specifying’ sequence 
that mediates PP1 interaction with other motifs and/or promoting secondary 
interactions (Bollen, 2001; Hurley et al., 2007; Carmody et al., 2008). In other 
words, the RVXF motif brings PP1 and its interactor in close enough proximity to 
enable other interactions to occur via different motifs, e.g. the [S/G]IL[K/L] motif. 
The occurrence of the RVXF motif in such a high number of proteins in the genome 
suggests that there should be additional regulatory mechanisms that would mediate 
binding of RVXF-containing proteins with PP1. The studies here suggest that many 
more PP1-interactors exist than previously thought. As more sensitive techniques 
become available, it would become easier to fully understand the plethora of PP1-
binding proteins.   
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Chapter four 
 
 
 
Regulation of the 14-3-3-phosphoproteome 
upon activation of the cAMP—PKA 
signalling pathway 
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4.1 Introduction 
 Many phosphorylated proteins bind to the family of phosphoprotein-binding 
proteins, 14-3-3s. 14-3-3s are dimers that engage with a pair of tandem 
phosphorylated sites within disordered regions and/or that straddle a functional 
domain (Johnson et al., 2010). Binding of a 14-3-3 dimer can force a conformational 
change in a target, or can mask a binding site, for example a DNA-binding domain 
or nuclear localisation sequence. In these ways, 14-3-3s can change the activity, 
localisation and interactions of target proteins (Aitken, 2006).  
The two consensus motifs of 14-3-3-binding sites overlap with the 
specificities of basophilic protein kinases in the CAMK and AGC families (section 
1.2.2), including PIMs, PKA, PKCs, PKB, p90RSK and AMPK (Johnson et al., 
2010). Our group has therefore exploited the specificity of 14-3-3s to identify many 
new downstream targets of the PI 3-kinase–PKB, (PKC)–Erk–p90RSK and AMPK 
pathways. PI 3-kinase–PKB and (PKC)–Erk–p90RSK are activated by insulin and 
growth factors, while AMPK is activated in cellular responses to energy stress. 
Defining the substrates of these pathways, and the interplay between them, is 
particularly important because PI 3-kinase–PKB and PKC–Erk–p90RSK are 
deregulated in diabetes and cancers, while activating AMPK by exercise and drugs 
seems to have beneficial effects in these diseases. The cAMP–PKA signalling has 
on the other hand been implicated in HIV-associated immunosuppression, lupus 
erythemathosus, neurological disorders, asthma and airway diseases (Kammer et al., 
1994; Aandahl et al., 1998; Billington and Hall, 2012). Our group has noticed that 
several proteins that were first identified for the binding to 14-3-3s in response to 
insulin also have their binding to 14-3-3 stimulated by the adenylate cyclase 
activator forskolin (unpublished). Based on this background, it would be useful and 
interesting to more fully define the sets of proteins that bind to 14-3-3 when 
intracellular cAMP levels are elevated, and compare them with existing data on the 
sets of proteins that bind to 14-3-3s when the PI 3-kinase–PKB pathway is activated. 
We therefore set out to identify those proteins that are uniquely targeted for 14-3-3 
binding by the cAMP–PKA pathway, and also proteins that bind to 14-3-3s in 
response to both pathways.      
The approach we took was 14-3-3 affinity purification of proteins from 
lysates of cells. Peptides from the captured proteins were then modified using the 
dimethyl isotope labelling method developed by Hsu et al (2003) and Boersema and 
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colleagues (2008). The labelling with this approach introduces a dimethyl group 
onto lysine residues on parallel sets of peptides, but with a 4 Dalton difference 
between samples due to different amounts of deuterium and C13 in the chemicals 
(light: +0 Da, intermediate: +4 Da; heavy: +8 Da); these modifications provide an 
indication as to the abundance of the different peptides in each preparation (Figure 
1.9). This method was used successfully in the MacKintosh laboratory to identify 
novel targets of the insulin–PI 3-kinase–PKB signalling pathway in cultured human 
cells (Dubois et al., 2009). Since then, a number of such screens have been 
performed in the group in studies of the PI 3-kinase–PKB signalling pathways and 
ERK–p90RSK signalling pathways (section 1.4.3). Each round of high-throughput 
mass spectrometry was followed by biochemical validation experiments that were 
then used to build up a core list of ‘gold standards’ to feed into further experiments.  
The sequencing of the amphioxus genome has helped considerably towards 
our understanding of 14-3-3 biology in humans and other vertebrate animals. Over 
500 million years ago, the vertebrate genome arose from two rounds of whole 
genome duplications (2R-WGD). While most of the resulting protein duplicates 
(termed 2R-ohnologues) were lost before the modern-day vertebrate species evolve,  
several hundred 2R-ohnologue protein families have been retained (Huminiecki et 
al., 2010; Makino et al., 2010) and these have been discovered to be highly enriched 
in 14-3-3-binding proteins (Tinti et al., 2012). In contrast, amphioxus is the basal-
most chordate, and is an invertebrate. Sequencing of the amphioxus genome has 
shown that its ancestors did not go through the 2R-WGD, which means that the 
amphioxus has one ‘ancestral’ protein for every human 2R-ohnologue family 
(Putnam et al., 2008; Tinti et al., 2012). Amphioxus is therefore a useful ‘proxy’ for 
our pre-2R-WGD ancestor.  
As described in Chapter 1, forskolin is a cAMP-elevating agent, which 
hence activates protein kinase A (PKA). The major PKA consensus is R-R-X-pS 
(see section 1.2.3.1) and this sequence overlaps with the optimal consensus 
sequences for 14-3-3 binding, which are mode I R-X-X-pS/pT-X-P and mode II R-
X-X-X-pS/pT-X-P. To identify PKA-regulated 14-3-3-binding proteins more 
systematically, we used 14-3-3 affinity capture and release to isolate proteins from 
lysates of cells stimulated with forskolin, in the absence or presence of the non-
specific PKA-inhibitor H-89. Competition with a synthetic peptide (ARAApSAPA) 
was used to eluate those proteins that had been captured specifically within the 
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central binding groove of the immobilised 14-3-3s. Half of each eluate was used to 
measure quantitative differences by differential isotope dimethyl labelling of tryptic 
digests and mass spectrometry (Boersema et al., 2008) while the rest  was used for  
phosphopeptide enrichment and identification. The results, and further 
developments, are given in the following sections.  
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4.2 Results 
 Large 14-3-3-phosphoproteomics screens are becoming increasingly 
valuable in uncovering the roles of these versatile signalling proteins; such screens 
provide a wealth of information on the different possible protein partners of 14-3-3s. 
However, no one screen is exhaustive since the mass spectrometric analyses of the 
proteins captured in each round of purification are stochastic, resulting in a ‘patchy’ 
picture of incomplete datasets for each round of analyses. Hence, more-and-more 
proteins are routinely uncovered in further rounds of purification, and improvements 
also come from newer and more sensitive mass spectrometry techniques being 
employed. Here, we used 14-3-3-affinity chromatography to identify those proteins 
that bind to the 14-3-3 proteins when the cAMP–PKA signalling pathway is 
activated. Cells were serum starved for 10 h to return the activation status of various 
signalling pathways to basal levels, and used as the baseline to obtain enrichment 
values for the following treatment conditions. The second condition used forskolin 
as the cAMP-elevatgent, while the non-specific PKA inhibitor H-89 was used in 
combination with forskolin as the third treatment. Cells were lysed and loaded onto 
14-3-3-affinity Sepharose columns; 14-3-3-binding proteins were eluted from the 
columns by competitive elution using the ARAApSAPA synthetic peptide. The 
proteins in the eluate were pre-fractionated by running an SDS-polyacrylamide gel 
in order to reduce the complexity in each of the protein mixtures used for subsequent 
analyses (Figure 4.1). Cell lysates were also immunoblotted for the phosphorylation 
of the PKA substrate VASP (vasodilator-stimulated phosphoprotein) at Ser157 as a 
control for the efficacy of the forskolin and H-89 (Figure 4.2).  The protein bands in 
the three treatment lanes were excised as labelled on Figure 4.1, reduced, alkylated 
and digested with trypsin. Half of the resulting peptides were labelled using the 
dimethyl labelling approach as described previously in Chapter 1 (Figure 1.9) and 
section 4.1 (Boersema et al., 2008). The other half set of peptides was used to enrich 
in phosphopeptides. Around 300 proteins were identified in the screen (Appendix 
IV), with several of these being ‘gold standards’ seen in previous 14-3-3-affinity 
capture experiments (Figure 4.3). These ‘gold standards’ are proteins which have 
been characterised as genuine 14-3-3-binding proteins and for which 14-3-3-binding 
phosphosites have been identified through biochemical experiments (173 gold 
standards sofar) (Johnson et al., 2011). I then used commercially-available 
antibodies to follow the purification of a few proteins that were identified in this 
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screen as potential 14-3-3-binding proteins (Figure 4.4). I chose to further test the 
three members of the DENND4 family of proteins (section 4.2.1), EML3 (section 
4.2.2) and ATG9a (section 4.2.3) as potential 14-3-3-binding candidates.   
 As the first step towards pinpointing 14-3-3-binding sites for the 14-3-3-
captured proteins, the unused half of the tryptic digests for the forskolin-treated 
samples generated from the preparations in Figure 4.1 were used to enrich for 
phosphopeptides. Columns made with C-8-Empore extraction disks and titanium 
dioxide beads were pre-washed with acetonitrile (ACN) and equilibrated in 0.2% 
trifluoroacetic acid (TFA). The tryptic peptides were adjusted to 70% ACN/ 3% 
TFA/ 250 mM lactic acid and loaded onto the columns. Three sequential washes 
were performed with 70% ACN/ 3% TFA/ 250 mM lactic acid, 70% ACN/ 3% TFA 
and 0.1% TFA respectively to remove unbound peptides and other contaminants. 
Bound phosphopeptides were eluted with a base (1% ammonium hydroxide) into 
tubes containing 50% TFA (5% of the total volume) and loaded onto the Orbitrap 
for analysis. The results were exciting as a number of 14-3-3-phosphopeptides were 
enriched and identified in these preparations (Appendix VI), including 14-3-3-
binding sites of AS160 (Ser 341), AKTS1 (Ser 183, Ser 246), KLC2 (Ser 582), 
NED4L (Ser 448), REEP3/4 (Ser 152), YAP1 (Ser 127) and ZNRF2 (Ser 19, Ser 
82).  
The other phosphosites identified were examined using bioinformatic 
analyses to search for further potential 14-3-3-binding sites:  
Sequence alignments of human and amphioxus proteins indicate that at least 
some of the 14-3-3-binding sites in human 2R-ohnologues are conserved in 
amphioxus, and were therefore derived from the 14-3-3-binding sites in the pre-2R-
WGD ancestor. We therefore carried out bioinfomatical comparisons of the 
phosphopeptide sequences which were identified experimentally, by matching them 
to the corresponding amphioxus protein sequences to predict the most likely 14-3-3-
binding sites (Appendix IV). The data will be a useful resource for future validation 
experiments: For example, to test whether mutagenesis of the pinpointed residues 
causes proteins to lose their binding to 14-3-3s. Additionally, I have manually tried 
to assign potential binding phosphosites based on the known 14-3-3-binding 
consensus motifs mode I RSX(pS)XP and mode II RX(F/Y)X(pS)XP (Appendix 
IV). 
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Figure 4.1: Coomassie-stained SDS-polyacrylamide gel of proteins that have 
been eluted from the 14-3-3-affinity Sepharose columns 
HEK293 cells were serum starved for 8 h. Serum starved cells were kept in either 
serum free medium, treated with forskolin (20 µM) for 30 min, or pre-treated with 
H-89 (30 μM) for 30 min before the addition of forskolin. Proteins in cell lysates 
were captured on 14-3-3-Sepharose affinity columns and specifically-bound proteins 
were eluted by competition with the ARAApSAPA 14-3-3-binding phosphopeptide 
to displace the proteins that bind to 14-3-3. The column eluates (75% of each) were 
loaded onto each lane of an SDS-polyacrylamide gel, which was stained with 
colloidal Coomassie blue for protein visualization. The lines and numbers represent 
the sections that were cut for further processing by the methods outlined in section 
2.2.15. 
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Figure 4.2: Western blots of phospho-Ser157-VASP and total VASP from the 
cell lysates used for the experiment in Figure 4.1 
HEK293 cells were serum starved for 8 h. Serum starved cells were kept either in 
serum free medium, treated with forskolin (20 µM) for 30 min, or pre-treated with 
H-89 (30 μM) before adding forskolin (20 µM) for 30 min. Immunoblots were 
performed with 40 μg of cell lysates run on SDS-PAGE and Western blotted with 
anti-phosphoSer157-VASP and anti-VASP.   
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Figure 4.3: Proteins identified in the cAMP–PKA-activated 14-3-3-
phosphoproteomic screen 
The proteins which were isolated using 14-3-3-affinity chromatography from lysates 
of cells stimulated with forskolin in the presence or absence of H-89 are plotted on a 
scatter graph. All proteins were normalised to their counterparts in the serum-starved 
conditions to obtain a ratio of those proteins which were enriched in the treatment 
(in this case forskolin only or H-89 and forskolin) conditions. Proteins with at least 
two unique peptides were then selected from the list. All the proteins identified in 
this screen are represented by a triangle; red triangles represent those proteins that 
are also in the ‘gold standard’ list.  
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Figure 4.4: Western blots of proteins that have been eluted from the 14-3-3-
Sepharose column 
HEK293 cells were serum starved for 10 h. Serum starved cells were kept in serum 
free medium, treated with forskolin (20 µM) for 30 min, or pretreated with H-89 (30 
μM) for 30 min before the addition of forskolin (20 µM). Proteins from the lysates 
(40 µg) were isolated by binding to 14-3-3-Sepharose (14-3-3 pulldowns (p.d.)). 
Western blots of the 14-3-3 pulldowns were performed using antibodies against the 
proteins indicated: ATG9A, TBC1D5, CCDC6 and VASP. 
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4.2.1 DENND4 proteins as 14-3-3-binding proteins 
 The DENND4 proteins DENND4A (also known as IRLB), DENND4B and 
DENND4C are members of the DENND (DENN domain) family of proteins. 
DENN-domain (Differentially Expressed in Normal and Neoplastic cells) containing 
proteins were first described as Rab GEFs (Guanine Exchange Factors) by the 
purification of Rab3 from bovine brain (Wada et al., 1997). DENND proteins are 
evolutionarily conserved and are found in most eukaryotes, including 
Caenorhabditis elegans, Arabidopsis thaliana, Drosophila, Homo sapiens and 
Schizosaccharomyces pombe. There are eight DENND families in humans encoded 
by eighteen genes (Figure 4.5); the families are grouped according to their sequence 
homology and domain organisation. These are DENND1A-1C, DENND2A-2D, 
DENND3, DENND4A-4C, DENND5A/5B, DENND6A/6B, MTMR5/13 and 
DENN/MADD (Marat et al., 2011). The DENN domain comprises a central DENN 
region flanked by an upstream (uDENN) and downstream (dDENN) DENN module; 
all of the DENND human proteins have the DENN domains at their amino terminal, 
with the exception of the DENND2 family, where the DENN region is at the 
carboxy end (Marat et al., 2011). Other than their DENN domain similarity, the 
DENND proteins do not share any common features. Although the DENND proteins 
were identified long ago and thought to be GEFs, their functional roles were not 
appreciated until recently. Seventeen of the DENND proteins were found to be 
specific GEFs for 10 Rab proteins (Yoshimura et al., 2010). Rab proteins are small 
GTPases, which cycle between a GDP-bound (inactive) and GTP-bound (active) 
state; active Rabs are involved in membrane trafficking (Marat et al., 2011). GEFs 
function by promoting GDP release and loading of GTP to the Rab protein thereby 
activating the Rabs (Pfeffer and Aivazian, 2004). On the other hand, GAPs 
(GTPase-activating proteins) promote GTP hydrolysis from the Rab proteins, 
thereby balancing the GDP-GTP cycle for the activation/inactivation of Rabs. 
Understanding the biological implications of DENND proteins are likely to provide 
insights into vesicle trafficking pathways and related human diseases.  
We came across DENND4 proteins during our 14-3-3-proteomics screen 
aimed at finding proteins which are highly enriched upon activation of the cAMP–
PKA pathway. Interestingly, all three DENND4 proteins were identified during this 
screen and we wanted to understand how this DENND family might interact with 
14-3-3s. DENND4 proteins comprise three members: DENND4A (also known as 
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IRLB), DENND4B and DENND4C. IRLB was the first DENND4 protein to be 
studied and it has been shown to interact with the ISRE in the promoter region of 
human Myc (Postel et al., 1996; Semova et al., 2003). However, although 
DENND4A and DENND4C each have a nuclear localisation signal, it remains 
unclear if they localise to the nucleus (Yoshimura et al., 2010; Marat et al., 2011). 
Additionally, DENND4 proteins have a MABP domain, which is thought to mediate 
membrane-specific interactions (de Souza and Aravind, 2010). DENND4 proteins 
have recently been shown to be involved in apical and basolateral sorting by 
interacting with Rab10 to control polarised trafficking (Yoshimura et al., 2010). 
Furthermore, DENND4C interaction with Rab10 has also been shown to promote 
GLUT4 trafficking by increasing GTP-binding to Rab10 in adipocytes (Sano et al., 
2011). Interestingly, GLUT4 trafficking also involves another pair of 14-3-3-binding 
proteins, TBC1D1 and TBC1D4/AS160, which functions as Rab GTPase activating 
proteins (GAPs) for Rab10, and which have been the subject of a major project in 
our laboratory. Upon insulin stimulation, PKB has been shown to phosphorylate 
TBC1D4, which alleviates its Rab GAP activity on Rab10, thereby promoting 
GLUT4 translocation to the plasma membrane; this phosphorylated TBC1D4 is also 
sequestered by 14-3-3 proteins (Sakamoto and Holman, 2008; Chen et al., 2008 
Sano et al., 2011). In contrast, one of the 14-3-3 binding sites for TBC1D1 is 
phosphorylated by non-insulin-activated kinases including AMPK.  It is therefore 
inferred that TBC1D4 and TBC1D1 mediate GLUT4 trafficking, and hence glucose 
homeostasis, in response to different stimuli (Chen et al., 2011). 
Since the full scale of 14-3-3 involvement in cellular trafficking is still at an 
early stage, it is exciting to find another family of protein, namely DENND4, 
involved in controlling GLUT4 trafficking being potentially able to interact with 
these adaptor-regulator 14-3-3s. Understanding the intricacies of these interactions 
might be potentially useful in controlling diabetes and other related diseases. We 
thus set out to understand more about the DENND4–14-3-3 interaction.       
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Figure 4.5: Representation of the domains in the DENND proteins found in 
humans.  
The eighteen DENN domain proteins in the human genome, with the three 
DENND4 proteins highlighted in pink. The gene names are aligned on the left and 
the protein name (if different) are in parentheses. The different domains in these 
proteins are: u, uDENN module; d, dDENN; MABP, MVB12-associated β-prism; 
CB, clathrin-binding motif; SRD, serine-rich domain; PRD, proline-rich domain; 
NLS, nuclear localisation sequence; poly-E, polyglutamic acid domain; poly-Q, 
polyglutamine domain; poly-D, polyaspartic acid domain; CalB, calmodulin-binding 
domain; ISRE, interferon-stimulated response element; AP-2IM, AP-2 interaction 
motif; DD, death domain; PPR, pentatricopeptide repeat; PLAT, polycycstin-
1/lipoxygenase/α-toxin domain; GRAM, glucosyltransferase/Rab-like GTPase 
activator/myotubularin domain; pseudo-phosph, pseudo-phosphatase domain           
(Source: Marat, Dokainish and McPherson, 2011).  
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4.2.1.1 DENND4 proteins share a high sequence similarity 
 DENND4 proteins share a high sequence homology with each other, which 
could explain in part the redundant functions they all exert on Rab10, both as the 
Rab GEF in GLUT4 trafficking and in the basolateral and apical sorting in polarised 
membrane trafficking (Yoshimura et al., 2010; Sano et al., 2011). Knocking down 
DENND4C did not completely abolish the Rab GEF on Rab10; similarly, cells with 
knockdown of DENND4A or DENND4B still showed RabGEF activity on Rab10, 
suggesting that the other DENND4 proteins are able to compensate for the silenced 
protein (Sano et al., 2011).  
This family of proteins is potentially a member of the 2R-ohnologue 
families, where the different members of a protein family have evolved by the two 
rounds of whole genome duplication that occurred at the evolutionary origins of the 
vertebrates (Manning and Scheeff, 2010; Huminiecki and Heldin, 2010; Makino and 
McLysaght, 2010, Tinti et al., 2012). Accordingly, in humans, DENND4A and 
DENND4C share a higher sequence similarity with each other rather than with 
DENND4B suggesting that DENND4A and DENND4C might share a more recent 
common ancestor compared to DENND4B, as seen from the phylogenetic tree 
analysis (Figure 4.6). The uDENN, core DENN and dDENN domains of the three 
proteins are shown in Figure 4.7.  
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Figure 4.6: Phylogenetic tree analysis of the DENND4 proteins in humans.  
The amino acids sequences of the three DENND4 proteins, namely DENND4A 
(MYCPP), DENND4B and DENND4C were retrieved from the UniProt database 
and aligned using the UniProt alignment tool, which also generated the phylogenetic 
tree (shown here) for these sequences.  
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Figure 4.7: Alignment of the DENN domain of the three DENND4 proteins 
The protein sequences of the DENN domains of DENND4A, DENND4B and 
DENND4C were retrieved from the UniProt database and aligned using JalView. 
The three underlined regions are the upper DENN (red), the core DENN (green) and 
the downstream DENN (yellow) domains respectively. The domains are underlined 
with respect to the domain numbering in DENND4C. The highly conserved residues 
are shaded in blue while the lesser-conserved residues among the three proteins are 
in lavender.   
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4.2.1.2 DENND4 family members bind 14-3-3 in a phosphorylation dependent 
manner 
 All three DENND4 family members were identified in the 14-3-3-
phosphoproteomic screen (Appendix V); this was interesting as a previous insulin–
PI 3-kinase screen in the lab had only identified DENND4A as a putative 14-3-3 
binding protein (Dubois et al., 2009). Since most 14-3-3-binding proteins have been 
shown to bind in a phosphorylation-dependent manner, we tested the binding of the 
DENND4 proteins under different states of phosphorylation. The DENND4 proteins 
were expressed as GFP fusions, with the tag at the N-terminus. While full-length 
constructs were obtained for DENND4A and DENND4B, it was rather difficult to 
clone DENND4C in its entirety and the work describe hereafter has been performed 
with a construct expressing residues 1017-1673 of DENND4C. The GFP-tag 
allowed for a clean immunoprecipitation (pull down) using the GFP-Trap® agarose 
beads, which bind to GFP with a high capacity and high affinity. HEK293 cells were 
transiently transfected to express GFP-DENND4A, GFP-DENND4B, and GFP-
DENND4C(1017-1673), and grown in DMEM containing 10% serum for 24 h 
before lysis. For each construct, three sets of pull-downs were done in parallel using 
3 mg of cell lysates each; one pull-down per condition was used in the subsequent 
dephosphorylation assay. The lysates were pre-cleared with protein G-Sepharose 
and the supernatant incubated with the GFP-Trap® beads for 1 h. After washing, the 
immunoprecipitated proteins were incubated in the absence or presence of purified 
lambda phosphatase and its co-factor manganese chloride to dephosphorylate 
samples in vitro. A control reaction where lambda phosphatase activity had been 
inhibited by prior incubation of the manganese chloride with EDTA was also 
performed. Proteins were denatured and separated by SDS-PAGE, transferred to 
nitrocellulose and analysed by 14-3-3 Far Western overlay analysis. GFP-
DENND4A, GFP-DENND4B and GFP-DENND4C immunoprecipitated from cells 
bound directly to 14-3-3s in the overlay, but binding was abolished in the sample 
dephosphorylated with lambda phosphatase, indicating that 14-3-3s can only interact 
with the phosphorylated DENND4 proteins (Figure 4.8).   
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4.2.1.3 Generation of stable cell lines expressing the GFP-tagged DENND4 
proteins 
 Perhaps because the DENND4 proteins are relatively large (ranging from 
163 to 216 kDa), they were difficult to express at optimum level between replicate 
experiments using transient transfection methods. We therefore decided to generate 
stable cell lines expressing the GFP-tagged DENND4 proteins using the Flp-In 
TRex system. This system confers the advantage of expressing the tagged protein at 
close to endogenous levels under the control of a tetracycline inducible promoter.  
4.2.1.4 GFP-DENND4A binds 14-3-3s mainly upon phorbol ester (PMA) 
stimulation, suggesting it could be phosphorylated by kinases in the PKC 
pathway 
Most known 14-3-3-binding motifs have basic residues at the -3 to the -5 
position relative to the phosphorylated site. Basophilic kinases of the AGC and 
CAMK families have been shown to prefer these consensus motifs and 
preferentially phosphorylate the majority of 14-3-3-binding proteins. To delineate 
which kinase and/or signalling pathway might be involved in phosphorylating these 
proteins, a panel of extracellular stimuli has been developed in the group. In this 
panel, various combinations of agonists and inhibitor are used in order to activate or 
inhibit certain pathways, which have been observed to be most involved in 
signalling to promote phosphorylations of proteins that consequently bind to 14-3-3. 
Cells transiently expressing GFP-DENND4A were serum starved for 6 h and treated 
as follows: IGF1 treatment leading to activation of the PI 3-kinase signalling 
cascade and PKB; IGF1 after prior inhibition with the PI 3-kinase and mTOR 
inhibitor PI-103; EGF to activate the classical MAPK/Erk cascade; phorbol ester 
(PMA) to activate the Erk cascade, the stress activated protein kinase p38 and some 
PKCs; PMA after prior inhibition of p90 RSK isoforms using BI-D1870; the 
adenylate cyclase activator forskolin; forskolin after prior inhibition of PKA using 
the nonspecific inhibitor H-89; the calcium ionophore A23187; A769662 as an 
activator of AMPK; and the protein phosphatase inhibitor calyculin A. The proteins 
from the lysates of cells exposed to these different treatments were pulled down 
using the GFP-Trap® agarose beads and analysed by the Far Western 14-3-3 
overlay assay. The phorbol ester PMA appears to be the major agonist to 
phosphorylate DENND4A which leads to its binding with 14-3-3s; interestingly, the 
p90RSK inhibitor BI-D1870 seems to reduce the phosphorylation (Figure 4.9). 
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There is also slight binding of DENND4A to 14-3-3s in response to the growth 
factor EGF, the calcium ionophore A23187, as well as forskolin (most likely 
through PKA).  
 
 
Figure 4.9: 14-3-3 binding of GFP-DENND4A in response to various kinase 
inhibitors and agonists 
Cells stably expressing GFP-DENND4A were induced with tetracycline for 24 
hours. These cells were serum-starved for 6 h and pre-treated with the indicated 
kinase inhibitors before stimulation (30 min with 1 μM PI-103, 10 μM BI-D1870, 30 
μM H-89). Stimulations were: 50 ng/ml IGF1 for 20 min; 100 ng/ml EGF for 15 
min; 100 ng/ml PMA for 30 min; 20 μM forskolin for 30 min; 10 μM A23187 for 20 
min; 50 μM A769662 for 1 h; 50 nM calyculin A for 5 min. GFP-DENND4A was 
isolated from 2.5 mg lysate on GFP-Trap. Samples were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with the indicated antibodies. Growth factor 
stimulated phosphorylation of PKB and Erk1/2, and phosphorylation of VASP by 
forskolin was tested by immunoblotting lysates (40 μg) with the indicated 
antibodies. SS-serum-starved, FSK-forskolin, Cal A-calyculin A. 
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4.2.1.5 GFP-DENND4B binds 14-3-3s under all cellular conditions tested  
Similarly, lysates of cells transiently expressing GFP-DENND4B were 
screened for binding of the protein to 14-3-3 after using the same panel of activators 
and inhibitors to identify the kinases likely to phosphorylate the protein. Under all 
conditions tested, DENND4B was seen to bind to 14-3-3s in the overlay assays 
(Figure 4.10). However, endogenous 14-3-3s were observed to co-
immunoprecipitate with DENND4B upon treatment with the PMA plus or minus the 
p90RSk inhibitor BI-D1870, the calcium ionophore A23187 and the phosphatase 
inhibitor calyculin A. This suggests that kinases activated in these pathways could 
be phosphorylating serine and/or threonine residues in DENND4B that could 
potentially mediate 14-3-3-binding. One possibility is that one 14-3-3-binding site 
on DENND4B is phosphorylated under all the conditions tested, and the other 
phosphorylated by kinases that are activated in response to PMA and A23187. To 
identify the kinases responsible for 14-3-3 binding, truncation mutants of 
DENND4B have been generated to pinpoint which part of the protein binds 14-3-3 
as the next step towards understanding regulation of DENND4B by 14-3-3s (section 
4.2.1.8).  
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Figure 4.10: 14-3-3 binding of GFP-DENND4B in response to various inhibitors 
and agonists 
HEK293 cells were transiently transfected to express GFP-DENND4B, and after 24 
h cells were serum-starved for 6 h and pre-treated with the indicated kinase 
inhibitors before stimulation (30 min with 1 μM PI-103, 10 μM BI-D1870, 30 μM 
H-89). Stimulations were: 50 ng/ml IGF1 for 20 min; 100 ng/ml EGF for 15 min; 
100 ng/ml PMA for 30 min; 20 μM forskolin for 30 min; 10 μM A23187 for 20 min; 
50 μM A769662 for 1 h; 50 nM calyculin A for 5 min. GFP-DENND4B was 
isolated from 2.5 mg lysate on GFP-Trap. Samples were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with the indicated antibodies. Growth factor 
stimulated phosphorylation of PKB and Erk1/2, and phosphorylation of VASP by 
forskolin was tested by immunoblotting lysates (40 μg) with the indicated 
antibodies. SS-serum-starved, Cal A-calyculin A. 
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4.2.1.6 GFP-DENND4C binds 14-3-3s pre-dominantly upon cAMP/PKA 
activation 
Interestingly, treatment with forskolin was observed to increase DENND4C 
binding to 14-3-3s in the Far-Western 14-3-3 overlay assay (Figure 4.11). This 
binding was inhibited by the non-specific PKA inhibitor H-89, suggesting that PKA 
might phosphorylate one or more of the 14-3-3-binding phosphosites on 
DENND4C. Co-immunoprecipitation of endogenous 14-3-3s also coincided with 
forskolin treatment and was decreased upon inhibition of PKA by H-89. 
Interestingly, PMA also induced the co-immunoprecipitation of endogenous 14-3-3s 
with DENND4C although no overlay signal could be detected under this treatment. 
Further analyses are required to pinpoint the phosphosites in DENND4C which 
mediate its binding to 14-3-3s. 
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Figure 4.11: 14-3-3 binding of GFP-DENND4C in response to various stimuli 
and inhibitors 
HEK293 cells were transiently transfected to express GFP-DENND4C, and after 24 
h cells were serum-starved for 6 h and pre-treated with the indicated kinase 
inhibitors (30 min with 1 μM PI-103, 10 μM BI-D1870, 30 μM H-89) before 
stimulation with growth factors and protein kinase activators. Stimulations were: 50 
ng/ml IGF1 for 20 min; 100 ng/ml EGF for 15 min; 100 ng/ml PMA for 30 min; 20 
μM forskolin for 30 min; 10 μM A23187 for 20 min; 50 μM A769662 for 1 h; 50 
nM calyculin A for 5 min. GFP-DENND4C was isolated from 2.5 mg lysate on 
GFP-Trap resin. Samples were separated by SDS-PAGE, transferred to 
nitrocellulose and probed with the indicated antibodies. Growth factor stimulated 
phosphorylation of PKB and Erk1/2, and phosphorylation of VASP by forskolin was 
tested by immunoblotting lysates (40 μg) with the indicated antibodies. SS-serum-
starved, Cal A-calyculin A. 
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4.2.1.7 In silico analysis of putative 14-3-3-binding phosphorylation sites on the 
DENND4 proteins 
 14-3-3 proteins dock onto phosphorylated serine or threonine residues on 
their target proteins. We did an in silico analysis of the three amino acid sequences 
of the DENND4 proteins and tried to match sequences that were close to the two 14-
3-3-binding motifs: RSX(pS)XP (mode I) and RX(F/Y)X(pS)XP (mode II) (Yaffe et 
al., 1997). Interestingly, DENND4A and DENND4C had multiple candidates as 
potential phosphorylation sites (7 and 4 respectively) while DENND4B had three. 
Since we did not have the full-length construct for DENND4C, we selected only 
those potential residues that were in the construct we obtained for residues 1017-
1673. These potential 14-3-3-binding serine residues in the DENND4 proteins 
(Table 4.1) were mutated to non-phosphorylatable alanine residues to check their 
interaction with 14-3-3s.  
Table 4.1: The potential 14-3-3-binding serine residues in the DENND4 
proteins and their corresponding alanine mutants  
IRLB 
(DENND4A) 
S338 pcDNA5 FRT/TO GFP IRLB S338A  DU36868  
S755 pcDNA5 FRT/TO GFP IRLB S755A  DU36869  
S1151 pcDNA5 FRT/TO GFP IRLB S1151A  DU36886  
S1251 pcDNA5 FRT/TO GFP IRLB S1251A  DU36865  
S1589 pcDNA5 FRT/TO GFP IRLB S1589A  DU36946  
S1609 pcDNA5 FRT/TO GFP IRLB S1609A  DU36866  
S1798 pcDNA5 FRT/TO GFP IRLB S1798A  DU36879  
DENND4B 
S343 pcDNA5 FRT/TO GFP DENND4B S343A  DU36830  
S732 pcDNA5 FRT/TO GFP DENND4B S732A  DU36831  
S961 pcDNA5 FRT/TO GFP DENND4B S961A  DU36832  
DENND4C 
S1042 pcDNA5 FRT/TO GFP DENND4C 1017-
end S1042A  DU36833  
S1404 pcDNA5 FRT/TO GFP DENND4C 1017-
end S1404A  DU36834  
S1426 pcDNA5 FRT/TO GFP DENND4C 1017-
end S1426A  DU36835  
S1608 pcDNA5 FRT/TO GFP DENND4C 1017-
end S1608A  DU36846  
 
4.2.1.8 Truncation mutants of DENND4B to determine 14-3-3-binding 
 From the 14-3-3-overlay kinase panel experiment (Figure 4.10), it was 
difficult to pinpoint the possible kinase(s) that could be phosphorylating DENND4B 
since the overlay signal was observed for all treatment conditions. We decided to 
use another approach to narrow down the part of the DENND4B protein responsible 
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for 14-3-3-binding. Using the GlobPlot analysis tool, we looked at the different 
regions in the predicted structure of DENND4B and truncated the protein into 
different fragments within disordered regions (Figure 4.12).  These fragments will 
be tested for binding to 14-3-3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Globplot analysis and truncation mutants of DENND4B 
The Globplot tool (http://www.globplot.embl.de) was used to analyse the 
DENND4B protein (O75064), which predicts disorder propensity upon Pfam 
domain predictions. Based on this information, truncation mutants of DENND4B 
were generated encompassing different combinations of the globular and DENN 
domains in DENND4B.  
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4.2.2 Characterisation of EML3 as a potential 14-3-3-binding protein 
EML3, also known as ELP95 (Echinoderm-like protein 95) was also 
identified in the cAMP–PKA-stimulated 14-3-3-phosphoproteomic screen and we 
set out to characterise this protein and its binding to 14-3-3s. EML3 was first 
identified in this laboratory by Pozuelo-Rubio et al. (2004), and subsequently by 
Dubois et al. (2009) as part of 14-3-3 affinity capture screens. In 2008, Tegha-
Dunghu and colleagues reported the co-localisation of EML3 with cytoplasmic 
microtubules during interphase and its association with spindle microtubules 
throughout mitosis (Tegha-Dunghu et al., 2008). Initial characterisation of EML3 as 
a 14-3-3 binding target was done by Drs Kathryn Geraghty and Kumara 
Dissanayake: they found that EML3 bound to 14-3-3s in a phosphorylation 
dependent manner. I started by stimulating cells expressing GFP-EML3 with the 
panel of inhibitors and agonists to try and identify the possible kinase(s) and/or 
pathway(s) involved in EML3 phosphorylation. The lysates from these treated cells 
were pre-cleared for an hour with protein G-Sepharose and then incubated with 14-
3-3-Sepharose beads for 2 h at 4°C. The beads were washed prior to elution with 2 x 
SDS-sample buffer. Proteins were run on an SDS-PAGE gel and analysed for 14-3-
3-binding. Interestingly, EML3 was found to bind 14-3-3s in response to stimulation 
with forskolin; consequently, treatment with the non-specific PKA inhibitor H-89 
abolished 14-3-3-binding (Figure 4.13). To find potential protein partners of EML3, 
the protein was expressed with a GFP-tag, pulled down on GFP-Trap beads, 
separated by one-dimensional SDS-PAGE and analysed by mass spectrometry 
techniques. Mass spectrometric analysis of GFP-tagged EML3 identified it as part of 
a complex with two other proteins, p32, a nuclear-encoded mitochondrial protein, 
and RanBP5, a member of the importin beta family (Figure 4.14; Geraghty and 
MacKintosh, unpublished results). In order to ascertain the phosphorylation sites of 
EML3 which mediated its binding to 14-3-3s, its amino acid sequence was scanned 
for potential 14-3-3-binding motifs. Two 14-3-3 binding sites of EML3, namely 
Ser127 and Ser147, both located in the N-terminal region of the protein were chosen 
as the most likely candidates (Dissanayake and MacKintosh, unpublished results). 
The GFP-EML3 protein was expressed and affinity purified on 14-3-3-Sepahrose 
beads; the immunoprecipitates were then analysed for EML3 binding to 14-3-3s. 
Both single and double mutations of these serine residues to their non-
phosphorylatable alanine counterparts disrupt binding to 14-3-3s, with Ser127 being 
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the pre-dominant site (Figure 4.15). Mutations of the 14-3-3 binding sites of EML3 
did not affect its interaction with either p32 or RanBP5 (Figure 4.15). Next, 
truncation mutants of EML3 were generated to elucidate the region(s) of EML3 
interacting with p32 and RanBP5 (Figure 4.16). Preliminary results suggest that 
both of these proteins bind EML3 at the C-terminal region involving the WD40 
repeat motifs (Figure 4.17). So far, it seems that the interaction of EML3 with 14-3-
3-s is independent of its interaction with RanBP5 and p32. Also, the results suggest 
that these interacting partners bind EML3 at different regions in the protein. Further 
experiments are required to understand the effect of 14-3-3-binding to EML3, and 
the effect of EML3 interactions with p32 and RanBP5.  
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Figure 4.13: 14-3-3 binding of GFP-EML3 in response to various kinase 
inhibitors and agonists 
HEK293 cells were transiently transfected to express GFP-EML3, and after 24 h 
cells were serum-starved for 6 h and pre-treated with the indicated kinase inhibitors 
before stimulation (30 min with 1 μM PI-103, 10 μM BI-D1870, 30 μM H-89). 
Stimulations were: 50 ng/ml IGF1 for 20 min; 100 ng/ml EGF for 15 min; 100 
ng/ml PMA for 30 min; 20 μM forskolin for 30 min; 10 μM A23187 for 20 min; 50 
μM A769662 for 1 h; 50 nM calyculin A for 5 min. GFP-EML3 was isolated from 
2.5 mg lysate on 14-3-3-Sepharose. Samples were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with the indicated antibodies. Growth factor 
stimulated phosphorylation of PKB and Erk1/2, and phosphorylation of VASP by 
forskolin was tested by immunoblotting lysates (40 μg) with the indicated 
antibodies. SS-serum-starved, FSK-forskolin, Cal A-calyculin A. 
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Figure 4.14: Coomassie-stained SDS-polyacrylamide gel of proteins that have 
been eluted from the GFP-EML3 pull down using GFP-Trap® beads 
HEK293 cells were transiently transfected with forms of GFP-EML3 (wild type, 
mutants without and with the HELP domains (NH and H respectively). Proteins in 
cell lysates were captured on GFP-Trap beads and bound proteins were eluted by 
boiling in 2X sample buffer. The column eluates (75% of each) were loaded onto 
each lane of an SDS-polyacrylamide gel, which was stained with colloidal 
Coomassie blue for protein visualization. The boxes represent the sections that were 
cut for further processing by the methods outlined in section 2.2.15. 
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Figure 4.17: Truncation mutants of EML3 to study RanBP5 and p32 binding 
HEK293 cells were transfected to transiently express EML3 wild-type and its 
truncated mutants as described in Figure 4.16. Cells were grown to 90% confluency 
before lysis. 3 mg of lysates for each sample were affinity purified on 14-3-3-
Sepharose beads and eluted using 2 x sample buffer. Samples were separated by 
SDS-PAGE, transferred to nitrocellulose and probed with the indicated antibodies.    
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4.2.3 Is ATG9a a novel 14-3-3-interacting protein?  
 Interestingly, a key player in the initiation of autophagy in mammalian cells 
was identified in my 14-3-3 screen, namely ATG9a. This was exciting as it 
implicated 14-3-3s in a novel function previously undescribed for these signalling 
proteins, and which might relate to the membrane trafficking interests of the group. 
Furthermore, another autophagy-related protein, ULK1 (Unc-like kinase 1), has 
been very recently shown to interact with 14-3-3s upon phosphorylation by AMPK 
during stress responses (Mack et al., 2012). Although ATG9 itself has been studied 
for a few years, its interaction with 14-3-3s has not been previously reported.  
 Autophagy is one of two major protein-degradation pathways in the cell, 
which maintain cellular homeostasis between protein synthesis and protein 
degradation. It has been shown to occur at basal levels to maintain balanced protein 
levels and is upregulated during cellular stress and nutrient starvation (Webber and 
Tooze, 2010). While autophagy degrades long-lived proteins and organelles to 
generate amino acids during starvation and stress to maintain cellular energy levels, 
the ubiquitin-proteasome pathway has been implicated in the degradation of short-
lived proteins (Webber and Tooze, 2010). It follows that deregulations in this 
pathway would have detrimental effects on the cell; consequently, defects in 
autophagy have been implicated in cancers, neurodegenerative diseases such as 
Parkinson’s, Huntington’s and Alzheimer’s, and more recently in muscular atrophies 
(Mizushima, 2009; Sanchez et al., 2012).  
Initiation of autophagy occurs through the formation of the autophagosome, 
which fuses with the lysosome, enabling the lysosomal hydrolases to degrade the 
sequestered proteins (Webber and Tooze, 2010). Proteins required for autophagy are 
named ‘autophagy related proteins’ (Atg) and yeast genetic screens have identified 
over 30 such proteins (Xie and Klionsky, 2007). Most of these Atg proteins have 
been found to transiently colocalise at the pre-autophagosomal structure (PAS) site, 
where they are recruited for autophagy (Suzuki et al., 2001; Kim et al., 2002). The 
core machinery for autophagy consists of a protein kinase complex (including Atg1 
(ULK1) and other Atg proteins such as Atg13 and Atg17), a phosphatidylinositol 3-
kinase complex (consisting of a class III PI 3-kinase Vps34, p150, Beclin1 and 
Atg14), two ubiquitin-like conjugation systems and Atg9 (Chan and Tooze, 2009; 
Simonsen and Tooze, 2009; Webber and Tooze, 2010).        
140 
 
 Atg9 is highly conserved protein among eukaryotes and was first identified 
in yeast genetic screens from cells having autophagic defects (Webber and Tooze, 
2010). Knockout of Atg9 plants have been shown to result in accelerated leaf 
senescence, while knocking down the protein in Drosophila melanogaster renders 
the fly more susceptible to infections by the vesicular stomatitis virus (VSV), and 
both the plant and fly phenotypes are directly linked to defects in autophagy (Liu et 
al., 2005; Shelly et al., 2009). Furthermore, deletion of the C. elegans orthologue of 
Atg9 reduces the life span of the worms (Toth et al., 2008). In yeast, Atg9 deficient 
cells are unable to form the autophagosome, resulting in a decreased total protein 
turnover and reduced survival rate during starvation (Lang et al., 2000; Noda et al., 
2000). Atg9 thus plays a very important role in ensuring autophagy occurs to 
maintain cellular growth in various organisms.  
Atg9 is a transmembrane protein with six membrane-spanning domains, with 
its amino- and carboxy-ends lying at the cytosolic face. There are two mammalian 
othologues of Atg9: Atg9a (referred to as Atg9 in this thesis) which is ubiquitously 
expressed and Atg9b whose expression is reportedly restricted to the placenta and 
pituitary gland (Yamada et al., 2005). Knockdown of Atg9 in HEK293 cells was 
shown to inhibit protein degradation and LC3 lipidation, implicating Atg9 in 
autophagy in mammalian cells (Yamada et al., 2005; Young et al., 2006). 
Additionally, Atg9 knockout mice have also been generated which indicate that 
Atg9 is required immediately after birth for survival (Saitoh et al., 2009). In nutrient 
rich conditions, Atg9 has been found to localise with the trans-Golgi network (TGN) 
and endosomal proteins. During starvation, Atg9 co-localises with markers of 
autophagy, including LC3 on pre-autophagosomes and both LC3 and Rab7 on 
degradative autophagosomes (Young et al., 2006). The trafficking of Atg9 from the 
TGN to the PAS has been shown to require ULK1 and Atg13, although no direct 
interaction has been shown to occur between ULK1 and Atg9 (Young et al., 2006; 
Chan et al., 2009). So far, the only known interactors of Atg9 are p38IP (p38 MAP 
kinase interacting protein, also known as FAM48) and the recently characterised 
myosin II which acts as a motor protein in the trafficking of Atg9 to the PAS during 
starvation (Tang et al., 2011).  
I wanted to characterise the potential interaction of Atg9 with 14-3-3s and 
started by testing whether Atg9 also bound 14-3-3s in a phosphorylation-dependent 
manner. To test this, I stably expressed GFP-ATG9 in HEK293 cells and pulled-
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down ATG9 using the GFP-Trap® beads. Prior to elution, the immunoprecipitates 
were subjected to dephosphorylation using lambda phosphatase as described in 
section 2.2.11. Samples were run on a gel and analysed using different antibodies 
which are routinely used to study 14-3-3 interactions. Interestingly, like most 14-3-
3-binding proteins, Atg9 also bound 14-3-3s in a phosphorylation-dependent manner 
(Figure 4.18). Next, I wanted to identify the probable kinase(s) involved in Atg9 
phosphorylation and used the standard panel of kinase inhibitors and agonists to 
screen for this. The phorbol ester PMA, which activate PKC and the cAMP agonist 
forskolin appeared to enhance Atg9 binding to 14-3-3s as seen from the Far Western 
overlay (Figure 4.19). These observations were confirmed using the 14-3-3 motif 
antibody which specifically recognises proteins displaying the 14-3-3-binding 
consensus motif (Figure 4.19). Intriguingly, the co-immunoprecipitation of 
endogenous 14-3-3s seemed to be in contrast to the above observations. It is possible 
that the endogenous 14-3-3s are interacting with another protein or proteins that 
interact with Atg9, and whose binding to 14-3-3s is differentially regulated 
compared with Atg9. 
To further investigate the interaction of Atg9 with 14-3-3s, and any other 
proteins, I therefore used using mass spectrometry to identify proteins that were co-
immunoprecipitated with stably expressed GFP-Atg9 from HEK293 cells using the 
GFP-Trap® beads. The immunoprecipitates were separated on an SDS-PAGE gel, 
stained with Coomassie Blue and the bands cut out and digested with trypsin 
(Figure 4.20). The peptides were then analysed using mass spectrometry and 
interestingly 14-3-3s were found to co-purify with Atg9 (Figure 4.20). Additionally, 
mTOR, a key regulator of autophagy was also found to co-purify with Atg9. The 
complete list of potential Atg9-interactors identified is listed in Appendix VII. 
Unfortunately, due to lack of time I could not pursue this further but it would be 
very interesting to further investigate these findings.  
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Figure 4.18: Phosphorylation-dependent binding of ATG9 to 14-3-3s   
HEK293 stably expressing GFP-ATG9 under the tet inducible promoter were grown 
to 90% confluency and induced with tetracycline 24 h prior to lysis. Cells were 
lysed and proteins were pulled down using the GFP-Trap® beads from 3 mg of 
clarified cell lysate. The immunoprecipitates were treated with buffer only or with 
50 mU/ml lambda phosphatase in the presence of its cofactor manganese chloride 
for 30 min at 30°C as indicated. A negative control for the lambda phosphatase was 
prepared by chelating the manganese chloride to EDTA prior to incubation with the 
phosphatase. The immunoprecipitated proteins were separated by SDS-PAGE, 
transferred to nitrocellulose and probed for binding to 14-3-3s using a 14-3-3 
overlay assay (Far Western), a 14-3-3-binding motif recognising antibody and the 
phospho-AKT substrate(PAS) antibody. Antibodies recognising ATG9 and GFP 
were used as loading control. 
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Figure 4.19: 14-3-3 binding of GFP-ATG9 in response to various kinase 
inhibitors and agonists 
HEK293 cells were transiently transfected to express GFP-ATG9, and after 24 h 
cells were serum-starved for 6 h and pre-treated with the indicated kinase inhibitors 
before stimulation (30 min with 1 μM PI-103, 10 μM BI-D1870, 30 μM H-89). 
Stimulations were: 50 ng/ml IGF1 for 20 min; 100 ng/ml EGF for 15 min; 100 
ng/ml PMA for 30 min; 20 μM forskolin for 30 min; 10 μM A23187 for 20 min; 50 
μM A769662 for 1 h; 50 nM calyculin A for 5 min. GFP-ATG9 was isolated from 
2.5 mg lysate on GFP-Trap. Samples were separated by SDS-PAGE, transferred to 
nitrocellulose and probed with the indicated antibodies. Growth factor stimulated 
phosphorylation of PKB and Erk1/2, and phosphorylation of VASP by forskolin was 
tested by immunoblotting lysates (40 μg) with the indicated antibodies. SS-serum-
starved, FSK-forskolin, Cal A-calyculin A. 
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4.3 Crosstalk between the cAMP–PKA and PI-3 kinase–PKB signalling 
pathways 
Many 14-3-3-binding proteins have been found to be phosphorylated in 
response to different kinases. One finding is that several proteins that bind to 14-3-
3s in response to PKB also bind to 14-3-3s in response to cAMP-elevating agents, 
such as the adenylate cyclase activator forskolin, probably due to phosphorylation 
by PKA.  
Of the 310 proteins identified in this cAMP–PKA screen, 282 of these were 
found to be common with previous screens for IGF1–PKB signalling (Figure 4.21) 
(MacKintosh group, unpublished results). Because the quantitative data shows 
regulation in each screen under the different stimuli used, it does not necessarily 
mean that proteins identified in the PKA screen with high +/- forskolin ratios would 
necessarily have also have high +/- IGF1 ratios in the other screens. For instance, 
ZNRF2 (Figure 4.22) is slightly phosphorylated in response to IGF-1, but is more 
strongly regulated by other stimuli, and is also pulled down in IGF1/insulin screens 
done in the lab. Coiled-coil domain 6 (CCDC6) (Dubois et al., 2009), whose binding 
to 14-3-3s needs phosphorylation of Ser240 by PKB does not seem to be 
phosphorylated by any other kinases tested in vitro (Figure 4.22) (MacKintosh 
group, unpublished results). However, CCDC6, initially identified in the insulin–
PKB 14-3-3 screen by Dubois et al (2009), was also identified in this cAMP–PKA 
screen. However, side-by-side comparison with IGF1 and forskolin (Figure 4.22) 
shows that the 14-3-3 binding signal for CCDC6 from IGF1-stimulated cells is 
markedly greater than that from forskolin-stimulated cells.  These comparisons 
emphasise the importance of quantitative comparisons across the panel of stimuli 
and inhibitors to obtain the ‘signalling signature’ of each protein. 
Although most signalling pathways are now well understood, the crosstalk 
occurring among them is not significantly appreciated. Additionally, as discussed 
previously, it seems surprising to find that the PI 3-kinase–PKB pathways and 
cAMP–PKA pathways have so many substrates in common because in many 
different physiological contexts, these two signalling pathways have opposite 
outcomes (section 1.5.5.1). A trial experiment with suspension HEK293 cells 
stimulated with forskolin showed an increased phosphorylation of PKB (Ser473) in 
these cells; it turned out that the media for suspension cells had minimal amounts of 
insulin, which in the presence of forskolin, seemed to enhance PKB phosphorylation 
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at Ser473. I decided to emulate this using monolayer HEK293 cells: cells were 
serum starved for 10 h and stimulated with different concentrations of insulin. Some 
of the cells were inhibited with PI-103 prior to insulin stimulation. When used in 
conjunction with PKA inhibiting or activating reagents, insulin was added to the 
cells 30 min before addition of either H-89 or forskolin. Interestingly, these results 
showed that insulin-dependent phosphorylation of PKB at Ser473 is enhanced when 
the cells are co-stimulated with forskolin (Figure 4.23). At lower concentration (5 
nM), inhibiting PKA using H-89 prior to forskolin stimulation in insulin-activated 
cells seemed to reduce PKB phosphorylation; this inhibition did not occur at higher 
concentration of insulin (10 nM) (Figure 4.23). Conversely, inhibiting the PI 3-
kinase pathway with PI-103 seemed to abolish phosphorylation of VASP at Ser157 
when insulin (as low as 1 nM) was present in the culture medium (Figure 4.23).  
It has been observed that inhibiting one pathway could lead to activation of 
another pathway. For example, inhibition of mTORC1 has been shown to activate 
the MAPK pathway in a PI 3-kinase-dependent manner in human cancer cells 
(Carracedo et al., 2008). Also, inhibition of MEK leads to increased PKB 
phosphorylation in EGFR-driven cancer cells (Faber et al., 2009; Hoeflich et al., 
2009; Mirzoeva et al., 2009; Yoon et al., 2009; Turke et al., 2012).  To test this in 
the context of PKA and PKB signalling, I inhibited serum-starved HEK293 cells 
with H-89 prior to addition of insulin, and looked at PKB phosphorylation (Ser473). 
Interestingly, H-89 seemed to enhance PKB phosphorylation when used in 
combination with insulin in this experiment (Figure 4.24). This result seemed in 
contrast to a previous report showing that H-89 was also able to inhibit PKB among 
other members of the AGC kinases, other than PKA (Bain et al., 2007). 
Furthermore, there was no difference to the phosphorylation of VASP at Ser157, 
which we currently use as a marker of PKA activation.  These results suggest there 
might be more than a simple inhibition of PKA by H-89, and potentially there might 
exist crosstalks occurring between the cAMP–PKA and PI 3-kinase–PKB/Akt 
signalling pathways. Further experiments are required to understand the 
complexities in these two signalling pathways.        
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Figure 4.21: Comparison of the proteins identified in the cAMP–PKA-activated 
screen with overlapping members in the PI 3-kinase–PKB-activated 14-3-3-
phosphoproteomic screens 
The proteins which were pulled-down using 14-3-3-affinity chromatography from 
lysates of cells stimulated with forskolin in the presence or absence of H-89 are 
plotted on a scatter graph. All proteins were normalised to their counterparts in the 
serum-starved conditions to obtain a ratio of those proteins that were enriched in the 
treatment (in this case forskolin only or H-89 and forskolin) conditions. Proteins 
with at least two unique peptides were then selected from the list. All the proteins 
identified in this screen are represented by triangles; blue triangles represent proteins 
that were uniquely identified in this screen using inhibition with H-89 and forskolin 
as agonist; white triangles represent those proteins that are common with 
IGF1/insulin-stimulated screens; red triangles represent those proteins that are also 
in the ‘gold standard’ list. The correlation value, r, denotes the correlation between 
the two treatment conditions.  
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Figure 4.22: Signalling signatures of the 14-3-3-binding phosphoproteome 
A panel of kinase inhibitors and agonists are routinely used to screen potential 14-3-
3-binding candidates. Proteins were expressed as GFP-tagged forms, and cells 
treated as indicated, before GFP-Trap immunoprecipitation and 14-3-3 Far-Western 
overlay assays were performed. Many of the 14-3-3-binding proteins studied in the 
MacKintosh laboratory have been observed to bind to 14-3-3s in response to 
phosphorylation by more than one kinase. The data in this figure was contributed by 
various members of the group, and not shown are the loading controls for GFP, and 
also assays of lysates that showed the efficacy of the stimuli and inhibitors.  
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4.4 Discussion  
For a long time, the role of 14-3-3 binding to proteins was not very well 
understood; there are hundreds of 14-3-3-binding proteins in the cell and as such 
understanding the complete functional role of 14-3-3s is quite an overwhelming 
task. Generally, 14-3-3s interact with phosphorylated proteins, and these 
phosphorylations have been attributed to members of the AGC and CAMK kinase 
families. Defining the signalling pathways that create the 14-3-3-binding sites on 
target proteins thus becomes crucial for understanding the global regulation of 14-3-
3s and their functions. Towards this aim, we used 14-3-3-affinity capture and release 
together with proteomics to explore the subset of proteins that interact with 14-3-3s 
upon activation of the cAMP–PKA signalling pathway. Around 300 proteins were 
identified; the majority of these were also identified in previous screens targeting the 
PI 3-kinase–PKB pathway. A minority of proteins only identified in this cAMP–
PKA screen included a previously undescribed interaction between 14-3-3s and a 
main player in autophagy, ATG9.  
In this screen, we used the dimethyl labelling approached to label peptides 
with different stable isotopes so as to be able to quantify peptide enrichments upon 
various treatments (Boersema et al., 2008). This technique confers several 
advantages as it is relatively easy to label the digested peptides and cheap compared 
to other labelling methods including SILAC. A major hurdle in using the dimethyl 
labelling is that the data are indicative of ratios and not absolute stoichiometry of the 
different proteins. For instance, a protein whose stoichiometry of phosphorylation 
changed from 0.1% to 2% in response to forskolin would have a +/- forskolin ratio 
of 20 (provided the peptides were sufficiently abundant and gave clear mass 
spectrometry signals), whereas another phosphorylation stoichiometry changed from 
5% to 100% would also have a ratio score of 20 in this screen. However, the latter 
protein would be considered a more relevant target of the signalling pathway. For 
instance, PANK2 which has an enrichment value of 1.02 upon forskolin stimulation 
and 0.79 upon H-89 and forskolin treatment does not clearly define a change in 
treatment (these values are represented as treatment/serum starved ratios). However, 
a closer inspection of PANK2 shows a clear regulation upon forskolin treatment 
(Figure 4.22). A similar phenomenon is seen with EML3, where the enrichment 
values (a ratio of 0.75 with forskolin/serum starved compared to -3.27 H-89 and 
forskolin/serum starved stimulation) in the high-throughput screen do not provide a 
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clear picture as to the regulation of the protein as observed when EML3 is expressed 
and screened through the panel of kinase inhibitors and activators (Figure 4.13). 
The plot graph suggests there is some difference in the two treatments; however, the 
fact that most of the points still lie fairly close to the line suggest otherwise. 
Nevertheless, this can still be accounted for by the fact that the relative values 
denote enrichment, and not stoichiometry, as discussed above. For instance, we see 
no relative enrichment between the two treatments for the proteins FAM122A and 
PANK2 which, however, have been observed to bind 14-3-3s in response to 
forskolin and this binding is reduced upon pre-treatment with H-89 (Figure 4.22) 
(Stafford, Synowsky and MacKintosh, unpublished results). In retrospect, it may 
have been preferable to cut the SDS-gels into fewer sections before differential 
isotope dimethyl labelling, because proteins may be unequally distributed on either 
side of the cut point in the different lanes. Furthermore, in such a large pull-down, 
those proteins binding to 14-3-3s with higher affinity and/or higher abundance in the 
cell would also be more enriched in the eluates; consequently, these proteins would 
also be proportionately labelled and represented as a higher fraction. Nonetheless, 
these screens are still important as they paint a portrait of the different proteins 
involved in 14-3-3-binding and provide an insight into the 14-3-3-phosphoproteome 
upon stimulation with different inhibitors and agonists. The data obtained from such 
screens then provides enough information to look at individual proteins 
systematically, which then gives a clearer picture of their regulation by 14-3-3s.  
 The phosphopeptide enrichment, although informative proved to be limited 
in terms of phosphopeptide yield. Since we were trialling the technique, it was still 
successful in identifying some known 14-3-3-binding phosphosites from the 
forskolin-treated samples (Appendix VI). However, further analysis confirmed that 
the column:peptide ratio we used was not optimal, which resulted in those peptides 
in higher abundance and/or binding better to the columns being eluted and 
subsequently identified preferentially (data not shown). For instance, we see AS160 
with five phosphopeptides identified, one of which is the 14-3-3-binding Ser341 
residue, but the second 14-3-3-phosphosite on this protein, namely phosphoSer642, 
was not identified (Geraghty et al., 2007; Appendix VI). The results show that the 
technique could be very useful for identifying 14-3-3-phosphosites if the yield could 
be improved. For instance, the column:peptide ratio could be enhanced by loading 
more peptides onto the columns. Furthermore, since the titanium dioxide beads have 
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a high binding capacity, the volume of the beads in the column could be amended 
depending on the amount of peptides. Overall, such enrichments would help 
considerably in identifying those phosphosites involved in 14-3-3-binding that do 
not conform to the known mode I and mode II binding sites. The benefit of 
persisting with this approach is that it would generate a short list of 14-3-3-binding 
sites from multiple proteins in one go. In this way, a priority list of residues would 
be generated for further testing by the conventional techniques of testing how non-
phosphorylatable alanine mutations affect binding of the phosphoprotein to 14-3-3s.  
It is becoming increasingly clear that 14-3-3s are able to bind multiple 
members of a protein family and differentially regulate their functions in cells. One 
of the first examples we had in the laboratory was of TBC1D1 and AS160 
(TBC1D4). Both of these closely-related proteins were shown to bind 14-3-3s in 
response to various stimuli and effect different cellular outcomes (Geraghty et al., 
2007; Chen et al., 2011). Other families have since been studied and shown to bind 
14-3-3s in the MacKintosh laboratory, including the REEP family (Reep1-4), the 
srGAPs, FAM122(A-C) and the RING-type E3 ubiquitin ligases ZNRF1 and 
ZNRF2 (Hoxhaj et al., 2012; Tinti et al., 2012; Olsson, Stafford and MacKintosh, 
unpublished results). Interestingly, another such family of proteins was captured by 
14-3-3s in response to forskolin, namely the DENND4s. These are proteins 
containing the DENN domain and which have been shown to function as Rab GEFs. 
There are eight such DENN-domain protein families and they are highly conserved 
throughout eukaryotes. From my experiments, the DENND4 family members, 
namely DENND4A (IRLB), DENND4B and DENND4C all bind to 14-3-3s in a 
phosphorylation-dependent manner in response to various stimuli (Figures 4.8-
4.11). This is very interesting as although they share a high degree of similarity, 
these proteins bind 14-3-3s in response to different stimuli: DENND4A binds 14-3-
3s pre-dominantly upon stimulation with the phorbol ester PMA which activates the 
PKC–ERK–p90RSK pathway while DENND4C binds 14-3-3s upon forskolin 
stimulation which activates the cAMP–PKA pathway, and to a lesser extent upon 
PMA stimulation (Figures 4.9 and 4.11). This is reminiscent with our recently 
proposed ‘lynchpin’ hypothesis whereby in a 14-3-3-binding family, one 14-3-3-
binding site is conserved, enabling the second site to evolve and be regulated by 
different kinases on the other family members; for example, here the DENND4 
proteins binding 14-3-3s in response to PMA but also other kinase activators 
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(Dubois et al., 2009; Johnson et al., 2011; Tinti et al., 2012). In such cases then, 
even minor changes in the amino acid sequence of the protein would enable the 
protein to be phosphorylated in response to different kinases, allowing the protein to 
be differentially regulated in response to different stimuli. This in turn generates an 
overload of signalling inputs for a single protein, which can then be used to explain 
the evolution of different members of a protein family being regulated by different 
stimuli, as in the case of the DENND4 proteins. A recent paper from our laboratory 
studying another 14-3-3-binding family, the REEPs, proposed the ‘MIMO’ (multiple 
input multiple output) hypothesis to describe the evolution of different proteins in a 
family being regulated by different stimuli to bind 14-3-3s, resulting in different 
outcomes (Tinti et al., 2012).    
The differential regulation of DENND4 binding to 14-3-3s suggests that 
these proteins have evolved to perform different functions as a response to 14-3-3-
binding; nonetheless, due to their high similarity, these proteins could also perform 
redundant functions to compensate for each other. For instance, Sano et al (2011) 
reported that knockdown of DENND4C did not completely abolish its function as 
the Rab GEF for Rab10 in mediating GLUT4 trafficking since it is possible that 
DENND4A or DENND4B could compensate for the silencing of DENND4C. This 
is not very surprising since all three DENND4 proteins are highly similar in the 
amino terminal, including the DENN domain regions; they only differ at their 
carboxy ends. Indeed, DENND4A and DENND4B have also been reported to 
function as Rab GEF for Rab10 in vitro (Yoshimura et al., 2010). It would be very 
interesting to delve further into the interactions of these DENND4 proteins with 14-
3-3s. DENND4C was recently reported to be the Rab GEF for Rab10, which is 
involved in GLUT4 trafficking. Interestingly, our laboratory showed how TBC1D1 
and AS160 also controlled GLUT4 trafficking in response to various stimuli whose 
phosphorylation promoted 14-3-3-binding to TBC1D1 and AS160 (Chen et al., 
2011; Ducommun et al., 2012). While AS160 has been shown to be the Rab GAP 
for Rab10, DENND4C was recently shown to be the Rab GEF for Rab10; this is 
indeed very interesting as both these proteins controlling Rab10 function bind 14-3-
3s. It would be very exciting to see if DENND4C binding to 14-3-3s also masks its 
intricate Rab GEF activity, as is the case with AS160.  
 Another protein we found bound to 14-3-3s in response to elevated cAMP 
levels in the cells was EML3. This protein was initially identified in a previous 14-
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3-3 screen in this laboratory back in 2006 by Kathryn Geraghty (Geraghty and 
MacKintosh, unpublished results). EML3 belongs to the EMAP (Echinoderm 
Microtubule Associated Protein) proteins, which were initially identified in sea 
urchins as the most abundant microtubule-binding proteins (Suprenant et al., 2000). 
EML3 has a HELP domain, common to all EMAP proteins, which has been shown 
to be required for direct microtubule-binding (Pollman et al., 2006). Consequently, 
EML3 has been shown to associate with cytoplasmic microtubules during all stages 
of the cell-cycle and constantly shuttles between the cytoplasm and the nuclei during 
interphase (Tegha-Dungu et al., 2008). Tegha-Dungu and colleagues (2008) went on 
to show how the presence of EML3 was critical for the correct alignment of 
chromosomes during metaphase (Tegha-Dungu et al., 2008). Furthermore, EML3 
also has seven WD40 repeats in its C-terminal, which bind to p32 and RanBP5 
(Figure 4.17).  
p32 has been described as a ‘moonlighting’ protein of multiple functions 
localising to various cellular compartments, including the nucleus, mitochondria and 
cytoplasm. p32 was originally identified through its co-purification with the splicing 
factor SF-2  and has a mitochondrial localisation signal (Krainer et al., 1991; Muta 
et al., 1997). The various reports on p32 only intensified the curiosity on this protein 
since it has been shown to be involved in oxidative phosphorylation, translation of 
mitochondria-encoded proteins and replication of viruses including HIV (Muta et 
al., 1997; Jiang et al., 1999; Zheng et al., 2003; Fogal et al., 2010).  Knocking down 
p32 in cancer cells promoted a shift from oxidative phosphorylation to glycolysis 
(Fogal et al., 2010). A potential role of p32 in the nucleo-cytoplasmic shuttling of 
proteins has also been proposed following observations that p32 binds to the 
adenovirus core protein V soon after viral infection with the result being both 
proteins then move into the nucleus with the help of dynein and microtubules 
(Matthews and Russell, 1998; Suomalainen et al., 1999; Leopold et al., 2000). In 
addition, the phosphorylation of p32 by Erk1 was shown to be required for the 
translocation of p32 into the nucleus (Majumdar et al., 2002).  
RanBP5, on the other hand, is an importin-beta family member, which was 
shown to be involved in the nuclear import of ribosomal proteins (Jäkel and Görlich, 
1998). This raises the possibility that EML3 may act together with RanBP5 in the 
nuclear trafficking of p32. Interestingly, EML3 binds to 14-3-3s at its N-terminal 
end through phosphorylated Ser127 and Ser147 residues (Figure 4.15). We still do 
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not know the effect of 14-3-3-binding to EML3; since these residues are not within 
the functional HELP domain, it would be hard to speculate as to whether 14-3-3-
binding to EML3 might affect its association with microtubules. Deletion of the 
HELP domain and WD40 repeats showed that EML3 failed to colocalise with 
microtubules during interphase and mitosis; in contrast, a truncated version of 
EML3 with the WD40 repeats deleted still colocalised with microtubules at 
interphase but the protein failed to accumulate at the mitotic spindles (Tegha-Dungu 
et al., 2008). In addition, knocking down EML3 resulted in the inhibition of cellular 
proliferation with cells accumulating during metaphase, inferring a role for EML3 at 
the spindle assembly checkpoint (Tegha-Dungu et al., 2008). These raise interesting 
questions about the possible function(s) of EML3-binding to 14-3-3s, p32 and 
RanBP5. It would be interesting to further analyse these interactions and to check if 
binding to 14-3-3s somehow prevented EML3 from accumulating in interphase 
nuclei and/or with spindle microtubules during mitosis (Tegha-Dughu et al., 2008). 
On the other hand, I showed that p32 and RanBP5 binding to EML3 do not depend 
on its interaction with 14-3-3s (Figure 4.15). It would be very exciting to know 
whether, in contrast, p32 and RanBP5 somehow altered EML3 binding to 14-3-3s. 
Also, it would be interesting to know whether viral replication was affected by 
knocking down EML3 and/or RanBP5.  
 A novel role of 14-3-3s in autophagy is becoming apparent as these docking 
proteins are shown to bind ATG9 (Figure 4.18), ULK1, Beclin-1 and Vps34, which 
are all key players in autophagy (Wang et al., 2010; Woo et al., 2010; Bach et al., 
2011; Pozuelo-Rubio, 2011; Mack et al., 2012). The Atg1 kinase homologues ULK1 
and ULK2 have been implicated in starvation-induced autophagy in mammals 
(Kuruyanagi et al., 1998; Chan et al., 2007). ULK1 forms a stable complex with 
mAtg13 and FIP200, and this complex is thought to be important in the regulation of 
autophagy in an mTOR-dependent manner (Jung et al., 2009; Hosokawa et al., 
2009). Phosphorylation of ULK1 by AMPK on Ser555 in vitro was shown to be 
critical for 14-3-3-binding (Bach et al., 2011); interestingly, a second site 
phosphorylated by PKB/Akt was also identified (Ser774) on ULK1 but whether this 
was the second site leading to 14-3-3-binding was not clear (Bach et al., 2011). 
Since mTORC1 has been shown to phosphorylate and inhibit ULK1-kinase activity, 
it has been proposed that activation of AMPK by AICAR blocks mTORC1 
inhibition on ULK1, thereby enabling the initiation of autophagy (Ganley et al., 
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2009; Jung et al., 2009; Hosokowa et al., 2009). Furthermore, AICAR-induced 
phosphorylation of Raptor has also been reported leading to 14-3-3-binding to 
Raptor and this in turn results in mTORC1 inhibition (Gwinn et al., 2008; Lee et al., 
2010). Although the precise outcome of 14-3-3-binding to ULK1 has not yet been 
elucidated, the fact that 14-3-3s are involved at multiple steps in the autophagy 
process hints at an important role.  
Another autophagic complex described to have a high binding to 14-3-3s 
involves the Beclin 1/hVps34 proteins. Beclin 1 was first identified as an interacting 
partner for the anti-apoptotic protein Bcl-2 and later shown to be a haploinsufficient 
tumour-suppressor gene with reduced expression in different cancers (Liang et al., 
1998; Aita et al., 1999; Yue et al., 2003; Funderberk et al., 2010). It is the 
mammalian orthologue of yeast Atg6 and has been shown to positively regulate 
autophagy (Liang et al., 1999). Depletion of 14-3-3τ expression has been shown to 
result in reduced Beclin 1 expression, affecting autophagy induction during serum 
starvation and rapamycin treatment (Wang et al., 2010). However, although Beclin 1 
expression was shown to be regulated by 14-3-3τ, no direct interaction between 
these two proteins was shown to occur; interestingly, Beclin 1 was also pulled down 
in my 14-3-3-screen (Appendix V) but a closer look at the amino acid sequence of 
the protein did not show any potential 14-3-3-binding sites. Interestingly however, 
Beclin 1 also forms a complex with hVps34, a vacuolar sorting protein involved in 
autophagosome formation (Zeng et al., 2006). Interestingly, 14-3-3ζ was shown to 
bind and inhibit hVps34 activity upon PMA stimulation, involving phosphorylation 
of Thr197 and Ser212 (Pozuelo-Rubio, 2011). This binding reduced the lipid kinase 
activity of hVps34, and this lipid kinase activity is essential during autophagy 
initiation. Remarkably, upon starvation, 14-3-3 ζ was shown to dissociate from 
hVps34, leading to activation of hVps34 and autophagy (Pozuelo-Rubio, 2011). 
These autophagic proteins are in agreement with the emerging idea that sets of 14-3-
3-binding protein families have co-evolved in the vertebrates, which regulate related 
functions, in this case autophagy. Similarly, sets of 14-3-3-binding proteins have 
been discovered in cellular metabolism and neurological pathologies (Tinti et al., 
2012).  
Although it is clear from our experiments that Atg9 also binds to 14-3-3s, 
much work has to be done to elucidate the result of such binding. Since most 14-3-3-
binding promotes survival pathways, it would be very exciting to see in what way 
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14-3-3-binding to Atg9 would affect autophagy. Furthermore, since 14-3-3s 
generally bind to their target through dually-phosphorylated serine and/or threonine 
residues, it would be crucial to find these binding sites. A manual analysis of the 
Atg9 amino acid sequence has suggested Ser761 as a potential 14-3-3-binding site 
but further analyses are required to test this. Data from the phosphopeptide 
enrichment analysis also has potential candidate sites (Appendix VI). Altogether, 
these results show promising new roles for 14-3-3s in the regulation of mammalian 
autophagy.    
Many proteins were identified in the two screens performed to capture 
targets that bind to 14-3-3s downstream of PI 3-kinase–PKB and of cAMP–PKA 
signalling, respectively.  However, determining the relative degree of regulation of 
any given protein by each pathway will require further biochemical analysis. One 
reason is that the MS data only report on ratios of protein abundances in two 
samples, not the absolute amounts. Therefore, if a stimulus increases the proportion 
of a protein binding to 14-3-3s from 1% to 5%, the ratio would be the same as for a 
protein that changed from 20% to 100% binding. Therefore, the MS experiments 
report on trends, but not stoichiometry. Additionally, a few proteins being studied in 
the MacKintosh laboratory are targeted by different kinases in different signalling 
pathways. Some proteins, e.g. PANK2, FAM122A, which are predominantly 
activated by forskolin (Figure 4.22) do not seem to have high ratios in this screen. 
This could simply be that although they are identified in the pull-down, the amount 
of the protein being pulled down is low relative to its 14-3-3-binding affinity.  
Another possibility for such observations in this pull down is the number of 
proteins competitively binding to 14-3-3s: those that bind best are quantified with 
higher ratios. When the protein in question is GFP-tagged and pulled down, a clearer 
regulation is observed with respect to 14-3-3 binding. For example, 
immunoprecipitated GFP-tagged PANK2 and FAM122A (C MacKintosh group, 
unpublished data) can be seen to be predominantly phosphorylated by forskolin in 
Figure 4.22 but the quantified data from the screen does not provide such a clear 
picture.  
In addition, there could also potentially be an overlap between PKA and 
PKB consensus phosphorylation motifs with each other, in addition to 14-3-3-
binding consensus motifs. For instance, the minimal motif required by PKA to 
phosphorylate its substrate is RRXS/T while PKB prefers the RXRXXS/T motif; 14-
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3-3s on the other hand have two consensus motifs mode I RSX(pS)XP and mode II 
RX(F/Y)X(pS)XP (Chapter 1). As can be seen, it would be very easy for 14-3-3-
binding protein to have a large overlap with PKB-phosphorylated substrates. This 
might in part explain why such a large proportion of proteins identified in the screen 
in this chapter have also been seen in previous IGF1/insulin–PI 3-kinase screens in 
the laboratory. Furthermore, since the consensus phosphorylation motif of PKA is so 
short, it also minimally overlaps with the PKB consensus motif, which means that 
motifs that satisfy the specificity requirements for both kinases are possible. For 
instance, ZNRF2 which was identified by Dubois et al. (2009), in an insulin-
stimulated 14-3-3-screen, has been shown to be regulated not by the insulin–PI 3-
kinase pathway but rather by the cAMP–PKA and PKC–Erk pathways (Hoxhaj et 
al., 2012). Hence, although these large proteomics screen are immensely valuable in 
generating a wealth of data, biochemical analysis of individual proteins are crucial 
as they provide a clearer picture of the regulation of the protein in question.     
Furthermore, another possibility for the observation of multiple proteins 
being highly enriched upon combined H-89 and forskolin treatment may be 
suggestive of a cAMP-dependent but PKA-independent event. Using fluorescence-
based reporters, Aye-Han and colleagues (2012) showed that treating cells with H-
89 and forskolin inhibits PKA but still triggers activation of cAMP. Thus, while 
using H-89 in combination with forskolin inhibits PKA, cAMP-mediated PKA-
independent events can still occur, through ERK, PKB or Epac for example 
(Chapter 1).  Moreover, H-89 has also been shown to inhibit other kinases in the 
AGC family including PKB, AMPK, MSK1, S6K1, PKD1, RSK1 and RSK2 among 
others (Bain et al., 2007). Nonetheless, in most cases a clear signature of the protein 
is observed when comparing its 14-3-3-binding occurring upon FSK stimulation, 
and which is then subsequently lost upon pre-treatment with H-89.  
Overall, my 14-3-3 screen generated a high number of potential 14-3-3-
binding candidates. The most interesting targets now need to be biochemically 
validated as 14-3-3-interactors and the functionality of this binding must be 
determined, for example with the DENND4 proteins and ATG9. 
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5.1 General conclusions 
 The work presented in this thesis explored the regulation of two major 
classes of proteins which regulate serine/threonine-phosphorylated proteins, namely 
protein phosphatases of the PPP family and 14-3-3s, upon activation of the cAMP-
PKA pathway. Reversible protein phosphorylation occurs in up to a third of all 
eukaryotic proteins (Bollen and Beullens, 2002). Remarkably, serine and threonine 
phosphorylations account for over 90% of all phosphorylated amino acids (Olsen et 
al., 2006). Protein phosphatases regulate proteins through dephosphorylation; on the 
other hand, phosphorylation of serine/threonine residues promote 14-3-3-binding to 
target proteins. Although not common, a few proteins are known to bind both 
protein phosphatases and 14-3-3s. For instance, MYPT1 was shown to be in a 
complex with PP1 and 14-3-3s in the regulation of cell adhesion (Zagorska et al., 
2010). Also FAM122A, initially identified as a 14-3-3-binding protein in our 
laboratory has also been observed to interact with PP2A, and the phosphatase and 
14-3-3s can exist together in a complex with FAM122A (Stafford, Murugesan and 
MacKintosh, unpublished results). Since we could not find any proteins whose 
interaction with protein phosphatases was clearly regulated by cAMP elevating 
agents from the phosphatase screens in Chapter 3, I decided to focus more on the 
14-3-3-phosphoproteomics studies.  
One of the major advantages of doing a high-throughput screen is the amount 
of information generated at one go; consequently it becomes a mammoth task to 
analyse all the individual proteins in such a screen. Nonetheless, these large-scale 
14-3-3-binding proteomic studies suggest that the 14-3-3-phosphoproteome is much 
larger than what was originally thought and no one screen is near saturation since 
new binding candidates are constantly being reported. Based on the known 14-3-3-
binding consensus motifs, members of the CAMK and AGC kinases are most likely 
to phosphorylate 14-3-3-binding targets; however, studying the full plethora of 14-3-
3-binding proteins is somewhat restricted to those kinases for which there are good 
agonists available. In addition, most 14-3-3-binding proteins have two tandemly 
phosphorylated sites generated by one or more kinases; binding to 14-3-3s in most 
cases results in regulation of the protein. Since each kinase on one of the two sites 
can have a different outcome, this generates a very tight regulatory control of the 
protein upon 14-3-3-binding.  Studies from our laboratory and others have been 
quite successful in identifying multiple proteins binding to 14-3-3s in response to 
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activation of different signalling pathways, including the IGF1/insulin–PI 3-kinase–
PKB, PKC–Erk–p90RSK and cAMP–PKA pathways. Extensive bioinformatical 
analyses conducted in our laboratory has generated an ‘overview’ of the 14-3-3-
interactome based on our own 14-3-3-screens and reported 14-3-3-interactions in the 
literature (Johnson et al., 2011; Tinti et al., 2012). Proteins that were biochemically 
validated, with their phosphosites elucidated were collected from the literature and 
labelled as ‘golden standards’ (Johnson et al., 2011). Furthermore, it had also been 
discovered that the lists of 14-3-3-binding phosphoproteins, both ‘golden standards’ 
and those identified in proteomics screens, are highly enriched in members of 
protein families of two to four members, whose origins were traced to the same 
point in evolution – two rounds of whole genome duplication at the origins of the 
vertebrates. Moreover, in several protein families, it was found most, if not all, 
members of a given protein family could bind to 14-3-3s. However, many of these 
protein members were also seen to be differentially regulated upon different stimuli, 
for example TBC1D1 and AS160, the REEP family and as shown in this thesis, the 
DENND4 family (Geraghty et al., 2007; Tinti et al., 2012). This is exciting because 
it means that the signal multiplexing properties of these families, with different 
family member being regulated by 14-3-3s in response to different signalling 
pathways, means that such signalling complexity may have been fundamental to the 
evolution of the vertebrate animals, including humans.  
Recent papers on whole genome duplications in vertebrates coupled to the 
recent genomic sequencing of amphioxus have helped our understanding of this 
observation. Around 500 million years ago, the vertebrate genome arose from two 
rounds of whole genome duplications (2R-WGD), from which several 2R-
ohnologue protein families then emerged (Huminiecki et al., 2010; Makino et al., 
2010). 2R-ohnologues have been described as those protein-coding genes, which 
were duplicated during the 2R-WGD. Amphioxus (also known as Branchiostoma 
and lancelet) is an invertebrate that is the most basal, least-derived member of the 
chordates. The amphioxus genome has shown that its ancestors did not go through 
the 2R-WGD, which means that the amphioxus has one ‘ancestral’ protein for every 
human 2R-ohnologue family (Putnam et al., 2008; Tinti et al., 2012). Most of the 
14-3-3-binding families in humans seem to have evolved from the 2R-WGD event. 
In these families, one or more members have a common 14-3-3-phosphosite, while 
the other site varies and could be regulated by different stimuli to effect different 
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functions, giving rise to the ‘lynchpin’ hypothesis (Tinti et al., 2012). The regulation 
of proteins in 2R-ohnologue families through multiple kinases generates a multiplex 
signalling system similar to the multiple input multiple output system (MIMO) 
(Tinti et al., 2012). 14-3-3-binding proteins are phosphorylated by kinases involved 
in different signalling pathways which regulate growth factor and developmental 
signalling, membrane trafficking and metabolism, deregulation of any component in 
these signalling pathways could result in diseases. A notable 91% association has 
been reported between 14-3-3-binding proteins (gold and silver standard proteins) 
and diseases including various cancers, diabetes and neurological disorders (Tinti et 
al., 2012). Understanding the intricate regulation of 14-3-3-binding proteins which 
are impaired in these signalling pathways leading to pathological conditions is thus 
very important.   
 
5.2 Future perspectives: 
Following up on proteins such as the DENND4s would be helpful towards 
understanding GLUT4 trafficking. Phosphorylation of AS160 by PKB at Ser341 and 
Thr642 upon insulin stimulation promotes 14-3-3 binding; this binding is thought to 
inhibit the RabGAP domain of AS160, so that it is no longer able to hydrolyse the 
GTP from Rab10 to control GLUT4 trafficking. The DENND4C protein has been 
reported to be a GEF that acts in GLUT4 trafficking (Sano et al., 2011). A key 
question arising from these studies is whether 14-3-3s somehow alter the GEF 
activity of the DENND4 proteins towards Rab10, to complement and coordinate 
with the regulation of AS160 and TBC1D1 by 14-3-3. For instance, does 14-3-3-
binding to DENND4C mask the GEF (DENN) domain of the protein, such that it 
can no longer promote Rab10 activity? In order to further investigate this, it would 
be critical to first identify the sites of phosphorylation on DENND4C that mediate 
14-3-3-binding. For example, since we now know DENND4C binding to 14-3-3s is 
promoted upon forskolin stimulation, PKA is the most likely kinase involved in 
phosphorylating this protein (Figure 4.11). In vitro assays could be performed to 
further test PKA as the upstream kinase for DENND4C phosphorylation. The 
regulation of Rab10 could potentially be another example of antagonising actions of 
PKA and PKB in the control of GLUT4 trafficking by promoting 14-3-3-binding to 
DENND4C and AS160 respectively. For instance, if PKA-induced 14-3-3-binding 
on DENND4C were to reduce/mask the GEF activity of DENND4C, this would 
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result in an overall decrease in GLUT4 trafficking by decreasing the GTP loading of 
the Rab proteins.  On the other hand, if PKA-mediated 14-3-3 binding were to 
activate the GEF activity of DENND4C, this would amplify the effects of inhibiting 
AS160 and enhance the GTP loading of the Rab proteins. Measuring GLUT4 levels 
following forskolin stimulation in DENND4C-expressing cells should potentially 
provide clues as to whether 14-3-3-binding alters the RabGEF activity of 
DENND4C. However, this would have to be performed in cells such as adipocytes 
that use GLUT4 for glucose import.  
The next experimental stage is prepared, as the potential 14-3-3-binding sites 
in our DENND4 constructs have been mutated to generate non-phosphorylatable 
alanine residues: biochemical analyses of these mutants should be fairly quick and 
provide clues into the probable 14-3-3-binding phosphosites of these DENND4 
proteins. Phosphomapping analyses of the protein could also be explored to find 
phosphorylated amino acids on the protein. Following on then, it would be very 
interesting to see whether abolishing the 14-3-3-binding sites on DENND4C would 
restore GLUT4 trafficking, even after forskolin stimulation.  
Another membrane trafficking protein that I identified and studied was Atg9. 
The increasing evidence of autophagy-deregulation in diseased states makes it 
imperative to fully understand the proteins regulating this process. In light of the 
recent evidence suggesting Atg9-containing vesicles form the autophagosome 
during autophagy initiation (Yamamoto et al., 2012), it would be exciting to 
understand how 14-3-3-binding to this autophagic protein might regulate its 
function. As a first step towards understanding 14-3-3-binding, it would be 
important to find the phosphosites of Atg9 which mediate 14-3-3-binding. As I 
mentioned in Chapter 4, a manual scan of the Atg9 amino acid sequence suggested 
Ser761 as a potential candidate for 14-3-3-binding. So far, I have been unable to find 
other possible candidate phosphosites, but doing an experimental phosphomapping 
analysis of Atg9 should help in identifying other phosphorylated residues. 
Furthermore, it would be interesting to explore the effects of 14-3-3-binding to Atg9 
with respect to autophagy. For instance, would 14-3-3-binding enhance or reduce 
Atg9 function in the initiation of autophagy? Stimulating cells with forskolin upon 
amino acid starvation and immunoblotting for markers of autophagy Rab7 and LC-3 
should provide insights into whether 14-3-3-binding alters Atg9 activity during 
autophagy. The known direct interactors of Atg9 thus far are quite restricted to 
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FAM48 and myosin II. A number of potential Atg9-interactors have been identified 
from my GFP-ATG9 gel using mass spectrometry data (Appendix VII). Validating 
some of these interactors would provide crucial understanding into autophagy. 14-3-
3s and mTOR (mammalian target of rapamycin) are both implicated in autophagy 
through their interactions with other autophagic proteins such as Beclin-1, Vps34 
and ULK1 (discussed in Chapter 4). Since mTOR has also been identified from the 
Coomassie gel of GFP-Atg9 pull down (Figure 4.20), it would be exciting to see 
whether mTOR is able to interact with Atg9 directly. mTOR has been implicated in 
the negative control of autophagy through its interactions with ULK1 and AMPK 
(Kim et al., 2011; Löffler et al., 2011). Notably, ULK1 has also been reported to 
bind 14-3-3s upon AMPK phosphorylation and although the immediate effect of this 
binding is still unknown, some AMPK-phosphorylation sites on ULK1 have recently 
been reported to be crucial in regulating Atg9 trafficking (Mack et al., 2012). 
Furthermore, Rab7, an early marker of autophagy was also co-immunoprecipitated 
with Atg9 along with a number of other Ras-related Rab proteins, although no 
previous interaction of Atg9 with Rab7 has been reported (Appendix VII). Proteins 
in nutrient sensing and membrane trafficking were identified in the Atg9 
immunoprecipitates, together with 14-3-3s and knowing whether these proteins 
really interact with Atg9 would very exciting and further help our understanding of 
the regulation of autophagy.  
Overall therefore, the data presented in my thesis has explored another 
pathway in 14-3-3-signalling, namely cAMP—PKA signalling, that involves several 
14-3-3-binding proteins and many potential candidates have emerged. I have shown 
how binding of the DENND4 proteins to 14-3-3s are regulated by different kinases, 
in agreement with the 2R-ohnologue proteins, the ‘lynchpin’ and ‘MIMO’ 
hypotheses. In summary, my studies have opened new avenues of 14-3-3 research 
that will hopefully be further explored in our laboratory and others.      
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Appendix I 
Proteins that were purified by microcystin-Sepharose affinity chromatography from cell lysates of HEK293 cells stimulated with or without 
forskolin and in the presence or absence of H-89. Peptides were extracted from the SDS gel (Figure 3.1) and identified from the SwissProt 
database (accession number; description) and their Mascot score (score) determined. The number of unique peptides (pep) identified in each 
protein is also listed along with the gel band (band) in which they were identified. Peptides were quantitatively measured using the MS Quant 
software following the dimethyl labelling. The ratios of the different treatment conditions are listed in the table below (SS-serum starved, Fsk-
forskolin, H-89+ Fsk-H-89 and forskolin).  
    
Accession number 
Mass 
[Da] Pep Score Description 
 
SS/SS  Fsk/SS 
 H-
89+Fsk/SS Band 
sp|P26368|U2AF2_HUMAN 53809 3 142 Splicing factor U2AF 65 kDa subunit U2AF2  1 17.391 0.404 7 
sp|P08670|VIME_HUMAN 53676 29 1466 Vimentin  VIM  1 16.113 5.456 8 
sp|Q99729|ROAA_HUMAN 36316 2 85 Heterogeneous nuclear ribonucleoprotein A/B HNRNPAB  1 14.535 0.082 11 
sp|P51148|RAB5C_HUMAN 23696 3 215 Ras-related protein Rab-5C  RAB5C        1 12.855 0.668 14 
sp|P12236|ADT3_HUMAN 33073 8 512 ADP/ATP translocase 3  SLC25A6        1 8.982 5.654 13 
sp|Q9Y277|VDAC3_HUMAN 30981 4 188 Voltage-dependent anion-selective channel protein 3  VDAC3  1 8.655 1.945 13 
sp|P83916|CBX1_HUMAN 21519 2 88 Chromobox protein homolog 1  CBX1        1 6.227 0.861 13 
sp|Q15233|NONO_HUMAN 54311 2 72 Non-POU domain-containing octamer-binding protein  NONO  1 5.989 0.905 7 
sp|P22087|FBRL_HUMAN 33877 3 103 rRNA 2'-O-methyltransferase fibrillarin FBL  1 5.816 0.949 12 
sp|Q9Y5B9|SP16H_HUMAN 120409 17 793 FACT complex subunit SPT16  SUPT16H        1 5.623 0.612 2 
sp|Q9NXA8|SIRT5_HUMAN 34543 6 360 NAD-dependent deacetylase sirtuin-5 SIRT5  1 5.135 4.024 13 
sp|P07196|NFL_HUMAN 61536 25 1311 Neurofilament light polypeptide  NEFL        1 4.868 4.707 6 
sp|P36542|ATPG_HUMAN 33032 4 212 ATP synthase subunit gamma, mitochondrial ATP5C1  1 4.766 3.32 13 
sp|P06899|H2B1J_HUMAN 13896 2 68 Histone H2B type 1-J  HIST1H2BJ        1 4.056 0.658 14 
sp|P50991|TCPD_HUMAN 58401 3 193 T-complex protein 1 subunit delta  CCT4        1 3.898 0.527 7 
sp|P10412|H14_HUMAN 21852 2 120 Histone H1.4  HIST1H1E    1 3.833 4.164 13 
sp|Q13409|DC1I2_HUMAN 71811 5 325 Cytoplasmic dynein 1 intermediate chain 2 DYNC1I2  1 3.694 4.668 6 
sp|Q16629|SFRS7_HUMAN 27578 3 110 Splicing factor, arginine/serine-rich 7 SFRS7  1 3.628 0.476 12 
sp|Q6NUP7|PP4R4_HUMAN 100472 7 355 Serine/threonine-protein phosphatase 4 regulatory subunit 4 PPP4R4  1 3.595 2.389 4 
sp|P50990|TCPQ_HUMAN 60153 4 188 T-complex protein 1 subunit theta  CCT8        1 3.581 0.443 7 
sp|Q5QNW6|H2B2F_HUMAN 13912 2 120 Histone H2B type 2-F  HIST2H2BF        1 3.465 0.641 13 
sp|P04844|RPN2_HUMAN 69355 3 157 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2  RPN2    1 3.306 1.406 7 
sp|Q71DI3|H32_HUMAN 15436 5 171 Histone H3.2  HIST2H3A    1 3.107 0.708 14 
sp|Q99623|PHB2_HUMAN 33276 13 793 Prohibitin-2  PHB2    1 3.095 3.024 12 
sp|P62195|PRS8_HUMAN 45768 2 114 26S protease regulatory subunit 8  PSMC5        1 3.095 1.733 10 
sp|P25705|ATPA_HUMAN 59828 12 789 ATP synthase subunit alpha, mitochondrial ATP5A1  1 3.069 1.401 8 
sp|O14579|COPE_HUMAN 34688 5 257 Coatomer subunit epsilon  COPE        1 2.947 1.882 12 
sp|Q13625|ASPP2_HUMAN 126222 15 669 Apoptosis-stimulating of p53 protein 2 TP53BP2  1 2.942 3.193 2 
sp|P21796|VDAC1_HUMAN 30868 9 456 Voltage-dependent anion-selective channel protein 1 VDAC1  1 2.901 0.884 12 
sp|Q13185|CBX3_HUMAN 20969 4 157 Chromobox protein homolog 3  CBX3        1 2.89 0.312 14 
sp|P16615|AT2A2_HUMAN 116336 7 285 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  ATP2A2  1 2.88 2.178 4 
sp|P41252|SYIC_HUMAN 145718 12 549 Isoleucyl-tRNA synthetase, cytoplasmic IARS  1 2.859 2.17 2 
sp|Q8NB46|ANR52_HUMAN 116829 18 1039 
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C  
ANKRD52  1 2.749 4.326 3 
sp|O96008|TOM40_HUMAN 38211 2 149 Mitochondrial import receptor subunit TOM40 homolog  TOMM40  1 2.732 1.396 11 
sp|Q9P2J5|SYLC_HUMAN 135577 8 327 Leucyl-tRNA synthetase, cytoplasmic  LARS        1 2.724 2.07 2 
sp|P08865|RSSA_HUMAN 32947 3 222 40S ribosomal protein SA  RPSA        1 2.71 1.847 12 
sp|P15927|RFA2_HUMAN 29342 2 104 Replication protein A 32 kDa subunit RPA2  1 2.634 1.908 13 
sp|P06748|NPM_HUMAN 32726 3 98 Nucleophosmin  NPM1    1 2.583 0.993 12 
sp|Q08945|SSRP1_HUMAN 81367 4 155 FACT complex subunit SSRP1  SSRP1        1 2.574 0.303 5 
sp|Q9BQE3|TBA1C_HUMAN 50548 5 290 Tubulin alpha-1C chain  TUBA1C        1 2.568 0.709 8 
sp|P35637|FUS_HUMAN 53622 9 420 RNA-binding protein FUS  FUS        1 2.488 2.827 6 
sp|P55060|XPO2_HUMAN 111145 9 469 Exportin-2  CSE1L    1 2.441 2.822 4 
sp|P45880|VDAC2_HUMAN 32060 8 428 Voltage-dependent anion-selective channel protein 2  VDAC2  1 2.429 0.808 12 
sp|Q14697|GANAB_HUMAN 107263 4 134 Neutral alpha-glucosidase AB  GANAB        1 2.34 1.749 3 
sp|P53621|COPA_HUMAN 139797 11 559 Coatomer subunit alpha  COPA        1 2.31 2.5 2 
sp|O43175|SERA_HUMAN 57356 13 825 D-3-phosphoglycerate dehydrogenase  PHGDH        1 2.26 1.507 8 
sp|Q99460|PSMD1_HUMAN 106795 6 364 26S proteasome non-ATPase regulatory subunit 1  PSMD1  1 2.231 0.997 3 
sp|P62136|PP1A_HUMAN 38229 16 992 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  PPP1CA  1 2.221 1.811 12 
sp|Q12904|AIMP1_HUMAN 34616 4 224 Aminoacyl tRNA synthase complex-interacting multifunctional       protein 1  AIMP1  1 2.212 0.765 11 
sp|P20340|RAB6A_HUMAN 23692 3 166 Ras-related protein Rab-6A  RAB6A        1 2.207 1.243 14 
sp|P40227|TCPZ_HUMAN 58444 6 280 T-complex protein 1 subunit zeta  CCT6A        1 2.159 0.545 7 
sp|P36957|ODO2_HUMAN 49041 2 85 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial DLST  1 2.146 1.019 9 
sp|Q9Y375|CIA30_HUMAN 37797 2 122 Complex I intermediate-associated protein 30, mitochondrial NDUFAF1  1 2.114 0.861 12 
sp|O94826|TOM70_HUMAN 68096 3 125 Mitochondrial import receptor subunit TOM70 TOMM70A  1 2.109 1.399 6 
sp|Q96A33|CCD47_HUMAN 56123 2 84 Coiled-coil domain-containing protein 47 CCDC47  1 2.097 0.52 7 
sp|P10515|ODP2_HUMAN 69466 3 133 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  DLAT        1 2.095 1.051 6 
sp|P05023|AT1A1_HUMAN 114135 7 387 Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1  1 2.07 1.66 4 
sp|O15084|ANR28_HUMAN 118237 20 1248 
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A  
ANKRD28  1 2.052 0.744 3 
sp|Q8N766|K0090_HUMAN 112145 3 158 Uncharacterized protein KIAA0090 KIAA0090  1 2.03 1.318 3 
sp|P62140|PP1B_HUMAN 37961 6 315 Serine/threonine-protein phosphatase PP1-beta catalytic       subunit  PPP1CB  1 2.028 1.824 12 
sp|P20700|LMNB1_HUMAN 66653 10 437 Lamin-B1  LMNB1    1 1.983 2.441 6 
sp|P67775|PP2AA_HUMAN 36142 14 924 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform  PPP2CA  1 1.972 4.391 12 
sp|P35606|COPB2_HUMAN 103278 9 320 Coatomer subunit beta'  COPB2        1 1.962 2.275 4 
sp|Q8TF05|PP4R1_HUMAN 108361 27 1394 Serine/threonine-protein phosphatase 4 regulatory subunit 1 PPP4R1  1 1.961 3.109 3 
sp|O00743|PPP6_HUMAN 35806 12 715 Serine/threonine-protein phosphatase 6 catalytic subunit PPP6C  1 1.951 2.048 12 
sp|Q86VP6|CAND1_HUMAN 137999 14 524 Cullin-associated NEDD8-dissociated protein 1  CAND1  1 1.935 1.708 2 
sp|P60510|PP4C_HUMAN 35628 13 743 Serine/threonine-protein phosphatase 4 catalytic subunit PPP4C  1 1.926 2.066 12 
sp|P63151|2ABA_HUMAN 52173 6 274 
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha 
isoform  PPP2R2A    1 1.91 1.784 8 
sp|O00410|IPO5_HUMAN 125032 8 425 Importin-5  IPO5    1 1.89 1.379 3 
sp|P00403|COX2_HUMAN 25719 3 161 Cytochrome c oxidase subunit 2  MT-CO2        1 1.89 0.599 14 
sp|O14980|XPO1_HUMAN 124447 7 212 Exportin-1  XPO1    1 1.824 1.053 3 
sp|O95816|BAG2_HUMAN 23928 2 78 BAG family molecular chaperone regulator 2 BAG2  1 1.813 0.328 14 
sp|P35998|PRS7_HUMAN 49002 5 261 26S protease regulatory subunit 7  PSMC2        1 1.798 1.742 9 
sp|Q13151|ROA0_HUMAN 30993 2 134 Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0  1 1.79 0.338 12 
sp|Q9H9B4|SFXN1_HUMAN 35881 9 521 Sideroflexin-1  SFXN1    1 1.737 1.967 12 
sp|Q13200|PSMD2_HUMAN 100877 13 695 26S proteasome non-ATPase regulatory subunit 2  PSMD2  1 1.714 1.538 4 
sp|P01891|1A68_HUMAN 41168 2 157 HLA class I histocompatibility antigen, A-68 alpha chain HLA-A  1 1.661 0.885 11 
sp|O95373|IPO7_HUMAN 120751 5 267 Importin-7  IPO7    1 1.651 1.345 3 
sp|P07437|TBB5_HUMAN 50095 3 280 Tubulin beta chain  TUBB    1 1.636 0.591 9 
sp|Q9NS69|TOM22_HUMAN 15512 2 133 Mitochondrial import receptor subunit TOM22 homolog TOMM22  1 1.628 0.531 14 
sp|Q14257|RCN2_HUMAN 36911 3 178 Reticulocalbin-2  RCN2    1 1.602 0.411 11 
sp|Q15393|SF3B3_HUMAN 136575 15 722 Splicing factor 3B subunit 3  SF3B3        1 1.588 0.979 2 
sp|P55786|PSA_HUMAN 103895 6 305 Puromycin-sensitive aminopeptidase NPEPPS  1 1.574 0.941 4 
sp|P62851|RS25_HUMAN 13791 4 159 40S ribosomal protein S25  RPS25        1 1.567 2.705 14 
sp|Q07955|SFRS1_HUMAN 27842 2 140 Splicing factor, arginine/serine-rich 1 SFRS1  1 1.562 0.318 12 
sp|Q92769|HDAC2_HUMAN 55899 2 65 Histone deacetylase 2  HDAC2        1 1.543 1.32 7 
sp|Q9UKM9|RALY_HUMAN 32501 2 68 RNA-binding protein Raly  RALY        1 1.514 0.458 12 
sp|P61106|RAB14_HUMAN 24110 6 247 Ras-related protein Rab-14  RAB14        1 1.513 1.881 14 
sp|P54136|SYRC_HUMAN 76129 6 279 Arginyl-tRNA synthetase, cytoplasmic RARS  1 1.5 1.45 6 
sp|Q9BPX3|CND3_HUMAN 115345 5 216 Condensin complex subunit 3  NCAPG        1 1.497 1.153 3 
sp|P29692|EF1D_HUMAN 31217 4 241 Elongation factor 1-delta  EEF1D        1 1.49 0.761 12 
sp|Q96AG4|LRC59_HUMAN 35308 3 124 Leucine-rich repeat-containing protein 59 LRRC59  1 1.485 1.325 12 
sp|P04843|RPN1_HUMAN 68641 16 741 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  RPN1    1 1.482 2.779 6 
sp|A6NKD9|CC85C_HUMAN 45467 2 89 Coiled-coil domain-containing protein 85C CCDC85C  1 1.481 1.787 9 
sp|Q8N8A2|ANR44_HUMAN 109360 15 632 
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B  
ANKRD44  1 1.479 0.711 3 
sp|Q09028|RBBP4_HUMAN 47911 5 217 Histone-binding protein RBBP4  RBBP4        1 1.472 0.347 9 
sp|P63244|GBLP_HUMAN 35511 2 101 Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1  1 1.458 1.127 12 
sp|Q9NVI7|ATD3A_HUMAN 71610 3 97 ATPase family AAA domain-containing protein 3A  ATAD3A  1 1.446 9.107 6 
sp|P56192|SYMC_HUMAN 102249 5 186 Methionyl-tRNA synthetase, cytoplasmic MARS  1 1.442 1.213 4 
sp|P53618|COPB_HUMAN 108214 3 97 Coatomer subunit beta  COPB1        1 1.435 1.599 4 
sp|Q02833|RASF7_HUMAN 40548 3 264 Ras association domain-containing protein 7 RASSF7  1 1.427 1.081 11 
sp|P51149|RAB7A_HUMAN 23760 7 445 Ras-related protein Rab-7a  RAB7A        1 1.408 0.92 14 
sp|O96000|NDUBA_HUMAN 21048 2 81 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10  NDUFB10  1 1.393 0.499 14 
sp|P26641|EF1G_HUMAN 50429 6 284 Elongation factor 1-gamma  EEF1G        1 1.391 4.717 9 
sp|Q9NRG9|AAAS_HUMAN 60392 2 75 Aladin  AAAS  1 1.388 1.133 8 
sp|O43242|PSMD3_HUMAN 61054 2 120 26S proteasome non-ATPase regulatory subunit 3  PSMD3  1 1.366 0.662 7 
sp|Q9BVC6|TM109_HUMAN 26194 2 109 Transmembrane protein 109  TMEM109        1 1.355 0.946 14 
sp|P36873|PP1G_HUMAN 37701 8 446 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit  PPP1CC  1 1.348 1.999 13 
sp|P49821|NDUV1_HUMAN 51469 4 167 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  NDUFV1  1 1.333 0.794 9 
sp|Q9BXL8|CDCA4_HUMAN 26553 2 98 Cell division cycle-associated protein 4 CDCA4  1 1.326 0.818 13 
sp|Q9UBN7|HDAC6_HUMAN 132932 11 523 Histone deacetylase 6  HDAC6        1 1.319 3.487 2 
sp|Q9H3U1|UN45A_HUMAN 104266 4 174 Protein unc-45 homolog A  UNC45A        1 1.315 1.104 4 
sp|Q14738|2A5D_HUMAN 70289 6 285 
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform  
PPP2R5D    1 1.311 0.687 6 
sp|Q9GZL7|WDR12_HUMAN 48191 2 77 Ribosome biogenesis protein WDR12  WDR12        1 1.309 0.255 9 
sp|P27694|RFA1_HUMAN 68723 13 573 Replication protein A 70 kDa DNA-binding subunit  RPA1  1 1.305 0.957 6 
sp|P68363|TBA1B_HUMAN 50804 14 955 Tubulin alpha-1B chain  TUBA1B        1 1.276 0.785 9 
sp|P61026|RAB10_HUMAN 22755 3 93 Ras-related protein Rab-10  RAB10        1 1.275 2.113 14 
sp|P17980|PRS6A_HUMAN 49458 5 180 26S protease regulatory subunit 6A  PSMC3        1 1.273 1.172 9 
sp|P46777|RL5_HUMAN 34569 5 207 60S ribosomal protein L5  RPL5        1 1.269 1.502 12 
sp|P52907|CAZA1_HUMAN 33073 5 359 F-actin-capping protein subunit alpha-1 CAPZA1  1 1.268 0.451 12 
sp|P29966|MARCS_HUMAN 31707 6 284 Myristoylated alanine-rich C-kinase substrate  MARCKS  1 1.26 1.613 6 
sp|Q15006|TTC35_HUMAN 34982 2 101 Tetratricopeptide repeat protein 35 TTC35  1 1.252 1.054 12 
sp|Q9BYD6|RM01_HUMAN 37113 2 84 39S ribosomal protein L1, mitochondrial MRPL1  1 1.249 0.828 12 
sp|O95292|VAPB_HUMAN 27439 2 89 Vesicle-associated membrane protein-associated protein B/C VAPB  1 1.237 0.819 13 
sp|P49368|TCPG_HUMAN 61066 14 675 T-complex protein 1 subunit gamma  CCT3        1 1.214 1.579 7 
sp|Q15029|U5S1_HUMAN 110336 5 278 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2  1 1.209 0.444 3 
sp|P23284|PPIB_HUMAN 23785 2 92 Peptidyl-prolyl cis-trans isomerase B PPIB  1 1.195 0.344 14 
sp|Q99873|ANM1_HUMAN 42059 3 155 Protein arginine N-methyltransferase 1 PRMT1  1 1.189 0.529 11 
sp|Q99832|TCPH_HUMAN 59842 5 234 T-complex protein 1 subunit eta  CCT7        1 1.185 2.483 7 
sp|P51114|FXR1_HUMAN 70020 2 68 Fragile X mental retardation syndrome-related protein 1 FXR1  1 1.18 0.471 6 
sp|P61586|RHOA_HUMAN 22096 4 208 Transforming protein RhoA  RHOA        1 1.176 0.83 14 
sp|Q8TEX9|IPO4_HUMAN 120179 2 73 Importin-4  IPO4    1 1.175 1.16 3 
sp|Q14498|RBM39_HUMAN 59628 2 89 RNA-binding protein 39  RBM39        1 1.17 0.684 6 
sp|P46782|RS5_HUMAN 23033 4 256 40S ribosomal protein S5  RPS5        1 1.166 1.906 14 
sp|O75306|NDUS2_HUMAN 52911 4 208 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial  NDUFS2  1 1.159 0.437 10 
sp|P14868|SYDC_HUMAN 57499 11 512 Aspartyl-tRNA synthetase, cytoplasmic DARS  1 1.158 0.839 8 
sp|Q9UNX3|RL26L_HUMAN 17246 2 75 60S ribosomal protein L26-like 1  RPL26L1        1 1.147 4.446 14 
sp|P62266|RS23_HUMAN 15969 3 137 40S ribosomal protein S23  RPS23        1 1.144 1.9 14 
sp|P31040|DHSA_HUMAN 73672 4 222 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial  SDHA  1 1.143 1.959 6 
sp|Q13257|MD2L1_HUMAN 23666 4 125 Mitotic spindle assembly checkpoint protein MAD2A  MAD2L1  1 1.138 1.245 14 
sp|O75396|SC22B_HUMAN 24896 4 164 Vesicle-trafficking protein SEC22b SEC22B  1 1.133 0.916 14 
sp|P09651|ROA1_HUMAN 38837 7 362 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1  1 1.121 0.228 12 
sp|Q15019|SEPT2_HUMAN 41689 3 160 Septin-2  SEPT2    1 1.12 0.546 11 
sp|P12956|XRCC6_HUMAN 70084 3 191 X-ray repair cross-complementing protein 6 XRCC6  1 1.115 0.345 6 
sp|Q9Y6G9|DC1L1_HUMAN 56829 4 189 Cytoplasmic dynein 1 light intermediate chain 1  DYNC1LI1  1 1.112 0.514 7 
sp|O00264|PGRC1_HUMAN 21772 6 385 Membrane-associated progesterone receptor component 1 PGRMC1  1 1.108 1.174 14 
sp|P83731|RL24_HUMAN 17882 2 119 60S ribosomal protein L24  RPL24        1 1.097 1.177 14 
sp|P00387|NB5R3_HUMAN 34441 2 100 NADH-cytochrome b5 reductase 3  CYB5R3        1 1.084 0.55 12 
sp|O43809|CPSF5_HUMAN 26268 2 75 Cleavage and polyadenylation specificity factor subunit 5 NUDT21  1 1.068 0.663 13 
sp|Q07812|BAX_HUMAN 21285 2 105 Apoptosis regulator BAX  BAX        1 1.055 0.957 14 
sp|P48047|ATPO_HUMAN 23377 4 215 ATP synthase subunit O, mitochondrial ATP5O  1 1.054 1.004 14 
sp|Q13310|PABP4_HUMAN 71080 5 212 Polyadenylate-binding protein 4  PABPC4        1 1.05 0.61 6 
sp|P61006|RAB8A_HUMAN 23824 3 111 Ras-related protein Rab-8A  RAB8A        1 1.047 1.152 14 
sp|P10398|ARAF_HUMAN 68341 3 96 Serine/threonine-protein kinase A-Raf ARAF  1 1.046 1.692 6 
sp|P09012|SNRPA_HUMAN 31259 3 128 U1 small nuclear ribonucleoprotein A SNRPA  1 1.045 0.33 12 
sp|Q16531|DDB1_HUMAN 128142 5 257 DNA damage-binding protein 1  DDB1        1 1.043 0.759 3 
sp|P46779|RL28_HUMAN 15795 3 123 60S ribosomal protein L28  RPL28        1 1.039 2.635 14 
sp|P11142|HSP7C_HUMAN 71082 23 1204 Heat shock cognate 71 kDa protein  HSPA8        1 1.038 2.669 6 
sp|Q9NYK5|RM39_HUMAN 39200 2 71 39S ribosomal protein L39, mitochondrial MRPL39  1 1.035 0.562 12 
sp|P14314|GLU2B_HUMAN 60357 4 234 Glucosidase 2 subunit beta  PRKCSH        1 1.033 1.661 6 
sp|P16949|STMN1_HUMAN 17292 2 143 Stathmin  STMN1    1 1.032 0.514 14 
sp|P17812|PYRG1_HUMAN 67332 2 100 CTP synthase 1  CTPS    1 1.023 0.929 6 
sp|P68371|TBB2C_HUMAN 50255 14 926 Tubulin beta-2C chain  TUBB2C        1 1.023 0.674 9 
sp|P10809|CH60_HUMAN 61187 17 1214 60 kDa heat shock protein, mitochondrial HSPD1  1 1.02 0.881 7 
sp|P31942|HNRH3_HUMAN 36960 4 169 Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3  1 1.017 0.511 12 
sp|Q9Y265|RUVB1_HUMAN 50538 10 561 RuvB-like 1  RUVBL1    1 1.012 0.66 9 
sp|Q15046|SYK_HUMAN 68461 9 317 Lysyl-tRNA synthetase  KARS      1 1.008 1.5 6 
sp|Q66LE6|2ABD_HUMAN 52580 2 68 
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform  
PPP2R2D    1 1.005 1.534 9 
sp|P43307|SSRA_HUMAN 32215 2 81 Translocon-associated protein subunit alpha SSR1  1 1.005 0.908 12 
sp|Q12972|PP1R8_HUMAN 38626 22 1195 Nuclear inhibitor of protein phosphatase 1 PPP1R8  1 1.005 0.827 11 
sp|P62333|PRS10_HUMAN 44430 4 170 26S protease regulatory subunit 10B PSMC6  1 0.999 0.961 11 
sp|Q9H788|SH24A_HUMAN 52922 9 459 SH2 domain-containing protein 4A  SH2D4A        1 0.997 1.021 9 
sp|P49755|TMEDA_HUMAN 25131 4 139 Transmembrane emp24 domain-containing protein 10  TMED10  1 0.994 1.576 14 
sp|Q9HCE1|MOV10_HUMAN 114512 5 194 Putative helicase MOV-10  MOV10        1 0.984 0.51 3 
sp|O14974|MYPT1_HUMAN 115610 3 90 Protein phosphatase 1 regulatory subunit 12A  PPP1R12A  1 0.983 4.205 3 
sp|Q02978|M2OM_HUMAN 34211 5 193 Mitochondrial 2-oxoglutarate/malate carrier protein  SLC25A11  1 0.977 0.626 13 
sp|Q9H0U4|RAB1B_HUMAN 22328 8 439 Ras-related protein Rab-1B  RAB1B        1 0.975 0.895 14 
sp|P51970|NDUA8_HUMAN 20548 2 85 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8  NDUFA8  1 0.968 0.71 14 
sp|P54920|SNAA_HUMAN 33667 5 159 Alpha-soluble NSF attachment protein NAPA  1 0.966 0.765 12 
sp|P38646|GRP75_HUMAN 73920 12 708 Stress-70 protein, mitochondrial  HSPA9        1 0.964 1.776 6 
sp|Q86V81|THOC4_HUMAN 26872 2 184 THO complex subunit 4  THOC4        1 0.956 0.733 13 
sp|P22626|ROA2_HUMAN 37464 8 460 Heterogeneous nuclear ribonucleoproteins A2/B1  HNRNPA2B1  1 0.943 0.159 12 
sp|P30153|2AAA_HUMAN 66065 30 1838 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha 
isoform  PPP2R1A    1 0.941 3.534 7 
sp|P62829|RL23_HUMAN 14970 4 175 60S ribosomal protein L23  RPL23        1 0.931 1.17 14 
sp|O75832|PSD10_HUMAN 24697 2 91 26S proteasome non-ATPase regulatory subunit 10  PSMD10  1 0.927 0.322 14 
sp|P50914|RL14_HUMAN 23531 3 156 60S ribosomal protein L14  RPL14        1 0.922 0.728 13 
sp|P31943|HNRH1_HUMAN 49484 7 319 Heterogeneous nuclear ribonucleoprotein H HNRNPH1  1 0.921 0.461 9 
sp|P55735|SEC13_HUMAN 36031 3 212 Protein SEC13 homolog  SEC13        1 0.92 0.867 12 
sp|Q15291|RBBP5_HUMAN 59800 2 71 Retinoblastoma-binding protein 5  RBBP5        1 0.919 0.967 6 
sp|P48739|PIPNB_HUMAN 31805 3 148 Phosphatidylinositol transfer protein beta isoform  PITPNB  1 0.913 0.959 12 
sp|P62277|RS13_HUMAN 17212 3 165 40S ribosomal protein S13  RPS13        1 0.908 1.223 14 
sp|P53041|PPP5_HUMAN 57412 31 1748 Serine/threonine-protein phosphatase 5 PPP5C  1 0.907 2.029 8 
sp|Q9UHG3|PCYOX_HUMAN 57003 3 100 Prenylcysteine oxidase 1  PCYOX1        1 0.906 0.85 8 
sp|P62820|RAB1A_HUMAN 22891 2 97 Ras-related protein Rab-1A  RAB1A        1 0.906 0.69 14 
sp|P08107|HSP71_HUMAN 70294 29 1612 Heat shock 70 kDa protein 1A/1B  HSPA1A        1 0.905 5.473 6 
sp|P35232|PHB_HUMAN 29843 13 716 Prohibitin  PHB    1 0.904 0.74 13 
sp|Q96HS1|PGAM5_HUMAN 32213 4 201 Serine/threonine-protein phosphatase PGAM5, mitochondrial PGAM5  1 0.902 0.54 12 
sp|P06576|ATPB_HUMAN 56525 17 1147 ATP synthase subunit beta, mitochondrial ATP5B  1 0.9 0.565 9 
sp|P62701|RS4X_HUMAN 29807 4 238 40S ribosomal protein S4, X isoform RPS4X  1 0.892 0.738 13 
sp|P35613|BASI_HUMAN 42573 6 238 Basigin  BSG  1 0.892 0.418 11 
sp|O14744|ANM5_HUMAN 73322 2 88 Protein arginine N-methyltransferase 5 PRMT5  1 0.888 0.822 6 
sp|Q9P032|NDUF4_HUMAN 20311 2 66 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4  
NDUFAF4  1 0.876 0.776 14 
sp|Q9BVA1|TBB2B_HUMAN 50377 2 119 Tubulin beta-2B chain  TUBB2B        1 0.872 0.645 9 
sp|P08195|4F2_HUMAN 68180 2 129 4F2 cell-surface antigen heavy chain SLC3A2  1 0.859 1.11 6 
sp|Q53H12|AGK_HUMAN 47564 2 89 Acylglycerol kinase, mitochondrial  AGK        1 0.858 0.46 10 
sp|O75489|NDUS3_HUMAN 30337 5 344 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial  NDUFS3  1 0.856 0.369 13 
sp|P39019|RS19_HUMAN 16051 3 127 40S ribosomal protein S19  RPS19        1 0.847 2.645 14 
sp|O60506|HNRPQ_HUMAN 69788 8 352 Heterogeneous nuclear ribonucleoprotein Q SYNCRIP  1 0.845 0.376 6 
sp|P24534|EF1B_HUMAN 24919 3 263 Elongation factor 1-beta  EEF1B2        1 0.842 0.481 13 
sp|P61009|SPCS3_HUMAN 20358 2 98 Signal peptidase complex subunit 3  SPCS3        1 0.836 0.955 14 
sp|Q13765|NACA_HUMAN 23370 2 220 Nascent polypeptide-associated complex subunit alpha NACA  1 0.835 0.591 12 
sp|P18621|RL17_HUMAN 21611 3 98 60S ribosomal protein L17  RPL17        1 0.817 0.472 14 
sp|P18124|RL7_HUMAN 29264 3 123 60S ribosomal protein L7  RPL7        1 0.812 0.41 13 
sp|P31930|QCR1_HUMAN 53297 3 177 Cytochrome b-c1 complex subunit 1, mitochondrial  UQCRC1  1 0.808 0.309 10 
sp|P61019|RAB2A_HUMAN 23702 5 329 Ras-related protein Rab-2A  RAB2A        1 0.806 0.635 14 
sp|Q07020|RL18_HUMAN 21735 2 107 60S ribosomal protein L18  RPL18        1 0.793 0.686 14 
sp|Q9Y230|RUVB2_HUMAN 51296 12 652 RuvB-like 2  RUVBL2    1 0.789 0.671 9 
sp|P62241|RS8_HUMAN 24475 7 270 40S ribosomal protein S8  RPS8        1 0.785 0.814 13 
sp|P11021|GRP78_HUMAN 72402 12 762 78 kDa glucose-regulated protein  HSPA5        1 0.783 1.267 6 
sp|Q96CS3|FAF2_HUMAN 52933 2 93 FAS-associated factor 2  FAF2        1 0.781 0.647 9 
sp|P06493|CDC2_HUMAN 34117 4 171 Cell division control protein 2 homolog CDC2  1 0.779 1.068 12 
sp|Q13283|G3BP1_HUMAN 52189 3 177 Ras GTPase-activating protein-binding protein 1  G3BP1  1 0.778 0.35 7 
sp|Q13347|EIF3I_HUMAN 36878 3 122 Eukaryotic translation initiation factor 3 subunit I EIF3I  1 0.777 0.718 12 
sp|P27824|CALX_HUMAN 67982 2 70 Calnexin  CANX    1 0.77 1.742 6 
sp|P30050|RL12_HUMAN 17979 5 338 60S ribosomal protein L12  RPL12        1 0.769 0.735 14 
sp|Q14232|EI2BA_HUMAN 33976 4 203 Translation initiation factor eIF-2B subunit alpha  EIF2B1  1 0.764 0.323 12 
sp|P62269|RS18_HUMAN 17708 5 263 40S ribosomal protein S18  RPS18        1 0.755 0.788 14 
sp|P46060|RAGP1_HUMAN 63958 4 231 Ran GTPase-activating protein 1  RANGAP1        1 0.755 0.78 6 
sp|O95831|AIFM1_HUMAN 67144 2 74 Apoptosis-inducing factor 1, mitochondrial AIFM1  1 0.754 0.668 6 
sp|P51991|ROA3_HUMAN 39799 5 192 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3  1 0.754 0.12 11 
sp|Q15366|PCBP2_HUMAN 38955 5 243 Poly(rC)-binding protein 2  PCBP2        1 0.753 0.307 12 
sp|O00148|DDX39_HUMAN 49611 4 225 ATP-dependent RNA helicase DDX39  DDX39        1 0.742 0.276 9 
sp|Q99497|PARK7_HUMAN 20050 7 298 Protein DJ-1  PARK7    1 0.738 0.521 14 
sp|P07197|NFM_HUMAN 102468 9 361 Neurofilament medium polypeptide  NEFM        1 0.737 1.014 3 
sp|P38919|IF4A3_HUMAN 47126 2 73 Eukaryotic initiation factor 4A-III EIF4A3  1 0.733 0.259 10 
sp|Q9Y266|NUDC_HUMAN 38276 11 556 Nuclear migration protein nudC  NUDC        1 0.732 0.271 11 
sp|P46459|NSF_HUMAN 83055 3 132 Vesicle-fusing ATPase  NSF      1 0.725 0.634 5 
sp|Q16775|GLO2_HUMAN 34240 3 129 Hydroxyacylglutathione hydrolase, mitochondrial  HAGH  1 0.722 0.485 13 
sp|P0C7M2|RA1L3_HUMAN 34373 2 112 Putative heterogeneous nuclear ribonucleoprotein A1-like 3 HNRPA1L3 1 0.721 0.149 11 
sp|Q9BY41|HDAC8_HUMAN 42301 3 225 Histone deacetylase 8  HDAC8        1 0.719 0.385 11 
sp|Q9H845|ACAD9_HUMAN 69344 3 93 Acyl-CoA dehydrogenase family member 9, mitochondrial ACAD9  1 0.718 0.567 7 
sp|Q9UPN7|SAPS1_HUMAN 97291 2 92 Serine/threonine-protein phosphatase 6 regulatory subunit 1 SAPS1  1 0.715 0.937 6 
sp|P19404|NDUV2_HUMAN 27659 4 235 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  NDUFV2  1 0.712 0.16 14 
sp|P53999|TCP4_HUMAN 14386 3 181 Activated RNA polymerase II transcriptional coactivator p15 SUB1  1 0.702 0.827 14 
sp|Q13362|2A5G_HUMAN 61421 3 117 
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform  
PPP2R5C    1 0.699 0.872 8 
sp|P17987|TCPA_HUMAN 60819 6 231 T-complex protein 1 subunit alpha  TCP1        1 0.696 0.888 7 
sp|Q15645|TRP13_HUMAN 48863 4 183 Thyroid receptor-interacting protein 13 TRIP13  1 0.696 0.477 10 
sp|P62263|RS14_HUMAN 16434 5 221 40S ribosomal protein S14  RPS14        1 0.692 1.353 14 
sp|P61978|HNRPK_HUMAN 51230 6 319 Heterogeneous nuclear ribonucleoprotein K HNRNPK  1 0.684 0.414 8 
sp|P17844|DDX5_HUMAN 69618 6 242 Probable ATP-dependent RNA helicase DDX5 DDX5  1 0.683 1.173 6 
sp|P35221|CTNA1_HUMAN 100693 2 128 Catenin alpha-1  CTNNA1    1 0.678 0.583 4 
sp|O75947|ATP5H_HUMAN 18537 3 122 ATP synthase subunit d, mitochondrial ATP5H  1 0.677 0.853 14 
sp|P24666|PPAC_HUMAN 18487 10 699 Low molecular weight phosphotyrosine protein phosphatase ACP1  1 0.677 0.633 14 
sp|P60709|ACTB_HUMAN 42052 15 959 Actin, cytoplasmic 1  ACTB      1 0.676 0.347 11 
sp|P07910|HNRPC_HUMAN 33707 8 469 Heterogeneous nuclear ribonucleoproteins C1/C2  HNRNPC  1 0.676 0.067 11 
sp|Q16740|CLPP_HUMAN 30446 2 121 Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial  CLPP  1 0.673 0.396 13 
sp|P08708|RS17_HUMAN 15597 3 144 40S ribosomal protein S17  RPS17        1 0.672 0.924 14 
sp|O14818|PSA7_HUMAN 28041 5 303 Proteasome subunit alpha type-7  PSMA7        1 0.672 0.437 13 
sp|Q9Y3I0|CV028_HUMAN 55688 2 62 UPF0027 protein C22orf28  C22orf28        1 0.672 0.433 8 
sp|O60664|PLIN3_HUMAN 47189 2 105 Perilipin-3  PLIN3    1 0.658 0.715 10 
sp|Q07021|C1QBP_HUMAN 31742 3 218 Complement component 1 Q subcomponent-binding protein, mitochondrial  C1QBP 1 0.649 0.308 13 
sp|Q8IVD9|NUDC3_HUMAN 40854 2 110 NudC domain-containing protein 3  NUDCD3        1 0.644 0.574 10 
sp|Q99614|TTC1_HUMAN 33961 2 74 Tetratricopeptide repeat protein 1  TTC1        1 0.641 0.754 11 
sp|Q13405|RM49_HUMAN 19243 4 202 39S ribosomal protein L49, mitochondrial MRPL49  1 0.636 0.538 14 
sp|P52597|HNRPF_HUMAN 45985 4 214 Heterogeneous nuclear ribonucleoprotein F HNRNPF  1 0.632 2.483 10 
sp|P62750|RL23A_HUMAN 17684 3 168 60S ribosomal protein L23a  RPL23A        1 0.631 1.665 14 
sp|P61353|RL27_HUMAN 15788 2 78 60S ribosomal protein L27  RPL27        1 0.626 1.037 14 
sp|Q9UJV9|DDX41_HUMAN 70477 4 193 Probable ATP-dependent RNA helicase DDX41 DDX41  1 0.624 1.164 6 
sp|P15880|RS2_HUMAN 31590 7 340 40S ribosomal protein S2  RPS2        1 0.623 0.284 12 
sp|Q15717|ELAV1_HUMAN 36240 8 422 ELAV-like protein 1  ELAVL1      1 0.613 0.244 12 
sp|P62280|RS11_HUMAN 18590 7 263 40S ribosomal protein S11  RPS11        1 0.61 1.038 14 
sp|P08238|HS90B_HUMAN 83554 52 2711 Heat shock protein HSP 90-beta  HSP90AB1        1 0.606 2.608 5 
sp|Q9HDC9|APMAP_HUMAN 46622 3 122 Adipocyte plasma membrane-associated protein  APMAP  1 0.599 0.509 10 
sp|P62913|RL11_HUMAN 20468 2 135 60S ribosomal protein L11  RPL11        1 0.594 0.622 14 
sp|P18085|ARF4_HUMAN 20612 3 101 ADP-ribosylation factor 4  ARF4        1 0.594 0.612 14 
sp|Q5T1J5|CHCH9_HUMAN 15708 2 158 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 9, mitochondrial  
CHCHD9   1 0.592 0.755 14 
sp|P38159|HNRPG_HUMAN 42306 4 223 Heterogeneous nuclear ribonucleoprotein G RBMX  1 0.591 0.131 11 
sp|Q9Y3F4|STRAP_HUMAN 38756 3 160 Serine-threonine kinase receptor-associated protein  STRAP  1 0.59 0.317 11 
sp|Q8WVM8|SCFD1_HUMAN 72676 6 320 Sec1 family domain-containing protein 1 SCFD1  1 0.583 0.583 6 
sp|P23396|RS3_HUMAN 26842 12 625 40S ribosomal protein S3  RPS3        1 0.582 0.398 13 
sp|P05388|RLA0_HUMAN 34423 10 541 60S acidic ribosomal protein P0  RPLP0        1 0.582 0.286 12 
sp|P62906|RL10A_HUMAN 24987 5 274 60S ribosomal protein L10a  RPL10A        1 0.574 0.37 13 
sp|Q13561|DCTN2_HUMAN 44318 3 252 Dynactin subunit 2  DCTN2      1 0.573 0.288 10 
sp|O43399|TPD54_HUMAN 22281 4 294 Tumor protein D54  TPD52L2      1 0.572 0.504 13 
sp|P42704|LPPRC_HUMAN 159003 29 1333 Leucine-rich PPR motif-containing protein, mitochondrial LRPPRC  1 0.564 0.662 2 
sp|P50990|TCPQ_HUMAN 60153 5 182 T-complex protein 1 subunit theta  CCT8        1 0.56 0.665 8 
sp|P51571|SSRD_HUMAN 19158 2 146 Translocon-associated protein subunit delta SSR4  1 0.559 1.127 14 
sp|P07195|LDHB_HUMAN 36900 4 188 L-lactate dehydrogenase B chain  LDHB        1 0.555 0.377 12 
sp|P62873|GBB1_HUMAN 38151 4 162 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GNB1  1 0.548 0.646 12 
sp|Q92900|RENT1_HUMAN 125578 2 76 Regulator of nonsense transcripts 1  UPF1        1 0.546 0.338 2 
sp|P62826|RAN_HUMAN 24579 4 229 GTP-binding nuclear protein Ran  RAN        1 0.543 0.428 13 
sp|Q9Y3A3|MOBL3_HUMAN 26529 5 245 Mps one binder kinase activator-like 3 MOBKL3  1 0.54 0.393 13 
sp|Q00577|PURA_HUMAN 35003 4 185 Transcriptional activator protein Pur-alpha PURA  1 0.536 0.169 11 
sp|P48643|TCPE_HUMAN 60089 5 177 T-complex protein 1 subunit epsilon  CCT5        1 0.532 0.438 7 
sp|Q9UBB4|ATX10_HUMAN 54196 5 260 Ataxin-10  ATXN10    1 0.531 0.666 9 
sp|P46781|RS9_HUMAN 22635 3 93 40S ribosomal protein S9  RPS9        1 0.529 0.888 14 
sp|Q5VTE0|EF1A3_HUMAN 50495 4 133 Putative elongation factor 1-alpha-like 3 EEF1AL3  1 0.524 0.535 10 
sp|O76071|CIAO1_HUMAN 38842 5 243 Probable cytosolic iron-sulfur protein assembly protein CIAO1  CIAO1  1 0.521 0.266 11 
sp|P15153|RAC2_HUMAN 21814 2 76 Ras-related C3 botulinum toxin substrate 2 RAC2  1 0.518 0.868 14 
sp|P52815|RM12_HUMAN 21563 3 141 39S ribosomal protein L12, mitochondrial MRPL12  1 0.517 0.34 14 
sp|Q9Y224|CN166_HUMAN 28165 4 260 UPF0568 protein C14orf166  C14orf166        1 0.516 0.203 13 
sp|Q92600|RCD1_HUMAN 33952 3 156 Cell differentiation protein RCD1 homolog RQCD1  1 0.513 0.33 13 
sp|Q16537|2A5E_HUMAN 55064 6 313 
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform  
PPP2R5E    1 0.509 0.693 9 
sp|P62917|RL8_HUMAN 28235 2 86 60S ribosomal protein L8  RPL8        1 0.508 0.671 13 
sp|Q15365|PCBP1_HUMAN 37987 3 155 Poly(rC)-binding protein 1  PCBP1        1 0.507 0.115 11 
sp|Q9H3G5|CPVL_HUMAN 54414 2 84 Probable serine carboxypeptidase CPVL CPVL  1 0.498 0.483 9 
sp|Q9Y3B3|TMED7_HUMAN 25498 3 145 Transmembrane emp24 domain-containing protein 7  TMED7  1 0.493 0.561 13 
sp|Q99536|VAT1_HUMAN 42122 7 365 Synaptic vesicle membrane protein VAT-1 homolog  VAT1  1 0.492 0.492 11 
sp|P55036|PSMD4_HUMAN 40939 2 113 26S proteasome non-ATPase regulatory subunit 4  PSMD4  1 0.488 0.217 10 
sp|P27348|1433T_HUMAN 28032 4 216 14-3-3 protein theta  YWHAQ      1 0.482 0.318 13 
sp|O75821|EIF3G_HUMAN 35874 3 124 Eukaryotic translation initiation factor 3 subunit G EIF3G  1 0.47 0.515 11 
sp|P63104|1433Z_HUMAN 27899 8 598 14-3-3 protein zeta/delta  YWHAZ        1 0.456 0.29 13 
sp|Q9Y3D0|FA96B_HUMAN 17766 2 112 Protein FAM96B  FAM96B    1 0.454 0.459 14 
sp|P62258|1433E_HUMAN 29326 6 298 14-3-3 protein epsilon  YWHAE        1 0.448 0.381 13 
sp|Q9BU61|NDUF3_HUMAN 20566 2 80 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3  
NDUFAF3  1 0.439 0.565 14 
sp|P60900|PSA6_HUMAN 27838 2 89 Proteasome subunit alpha type-6  PSMA6        1 0.439 0.411 13 
sp|Q14103|HNRPD_HUMAN 38581 4 260 Heterogeneous nuclear ribonucleoprotein D0 HNRNPD  1 0.437 0.083 11 
sp|Q9Y5K5|UCHL5_HUMAN 37868 3 90 Ubiquitin carboxyl-terminal hydrolase isozyme L5  UCHL5  1 0.436 0.364 11 
sp|P02768|ALBU_HUMAN 71317 6 203 Serum albumin  ALB    1 0.436 0.359 6 
sp|P19338|NUCL_HUMAN 76625 9 333 Nucleolin  NCL    1 0.427 0.637 6 
sp|P49770|EI2BB_HUMAN 39193 5 160 Translation initiation factor eIF-2B subunit beta  EIF2B2  1 0.425 0.176 11 
sp|P14866|HNRPL_HUMAN 64720 6 317 Heterogeneous nuclear ribonucleoprotein L HNRNPL  1 0.421 0.09 6 
sp|P30049|ATPD_HUMAN 17479 3 174 ATP synthase subunit delta, mitochondrial ATP5D  1 0.42 0.939 14 
sp|Q9NWS0|PIHD1_HUMAN 32513 3 134 PIH1 domain-containing protein 1  PIH1D1        1 0.416 0.613 12 
sp|P07900|HS90A_HUMAN 85006 28 1429 Heat shock protein HSP 90-alpha  HSP90AA1        1 0.406 2.055 5 
sp|P50148|GNAQ_HUMAN 42400 2 88 Guanine nucleotide-binding protein G(q) subunit alpha GNAQ  1 0.404 0.396 11 
sp|P22392|NDKB_HUMAN 17401 5 195 Nucleoside diphosphate kinase B  NME2        1 0.397 0.337 14 
sp|P43487|RANG_HUMAN 23467 4 183 Ran-specific GTPase-activating protein RANBP1  1 0.386 0.407 13 
sp|P11940|PABP1_HUMAN 70854 15 873 Polyadenylate-binding protein 1  PABPC1        1 0.385 0.229 6 
sp|O43324|MCA3_HUMAN 19855 2 85 Eukaryotic translation elongation factor 1 epsilon-1 EEF1E1  1 0.378 0.319 14 
sp|P09661|RU2A_HUMAN 28512 3 195 U2 small nuclear ribonucleoprotein A' SNRPA1  1 0.377 0.381 13 
sp|P62249|RS16_HUMAN 16549 5 212 40S ribosomal protein S16  RPS16        1 0.367 0.489 14 
sp|O00425|IF2B3_HUMAN 64008 8 323 Insulin-like growth factor 2 mRNA-binding protein 3  IGF2BP3  1 0.36 0.738 6 
sp|P47756|CAPZB_HUMAN 31616 2 106 F-actin-capping protein subunit beta CAPZB  1 0.357 0.314 12 
sp|P61224|RAP1B_HUMAN 21040 3 132 Ras-related protein Rap-1b  RAP1B        1 0.355 0.994 14 
sp|P08754|GNAI3_HUMAN 41076 2 96 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3  1 0.351 0.242 11 
sp|Q9NZI8|IF2B1_HUMAN 63783 15 762 Insulin-like growth factor 2 mRNA-binding protein 1  IGF2BP1  1 0.347 0.477 6 
sp|Q15293|RCN1_HUMAN 38866 4 193 Reticulocalbin-1  RCN1    1 0.345 0.196 11 
sp|Q16543|CDC37_HUMAN 44953 9 624 Hsp90 co-chaperone Cdc37  CDC37        1 0.343 0.424 10 
sp|Q9Y5S9|RBM8A_HUMAN 19934 2 117 RNA-binding protein 8A  RBM8A        1 0.341 0.111 14 
sp|Q9Y2Z0|SUGT1_HUMAN 41284 18 951 Suppressor of G2 allele of SKP1 homolog SUGT1  1 0.338 0.17 11 
sp|P61289|PSME3_HUMAN 29602 2 132 Proteasome activator complex subunit 3 PSME3  1 0.331 0.154 12 
sp|Q9HB71|CYBP_HUMAN 26308 2 72 Calcyclin-binding protein  CACYBP        1 0.323 0.244 13 
sp|P12273|PIP_HUMAN 16847 2 135 Prolactin-inducible protein  PIP        1 0.32 0.229 14 
sp|O14950|ML12B_HUMAN 19824 5 253 Myosin regulatory light chain 12B  MYL12B        1 0.307 0.355 14 
sp|P60174|TPIS_HUMAN 26938 2 82 Triosephosphate isomerase  TPI1        1 0.307 0.208 13 
sp|P28072|PSB6_HUMAN 25570 2 106 Proteasome subunit beta type-6  PSMB6        1 0.297 0.352 14 
sp|P31025|LCN1_HUMAN 19409 2 134 Lipocalin-1  LCN1    1 0.296 0.17 14 
sp|Q12905|ILF2_HUMAN 43263 9 517 Interleukin enhancer-binding factor 2 ILF2  1 0.29 0.085 11 
sp|P63208|SKP1_HUMAN 18817 2 125 S-phase kinase-associated protein 1  SKP1        1 0.287 0.281 14 
sp|Q96DG6|CMBL_HUMAN 28372 8 374 Carboxymethylenebutenolidase homolog CMBL  1 0.284 0.269 13 
sp|O95433|AHSA1_HUMAN 38421 4 165 Activator of 90 kDa heat shock protein ATPase homolog 1 AHSA1  1 0.279 0.231 11 
sp|P00492|HPRT_HUMAN 24792 2 105 Hypoxanthine-guanine phosphoribosyltransferase  HPRT1  1 0.261 0.268 13 
sp|Q9UBQ5|EIF3K_HUMAN 25329 2 128 Eukaryotic translation initiation factor 3 subunit K EIF3K  1 0.257 0.357 14 
sp|Q5H9R7|SAPS3_HUMAN 98577 7 308 Serine/threonine-protein phosphatase 6 regulatory subunit 3 SAPS3  1 0.255 0.236 5 
sp|Q06830|PRDX1_HUMAN 22324 6 301 Peroxiredoxin-1  PRDX1    1 0.246 0.302 14 
sp|P32119|PRDX2_HUMAN 22049 2 76 Peroxiredoxin-2  PRDX2    1 0.246 0.231 14 
sp|P12277|KCRB_HUMAN 42902 3 175 Creatine kinase B-type  CKB      1 0.236 0.163 11 
sp|P61421|VA0D1_HUMAN 40759 3 112 V-type proton ATPase subunit d 1 ATP6V0D1  1 0.234 25.931 11 
sp|Q15185|TEBP_HUMAN 18971 3 133 Prostaglandin E synthase 3  PTGES3        1 0.227 0.294 14 
sp|P12814|ACTN1_HUMAN 103563 4 189 Alpha-actinin-1  ACTN1    1 0.222 0.296 4 
sp|P62899|RL31_HUMAN 14454 3 130 60S ribosomal protein L31  RPL31        1 0.218 0.907 14 
sp|P09211|GSTP1_HUMAN 23569 2 82 Glutathione S-transferase P  GSTP1        1 0.215 0.293 14 
sp|P62424|RL7A_HUMAN 30148 3 123 60S ribosomal protein L7a  RPL7A        1 0.211 0.128 12 
sp|P35268|RL22_HUMAN 14835 3 214 60S ribosomal protein L22  RPL22        1 0.208 0.187 14 
sp|P06733|ENOA_HUMAN 47481 3 257 Alpha-enolase  ENO1    1 0.204 0.251 10 
sp|P26378|ELAV4_HUMAN 42028 3 160 ELAV-like protein 4  ELAVL4      1 0.203 0.44 11 
sp|Q5MIZ7|P4R3B_HUMAN 98181 2 113 Serine/threonine-protein phosphatase 4 regulatory subunit  3B SMEK2  1 0.2 0.406 5 
sp|P67809|YBOX1_HUMAN 35903 3 302 Nuclease-sensitive element-binding protein 1  YBX1  1 0.199 0.093 11 
sp|Q3MHD2|LSM12_HUMAN 21972 2 123 Protein LSM12 homolog  LSM12        1 0.197 0.164 13 
sp|P06753|TPM3_HUMAN 32856 2 90 Tropomyosin alpha-3 chain  TPM3        1 0.192 0.096 13 
sp|Q9Y6M1|IF2B2_HUMAN 66195 3 114 Insulin-like growth factor 2 mRNA-binding protein 2  IGF2BP2  1 0.191 0.128 6 
sp|P13073|COX41_HUMAN 19621 3 119 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1  1 0.185 0.435 14 
sp|Q96A72|MGN2_HUMAN 17322 2 90 Protein mago nashi homolog 2  MAGOHB        1 0.164 0.072 14 
sp|Q15907|RB11B_HUMAN 24588 3 110 Ras-related protein Rab-11B  RAB11B        1 0.157 1.171 13 
sp|P61247|RS3A_HUMAN 30154 4 166 40S ribosomal protein S3a  RPS3A        1 0.155 0.088 12 
sp|P30154|2AAB_HUMAN 66799 2 49 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform  
PPP2R1B    1 0.133 0.523 7 
sp|Q15370|ELOB_HUMAN 13239 3 102 Transcription elongation factor B polypeptide 2  TCEB2  1 0.126 0.127 14 
sp|P60660|MYL6_HUMAN 17090 6 339 Myosin light polypeptide 6  MYL6        1 0.106 0.143 14 
sp|Q9NY27|PP4R2_HUMAN 47268 20 1184 Serine/threonine-protein phosphatase 4 regulatory subunit 2 PPP4R2  1 0.105 1.399 8 
sp|O75170|SAPS2_HUMAN 106358 18 865 Serine/threonine-protein phosphatase 6 regulatory subunit 2 SAPS2  1 0.096 0.537 4 
sp|Q6IN85|P4R3A_HUMAN 95935 21 1127 Serine/threonine-protein phosphatase 4 regulatory subunit 3A  SMEK1  1 0.089 0.49 5 
sp|P12004|PCNA_HUMAN 29092 5 192 Proliferating cell nuclear antigen  PCNA        1 0.047 0.034 12 
sp|P05141|ADT2_HUMAN 33102 11 543 ADP/ATP translocase 2  SLC25A5        1 0.038 0.027 12 
 
 
 
 
 
 
 
Appendix II 
Proteins were purified using GFP-Trap® beads from lysates of cells stably expressing GFP-TAP-PP1β, which were stimulated with 
forskolin or not, and in the presence or absence of H-89. Peptides were digested from the SDS gel (Figure 3.5) and identified from 
the SwissProt database (accession number; description) and their Mascot score (score) determined.  The corresponding gel band 
(band) in which they were identified is given below. Peptides were quantitatively measured using the MS Quant software following 
the dimethyl labelling. The ratios of the different treatment conditions are listed in the table below (SS-serum starved, Fsk-forskolin, 
H-89+ Fsk-H-89 and forskolin).     
 
Accession number SPROT_description Score mass 
 
SS/SS  Fsk/SS 
 H-89+ 
Fsk/SS band 
sp|P08865|RSSA_HUMAN 40S ribosomal protein SA RPSA  61 32947 1 1.425 0.663 7 
sp|P10809|CH60_HUMAN 60 kDa heat shock protein, mitochondrial HSPD1  1038 61187 1 0.72 1.288 5 
sp|P05388|RLA0_HUMAN 60S acidic ribosomal protein P0 RPLP0  303 34423 1 2.527 1.348 7 
sp|P39023|RL3_HUMAN 60S ribosomal protein L3 RPL3  63 46365 1 2.833 1.251 7 
sp|P36578|RL4_HUMAN 60S ribosomal protein L4 RPL4  340 47953 1 3.282 1.636 7 
sp|P46777|RL5_HUMAN 60S ribosomal protein L5 RPL5  61 34569 1 2.954 1.672 7 
sp|Q02878|RL6_HUMAN 60S ribosomal protein L6 RPL6  114 32765 1 2.908 2.021 7 
sp|P11021|GRP78_HUMAN 78 kDa glucose-regulated protein HSPA5  1835 72402 1 0.715 0.715 4 
sp|P60709|ACTB_HUMAN Actin, cytoplasmic 1 ACTB  269 42052 1 2.147 1.128 7 
sp|Q9P0K7|RAI14_HUMAN Ankycorbin RAI14  820 110601 1 1.105 1.215 2 
sp|Q96KQ4|ASPP1_HUMAN Apoptosis-stimulating of p53 protein 1 PPP1R13B  376 120062 1 1.004 0.418 2 
sp|Q13625|ASPP2_HUMAN Apoptosis-stimulating of p53 protein 2 TP53BP2  2274 126222 1 3.297 1.943 1 
sp|P25705|ATPA_HUMAN ATP synthase subunit alpha, mitochondrial ATP5A1  908 59828 1 0.995 0.569 6 
sp|P06576|ATPB_HUMAN ATP synthase subunit beta, mitochondrial ATP5B  417 56525 1 0.79 0.684 6 
sp|Q9NVI7|ATD3A_HUMAN ATPase family AAA domain-containing protein 3A ATAD3A  379 71610 1 0.888 0.479 4 
sp|P07814|SYEP_HUMAN Bifunctional aminoacyl-tRNA synthetase EPRS  104 172080 1 1.026 0.927 1 
sp|P27708|PYR1_HUMAN CAD protein CAD  724 245167 1 1.508 0.803 1 
sp|P27824|CALX_HUMAN Calnexin CANX  61 67982 1 1.137 0.678 3 
sp|Q00610|CLH1_HUMAN Clathrin heavy chain 1 CLTC  56 193260 1 0.783 0.838 1 
sp|A6NKD9|CC85C_HUMAN Coiled-coil domain-containing protein 85C CCDC85C  1124 45467 1 0.901 0.618 6 
sp|Q69YQ0|CYTSA_HUMAN Cytospin-A CYTSA  168 124915 1 0.984 0.443 2 
sp|O43175|SERA_HUMAN D-3-phosphoglycerate dehydrogenase PHGDH  561 57356 1 0.866 0.803 5 
sp|Q16531|DDB1_HUMAN DNA damage-binding protein 1 DDB1  972 128142 1 0.882 0.987 2 
sp|P78527|PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit PRKDC  1222 473749 1 0.695 0.194 1 
sp|O14802|RPC1_HUMAN DNA-directed RNA polymerase III subunit RPC1 POLR3A  75 157537 1 1.267 1.572 1 
sp|P31689|DNJA1_HUMAN DnaJ homolog subfamily A member 1 DNAJA1  347 45581 1 1.782 0.711 7 
sp|O60884|DNJA2_HUMAN DnaJ homolog subfamily A member 2 DNAJA2  239 46344 1 2.232 1.314 7 
sp|O95793|STAU1_HUMAN Double-stranded RNA-binding protein Staufen homolog 1 STAU1  207 63428 1 1.161 1.872 5 
sp|Q8IUD2|RB6I2_HUMAN ELKS/Rab6-interacting/CAST family member 1 ERC1  66 128236 1 1.506 1.232 2 
sp|P26641|EF1G_HUMAN Elongation factor 1-gamma EEF1G  74 50429 1 1.089 0.877 7 
sp|P13639|EF2_HUMAN Elongation factor 2 EEF2  101 96246 1 0.723 2.788 2 
sp|P14625|ENPL_HUMAN Endoplasmin HSP90B1  65 92696 1 0.732 0.776 2 
sp|O94905|ERLN2_HUMAN Erlin-2 ERLIN2  146 38044 1 3.107 1.489 7 
sp|Q8WVX9|FACR1_HUMAN Fatty acyl-CoA reductase 1 FAR1  296 59661 1 0.792 0.593 6 
sp|P04075|ALDOA_HUMAN Fructose-bisphosphate aldolase A ALDOA  89 39851 1 1.505 1.824 7 
sp|P49448|DHE4_HUMAN Glutamate dehydrogenase 2, mitochondrial GLUD2  49 61738 1 0.871 0.547 5 
sp|Q9BQ67|GRWD1_HUMAN Glutamate-rich WD repeat-containing protein 1 GRWD1  43 49787 1 0.946 0.534 6 
sp|P13807|GYS1_HUMAN Glycogen [starch] synthase, muscle GYS1  217 84531 1 2.361 18.633 3 
sp|P46976|GLYG_HUMAN Glycogenin-1 GYG1  70 39701 1 2.674 15.442 7 
sp|Q9HAV0|GBB4_HUMAN Guanine nucleotide-binding protein subunit beta-4 GNB4  44 38284 1 1.312 0.369 7 
sp|O00165|HAX1_HUMAN HCLS1-associated protein X-1 HAX1  63 31601 1 1.25 0.533 7 
sp|P08107|HSP71_HUMAN Heat shock 70 kDa protein 1A/1B HSPA1A  2481 70294 1 1.314 1.082 4 
sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein HSPA8  2708 71082 1 1.273 1.122 4 
sp|P07900|HS90A_HUMAN Heat shock protein HSP 90-alpha HSP90AA1  574 85006 1 1.795 0.656 2 
sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta HSP90AB1  1034 83554 1 1.183 0.717 3 
sp|P54652|HSP72_HUMAN Heat shock-related 70 kDa protein 2 HSPA2  102 70263 1 2.817 1.704 3 
sp|Q13151|ROA0_HUMAN Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0  52 30993 1 0.764 0.438 7 
sp|Q14103|HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 HNRNPD  82 38581 1 1.111 0.861 7 
sp|P52597|HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F HNRNPF  83 45985 1 0.677 0.511 7 
sp|P31943|HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H HNRNPH1  303 49484 1 1.643 0.747 6 
sp|P52272|HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M HNRNPM  49 77749 1 1.078 1.483 3 
sp|Q00839|HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U HNRNPU  85 91269 1 0.865 1.007 2 
sp|Q9BUJ2|HNRL1_HUMAN Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPUL1  521 96250 1 1.07 1.122 2 
sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1  189 37464 1 1.131 0.574 7 
sp|Q86X55|CARM1_HUMAN Histone-arginine methyltransferase CARM1 CARM1  81 63989 1 0.758 1.96 5 
sp|O14654|IRS4_HUMAN Insulin receptor substrate 4 IRS4  739 134711 1 2.956 1.435 1 
sp|Q53GT1|KLH22_HUMAN Kelch-like protein 22 KLHL22  57 72648 1 1.238 1.525 4 
sp|Q8NI77|KI18A_HUMAN Kinesin-like protein KIF18A KIF18A  63 103414 1 1.517 1.423 2 
sp|Q9BTT6|LRRC1_HUMAN Leucine-rich repeat-containing protein 1 LRRC1  161 59946 1 1.294 2.164 5 
sp|P07195|LDHB_HUMAN L-lactate dehydrogenase B chain LDHB  63 36900 1 1.001 0.703 7 
sp|Q3ZCQ8|TIM50_HUMAN Mitochondrial import inner membrane translocase subunit TIM50 TIMM50  256 39850 1 1.563 0.648 7 
sp|O94842|TOX4_HUMAN Myosin light chain kinase 2, skeletal/cardiac muscle MYLK2  374 65214 1 1.106 1.86 3 
sp|Q12972|PP1R8_HUMAN Nuclear inhibitor of protein phosphatase 1 PPP1R8  663 38626 1 2.831 1.664 7 
sp|P67809|YBOX1_HUMAN Nuclease-sensitive element-binding protein 1 YBX1  139 35903 1 2.237 1.3 7 
sp|Q14318|FKBP8_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP8 FKBP8  77 44990 1 0.934 0.557 6 
sp|Q00325|MPCP_HUMAN Phosphate carrier protein, mitochondrial SLC25A3  60 40525 1 1.068 0.651 7 
sp|Q9NWS0|PIHD1_HUMAN PIH1 domain-containing protein 1 PIH1D1  302 32513 1 1.716 2.572 7 
sp|Q15365|PCBP1_HUMAN Poly(rC)-binding protein 1 PCBP1  56 37987 1 0.822 0.503 7 
sp|Q15366|PCBP2_HUMAN Poly(rC)-binding protein 2 PCBP2  55 38955 1 1.653 1.118 7 
sp|P11940|PABP1_HUMAN Polyadenylate-binding protein 1 PABPC1  228 70854 1 1.086 0.607 4 
sp|Q99623|PHB2_HUMAN Prohibitin-2 PHB2  201 33276 1 2.26 1.644 7 
sp|Q8NG31|CASC5_HUMAN Protein CASC5 CASC5  161 268190 1 1.057 1.24 1 
sp|Q96SW2|CRBN_HUMAN Protein cereblon CRBN  470 51425 1 0.834 0.63 6 
sp|Q96RT1|LAP2_HUMAN Protein LAP2 ERBB2IP  58 158941 1 0.91 0.626 1 
sp|Q7Z3U7|MON2_HUMAN Protein MON2 homolog MON2  44 192475 1 1.25 0.532 1 
sp|O60927|PP1RB_HUMAN Protein phosphatase 1 regulatory subunit 11 PPP1R11  43 14229 1 1.104 1.1 8 
sp|O14974|MYPT1_HUMAN Protein phosphatase 1 regulatory subunit 12A PPP1R12A  4550 115610 1 1.143 0.784 2 
sp|O60237|MYPT2_HUMAN Protein phosphatase 1 regulatory subunit 12B PPP1R12B  733 110793 1 1.098 0.739 2 
sp|Q9BZL4|PP12C_HUMAN Protein phosphatase 1 regulatory subunit 12C PPP1R12C  2040 85286 1 1.158 1.163 2 
sp|Q86XI6|PPR3B_HUMAN Protein phosphatase 1 regulatory subunit 3B PPP1R3B  195 33073 1 2.283 2.457 7 
sp|O95685|PPR3D_HUMAN Protein phosphatase 1 regulatory subunit 3D PPP1R3D  228 33280 1 5.325 23.153 7 
sp|Q15435|PP1R7_HUMAN Protein phosphatase 1 regulatory subunit 7 PPP1R7  1644 41653 1 3.02 1.687 7 
sp|Q14160|SCRIB_HUMAN Protein scribble homolog SCRIB  119 175748 1 1.584 1.555 1 
sp|Q92734|TFG_HUMAN Protein TFG TFG  77 43478 1 1.016 0.797 6 
sp|O15027|SC16A_HUMAN Protein transport protein Sec16A SEC16A  153 234855 1 1.101 0.953 1 
sp|P61619|S61A1_HUMAN Protein transport protein Sec61 subunit alpha isoform 1 SEC61A1  46 52687 1 2.06 1.017 7 
sp|Q9P035|PTAD1_HUMAN Protein tyrosine phosphatase-like protein PTPLAD1 PTPLAD1  110 43360 1 2.698 1.088 7 
sp|P41236|IPP2_HUMAN Putative protein phosphatase inhibitor 2-like protein 3 PPP1R2P3  101 23091 1 0.246 0.706 8 
sp|P31751|AKT2_HUMAN RAC-alpha serine/threonine-protein kinase AKT1  72 56050 0 0 0 3 
sp|Q02833|RASF7_HUMAN Ras association domain-containing protein 7 RASSF7  175 40548 1 1.689 1.001 7 
sp|Q8NHQ8|RASF8_HUMAN Ras association domain-containing protein 8 RASSF8  296 48526 1 0.86 0.512 6 
sp|Q8WUF5|IASPP_HUMAN RelA-associated inhibitor PPP1R13L  767 89378 1 1.383 1.28 2 
sp|Q15293|RCN1_HUMAN Reticulocalbin-1 RCN1  41 38866 1 2.243 1.215 7 
sp|O94822|RN160_HUMAN RING finger protein 160 RNF160  126 203077 1 1.008 1.012 1 
sp|Q9H6T3|RPAP3_HUMAN RNA polymerase II-associated protein 3 RPAP3  333 75957 1 0.758 1.418 3 
sp|Q01844|EWS_HUMAN RNA-binding protein EWS EWSR1  268 68721 1 1.077 1 3 
sp|Q9Y265|RUVB1_HUMAN RuvB-like 1 RUVBL1  778 50538 1 0.579 0.93 6 
sp|Q9Y230|RUVB2_HUMAN RuvB-like 2 RUVBL2  2520 51296 1 0.776 1.036 6 
sp|P16615|AT2A2_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2  391 116336 1 0.97 0.671 2 
sp|Q96QC0|PP1RA_HUMAN Serine/threonine-protein phosphatase 1 regulatory subunit 10 PPP1R10  730 99338 1 1.299 1.481 2 
sp|Q08209|PP2BA_HUMAN 
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 
PPP3CA  46 59335 1 1.002 1.262 3 
sp|Q96HS1|PGAM5_HUMAN Serine/threonine-protein phosphatase PGAM5, mitochondrial PGAM5  158 32213 1 2.669 1.382 7 
sp|P62136|PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit PPP1CA  63 38229 1 1.477 1.483 7 
sp|P62140|PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit PPP1CB  4176 37961 1 1.152 0.866 3 
sp|P36873|PP1G_HUMAN Serine/threonine-protein phosphatase PP1-gamma catalytic subunit PPP1CC  79 37701 1 1.32 1.079 7 
sp|Q9H788|SH24A_HUMAN SH2 domain-containing protein 4A SH2D4A  1359 52922 1 0.846 0.45 6 
sp|P05023|AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1  282 114135 1 0.87 0.617 2 
sp|P38646|GRP75_HUMAN Stress-70 protein, mitochondrial HSPA9  2554 73920 1 0.946 1.113 4 
sp|P17987|TCPA_HUMAN T-complex protein 1 subunit alpha TCP1  1942 60819 1 0.902 0.8 5 
sp|P78371|TCPB_HUMAN T-complex protein 1 subunit beta CCT2  2379 57794 1 0.946 0.797 5 
sp|P50991|TCPD_HUMAN T-complex protein 1 subunit delta CCT4  1786 58401 1 0.889 0.838 5 
sp|P48643|TCPE_HUMAN T-complex protein 1 subunit epsilon CCT5  1093 60089 1 0.939 0.849 5 
sp|Q99832|TCPH_HUMAN T-complex protein 1 subunit eta CCT7  2615 59842 1 1.08 0.91 5 
sp|P49368|TCPG_HUMAN T-complex protein 1 subunit gamma CCT3  1609 61066 1 0.994 0.91 5 
sp|P50990|TCPQ_HUMAN T-complex protein 1 subunit theta CCT8  3197 60153 1 0.978 0.937 5 
sp|P40227|TCPZ_HUMAN T-complex protein 1 subunit zeta CCT6A  1058 58444 1 1.097 1.256 5 
sp|Q92526|TCPW_HUMAN T-complex protein 1 subunit zeta-2 CCT6B  392 58299 1 0.396 0.24 5 
sp|Q13263|TIF1B_HUMAN Transcription intermediary factor 1-beta TRIM28  44 90261 1 0.821 0.652 2 
sp|P55072|TERA_HUMAN Transitional endoplasmic reticulum ATPase VCP  196 89950 1 0.73 0.785 2 
sp|Q92616|GCN1L_HUMAN Translational activator GCN1 GCN1L1  223 294967 1 0.766 0.488 1 
sp|P43307|SSRA_HUMAN Translocon-associated protein subunit alpha SSR1  109 32215 1 4.159 0.954 7 
sp|Q9UPQ9|TNR6B_HUMAN Trinucleotide repeat-containing gene 6B protein TNRC6B  39 194739 1 1.331 1.479 1 
sp|P68363|TBA1B_HUMAN Tubulin alpha-1B chain TUBA1B  2221 50804 1 0.823 0.383 6 
sp|P07437|TBB5_HUMAN Tubulin beta chain TUBB  3358 50095 1 0.781 0.472 6 
sp|Q13885|TBB2A_HUMAN Tubulin beta-2A chain TUBB2A  2737 50274 1 0.837 0.301 6 
sp|Q9BVA1|TBB2B_HUMAN Tubulin beta-2B chain TUBB2B  2787 50377 1 0.711 0.353 6 
sp|P68371|TBB2C_HUMAN Tubulin beta-2C chain TUBB2C  3707 50255 1 0.816 0.373 6 
sp|Q9BUF5|TBB6_HUMAN Tubulin beta-6 chain TUBB6  631 50281 1 0.452 0.154 6 
sp|Q9BZF9|UACA_HUMAN Uveal autoantigen with coiled-coil domains and ankyrin repeats UACA  711 163545 1 1.965 1.416 1 
sp|P08670|VIME_HUMAN Vimentin VIM  94 53676 1 0.955 0.413 6 
sp|P21796|VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 VDAC1  45 30868 1 1.838 0.909 7 
sp|P45880|VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2 VDAC2  50 32060 1 1.549 0.897 7 
sp|Q6UXN9|WDR82_HUMAN WD repeat-containing protein 82 WDR82  78 35456 1 6.186 3.984 7 
sp|Q96MX6|WDR92_HUMAN WD repeat-containing protein 92 WDR92  267 40171 1 1.468 2.636 7 
sp|P49750|YLPM1_HUMAN YLP motif-containing protein 1 YLPM1  140 220077 1 1.208 1.101 1 
sp|O95405|ZFYV9_HUMAN Zinc finger FYVE domain-containing protein 9 ZFYVE9  344 158926 1 2.544 1.948 1 
sp|O95229|ZWINT_HUMAN ZW10 interactor ZWINT  52 31331 1 1.878 1.621 7 
 
Appendix III 
Proteins were purified using GFP-Trap® beads from lysates of cells stably expressing GFP-TAP-PP1α, GFP-TAP-PP1β and GFP-TAP-
PP1γ. Peptides were extracted from the SDS gel (Figure 3.10) and identified from the UniProt database (UniProt; description). Peptides 
were quantitatively measured using the MS Quant software following the dimethyl labelling. For each protein, the sum of the raw 
intensity values obtained from the three preparations is also given.  
 
Uniprot Protein Descriptions Peps 
MW 
(kDa) 
Intensity 
Intensity 
PP1 alpha 
Intensity 
PP1 beta 
Intensity PP1 
gamma 
O00264 
PGRC1_HUMAN Membrane-associated progesterone receptor component 1 
PGRMC1  2 21.67 1990000 263480 1096300 630230 
O00303 EIF3F_HUMAN Eukaryotic translation initiation factor 3 subunit F EIF3F  2 37.56 3264300 125970 2823400 314850 
O14818 PSA7_HUMAN Proteasome subunit alpha type-7 PSMA7  2 27.89 3589700 479160 1416500 1694000 
Q5SRD1 
TI23B_HUMAN Putative mitochondrial import inner membrane translocase subunit 
Tim23B TIMM23B  2 28.05 2398600 796530 826910 775120 
O43143 
DHX15_HUMAN Putative pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15 DHX15  2 90.93 21254000 14210000 6197000 847050 
O43813 LANC1_HUMAN LanC-like protein 1 LANCL1  2 45.28 2282200 184690 1009000 1088500 
P15531 NDKA_HUMAN Nucleoside diphosphate kinase A NME1  2 17.15 2886500 378820 1611500 896180 
O60812 HNRCL_HUMAN Heterogeneous nuclear ribonucleoprotein C-like 1 HNRNPCL1  2 32.14 3129700 412270 1762800 954610 
O60814 H2B1K_HUMAN Histone H2B type 1-K HIST1H2BK  2 13.89 9794300 749420 4518700 4526200 
O75190 DNJB6_HUMAN DnaJ homolog subfamily B member 6 DNAJB6  2 36.09 1677200 496290 593720 587230 
O75489 
NDUS3_HUMAN NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial NDUFS3  2 30.24 1404800 329960 697310 377540 
O75533 SF3B1_HUMAN Splicing factor 3B subunit 1 SF3B1  2 145.83 2313400 725960 514670 1072800 
O95347 SMC2_HUMAN Structural maintenance of chromosomes protein 2 SMC2  2 135.65 2030000 576850 1212200 240920 
O95831 AIFM1_HUMAN Apoptosis-inducing factor 1, mitochondrial AIFM1  2 66.90 2039300 1368400 419100 251790 
P01111 RASN_HUMAN GTPase NRas NRAS  2 21.23 5760800 382930 768000 4609900 
P05198 IF2A_HUMAN Eukaryotic translation initiation factor 2 subunit 1 EIF2S1  2 36.11 1444100 166140 676610 601320 
P05387 RLA2_HUMAN 60S acidic ribosomal protein P2 RPLP2  2 11.67 5034900 634660 2213500 2186700 
P07737 PROF1_HUMAN Profilin-1 PFN1  2 15.05 2262300 344090 1189000 729160 
P09104 ENOG_HUMAN Gamma-enolase ENO2  2 47.27 9967200 839770 5900200 3227300 
P10606 COX5B_HUMAN Cytochrome c oxidase subunit 5B, mitochondrial COX5B  2 13.70 2282300 455550 639760 1187000 
P14866 HNRPL_HUMAN Heterogeneous nuclear ribonucleoprotein L HNRNPL  2 64.13 858750 173630 393910 291210 
P22087 FBRL_HUMAN rRNA 2-O-methyltransferase fibrillarin FBL  2 33.78 40577000 5016600 31394000 4166600 
P23526 SAHH_HUMAN Adenosylhomocysteinase AHCY  2 47.72 1961700 407430 609620 944690 
P23528 COF1_HUMAN Cofilin-1 CFL1  2 18.50 13612000 1514900 8331400 3765200 
P24666 PPAC_HUMAN Low molecular weight phosphotyrosine protein phosphatase ACP1 2 18.04 4297500 478830 645330 3173300 
P25789 PSA4_HUMAN Proteasome subunit alpha type-4 PSMA4  2 29.48 3905600 739220 2421600 744770 
P26640 SYVC_HUMAN Valine--tRNA ligase VARS  2 140.47 2212500 406990 306010 1499500 
P27348 1433T_HUMAN 14-3-3 protein theta YWHAQ  2 27.76 648960 40230 342010 266720 
P27694 RFA1_HUMAN Replication protein A 70 kDa DNA-binding subunit RPA1  2 68.14 7397900 473520 6394200 530150 
P27797 CALR_HUMAN Calreticulin CALR  2 48.14 1464700 365930 811890 286860 
P28066 PSA5_HUMAN Proteasome subunit alpha type-5 PSMA5  2 26.41 2125000 361190 1168700 595050 
P29692 EF1D_HUMAN Elongation factor 1-delta EEF1D  2 31.12 4433300 454080 1926100 2053100 
P32119 PRDX2_HUMAN Peroxiredoxin-2 PRDX2  2 21.89 4494300 1577800 738240 2178200 
P32969 RL9_HUMAN 60S ribosomal protein L9 RPL9  2 21.86 2154900 253280 832140 1069500 
P34932 HSP74_HUMAN Heat shock 70 kDa protein 4 HSPA4  2 94.33 6605500 1401300 802060 4402100 
P38919 IF4A3_HUMAN Eukaryotic initiation factor 4A-III EIF4A3  2 46.87 2352000 388410 835620 1128000 
P39019 RS19_HUMAN 40S ribosomal protein S19 RPS19  2 16.06 11593000 1443600 5407700 4741900 
P42677 RS27_HUMAN 40S ribosomal protein S27 RPS27  2 9.46 9171700 1806500 4357100 3008100 
P42766 RL35_HUMAN 60S ribosomal protein L35 RPL35  2 14.55 2791400 174330 1618500 998580 
P46782 RS5_HUMAN 40S ribosomal protein S5 RPS5  2 22.88 22718000 2649500 15808000 4260400 
Q9NQ39 RS10L_HUMAN Putative 40S ribosomal protein S10-like RPS10P5 PE=5 SV=1 2 20.12 10766000 1206600 5876800 3682700 
P49411 EFTU_HUMAN Elongation factor Tu, mitochondrial TUFM  2 49.54 3642400 602590 2310400 729430 
P50914 RL14_HUMAN 60S ribosomal protein L14 RPL14  2 23.43 6871200 728500 3347200 2795500 
P52907 CAZA1_HUMAN F-actin-capping protein subunit alpha-1 CAPZA1  2 32.92 3255100 380310 1777300 1097500 
P53985 MOT1_HUMAN Monocarboxylate transporter 1 SLC16A1  2 53.94 1228400 267820 485880 474750 
P54136 SYRC_HUMAN Arginine--tRNA ligase, cytoplasmic RARS  2 75.38 5290600 787540 3158200 1344800 
P55209 NP1L1_HUMAN Nucleosome assembly protein 1-like 1 NAP1L1  2 45.37 3893200 271770 3026600 594750 
P59190 RAB15_HUMAN Ras-related protein Rab-15 RAB15  2 24.39 154600000 151080000 1176500 2350100 
P60174 TPIS_HUMAN Triosephosphate isomerase TPI1  2 30.79 4588100 736860 736060 3115200 
P61224 RAP1B_HUMAN Ras-related protein Rap-1b RAP1B  2 20.83 2808700 158570 1969700 680340 
P62081 RS7_HUMAN 40S ribosomal protein S7 RPS7  2 22.13 15305000 593460 5657800 9054100 
P62244 RS15A_HUMAN 40S ribosomal protein S15a RPS15A  2 14.84 25609000 298970 1086000 24224000 
P62318 SMD3_HUMAN Small nuclear ribonucleoprotein Sm D3 SNRPD3  2 13.92 4045400 648790 1453600 1943000 
Q15907 RB11B_HUMAN Ras-related protein Rab-11B RAB11B  2 24.49 4034500 1007100 493560 2533900 
P62805 H4_HUMAN Histone H4 HIST1H4A  2 11.37 7477000 542080 1798800 5136100 
P62826 RAN_HUMAN GTP-binding nuclear protein Ran RAN  2 24.42 4236500 387240 2425600 1423700 
P62851 RS25_HUMAN 40S ribosomal protein S25 RPS25  2 13.74 12283000 954930 6086400 5241900 
P62854 RS26_HUMAN 40S ribosomal protein S26 RPS26  2 13.02 8586900 493800 5784600 2308500 
P62899 RL31_HUMAN 60S ribosomal protein L31 RPL31  2 14.46 6470800 231030 2308700 3931100 
P62995 TRA2B_HUMAN Transformer-2 protein homolog beta TRA2B  2 33.67 7097100 1455100 2805500 2836500 
P63151 
2ABA_HUMAN Serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform PPP2R2A  2 51.69 1319700 226370 518920 574360 
P82933 RT09_HUMAN 28S ribosomal protein S9, mitochondrial MRPS9  2 45.83 1205600 151170 782290 272180 
P84098 RL19_HUMAN 60S ribosomal protein L19 RPL19  2 23.47 4276600 563490 2492500 1220600 
P84103 SRSF3_HUMAN Serine/arginine-rich splicing factor 3 SRSF3  2 19.33 4213200 559360 2731200 922640 
Q01844 EWS_HUMAN RNA-binding protein EWS EWSR1  2 68.48 17205000 349120 8625000 8231100 
Q04837 SSBP_HUMAN Single-stranded DNA-binding protein, mitochondrial SSBP1  2 17.26 17296000 702510 14403000 2191100 
Q06787 FMR1_HUMAN Fragile X mental retardation protein 1 FMR1  2 71.17 7639900 1093300 1514100 5032400 
Q07955 SRSF1_HUMAN Serine/arginine-rich splicing factor 1 SRSF1  2 27.74 3188300 1296100 699090 1193100 
Q13148 TADBP_HUMAN TAR DNA-binding protein 43 TARDBP  2 44.74 1247700 118650 516580 612470 
Q13243 SRSF5_HUMAN Serine/arginine-rich splicing factor 5 SRSF5  2 31.26 1824400 231240 636760 956440 
Q13257 MD2L1_HUMAN Mitotic spindle assembly checkpoint protein MAD2A MAD2L1  2 23.51 2613000 574230 1496600 542230 
Q13409 DC1I2_HUMAN Cytoplasmic dynein 1 intermediate chain 2 DYNC1I2  2 71.46 862990 288160 172640 402190 
Q13765 NACA_HUMAN Nascent polypeptide-associated complex subunit alpha NACA  2 23.38 2272100 317940 714430 1239700 
Q14257 RCN2_HUMAN Reticulocalbin-2 RCN2  2 36.88 4916100 669760 1755800 2490600 
Q14978 NOLC1_HUMAN Nucleolar and coiled-body phosphoprotein 1 NOLC1  2 73.60 5793700 238000 1227200 4328500 
Q15084 PDIA6_HUMAN Protein disulfide-isomerase A6 PDIA6  2 48.12 2281000 323710 578510 1378800 
Q15717 ELAV1_HUMAN ELAV-like protein 1 ELAVL1  2 36.09 4779800 1732200 1424400 1623200 
Q16576 RBBP7_HUMAN Histone-binding protein RBBP7 RBBP7  2 47.82 1526900 487150 330380 709320 
Q16629 SRSF7_HUMAN Serine/arginine-rich splicing factor 7 SRSF7  2 27.37 3258800 443050 824020 1991800 
Q53GT1 KLH22_HUMAN Kelch-like protein 22 KLHL22  2 71.67 5119700 732380 3328800 1058500 
Q8N7X1 RMXL3_HUMAN RNA-binding motif protein, X-linked-like-3 RBMXL3 2 114.94 6639300 1131600 1774300 3733400 
Q8NC51 PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein SERBP1  2 44.97 1882200 100690 496890 1284600 
Q8WVX9 FACR1_HUMAN Fatty acyl-CoA reductase 1 FAR1  2 59.36 1703100 357360 598970 746780 
Q8WXF1 PSPC1_HUMAN Paraspeckle component 1 PSPC1  2 58.74 1909500 587610 863980 457890 
Q92878 RAD50_HUMAN DNA repair protein RAD50 RAD50  2 153.89 1539600 187270 385730 966560 
Q92945 FUBP2_HUMAN Far upstream element-binding protein 2 KHSRP  2 73.11 9840900 567590 5810000 3463200 
Q99873 ANM1_HUMAN Protein arginine N-methyltransferase 1 PRMT1  2 41.52 7592400 961990 3117800 3512700 
Q9BTT6 LRRC1_HUMAN Leucine-rich repeat-containing protein 1 LRRC1  2 59.24 15743000 4937400 7378500 3427500 
Q9GZN8 CT027_HUMAN UPF0687 protein C20orf27 C20orf27  2 19.29 10142000 4393900 615050 5133000 
Q9H1R3 MYLK2_HUMAN Myosin light chain kinase 2, skeletal/cardiac muscle MYLK2  2 64.68 2.952E+09 796940000 130650000 2023900000 
Q9NTJ3 SMC4_HUMAN Structural maintenance of chromosomes protein 4 SMC4  2 147.18 837800 136060 384990 316750 
Q9NUG6 PDRG1_HUMAN p53 and DNA damage-regulated protein 1 PDRG1 2 15.51 3657000 953070 478960 2225000 
Q9NX63 
CHCH3_HUMAN Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, 
mitochondrial CHCHD3  2 26.15 1487000 274160 681590 531210 
Q9P035 HACD3_HUMAN 3-hydroxyacyl-CoA dehydratase 3 PTPLAD1  2 43.16 1597700 290050 523240 784400 
Q9UQE7 SMC3_HUMAN Structural maintenance of chromosomes protein 3 SMC3  2 141.54 1240500 656560 281790 302190 
Q9Y277 VDAC3_HUMAN Voltage-dependent anion-selective channel protein 3 VDAC3  2 30.66 1303200 196260 163110 943860 
Q9Y3U8 RL36_HUMAN 60S ribosomal protein L36 RPL36  2 12.25 8922800 706030 3914300 4302500 
Q13838 DX39B_HUMAN Spliceosome RNA helicase DDX39B DDX39B  3 48.99 34811000 9896700 21179000 3735300 
O14979 HNRDL_HUMAN Heterogeneous nuclear ribonucleoprotein D-like HNRPDL  3 46.44 2778000 470450 367770 1939800 
O43707 ACTN4_HUMAN Alpha-actinin-4 ACTN4  3 104.85 12136000 516760 5829600 5789600 
O60506 HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q SYNCRIP  3 69.60 4749200 1092700 934270 2722300 
O60884 DNJA2_HUMAN DnaJ homolog subfamily A member 2 DNAJA2  3 45.75 4561000 821350 2510900 1228800 
O95685 PPR3D_HUMAN Protein phosphatase 1 regulatory subunit 3D PPP1R3D  3 32.56 14941000 2732800 2307200 9900900 
P00403 COX2_HUMAN Cytochrome c oxidase subunit 2 MT-CO2  3 25.57 8678800 1346900 3237300 4094500 
P07910 HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC  3 33.67 24661000 2082700 11812000 10766000 
P0CG48 UBC_HUMAN Polyubiquitin-C UBC  3 77.03 79493000 10503000 33640000 35349000 
P13807 GYS1_HUMAN Glycogen [starch] synthase, muscle GYS1  3 83.79 3232200 191840 1289000 1751300 
P18621 RL17_HUMAN 60S ribosomal protein L17 RPL17  3 21.40 4430300 597980 1844400 1988000 
P27635 RL10_HUMAN 60S ribosomal protein L10 RPL10  3 24.60 5519100 548670 1946700 3023700 
P30050 RL12_HUMAN 60S ribosomal protein L12 RPL12  3 17.82 21342000 1478800 11324000 8538900 
P31946 1433B_HUMAN 14-3-3 protein beta/alpha YWHAB  3 28.08 2153300 175700 1715700 261920 
P35268 RL22_HUMAN 60S ribosomal protein L22 RPL22  3 14.79 18567000 2833800 8795100 6938000 
P35637 FUS_HUMAN RNA-binding protein FUS FUS  3 53.43 7841300 1476000 4606400 1758900 
P36542 ATPG_HUMAN ATP synthase subunit gamma, mitochondrial ATP5C1  3 33.00 5059400 637700 1536300 2885300 
P38159 RBMX_HUMAN RNA-binding motif protein, X chromosome RBMX  3 42.33 21727000 1540700 10519000 9666600 
P43307 SSRA_HUMAN Translocon-associated protein subunit alpha SSR1  3 32.24 20870000 1416900 3106500 16347000 
P48047 ATPO_HUMAN ATP synthase subunit O, mitochondrial ATP5O  3 23.28 5251500 806650 850990 3593900 
P49006 MRP_HUMAN MARCKS-related protein MARCKSL1  3 19.53 16923000 416260 12817000 3689900 
P52292 IMA2_HUMAN Importin subunit alpha-2 KPNA2  3 57.86 1889500 226550 649580 1013300 
P53007 TXTP_HUMAN Tricarboxylate transport protein, mitochondrial SLC25A1  3 34.01 4825100 798940 1045400 2980800 
P61353 RL27_HUMAN 60S ribosomal protein L27 RPL27  3 15.80 13586000 1049300 4671000 7866100 
P61981 1433G_HUMAN 14-3-3 protein gamma YWHAG  3 28.30 1465800 203730 744870 517170 
P62241 RS8_HUMAN 40S ribosomal protein S8 RPS8  3 24.21 13150000 1756800 4612500 6780400 
P62277 RS13_HUMAN 40S ribosomal protein S13 RPS13  3 17.22 7431300 610340 4028900 2792100 
P62750 RL23A_HUMAN 60S ribosomal protein L23a RPL23A  3 17.70 13076000 1959000 5511800 5604800 
P62917 RL8_HUMAN 60S ribosomal protein L8 RPL8  3 28.02 11688000 757020 4750700 6179900 
Q01130 SRSF2_HUMAN Serine/arginine-rich splicing factor 2 SRSF2  3 25.48 5880900 2602000 1319300 1959700 
Q08380 LG3BP_HUMAN Galectin-3-binding protein LGALS3BP  3 65.33 29865000 2243500 23216000 4406000 
Q12904 
AIMP1_HUMAN Aminoacyl tRNA synthase complex-interacting multifunctional 
protein 1 AIMP1  3 34.35 2048000 258430 685320 1104300 
Q12905 ILF2_HUMAN Interleukin enhancer-binding factor 2 ILF2  3 43.06 23912000 2637300 10946000 10328000 
Q13151 ROA0_HUMAN Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0  3 30.84 12151000 1325500 3068600 7756600 
Q14103 HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 HNRNPD  3 38.43 19049000 3571900 7791700 7685800 
Q15029 U5S1_HUMAN 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2  3 109.43 604190 133450 13412 457320 
Q3ZCQ8 
TIM50_HUMAN Mitochondrial import inner membrane translocase subunit TIM50 
TIMM50  3 39.65 8671900 1947200 3065900 3658800 
Q5T9A4 ATD3B_HUMAN ATPase family AAA domain-containing protein 3B ATAD3B  3 72.57 178410 33735 94447 50231 
Q7Z417 NUFP2_HUMAN Nuclear fragile X mental retardation-interacting protein 2 NUFIP2  3 76.12 1393900 311300 639440 443130 
Q92616 GCN1L_HUMAN Translational activator GCN1 GCN1L1  3 292.75 3723600 354490 1466000 1903000 
Q92896 GSLG1_HUMAN Golgi apparatus protein 1 GLG1  3 134.55 1780400 752960 719890 307550 
Q96HS1 
PGAM5_HUMAN Serine/threonine-protein phosphatase PGAM5, mitochondrial 
PGAM5  3 32.00 36851000 9299300 7583700 19968000 
Q96P70 IPO9_HUMAN Importin-9 IPO9  3 115.96 2589000 1023000 990260 575660 
Q9P2K8 E2AK4_HUMAN Eukaryotic translation initiation factor 2-alpha kinase 4 EIF2AK4  3 186.91 3091400 1956200 489810 645340 
Q9UHV9 PFD2_HUMAN Prefoldin subunit 2 PFDN2  3 16.65 8630700 1514100 1505800 5610800 
Q9UMS4 PRP19_HUMAN Pre-mRNA-processing factor 19 PRPF19  3 55.18 5798500 600410 3184500 2013600 
Q9Y262 EIF3L_HUMAN Eukaryotic translation initiation factor 3 subunit L EIF3L  3 66.73 1143900 290940 458490 394520 
Q9Y2W1 TR150_HUMAN Thyroid hormone receptor-associated protein 3 THRAP3  3 108.66 1376300 288860 899860 187530 
Q9Y3I0 RTCB_HUMAN tRNA-splicing ligase RtcB homolog C22orf28  3 55.21 7051600 2668000 1952100 2431400 
O00567 NOP56_HUMAN Nucleolar protein 56 NOP56  4 66.05 3844700 725130 1442400 1677200 
O43175 SERA_HUMAN D-3-phosphoglycerate dehydrogenase PHGDH  4 56.65 2812700 1063500 587310 1161900 
O43390 HNRPR_HUMAN Heterogeneous nuclear ribonucleoprotein R HNRNPR  4 70.94 19185000 4093700 10187000 4904100 
O60927 PP1RB_HUMAN Protein phosphatase 1 regulatory subunit 11 PPP1R11  4 13.95 31278000 3144400 5067400 23066000 
O75643 U520_HUMAN U5 small nuclear ribonucleoprotein 200 kDa helicase SNRNP200  4 244.50 4884400 1051600 2815600 1017200 
O75955 FLOT1_HUMAN Flotillin-1 FLOT1  4 47.36 16479000 2695300 5471600 8312100 
O95793 STAU1_HUMAN Double-stranded RNA-binding protein Staufen homolog 1 STAU1  4 63.18 4189600 887130 908360 2394100 
P00338 LDHA_HUMAN L-lactate dehydrogenase A chain LDHA  4 36.69 4398600 1419900 1941800 1036900 
P04843 
RPN1_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 RPN1  4 68.57 5990200 704570 3618500 1667200 
P08865 RSSA_HUMAN 40S ribosomal protein SA RPSA  4 32.85 84344000 1393400 9429200 73522000 
P12004 PCNA_HUMAN Proliferating cell nuclear antigen PCNA  4 28.77 8144400 934610 4264000 2945900 
P14618 KPYM_HUMAN Pyruvate kinase isozymes M1/M2 PKM2  4 57.94 8200200 1620800 4929800 1649700 
P19388 
RPAB1_HUMAN DNA-directed RNA polymerases I, II, and III subunit RPABC1 
POLR2E  4 24.55 20270000 12202000 1510400 6557400 
P26196 DDX6_HUMAN Probable ATP-dependent RNA helicase DDX6 DDX6  4 54.42 5334500 1304000 1392200 2638200 
P26641 EF1G_HUMAN Elongation factor 1-gamma EEF1G  4 50.12 12291000 1240200 3253900 7796800 
P39656 
OST48_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
48 kDa subunit DDOST  4 50.80 5376200 1623900 1899900 1852400 
P40429 RL13A_HUMAN 60S ribosomal protein L13a RPL13A  4 23.58 7398600 652570 2641500 4104500 
P55060 XPO2_HUMAN Exportin-2 CSE1L  4 110.42 4546700 598940 966550 2981200 
P62249 RS16_HUMAN 40S ribosomal protein S16 RPS16  4 16.45 8659800 693370 4676700 3289600 
P62263 RS14_HUMAN 40S ribosomal protein S14 RPS14  4 16.27 5783300 583920 2412900 2786500 
P62269 RS18_HUMAN 40S ribosomal protein S18 RPS18  4 17.72 8144100 699430 3425700 4018900 
P62280 RS11_HUMAN 40S ribosomal protein S11 RPS11  4 18.43 6699200 518970 3711600 2468600 
P62701 RS4X_HUMAN 40S ribosomal protein S4, X isoform RPS4X  4 29.60 7920200 742830 3171900 4005400 
P62753 RS6_HUMAN 40S ribosomal protein S6 RPS6  4 28.68 11571000 1924500 4014700 5632300 
P62829 RL23_HUMAN 60S ribosomal protein L23 RPL23  4 14.87 12238000 1221700 7380200 3636400 
P62873 
GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 
GNB1  4 37.38 1814800 242610 492420 1079800 
P62879 
GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 
GNB2  4 37.33 125320000 7736500 52181000 65406000 
P62888 RL30_HUMAN 60S ribosomal protein L30 RPL30  4 12.78 6240700 673250 3312200 2255300 
P62913 RL11_HUMAN 60S ribosomal protein L11 RPL11  4 20.25 763990000 7840700 729310000 26839000 
P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A PPIA  4 18.01 4969900 329520 2323500 2316900 
P63244 GBLP_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1  4 35.08 7881800 1780000 2201000 3900800 
P78347 GTF2I_HUMAN General transcription factor II-I GTF2I  4 112.42 1463000 133290 746200 583480 
P83731 RL24_HUMAN 60S ribosomal protein L24 RPL24  4 17.78 18035000 3191900 7170000 7672600 
Q07020 RL18_HUMAN 60S ribosomal protein L18 RPL18  4 21.63 24352000 3298300 10727000 10327000 
Q14254 FLOT2_HUMAN Flotillin-2 FLOT2  4 47.06 26213000 7577300 9139900 9495600 
Q14444 CAPR1_HUMAN Caprin-1 CAPRIN1  4 78.37 57751000 2756000 27280000 27715000 
Q15834 CC85B_HUMAN Coiled-coil domain-containing protein 85B CCDC85B  4 22.09 23413000 4635500 15351000 3426600 
Q7KZF4 SND1_HUMAN Staphylococcal nuclease domain-containing protein 1 SND1  4 102.00 7409500 327980 3049900 4031600 
Q9HCE1 MOV10_HUMAN Putative helicase MOV-10 MOV10  4 113.67 4371600 101460 2299100 1971100 
Q9NYF8 BCLF1_HUMAN Bcl-2-associated transcription factor 1 BCLAF1  4 106.12 1721400 231270 925010 565070 
Q9Y3F4 STRAP_HUMAN Serine-threonine kinase receptor-associated protein STRAP  4 38.44 11021000 1601600 4603000 4816000 
Q9Y6M1 IF2B2_HUMAN Insulin-like growth factor 2 mRNA-binding protein 2 IGF2BP2  4 66.12 11499000 2929600 7311300 1257600 
O14802 RPC1_HUMAN DNA-directed RNA polymerase III subunit RPC1 POLR3A  5 155.64 12770000 1731200 7277000 3762000 
O94905 ERLN2_HUMAN Erlin-2 ERLIN2  5 37.84 6854000 558360 4415000 1880600 
O95373 IPO7_HUMAN Importin-7 IPO7  5 119.52 4916100 1042000 797540 3076500 
P12956 XRCC6_HUMAN X-ray repair cross-complementing protein 6 XRCC6  5 69.84 13270000 1690500 7963000 3616500 
P16989 DBPA_HUMAN DNA-binding protein A CSDA  5 40.09 5487500 1946100 2120700 1420800 
P35579 MYH9_HUMAN Myosin-9 MYH9  5 226.53 21627000 1906200 8891800 10829000 
P42285 SK2L2_HUMAN Superkiller viralicidic activity 2-like 2 SKIV2L2  5 117.80 3093300 517520 1364000 1211800 
P45880 VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2 VDAC2  5 31.57 35949000 12778000 5137900 18033000 
P51991 ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3  5 39.59 15436000 1091700 11513000 2831000 
P53621 COPA_HUMAN Coatomer subunit alpha COPA  5 138.34 6808200 2634900 1594900 2578500 
P61247 RS3A_HUMAN 40S ribosomal protein S3a RPS3A  5 29.95 36701000 2252700 13038000 21410000 
P61978 HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K HNRNPK  5 50.98 7495300 1945300 1640200 3909800 
Q5JWF2 
GNAS1_HUMAN Guanine nucleotide-binding protein G(s) subunit alpha isoforms 
XLas GNAS  5 111.02 25273000 3999900 11990000 9283400 
P63104 1433Z_HUMAN 14-3-3 protein zeta/delta YWHAZ  5 27.75 3338100 506360 1522500 1309200 
P80723 BASP1_HUMAN Brain acid soluble protein 1 BASP1  5 22.69 3709600 295420 2102100 1312100 
Q01085 TIAR_HUMAN Nucleolysin TIAR TIAL1  5 41.59 27330000 2466400 13966000 10898000 
Q03252 LMNB2_HUMAN Lamin-B2 LMNB2  5 67.69 19727000 1225300 10685000 7816100 
Q04637 IF4G1_HUMAN Eukaryotic translation initiation factor 4 gamma 1 EIF4G1  5 175.49 10792000 2585400 6772200 1434100 
Q06830 PRDX1_HUMAN Peroxiredoxin-1 PRDX1  5 22.11 21566000 3236300 11558000 6771300 
Q14152 EIF3A_HUMAN Eukaryotic translation initiation factor 3 subunit A EIF3A  5 166.57 14559000 2096200 8478200 3984700 
Q15365 PCBP1_HUMAN Poly(rC)-binding protein 1 PCBP1  5 37.50 58145000 41147000 8447400 8550400 
Q58FF6 
H90B4_HUMAN Putative heat shock protein HSP 90-beta 4 HSP90AB4P PE=5 
SV=1 5 58.26 4582200 137030 3288000 1157200 
Q6P2Q9 PRP8_HUMAN Pre-mRNA-processing-splicing factor 8 PRPF8  5 273.60 9307600 3305500 3238400 2763700 
Q8TEX9 IPO4_HUMAN Importin-4 IPO4  5 118.71 1251900 128750 234620 888570 
Q96PK6 RBM14_HUMAN RNA-binding protein 14 RBM14  5 69.49 11823000 1309000 3381800 7132000 
Q9NVI7 ATD3A_HUMAN ATPase family AAA domain-containing protein 3A ATAD3A  5 71.37 8251900 3318400 3085600 1847900 
O43795 MYO1B_HUMAN Myosin-Ib MYO1B 6 131.98 7081200 1926100 3501000 1654100 
P04075 ALDOA_HUMAN Fructose-bisphosphate aldolase A ALDOA  6 39.42 16297000 2763000 5719000 7815400 
P16402 H13_HUMAN Histone H1.3 HIST1H1D  6 22.35 89197000 11480000 18964000 58752000 
P14625 ENPL_HUMAN Endoplasmin HSP90B1  6 92.47 13692000 915580 2619400 10157000 
P31689 DNJA1_HUMAN DnaJ homolog subfamily A member 1 DNAJA1  6 44.87 12012000 2620100 4608700 4783200 
P31942 HNRH3_HUMAN Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3  6 36.93 18907000 3755900 4984300 10167000 
P46777 RL5_HUMAN 60S ribosomal protein L5 RPL5  6 34.36 23495000 2370100 2989600 18135000 
P46781 RS9_HUMAN 40S ribosomal protein S9 RPS9  6 22.59 27557000 3055300 10843000 13659000 
P50402 EMD_HUMAN Emerin EMD  6 28.99 18527000 3925300 6556200 8045900 
P55072 TERA_HUMAN Transitional endoplasmic reticulum ATPase VCP  6 89.32 39064000 3538700 20219000 15306000 
P60842 IF4A1_HUMAN Eukaryotic initiation factor 4A-I EIF4A1  6 46.15 14135000 1691400 7623600 4820000 
P62258 1433E_HUMAN 14-3-3 protein epsilon YWHAE  6 29.17 29131000 4386500 15313000 9431800 
P63096 GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1  6 40.36 26108000 9304500 9200300 7602800 
P68871 HBB_HUMAN Hemoglobin subunit beta HBB  6 16.00 26747000 2954700 19903000 3889000 
Q13263 TIF1B_HUMAN Transcription intermediary factor 1-beta TRIM28  6 88.55 26105000 5627800 11113000 9364600 
Q14126 DSG2_HUMAN Desmoglein-2 DSG2  6 122.29 21621000 3221900 11282000 7117100 
Q14318 FKBP8_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP8 FKBP8  6 44.56 8171700 1748200 3132600 3290900 
Q15366 PCBP2_HUMAN Poly(rC)-binding protein 2 PCBP2  6 38.58 13664000 2295200 5239200 6130000 
Q16891 IMMT_HUMAN Mitochondrial inner membrane protein IMMT  6 83.68 8803800 2428700 2034700 4340400 
Q86VP6 CAND1_HUMAN Cullin-associated NEDD8-dissociated protein 1 CAND1  6 136.37 9338000 861870 2618100 5858000 
Q9BQG0 MBB1A_HUMAN Myb-binding protein 1A MYBBP1A  6 148.85 8791600 5742100 1913300 1136200 
Q9P2J5 SYLC_HUMAN Leucine--tRNA ligase, cytoplasmic LARS  6 134.46 10328000 8045400 1719800 563130 
Q9UPQ9 TNR6B_HUMAN Trinucleotide repeat-containing gene 6B protein TNRC6B  6 194.00 10030000 1151900 5710000 3168600 
Q9UQ80 PA2G4_HUMAN Proliferation-associated protein 2G4 PA2G4  6 43.79 17764000 1746100 4825400 11193000 
O75864 PPR37_HUMAN Protein phosphatase 1 regulatory subunit 37 PPP1R37  7 74.78 9231000 3818400 4383800 1028800 
P04899 GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2  7 40.45 6694300 438220 3092900 3163200 
P05023 AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1  7 112.89 33949000 2060100 15826000 16063000 
P07195 LDHB_HUMAN L-lactate dehydrogenase B chain LDHB  7 36.64 13562000 2479400 3794700 7287800 
P08754 GNAI3_HUMAN Guanine nucleotide-binding protein G(k) subunit alpha GNAI3  7 40.53 36964000 2051800 27419000 7492600 
P09651 ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1  7 38.75 34626000 3500500 7779900 23346000 
P15880 RS2_HUMAN 40S ribosomal protein S2 RPS2  7 31.32 189760000 3938700 68566000 117250000 
P41252 SYIC_HUMAN Isoleucine--tRNA ligase, cytoplasmic IARS  7 144.50 8517000 2548100 2611800 3357100 
P62424 RL7A_HUMAN 60S ribosomal protein L7a RPL7A  7 30.00 46533000 2625600 14920000 28987000 
P62906 RL10A_HUMAN 60S ribosomal protein L10a RPL10A  7 24.83 22114000 1587500 7845200 12681000 
Q02878 RL6_HUMAN 60S ribosomal protein L6 RPL6  7 32.73 25714000 1743300 3844300 20126000 
Q13283 G3BP1_HUMAN Ras GTPase-activating protein-binding protein 1 G3BP1  7 52.16 16786000 8864400 4954000 2968100 
Q14974 IMB1_HUMAN Importin subunit beta-1 KPNB1  7 97.17 53491000 2456400 32760000 18275000 
Q6PKG0 LARP1_HUMAN La-related protein 1 LARP1  7 123.51 18934000 6940800 6467900 5525400 
Q6S8J3 POTEE_HUMAN POTE ankyrin domain family member E POTEE  7 121.36 13860000 2706900 10424000 728840 
Q92734 TFG_HUMAN Protein TFG TFG  7 43.45 31245000 2853400 11101000 17291000 
Q96SW2 CRBN_HUMAN Protein cereblon CRBN  7 50.55 29271000 5474300 16737000 7059900 
Q9NWS0 PIHD1_HUMAN PIH1 domain-containing protein 1 PIH1D1  7 32.36 182380000 28545000 14796000 139040000 
P06748 NPM_HUMAN Nucleophosmin NPM1  8 32.58 97545000 7093900 23016000 67436000 
P12235 ADT1_HUMAN ADP/ATP translocase 1 SLC25A4  8 33.06 2799100 233370 2502300 63400 
P12277 KCRB_HUMAN Creatine kinase B-type CKB  8 42.64 29750000 2328900 15637000 11784000 
P18124 RL7_HUMAN 60S ribosomal protein L7 RPL7  8 29.23 56785000 8049700 18525000 30210000 
P21796 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 VDAC1  8 30.77 15767000 2902400 4690800 8173800 
P22626 ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1  8 37.43 31874000 3355200 10576000 17943000 
P26373 RL13_HUMAN 60S ribosomal protein L13 RPL13  8 24.26 33963000 2809600 16913000 14240000 
P35232 PHB_HUMAN Prohibitin PHB  8 29.80 44942000 2826200 23486000 18630000 
P41236 IPP2_HUMAN Protein phosphatase inhibitor 2 PPP1R2  8 23.02 296360000 46228000 91122000 159010000 
P42704 
LPPRC_HUMAN Leucine-rich PPR motif-containing protein, mitochondrial 
LRPPRC  8 157.90 6314500 2352500 1488700 2473300 
P43243 MATR3_HUMAN Matrin-3 MATR3  8 94.62 13135000 525810 3612000 8997300 
P67809 YBOX1_HUMAN Nuclease-sensitive element-binding protein 1 YBX1  8 35.92 30067000 3627000 14775000 11664000 
P68104 EF1A1_HUMAN Elongation factor 1-alpha 1 EEF1A1  8 50.14 71923000 6712600 31996000 33215000 
Q00325 MPCP_HUMAN Phosphate carrier protein, mitochondrial SLC25A3  8 40.09 89217000 16203000 29655000 43359000 
Q02833 RASF7_HUMAN Ras association domain-containing protein 7 RASSF7 8 39.95 13485000 2041900 6671400 4771300 
Q12906 ILF3_HUMAN Interleukin enhancer-binding factor 3 ILF3  8 95.34 42053000 5702900 8952500 27397000 
Q14157 UBP2L_HUMAN Ubiquitin-associated protein 2-like UBAP2L  8 114.53 17791000 2327300 7032500 8430900 
Q8IWU2 LMTK2_HUMAN Serine/threonine-protein kinase LMTK2 LMTK2  8 164.90 3785600 801930 826250 2157400 
Q96SB3 NEB2_HUMAN Neurabin-2 PPP1R9B  8 89.19 10582000 1548900 1344200 7689300 
O00425 IF2B3_HUMAN Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3  9 63.70 15672000 2686700 3752900 9232700 
O94763 RMP_HUMAN Unconventional prefoldin RPB5 interactor RMP  9 59.83 65470000 14398000 8132300 42940000 
P06576 ATPB_HUMAN ATP synthase subunit beta, mitochondrial ATP5B  9 56.56 105420000 7315100 81466000 16637000 
P07814 SYEP_HUMAN Bifunctional glutamate/proline--tRNA ligase EPRS  9 170.59 15491000 2977800 5533500 6980000 
P31943 HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H HNRNPH1  9 49.23 63073000 5132000 29287000 28654000 
P35580 MYH10_HUMAN Myosin-10 MYH10  9 229.00 21643000 3766200 9608000 8268800 
P39023 RL3_HUMAN 60S ribosomal protein L3 RPL3  9 46.11 52947000 4114700 27939000 20894000 
Q16543 CDC37_HUMAN Hsp90 co-chaperone Cdc37 CDC37  9 44.47 36004000 8904800 5753000 21347000 
Q92900 RENT1_HUMAN Regulator of nonsense transcripts 1 UPF1  9 124.34 13509000 5418700 3183300 4907000 
Q99623 PHB2_HUMAN Prohibitin-2 PHB2  9 33.30 20655000 2779000 5057600 12818000 
Q9H361 PABP3_HUMAN Polyadenylate-binding protein 3 PABPC3  9 70.03 5166400 661990 933590 3570800 
Q9P0K7 RAI14_HUMAN Ankycorbin RAI14  9 110.04 14483000 1586400 12177000 719520 
P36578 RL4_HUMAN 60S ribosomal protein L4 RPL4  10 47.70 31305000 1929000 11390000 17986000 
P49327 FAS_HUMAN Fatty acid synthase FASN  10 273.42 23804000 3825600 12317000 7660900 
P49790 NU153_HUMAN Nuclear pore complex protein Nup153 NUP153  10 153.94 23563000 2175800 9387900 11999000 
P62736 ACTA_HUMAN Actin, aortic smooth muscle ACTA2  10 42.01 28233000 3129800 11733000 13371000 
Q00839 HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U HNRNPU  10 90.58 221170000 8636300 125080000 87453000 
Q15233 NONO_HUMAN Non-POU domain-containing octamer-binding protein NONO  10 54.23 55880000 8163300 17364000 30352000 
Q15393 SF3B3_HUMAN Splicing factor 3B subunit 3 SF3B3  10 135.58 15825000 11167000 2545700 2112400 
Q8NHQ8 RASF8_HUMAN Ras association domain-containing protein 8 RASSF8  10 48.33 74753000 7522200 44559000 22672000 
Q96MX6 WDR92_HUMAN WD repeat-containing protein 92 WDR92  10 39.74 21642000 6567700 4312900 10762000 
O00571 DDX3X_HUMAN ATP-dependent RNA helicase DDX3X DDX3X  11 73.24 17744000 2146900 5582400 10015000 
P04406 G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase GAPDH  11 36.05 120710000 8332200 39470000 72908000 
P09874 PARP1_HUMAN Poly [ADP-ribose] polymerase 1 PARP1  11 113.08 22023000 1292400 7626100 13105000 
P12236 ADT3_HUMAN ADP/ATP translocase 3 SLC25A6  11 32.87 33358000 7572800 8888100 16897000 
P16615 AT2A2_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2  11 114.76 39729000 2469400 20326000 16933000 
P48643 TCPE_HUMAN T-complex protein 1 subunit epsilon CCT5  11 59.67 50736000 22757000 18504000 9474600 
P52597 HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F HNRNPF  11 45.67 59438000 7330400 23658000 28450000 
P53396 ACLY_HUMAN ATP-citrate synthase ACLY  11 120.84 14572000 5445700 4200400 4926100 
Q69YQ0 CYTSA_HUMAN Cytospin-A SPECC1L  11 124.60 4338200 74481 3889200 374590 
Q6UXN9 WDR82_HUMAN WD repeat-containing protein 82 WDR82  11 35.08 86352000 13604000 23296000 49453000 
Q9UJS0 CMC2_HUMAN Calcium-binding mitochondrial carrier protein Aralar2 SLC25A13  11 74.18 22168000 5913000 5574700 10680000 
O94842 TOX4_HUMAN TOX high mobility group box family member 4 TOX4  12 66.19 225450000 4647100 83840000 136960000 
P05141 ADT2_HUMAN ADP/ATP translocase 2 SLC25A5  12 32.85 384090000 94845000 109980000 179270000 
P05388 RLA0_HUMAN 60S acidic ribosomal protein P0 RPLP0  12 34.27 205060000 13137000 46938000 144980000 
P13639 EF2_HUMAN Elongation factor 2 EEF2  12 95.34 64426000 4096000 18704000 41626000 
P25705 ATPA_HUMAN ATP synthase subunit alpha, mitochondrial ATP5A1  12 59.75 59651000 18939000 19126000 21585000 
P46013 KI67_HUMAN Antigen KI-67 MKI67  12 358.69 8760900 1262400 3842000 3656500 
P49368 TCPG_HUMAN T-complex protein 1 subunit gamma CCT3  12 60.53 139850000 69877000 58257000 11718000 
P49750 YLPM1_HUMAN YLP motif-containing protein 1 YLPM1  12 219.98 15827000 2865500 5123500 7837600 
Q13310 PABP4_HUMAN Polyadenylate-binding protein 4 PABPC4  12 70.78 68315000 18139000 19039000 31136000 
Q14160 SCRIB_HUMAN Protein scribble homolog SCRIB  12 174.88 15572000 5196700 2639700 7735600 
Q9BUF5 TBB6_HUMAN Tubulin beta-6 chain TUBB6  12 49.86 14362000 3119500 6878100 4365000 
Q9H2D6 TARA_HUMAN TRIO and F-actin-binding protein TRIOBP  12 261.37 52842000 20552000 22459000 9830500 
Q9H788 SH24A_HUMAN SH2 domain-containing protein 4A SH2D4A  12 52.73 150010000 15695000 70797000 63515000 
Q9NR30 DDX21_HUMAN Nucleolar RNA helicase 2 DDX21  12 87.34 74994000 6323900 31990000 36679000 
O95405 ZFYV9_HUMAN Zinc finger FYVE domain-containing protein 9 ZFYVE9  13 156.40 44636000 4070900 16880000 23685000 
P06733 ENOA_HUMAN Alpha-enolase ENO1  13 47.17 80436000 9199500 42030000 29206000 
P10809 CH60_HUMAN 60 kDa heat shock protein, mitochondrial HSPD1  13 61.05 56889000 35593000 13678000 7618900 
P40227 TCPZ_HUMAN T-complex protein 1 subunit zeta CCT6A  13 58.02 200690000 57429000 125690000 17566000 
Q13509 TBB3_HUMAN Tubulin beta-3 chain TUBB3  13 50.43 10885000 2888400 6504800 1491400 
Q7L2E3 DHX30_HUMAN Putative ATP-dependent RNA helicase DHX30 DHX30  13 133.94 7116000 1372600 2105100 3638300 
A6NKD9 CC85C_HUMAN Coiled-coil domain-containing protein 85C CCDC85C  14 45.21 116920000 29474000 48234000 39216000 
O60237 MYPT2_HUMAN Protein phosphatase 1 regulatory subunit 12B PPP1R12B  14 110.40 12428000 3778000 7871500 778240 
O94822 LTN1_HUMAN E3 ubiquitin-protein ligase listerin LTN1  14 200.55 19826000 4348300 9261200 6216600 
P17844 DDX5_HUMAN Probable ATP-dependent RNA helicase DDX5 DDX5  14 69.15 42169000 5785200 21385000 14998000 
P17987 TCPA_HUMAN T-complex protein 1 subunit alpha TCP1  14 60.34 226680000 64749000 118940000 42985000 
P23246 SFPQ_HUMAN Splicing factor, proline- and glutamine-rich SFPQ  14 76.15 221020000 10572000 112970000 97486000 
P36873 
PP1G_HUMAN Serine/threonine-protein phosphatase PP1-gamma catalytic 
subunit PPP1CC  14 36.98 224200000 92292000 9411500 122500000 
P52272 HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M HNRNPM  14 77.52 56544000 6118000 15031000 35395000 
P68366 TBA4A_HUMAN Tubulin alpha-4A chain TUBA4A  14 49.92 924930 192250 624910 107780 
Q12972 PP1R8_HUMAN Nuclear inhibitor of protein phosphatase 1 PPP1R8  14 38.48 286390000 45088000 108790000 132510000 
Q8WWM7 ATX2L_HUMAN Ataxin-2-like protein ATXN2L  14 113.37 22939000 5936600 5667800 11335000 
Q92841 DDX17_HUMAN Probable ATP-dependent RNA helicase DDX17 DDX17  14 72.37 332070000 155530000 78280000 98264000 
Q99832 TCPH_HUMAN T-complex protein 1 subunit eta CCT7  14 59.37 103890000 28451000 68798000 6636600 
Q9BUJ2 
HNRL1_HUMAN Heterogeneous nuclear ribonucleoprotein U-like protein 1 
HNRNPUL1  14 95.74 290450000 7288100 163350000 119820000 
P20700 LMNB1_HUMAN Lamin-B1 LMNB1  15 66.41 168260000 21171000 84476000 62617000 
P78371 TCPB_HUMAN T-complex protein 1 subunit beta CCT2  15 57.49 52999000 19272000 19024000 14704000 
Q9H6T3 RPAP3_HUMAN RNA polymerase II-associated protein 3 RPAP3  15 75.72 45453000 15330000 6374800 23748000 
Q9Y265 RUVB1_HUMAN RuvB-like 1 RUVBL1  15 50.23 159890000 27094000 13279000 119510000 
P19338 NUCL_HUMAN Nucleolin NCL  16 76.61 374260000 35806000 212090000 126370000 
P23396 RS3_HUMAN 40S ribosomal protein S3 RPS3  16 26.69 157510000 32821000 54290000 70399000 
Q08211 DHX9_HUMAN ATP-dependent RNA helicase A DHX9  16 140.96 91019000 7686800 66548000 16785000 
Q9NZI8 IF2B1_HUMAN Insulin-like growth factor 2 mRNA-binding protein 1 IGF2BP1  16 63.48 70209000 9547400 19554000 41108000 
Q9Y230 RUVB2_HUMAN RuvB-like 2 RUVBL2  16 51.16 588780000 98278000 136760000 353740000 
P62136 
PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
PPP1CA  17 37.51 497390000 327950000 21760000 147670000 
Q00610 CLH1_HUMAN Clathrin heavy chain 1 CLTC  17 191.61 47550000 4108700 25655000 17786000 
Q9BQE3 TBA1C_HUMAN Tubulin alpha-1C chain TUBA1C  17 49.90 8163900 1773900 3075100 3314900 
P50991 TCPD_HUMAN T-complex protein 1 subunit delta CCT4  18 57.92 137880000 21195000 88758000 27930000 
P62140 
PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit 
PPP1CB  18 37.19 711640000 96634000 331810000 283190000 
Q13885 TBB2A_HUMAN Tubulin beta-2A chain TUBB2A  18 49.91 16005000 3084700 6564400 6355600 
Q96QC0 
PP1RA_HUMAN Serine/threonine-protein phosphatase 1 regulatory subunit 10 
PPP1R10  18 99.06 606260000 11377000 302290000 292580000 
Q9BZF9 
UACA_HUMAN Uveal autoantigen with coiled-coil domains and ankyrin repeats 
UACA  18 162.50 10290000 1866800 6873900 1548900 
P11940 PABP1_HUMAN Polyadenylate-binding protein 1 PABPC1  19 70.67 236150000 51258000 81154000 103740000 
P68363 TBA1B_HUMAN Tubulin alpha-1B chain TUBA1B  19 50.15 1.383E+09 337150000 594730000 450830000 
P08670 VIME_HUMAN Vimentin VIM  20 53.65 88437000 26200000 34993000 27244000 
P50990 TCPQ_HUMAN T-complex protein 1 subunit theta CCT8  20 59.62 119180000 42524000 41808000 34848000 
P68371 TBB4B_HUMAN Tubulin beta-4B chain TUBB4B  20 49.83 1.139E+09 176430000 593400000 369550000 
P07437 TBB5_HUMAN Tubulin beta chain TUBB  21 49.67 1.26E+09 250280000 494290000 514900000 
Q8WUF5 IASPP_HUMAN RelA-associated inhibitor PPP1R13L  21 89.09 85900000 22728000 39471000 23700000 
P11021 GRP78_HUMAN 78 kDa glucose-regulated protein HSPA5  22 72.33 314740000 74026000 136070000 104640000 
Q13625 ASPP2_HUMAN Apoptosis-stimulating of p53 protein 2 TP53BP2  22 125.61 384000000 197590000 126860000 59545000 
Q9BZL4 PP12C_HUMAN Protein phosphatase 1 regulatory subunit 12C PPP1R12C  22 84.88 81083000 4875800 68310000 7897600 
Q96KQ4 ASPP1_HUMAN Apoptosis-stimulating of p53 protein 1 PPP1R13B  23 119.56 102470000 12636000 50107000 39723000 
Q96RT1 LAP2_HUMAN Protein LAP2 ERBB2IP  23 158.30 201850000 51190000 13762000 136890000 
O14654 IRS4_HUMAN Insulin receptor substrate 4 IRS4  24 133.77 97303000 44358000 34832000 18112000 
Q15435 PP1R7_HUMAN Protein phosphatase 1 regulatory subunit 7 PPP1R7  24 41.56 1.639E+09 181660000 476830000 980200000 
Q9H792 PEAK1_HUMAN Pseudopodium-enriched atypical kinase 1 PEAK1  24 193.10 41215000 17337000 8885100 14992000 
P08107 HSP71_HUMAN Heat shock 70 kDa protein 1A/1B HSPA1A  26 70.05 2.626E+09 679140000 866750000 1079700000 
P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha HSP90AA1  27 84.66 645930000 94535000 161090000 390310000 
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein HSPA8  27 70.90 848120000 137370000 262330000 448420000 
P08238 HS90B_HUMAN Heat shock protein HSP 90-beta HSP90AB1  28 83.26 2.355E+09 112550000 680150000 1562200000 
P38646 GRP75_HUMAN Stress-70 protein, mitochondrial HSPA9  28 73.68 1.017E+09 249330000 332490000 434880000 
Q14684 RRP1B_HUMAN Ribosomal RNA processing protein 1 homolog B RRP1B  29 84.43 971910000 35669000 314730000 621510000 
P27708 PYR1_HUMAN CAD protein CAD  30 242.98 115290000 25552000 52310000 37424000 
Q16531 DDB1_HUMAN DNA damage-binding protein 1 DDB1  37 126.97 203100000 24195000 55835000 123070000 
O14974 MYPT1_HUMAN Protein phosphatase 1 regulatory subunit 12A PPP1R12A  45 115.28 268120000 9522900 246310000 12295000 
 
 
 
 
Appendix IVa 
Proteins listed in Appendix III were used to determine the ratio of the different isoform preferences from the raw intensity values. The raw 
intensity values of each isoform was divided as follows: alpha/beta (A/B); alpha/gamma (A/G); beta/alpha (B/A); beta/gamma (B/G); 
gamma/alpha (G/A); gamma/beta (G/B). Values were then converted to log 2  and are listed below.  
 
Uniprot  Uniprot description Log 2 A/B Log 2 A/G Log 2 B/A Log 2 B/G Log 2 G/A Log 2 G/B 
A6NKD9 CC85C Coiled-coil domain-containing protein 85C CCDC85C 0.680 1.082 1.898 0.352 -0.901 -0.352 
O00264 PGRC1 Membrane-associated progesterone receptor component 1 PGRMC1 -0.666 0.236 0.414 0.852 -0.372 -0.852 
O00303 EIF3F Eukaryotic translation initiation factor 3 subunit F EIF3F -3.096 0.172 0.481 3.218 -0.133 -3.218 
O00425 IF2B3 Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 0.908 -0.287 1.698 -1.245 1.252 1.245 
O00567 NOP56 Nucleolar protein 56 NOP56 0.398 0.284 0.198 -0.164 -0.106 0.164 
O00571 DDX3X ATP-dependent RNA helicase DDX3X DDX3X 0.012 -0.728 -0.193 -0.789 -0.134 0.789 
O14654 IRS4 Insulin receptor substrate 4 IRS4 1.739 2.786 -1.764 0.997 -1.622 -0.997 
O14802 RPC1 DNA-directed RNA polymerase III subunit RPC1 POLR3A -0.681 0.374 0.517 1.006 0.618 -1.006 
O14818 PSA7 Proteasome subunit alpha type-7 PSMA7  -0.173 -0.328 2.106 -0.204 2.009 0.204 
O14974 MYPT1 Protein phosphatase 1 regulatory subunit 12A PPP1R12A -3.303 1.125 2.033 4.378 -3.357 -4.378 
O14979 HNRDL Heterogeneous nuclear ribonucleoprotein D-like HNRPDL 1.746 -0.550 -1.176 -2.345 -0.558 2.345 
O43143 DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15  2.588 5.562 -1.159 2.925 -0.319 -2.925 
O43175 SERA D-3-phosphoglycerate dehydrogenase PHGDH 2.247 1.366 -3.097 -0.931 -3.919 0.931 
O43390 HNRPR Heterogeneous nuclear ribonucleoprotein R HNRNPR 0.075 1.233 0.017 1.108 0.618 -1.108 
O43707 ACTN4 Alpha-actinin-4 ACTN4 -2.105 -1.992 -0.340 0.064 0.023 -0.064 
O43795 MYO1B Myosin-Ib MYO1B 0.528 1.713 0.307 1.136 0.392 -1.136 
O43813 LANC1 LanC-like protein 1 LANCL1 -1.059 -1.065 0.598 -0.056 0.176 0.056 
O60237 MYPT2 Protein phosphatase 1 regulatory subunit 12B PPP1R12B 0.331 3.773 -2.029 3.392 -3.207 -3.392 
O60506 HNRPQ Heterogeneous nuclear ribonucleoprotein Q SYNCRIP 1.616 0.177 1.552 -1.489 1.486 1.489 
O60812 HNRCL Heterogeneous nuclear ribonucleoprotein C-like 1 HNRNPCL1 -0.706 0.282 1.651 0.939 1.301 -0.939 
O60814 H2B1K Histone H2B type 1-K HIST1H2BK  -1.202 -1.101 -1.495 0.051 -2.321 -0.051 
O60884 DNJA2 DnaJ homolog subfamily A member 2 DNAJA2 -0.222 0.913 0.095 1.085 -0.903 -1.085 
O60927 PP1RB Protein phosphatase 1 regulatory subunit 11 PPP1R11 0.702 -1.381 -1.376 -2.133 -1.288 2.133 
O75190 DNJB6 DnaJ homolog subfamily B member 6 DNAJB6  1.132 1.251 2.087 0.070 -0.291 -0.070 
O75489 NDUS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 0.311 1.299 -0.121 0.939 0.701 -0.939 
O75533 SF3B1 Splicing factor 3B subunit 1 SF3B1 1.887 0.930 -1.313 -1.006 0.679 1.006 
O75643 U520 U5 small nuclear ribonucleoprotein 200 kDa helicase SNRNP200 -0.030 1.542 -1.457 1.523 -0.544 -1.523 
O75864 PPR37 Protein phosphatase 1 regulatory subunit 37 PPP1R37 1.191 3.386 1.441 2.145 0.674 -2.145 
O75955 FLOT1 Flotillin-1 FLOT1 0.369 -0.131 0.610 -0.549 -0.188 0.549 
O94763 RMP Unconventional prefoldin RPB5 interactor RMP 2.215 -0.083 -0.240 -2.347 -1.828 2.347 
O94822 LTN1 E3 ubiquitin-protein ligase listerin LTN1 0.300 0.978 0.213 0.629 1.288 -0.629 
O94842 TOX4 TOX high mobility group box family member 4 TOX4 -2.783 -3.388 1.917 -0.654 1.853 0.654 
O94905 ERLN2 Erlin-2 ERLIN2  -1.593 -0.258 0.835 1.285 0.052 -1.285 
O95347 SMC2 Structural maintenance of chromosomes protein 2 SMC2 0.319 2.753 0.338 2.385 -1.913 -2.385 
O95373 IPO7 Importin-7 IPO7 1.776 -0.068 -0.679 -1.894 -1.065 1.894 
O95405 ZFYV9 Zinc finger FYVE domain-containing protein 9 ZFYVE9 -0.661 -1.047 -2.020 -0.435 -0.216 0.435 
O95685 PPR3D Protein phosphatase 1 regulatory subunit 3D PPP1R3D 1.635 -0.363 -2.770 -2.048 -3.701 2.048 
O95793 STAU1 Double-stranded RNA-binding protein Staufen homolog 1 STAU1 1.356 0.061 -0.076 -1.344 -0.523 1.344 
O95831 AIFM1 Apoptosis-inducing factor 1, mitochondrial AIFM1 3.098 3.936 1.253 0.789 0.637 -0.789 
P00338 LDHA L-lactate dehydrogenase A chain LDHA 0.939 1.947 -1.475 0.959 -0.624 -0.959 
P00403 COX2 Cytochrome c oxidase subunit 2 MT-CO2 0.125 -0.110 1.070 -0.285 -0.163 0.285 
P01111 RASN GTPase NRas NRAS  0.386 -2.096 -2.114 -2.532 -1.508 2.532 
P04075 ALDOA Fructose-bisphosphate aldolase A ALDOA 0.341 -0.006 -0.125 -0.397 0.127 0.397 
P04406 G3P Glyceraldehyde-3-phosphate dehydrogenase GAPDH -0.854 -1.636 -0.900 -0.832 -0.095 0.832 
P04843 RPN1 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit -0.970 0.251 0.222 1.172 -1.110 -1.172 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 -1.429 -1.358 -4.227 0.021 -1.253 -0.021 
P05023 AT1A1 Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1  -1.551 -1.469 4.317 0.032 0.853 -0.032 
P05141 ADT2 ADP/ATP translocase 2 SLC25A5  1.177 0.575 -1.266 -0.651 -1.931 0.651 
P05198 IF2A Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 -0.636 -0.362 -2.129 0.224 -0.996 -0.224 
P05387 RLA2 60S acidic ribosomal protein P2 RPLP2 -0.412 -0.291 -0.183 0.071 0.870 -0.071 
P05388 RLA0 60S acidic ribosomal protein P0 RPLP0  -0.447 -1.970 -2.380 -1.573 -2.139 1.573 
P06576 ATPB ATP synthase subunit beta, mitochondrial ATP5B -2.087 0.308 0.949 2.346 1.059 -2.346 
P06733 ENOA Alpha-enolase ENO1 -0.801 -0.173 -0.011 0.579 0.745 -0.579 
P06748 NPM Nucleophosmin NPM1 -0.308 -1.755 0.496 -1.497 -0.103 1.497 
P07195 LDHB L-lactate dehydrogenase B chain LDHB 0.776 -0.062 -1.295 -0.888 -0.460 0.888 
P07437 TBB5 Tubulin beta chain TUBB 0.409 0.453 -2.587 -0.005 -5.545 0.005 
P07737 PROF1 Profilin-1 PFN1 -0.398 0.410 -0.773 0.759 -0.071 -0.759 
P07814 SYEP Bifunctional glutamate/proline--tRNA ligase EPRS 0.496 0.265 1.724 -0.281 -0.350 0.281 
P07900 HS90A Heat shock protein HSP 90-alpha HSP90AA1 0.621 -0.552 -0.575 -1.223 -0.609 1.223 
P07910 HNRPC Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC -1.113 -0.876 0.222 0.188 -0.896 -0.188 
P08107 HSP71 Heat shock 70 kDa protein 1A/1B HSPA1A 1.039 0.825 -1.131 -0.263 -1.234 0.263 
P08238 HS90B Heat shock protein HSP 90-beta HSP90AB1 -1.205 -2.301 0.418 -1.146 -0.334 1.146 
P08670 VIME Vimentin VIM 0.973 1.437 -0.292 0.415 -2.883 -0.415 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 -2.350 -0.375 -3.388 1.925 -3.077 -1.925 
P08865 RSSA 40S ribosomal protein SA RPSA -1.368 -4.228 0.863 -2.909 0.830 2.909 
P09104 ENOG Gamma-enolase ENO2 -1.422 -0.449 0.695 0.924 0.700 -0.924 
P09651 ROA1 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 0.238 -1.244 0.002 -1.532 1.175 1.532 
P09874 PARP1 Poly [ADP-ribose] polymerase 1 PARP1 -1.170 -1.848 0.801 -0.727 1.868 0.727 
P0CG48 UBC Polyubiquitin-C UBC ;>spP0CG47UBB Polyubiquitin-B UBB -0.289 -0.257 0.549 -0.018 -1.201 0.018 
P10606 COX5B Cytochrome c oxidase subunit 5B, mitochondrial COX5B 0.900 0.112 0.626 -0.838 -0.550 0.838 
P10809 CH60 60 kDa heat shock protein, mitochondrial HSPD1 2.770 3.718 3.096 0.898 -0.155 -0.898 
P11021 GRP78 78 kDa glucose-regulated protein HSPA5 0.512 0.994 -0.734 0.433 -1.038 -0.433 
P11142 HSP7C Heat shock cognate 71 kDa protein HSPA8 0.457 -0.213 -1.672 -0.720 -1.571 0.720 
P11940 PABP1 Polyadenylate-binding protein 1 PABPC1 0.728 0.477 -0.650 -0.300 -0.441 0.300 
P12004 PCNA Proliferating cell nuclear antigen PCNA -0.799 -0.163 0.802 0.587 0.190 -0.587 
P12235 ADT1 ADP/ATP translocase 1 SLC25A4 -2.032 3.374 1.423 5.356 0.465 -5.356 
P12236 ADT3 ADP/ATP translocase 3 SLC25A6 1.159 0.336 0.127 -0.873 1.995 0.873 
P12277 KCRB Creatine kinase B-type CKB -1.357 -0.845 1.593 0.462 0.275 -0.462 
P12956 XRCC6 X-ray repair cross-complementing protein 6 XRCC6 -0.845 0.397 3.237 1.192 3.082 -1.192 
P13639 EF2 Elongation factor 2 EEF2 -0.801 -1.851 -0.645 -1.100 -0.414 1.100 
P13807 GYS1 Glycogen [starch] synthase, muscle GYS1  -1.358 -1.697 0.297 -0.388 -0.475 0.388 
P14618 KPYM Pyruvate kinase isozymes M1/M2 PKM2 -0.214 1.468 1.256 1.633 -1.745 -1.633 
P14625 ENPL Endoplasmin HSP90B1 -0.126 -1.978 -0.548 -1.901 -0.564 1.901 
P14866 HNRPL Heterogeneous nuclear ribonucleoprotein L HNRNPL 0.209 0.748 -0.368 0.490 0.148 -0.490 
P15531 NDKA Nucleoside diphosphate kinase A NME1  -0.698 0.251 -1.119 0.900 -1.151 -0.900 
P15880 RS2 40S ribosomal protein S2 RPS2 -2.731 -3.402 -0.920 -0.720 0.726 0.720 
P16402 H13 Histone H1.3 HIST1H1D  0.666 -0.862 1.966 -1.578 1.132 1.578 
P16615 AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2  -1.651 -1.284 0.252 0.317 -1.224 -0.317 
P16989 DBPA DNA-binding protein A CSDA 1.266 1.948 -2.229 0.632 -3.055 -0.632 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 DDX5 -0.496 0.119 0.854 0.566 1.652 -0.566 
P17987 TCPA T-complex protein 1 subunit alpha TCP1 0.513 2.085 -0.369 1.522 0.677 -1.522 
P18124 RL7 60S ribosomal protein L7 RPL7 0.188 -0.414 1.364 -0.652 1.603 0.652 
P18621 RL17 60S ribosomal protein L17 RPL17 -0.235 -0.239 -1.084 -0.054 -0.345 0.054 
P19338 NUCL Nucleolin NCL -1.176 -0.326 0.658 0.801 0.948 -0.801 
P19388 RPAB1 DNA-directed RNA polymerases I, II, and III subunit RPABC1 POLR2E 4.405 2.390 -1.406 -2.064 -1.768 2.064 
P20700 LMNB1 Lamin-B1 LMNB1 -0.606 -0.071 1.429 0.486 1.375 -0.486 
P21796 VDAC1 Voltage-dependent anion-selective channel protein 1 VDAC1 0.698 0.000 2.350 -0.747 0.392 0.747 
P22087 FBRL rRNA 2-O-methyltransferase fibrillarin FBL  -1.255 1.762 0.194 2.967 -0.262 -2.967 
P22626 ROA2 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 -0.266 -0.925 -0.975 -0.709 -0.674 0.709 
P23246 SFPQ Splicing factor, proline- and glutamine-rich SFPQ -2.027 -1.711 -0.512 0.266 -0.978 -0.266 
P23396 RS3 40S ribosomal protein S3 RPS3 0.664 0.393 -1.455 -0.321 -2.769 0.321 
P23526 SAHH Adenosylhomocysteinase AHCY 0.809 0.280 1.095 -0.578 0.653 0.578 
P23528 COF1 Cofilin-1 CFL1 ;>spQ9Y281COF2 Cofilin-2 CFL2 -1.069 0.180 1.358 1.200 1.714 -1.200 
P24666 PPAC Low molecular weight phosphotyrosine protein phosphatase ACP1 0.960 -1.235 -0.666 -2.244 0.879 2.244 
P25705 ATPA ATP synthase subunit alpha, mitochondrial ATP5A1 1.376 1.305 1.202 -0.121 1.118 0.121 
P25789 PSA4 Proteasome subunit alpha type-4 PSMA4 -0.321 1.483 0.341 1.755 1.767 -1.755 
P26196 DDX6 Probable ATP-dependent RNA helicase DDX6 DDX6 1.296 0.477 3.195 -0.868 1.601 0.868 
P26373 RL13 60S ribosomal protein L13 RPL13 -1.199 -0.848 -0.539 0.302 -0.042 -0.302 
P26640 SYVC Valine--tRNA ligase VARS 1.802 -0.388 1.362 -2.239 -1.081 2.239 
P26641 EF1G Elongation factor 1-gamma EEF1G -0.001 -1.159 0.706 -1.207 -0.266 1.207 
P27348 1433T 14-3-3 protein theta YWHAQ -1.697 -1.235 -1.745 0.412 0.567 -0.412 
P27635 RL10 60S ribosomal protein L10 RPL10  -0.437 -0.969 1.123 -0.582 1.004 0.582 
P27694 RFA1 Replication protein A 70 kDa DNA-binding subunit RPA1 -2.365 1.331 -0.982 3.646 -0.040 -3.646 
P27708 PYR1 CAD protein CAD 0.357 0.943 3.096 0.537 2.562 -0.537 
P27797 CALR Calreticulin CALR 0.241 1.845 1.114 1.555 0.893 -1.555 
P28066 PSA5 Proteasome subunit alpha type-5 PSMA5 -0.304 0.774 -0.265 1.028 -0.371 -1.028 
P29692 EF1D Elongation factor 1-delta EEF1D -0.694 -0.683 0.301 -0.038 0.480 0.038 
P30050 RL12 60S ribosomal protein L12 RPL12 -1.546 -1.036 -1.636 0.461 -0.470 -0.461 
P31689 DNJA1 DnaJ homolog subfamily A member 1 DNAJA1 0.576 0.625 -0.208 0.000 -0.731 0.000 
P31942 HNRH3 Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 0.982 0.057 -0.093 -0.975 1.056 0.975 
P31943 HNRH1 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 -1.122 -0.987 -1.616 0.085 -0.160 -0.085 
P31946 1433B 14-3-3 protein beta/alpha YWHAB -1.897 0.918 -0.075 2.765 -1.216 -2.765 
P32119 PRDX2 Peroxiredoxin-2 PRDX2 2.486 1.029 2.466 -1.507 1.863 1.507 
P32969 RL9 60S ribosomal protein L9 RPL9 -0.326 -0.584 -0.621 -0.308 0.569 0.308 
P34932 HSP74 Heat shock 70 kDa protein 4 HSPA4 2.195 -0.158 1.205 -2.403 2.318 2.403 
P35232 PHB Prohibitin PHB -1.664 -1.227 -1.038 0.388 -0.808 -0.388 
P35268 RL22 60S ribosomal protein L22 RPL22 -0.244 0.202 -2.195 0.396 0.175 -0.396 
P35579 MYH9 Myosin-9 MYH9 -0.831 -1.012 -0.457 -0.231 0.230 0.231 
P35580 MYH10 Myosin-10 MYH10 0.039 0.359 -0.594 0.270 -1.416 -0.270 
P35637 FUS RNA-binding protein FUS FUS -0.252 1.241 0.636 1.443 0.379 -1.443 
P36542 ATPG ATP synthase subunit gamma, mitochondrial ATP5C1 0.122 -0.684 -0.356 -0.855 0.629 0.855 
P36578 RL4 60S ribosomal protein L4 RPL4 -1.171 -1.727 -0.070 -0.605 -2.697 0.605 
P36873 PP1G Serine/threonine-protein phosphatase PP1-gamma catalytic subunit PPP1 4.684 1.085 -0.908 -3.648 0.304 3.648 
P38159 RBMX RNA-binding motif protein, X chromosome RBMX -1.381 -1.156 0.782 0.176 0.034 -0.176 
P38646 GRP75 Stress-70 protein, mitochondrial HSPA9 0.975 0.691 -0.285 -0.334 0.061 0.334 
P38919 IF4A3 Eukaryotic initiation factor 4A-III EIF4A3 0.285 -0.044 -0.001 -0.379 -2.327 0.379 
P39019 RS19 40S ribosomal protein S19 RPS19 -0.515 -0.222 0.663 0.243 0.493 -0.243 
P39023 RL3 60S ribosomal protein L3 RPL3 -1.373 -0.850 -0.739 0.473 0.787 -0.473 
P39656 OST48 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kD 1.164 1.304 0.130 0.090 0.684 -0.090 
P40227 TCPZ T-complex protein 1 subunit zeta CCT6A 0.260 3.203 2.347 2.893 1.418 -2.893 
P40429 RL13A 60S ribosomal protein L13a RPL13A  -0.627 -1.159 -1.645 -0.582 -0.639 0.582 
P41236 IPP2 Protein phosphatase inhibitor 2 PPP1R2  0.411 -0.289 -0.524 -0.749 1.310 0.749 
P41252 SYIC Isoleucine--tRNA ligase, cytoplasmic IARS 1.355 1.096 -1.776 -0.308 0.085 0.308 
P42285 SK2L2 Superkiller viralicidic activity 2-like 2 SKIV2L2 -0.008 0.266 -1.437 0.224 -2.306 -0.224 
P42677 RS27 40S ribosomal protein S27 RPS27  0.120 0.758 -0.411 0.588 0.305 -0.588 
P42704 LPPRC Leucine-rich PPR motif-containing protein, mitochondrial LRPPRC 2.051 1.422 -1.739 -0.679 -2.769 0.679 
P42766 RL35 60S ribosomal protein L35 RPL35 -1.824 -1.024 1.357 0.750 0.862 -0.750 
P43243 MATR3 Matrin-3 MATR3 -1.390 -2.603 0.216 -1.263 0.057 1.263 
P43307 SSRA Translocon-associated protein subunit alpha SSR1 0.258 -2.034 0.795 -2.342 -0.946 2.342 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 2 VDAC2 2.705 0.997 0.215 -1.758 -1.451 1.758 
P46013 KI67 Antigen KI-67 MKI67 -0.215 -0.041 1.060 0.125 1.082 -0.125 
P46777 RL5 60S ribosomal protein L5 RPL5 1.055 -1.442 -3.285 -2.547 -0.058 2.547 
P46781 RS9 40S ribosomal protein S9 RPS9 -0.437 -0.667 -1.492 -0.279 -1.806 0.279 
P46782 RS5 40S ribosomal protein S5 RPS5 -1.186 0.808 -0.938 1.945 -1.930 -1.945 
P48047 ATPO ATP synthase subunit O, mitochondrial ATP5O 1.313 -0.662 -0.776 -2.025 0.079 2.025 
P48643 TCPE T-complex protein 1 subunit epsilon CCT5 1.689 2.758 1.981 1.019 -0.503 -1.019 
P49006 MRP MARCKS-related protein MARCKSL1 -3.554 -1.654 0.607 1.850 0.088 -1.850 
P49327 FAS Fatty acid synthase FASN -0.296 0.492 1.735 0.739 1.196 -0.739 
P49368 TCPG T-complex protein 1 subunit gamma CCT3 1.653 4.070 -1.347 2.367 -0.049 -2.367 
P49411 EFTU Elongation factor Tu, mitochondrial TUFM -0.548 1.218 -2.050 1.717 -1.405 -1.717 
P49750 YLPM1 YLP motif-containing protein 1 YLPM1 0.552 0.042 -0.810 -0.560 -2.003 0.560 
P49790 NU153 Nuclear pore complex protein Nup153 NUP153 -0.719 -0.970 -0.299 -0.300 -0.961 0.300 
P50402 EMD Emerin EMD 0.650 0.458 1.390 -0.242 2.620 0.242 
P50914 RL14 60S ribosomal protein L14 RPL14 -0.810 -0.446 -2.975 0.314 -3.814 -0.314 
P50990 TCPQ T-complex protein 1 subunit theta CCT8 1.415 1.781 -0.008 0.316 -1.560 -0.316 
P50991 TCPD T-complex protein 1 subunit delta CCT4 -0.676 1.096 -0.530 1.722 -0.651 -1.722 
P51991 ROA3 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 -2.008 0.119 3.112 2.078 2.803 -2.078 
P52272 HNRPM Heterogeneous nuclear ribonucleoprotein M HNRNPM 0.094 -1.039 -0.518 -1.182 -0.057 1.182 
P52292 IMA2 Importin subunit alpha-2 KPNA2 -0.129 -0.667 3.555 -0.588 1.671 0.588 
P52597 HNRPF Heterogeneous nuclear ribonucleoprotein F HNRNPF -0.300 -0.463 -0.039 -0.212 -0.342 0.212 
P52907 CAZA1 F-actin-capping protein subunit alpha-1 CAPZA1  -0.834 -0.035 0.832 0.749 1.029 -0.749 
P53007 TXTP Tricarboxylate transport protein, mitochondrial SLC25A1 1.003 -0.406 -3.999 -1.458 -0.132 1.458 
P53396 ACLY ATP-citrate synthase ACLY 1.765 1.638 -0.528 -0.176 -1.697 0.176 
P53621 COPA Coatomer subunit alpha COPA 2.115 1.525 3.303 -0.639 -1.108 0.639 
P53985 MOT1 Monocarboxylate transporter 1 SLC16A1 0.531 0.668 -0.331 0.087 -3.756 -0.087 
P54136 SYRC Arginine--tRNA ligase, cytoplasmic RARS -0.613 0.722 -0.222 1.285 0.486 -1.285 
P55060 XPO2 Exportin-2 CSE1L 0.700 -0.822 0.699 -1.571 -0.235 1.571 
P55072 TERA Transitional endoplasmic reticulum ATPase VCP -1.124 -0.619 -0.310 0.455 -1.283 -0.455 
P55209 NP1L1 Nucleosome assembly protein 1-like 1 NAP1L1 -2.087 0.364 -1.594 2.401 0.835 -2.401 
P59190 RAB15 Ras-related protein Rab-15 RAB15  8.395 7.500 0.977 -0.944 2.708 0.944 
P60174 TPIS Triosephosphate isomerase TPI1 1.392 -0.586 -0.301 -2.028 0.418 2.028 
P60842 IF4A1 Eukaryotic initiation factor 4A-I EIF4A1  -0.782 -0.017 -0.398 0.715 -0.267 -0.715 
P61224 RAP1B Ras-related protein Rap-1b RAP1B  -2.244 -0.607 2.087 1.587 -0.347 -1.587 
P61247 RS3A 40S ribosomal protein S3a RPS3A -1.143 -1.755 0.308 -0.662 1.772 0.662 
P61353 RL27 60S ribosomal protein L27 RPL27 -0.764 -1.412 0.719 -0.698 0.986 0.698 
P61978 HNRPK Heterogeneous nuclear ribonucleoprotein K HNRNPK 1.637 0.487 1.177 -1.199 0.342 1.199 
P61981 1433G 14-3-3 protein gamma YWHAG -0.480 0.150 -0.351 0.580 -0.967 -0.580 
P62081 RS7 40S ribosomal protein S7 RPS7 -1.863 -2.438 -1.163 -0.625 -1.287 0.625 
P62136 PP1A Serine/threonine-protein phosphatase PP1-alpha catalytic subunit PPP1 5.304 2.645 0.077 -2.709 1.203 2.709 
P62140 PP1B Serine/threonine-protein phosphatase PP1-beta catalytic subunit PPP1C -0.389 -0.057 -0.727 0.282 -0.460 -0.282 
P62241 RS8 40S ribosomal protein S8 RPS8 -0.002 -0.455 -0.894 -0.502 0.954 0.502 
P62244 RS15A 40S ribosomal protein S15a RPS15A -0.471 -4.847 -1.320 -4.426 -0.697 4.426 
P62249 RS16 40S ribosomal protein S16 RPS16 -1.363 -0.752 0.913 0.561 2.196 -0.561 
P62258 1433E 14-3-3 protein epsilon YWHAE -0.413 0.389 1.171 0.753 1.865 -0.753 
P62263 RS14 40S ribosomal protein S14 RPS14 -0.657 -0.761 -3.674 -0.154 -3.744 0.154 
P62269 RS18 40S ribosomal protein S18 RPS18 -0.902 -1.029 -0.199 -0.177 -0.060 0.177 
P62277 RS13 40S ribosomal protein S13 RPS13 -1.332 -0.700 0.800 0.583 0.179 -0.583 
P62280 RS11 40S ribosomal protein S11 RPS11 -1.448 -0.756 -0.552 0.642 0.614 -0.642 
P62318 SMD3 Small nuclear ribonucleoprotein Sm D3 SNRPD3 0.227 -0.089 -2.383 -0.365 -0.254 0.365 
P62424 RL7A 60S ribosomal protein L7a RPL7A -1.116 -1.971 -2.354 -0.904 -1.687 0.904 
P62701 RS4X 40S ribosomal protein S4, X isoform RPS4X -0.704 -0.937 -1.398 -0.283 0.413 0.283 
P62736 ACTA Actin, aortic smooth muscle ACTA2  -0.516 -0.601 -1.684 -0.135 -0.374 0.135 
P62750 RL23A 60S ribosomal protein L23a RPL23A -0.102 -0.023 0.667 0.030 -0.219 -0.030 
P62753 RS6 40S ribosomal protein S6 RPS6 0.330 -0.055 1.665 -0.435 1.244 0.435 
P62805 H4 Histone H4 HIST1H4A -0.340 -1.750 -0.526 -1.460 0.729 1.460 
P62826 RAN GTP-binding nuclear protein Ran RAN -1.257 -0.385 -2.338 0.822 0.807 -0.822 
P62829 RL23 60S ribosomal protein L23 RPL23 -1.204 -0.080 0.555 1.075 -3.370 -1.075 
P62851 RS25 40S ribosomal protein S25 RPS25 -1.282 -0.963 2.419 0.269 -0.781 -0.269 
P62854 RS26 40S ribosomal protein S26 RPS26  -2.160 -0.731 -5.304 1.379 -2.628 -1.379 
P62873 GBB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GNB1 0.369 -0.660 0.390 -1.079 0.074 1.079 
P62879 GBB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 GNB2 -1.363 -1.586 -4.684 -0.272 -1.068 0.272 
P62888 RL30 60S ribosomal protein L30 RPL30 -0.908 -0.250 0.002 0.608 0.955 -0.608 
P62899 RL31 60S ribosomal protein L31 RPL31 -1.931 -2.595 -0.119 -0.714 0.078 0.714 
P62906 RL10A 60S ribosomal protein L10a RPL10A -0.915 -1.504 3.342 -0.639 3.208 0.639 
P62913 RL11 60S ribosomal protein L11 RPL11 -5.149 -0.282 -0.701 4.818 1.398 -4.818 
P62917 RL8 60S ribosomal protein L8 RPL8 -1.259 -1.535 -0.959 -0.326 1.252 0.326 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A PPIA -1.427 -1.320 1.428 0.058 1.337 -0.058 
P62995 TRA2B Transformer-2 protein homolog beta TRA2B 0.443 0.531 -1.191 0.038 -3.369 -0.038 
P63096 GNAI1 Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1 1.407 1.785 -1.634 0.329 0.380 -0.329 
P63104 1433Z 14-3-3 protein zeta/delta YWHAZ -0.198 0.123 0.447 0.272 -0.412 -0.272 
P63151 2ABA Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B  0.194 0.150 -2.486 -0.093 -1.012 0.093 
P63244 GBLP Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 1.084 0.362 0.399 -0.772 -0.393 0.772 
P67809 YBOX1 Nuclease-sensitive element-binding protein 1 YBX1 -0.636 -0.191 1.017 0.395 0.269 -0.395 
P68104 EF1A1 Elongation factor 1-alpha 1 EEF1A1  -0.863 -0.813 -1.419 0.000 -1.735 0.000 
P68363 TBA1B Tubulin alpha-1B chain TUBA1B  0.572 1.075 0.322 0.453 -1.466 -0.453 
P68366 TBA4A Tubulin alpha-4A chain TUBA4A -0.310 2.329 0.304 2.589 -0.757 -2.589 
P68371 TBB4B Tubulin beta-4B chain TUBB4B -0.359 0.427 0.174 0.737 0.345 -0.737 
P68871 HBB Hemoglobin subunit beta HBB -1.361 1.097 -0.834 2.409 -1.837 -2.409 
P78347 GTF2I General transcription factor II-I GTF2I -1.095 -0.636 -0.356 0.409 -0.926 -0.409 
P78371 TCPB T-complex protein 1 subunit beta CCT2 1.409 1.884 -8.394 0.425 -7.483 -0.425 
P80723 BASP1 Brain acid soluble protein 1 BASP1 -1.441 -0.657 -0.347 0.734 0.891 -0.734 
P82933 RT09 28S ribosomal protein S9, mitochondrial MRPS9 -0.981 0.645 1.551 1.577 -2.618 -1.577 
P83731 RL24 60S ribosomal protein L24 RPL24 0.223 0.228 1.257 -0.044 0.401 0.044 
P84098 RL19 60S ribosomal protein L19 RPL19 -0.755 0.379 2.245 1.084 0.624 -1.084 
P84103 SRSF3 Serine/arginine-rich splicing factor 3 SRSF3 -0.897 0.772 0.318 1.619 -0.252 -1.619 
Q00325 MPCP Phosphate carrier protein, mitochondrial SLC25A3 0.518 0.074 1.177 -0.494 0.115 0.494 
Q00610 CLH1 Clathrin heavy chain 1 CLTC -1.252 -0.620 -0.386 0.582 2.113 -0.582 
Q00839 HNRPU Heterogeneous nuclear ribonucleoprotein U HNRNPU -2.466 -1.846 -2.419 0.570 -0.146 -0.570 
Q01085 TIAR Nucleolysin TIAR TIAL1 -1.111 -0.650 -1.950 0.412 -0.935 -0.412 
Q01130 SRSF2 Serine/arginine-rich splicing factor 2 SRSF2  2.370 1.903 -0.020 -0.517 0.969 0.517 
Q01844 EWS RNA-binding protein EWS EWSR1 -3.236 -3.066 1.382 0.121 1.173 -0.121 
Q02833 RASF7 Ras association domain-containing protein 7 RASSF7 -0.318 0.269 0.001 0.537 0.418 -0.537 
Q02878 RL6 60S ribosomal protein L6 RPL6 0.250 -2.035 -2.157 -2.334 -1.620 2.334 
Q03252 LMNB2 Lamin-B2 LMNB2 -1.734 -1.180 2.365 0.505 -1.314 -0.505 
Q04637 IF4G1 Eukaryotic translation initiation factor 4 gamma 1 EIF4G1 0.001 2.344 0.437 2.293 0.985 -2.293 
Q04837 SSBP Single-stranded DNA-binding protein, mitochondrial SSBP1 -2.967 -0.147 0.915 2.770 1.521 -2.770 
Q06787 FMR1 Fragile X mental retardation protein 1 FMR1  0.921 -0.709 5.150 -1.679 0.298 1.679 
Q06830 PRDX1 Peroxiredoxin-1 PRDX1 -0.446 0.429 1.547 0.825 1.053 -0.825 
Q07020 RL18 60S ribosomal protein L18 RPL18 -0.311 -0.153 1.200 0.109 0.865 -0.109 
Q07955 SRSF1 Serine/arginine-rich splicing factor 1 SRSF1 2.281 1.613 0.627 -0.717 1.176 0.717 
Q08211 DHX9 ATP-dependent RNA helicase A DHX9 -1.724 0.367 0.810 2.041 0.463 -2.041 
Q08380 LG3BP Galectin-3-binding protein LGALS3BP -1.981 0.520 0.235 2.451 0.256 -2.451 
Q12904 AIMP1 Aminoacyl tRNA synthase complex-interacting multifunctional protein -0.017 -0.602 0.312 -0.635 0.170 0.635 
Q12905 ILF2 Interleukin enhancer-binding factor 2 ILF2 -0.663 -0.476 0.755 0.138 -0.362 -0.138 
Q12906 ILF3 Interleukin enhancer-binding factor 3 ILF3 0.740 -0.770 0.244 -1.560 -0.185 1.560 
Q12972 PP1R8 Nuclear inhibitor of protein phosphatase 1 PPP1R8 0.120 -0.062 1.205 -0.231 0.097 0.231 
Q13148 TADBP TAR DNA-binding protein 43 TARDBP -0.732 -0.874 0.103 -0.192 0.040 0.192 
Q13151 ROA0 Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0 0.179 -1.055 -0.222 -1.284 -0.212 1.284 
Q13243 SRSF5 Serine/arginine-rich splicing factor 5 SRSF5  -0.071 -0.555 0.764 -0.533 1.429 0.533 
Q13257 MD2L1 Mitotic spindle assembly checkpoint protein MAD2A MAD2L1 0.008 1.576 1.374 1.518 0.867 -1.518 
Q13263 TIF1B Transcription intermediary factor 1-beta TRIM28 0.409 0.759 0.909 0.301 0.267 -0.301 
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1 G3BP1 2.230 3.072 1.931 0.793 2.612 -0.793 
Q13310 PABP4 Polyadenylate-binding protein 4 PABPC4 1.321 0.714 1.825 -0.656 1.041 0.656 
Q13409 DC1I2 Cytoplasmic dynein 1 intermediate chain 2 DYNC1I2 2.130 1.013 1.081 -1.166 1.130 1.166 
Q13509 TBB3 Tubulin beta-3 chain TUBB3 0.219 2.447 1.172 2.179 1.744 -2.179 
Q13625 ASPP2 Apoptosis-stimulating of p53 protein 2 TP53BP2 2.030 3.224 -1.055 1.145 1.459 -1.145 
Q13765 NACA Nascent polypeptide-associated complex subunit alpha NACA 0.222 -0.469 -0.249 -0.741 2.052 0.741 
Q13838 DX39B Spliceosome RNA helicase DDX39B DDX39B  0.293 2.899 -0.187 2.557 0.431 -2.557 
Q13885 TBB2A Tubulin beta-2A chain TUBB2A  0.301 0.451 1.117 0.100 1.988 -0.100 
Q14103 HNRPD Heterogeneous nuclear ribonucleoprotein D0 HNRNPD 0.265 0.388 1.260 0.074 1.552 -0.074 
Q14126 DSG2 Desmoglein-2 DSG2 -0.418 0.350 0.326 0.718 0.601 -0.718 
Q14152 EIF3A Eukaryotic translation initiation factor 3 subunit A EIF3A -0.626 0.567 0.447 1.143 1.987 -1.143 
Q14157 UBP2L Ubiquitin-associated protein 2-like UBAP2L -0.205 -0.363 0.412 -0.208 0.308 0.208 
Q14160 SCRIB Protein scribble homolog SCRIB 2.368 0.920 -2.214 -1.497 0.100 1.497 
Q14254 FLOT2 Flotillin-2 FLOT2 1.120 1.168 -0.741 -0.001 0.245 0.001 
Q14257 RCN2 Reticulocalbin-2 RCN2 0.000 -0.401 -0.179 -0.451 1.072 0.451 
Q14318 FKBP8 Peptidyl-prolyl cis-trans isomerase FKBP8 FKBP8 0.549 0.581 -0.238 -0.017 1.261 0.017 
Q14444 CAPR1 Caprin-1 CAPRIN1 -1.917 -1.836 0.266 0.031 0.942 -0.031 
Q14684 RRP1B Ribosomal RNA processing protein 1 homolog B RRP1B -1.751 -2.629 2.009 -0.928 -0.102 0.928 
Q14974 IMB1 Importin subunit beta-1 KPNB1 -2.347 -1.401 -4.404 0.896 -2.373 -0.896 
Q14978 NOLC1 Nucleolar and coiled-body phosphoprotein 1 NOLC1 -0.976 -2.691 -2.656 -1.765 -0.845 1.765 
Q15029 U5S1 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 4.705 -0.283 0.682 -5.038 -0.357 5.038 
Q15084 PDIA6 Protein disulfide-isomerase A6 PDIA6 0.553 -0.597 0.971 -1.199 -0.234 1.199 
Q15233 NONO Non-POU domain-containing octamer-binding protein NONO 0.302 -0.401 1.752 -0.752 2.646 0.752 
Q15365 PCBP1 Poly(rC)-binding protein 1 PCBP1 3.675 3.760 0.894 0.036 0.133 -0.036 
Q15366 PCBP2 Poly(rC)-binding protein 2 PCBP2  0.200 0.076 1.448 -0.173 0.773 0.173 
Q15393 SF3B3 Splicing factor 3B subunit 3 SF3B3 3.524 3.896 1.333 0.323 0.717 -0.323 
Q15435 PP1R7 Protein phosphatase 1 regulatory subunit 7 PPP1R7 -0.002 -0.938 0.657 -0.986 0.778 0.986 
Q15717 ELAV1 ELAV-like protein 1 ELAVL1  1.673 1.588 0.471 -0.135 4.863 0.135 
Q15834 CC85B Coiled-coil domain-containing protein 85B CCDC85B -0.337 1.930 1.364 2.217 0.769 -2.217 
Q15907 RB11B Ras-related protein Rab-11B RAB11B  2.419 0.163 0.902 -2.306 1.046 2.306 
Q16531 DDB1 DNA damage-binding protein 1 DDB1 0.184 -0.853 0.516 -1.086 0.239 1.086 
Q16543 CDC37 Hsp90 co-chaperone Cdc37 CDC37 2.021 0.232 2.732 -1.838 3.419 1.838 
Q16576 RBBP7 Histone-binding protein RBBP7 RBBP7  1.951 0.952 1.282 -1.049 0.980 1.049 
Q16629 SRSF7 Serine/arginine-rich splicing factor 7 SRSF7 0.495 -0.675 2.160 -1.220 0.748 1.220 
Q16891 IMMT Mitochondrial inner membrane protein IMMT 1.646 0.656 -0.120 -1.039 -0.741 1.039 
Q3ZCQ8 TIM50 Mitochondrial import inner membrane translocase subunit TIM50 TIMM50 0.736 0.584 -0.664 -0.201 -0.376 0.201 
Q53GT1 KLH22 Kelch-like protein 22 KLHL22 -0.794 0.962 1.143 1.707 1.772 -1.707 
Q58FF6 H90B4 Putative heat shock protein HSP 90-beta 4 HSP90AB4P  -3.194 -1.584 0.704 1.560 0.954 -1.560 
Q5JWF2 GNAS1 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas -0.193 0.279 1.187 0.423 -0.792 -0.423 
Q5SRD1 TI23B Putative mitochondrial import inner membrane translocase subunit Tim 1.336 1.533 -0.329 0.147 0.072 -0.147 
Q5T9A4 ATD3B ATPase family AAA domain-containing protein 3B ATAD3B -0.095 0.919 1.863 0.965 2.454 -0.965 
Q69YQ0 CYTSA Cytospin-A SPECC1L -4.316 -0.837 0.003 3.430 0.472 -3.430 
Q6P2Q9 PRP8 Pre-mRNA-processing-splicing factor 8 PRPF8 1.420 1.752 0.438 0.282 0.684 -0.282 
Q6PKG0 LARP1 La-related protein 1 LARP1 1.492 1.823 1.369 0.281 4.245 -0.281 
Q6S8J3 POTEE POTE ankyrin domain family member E POTEE  -0.555 3.387 0.982 3.892 -0.629 -3.892 
Q6UXN9 WDR82 WD repeat-containing protein 82 WDR82 0.614 -0.368 -1.841 -1.032 -1.611 1.032 
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 1 SND1 -1.827 -2.126 -2.419 -0.349 0.664 0.349 
Q7L2E3 DHX30 Putative ATP-dependent RNA helicase DHX30 DHX30 0.773 0.087 -0.913 -0.736 0.371 0.736 
Q7Z417 NUFP2 Nuclear fragile X mental retardation-interacting protein 2 NUFIP2 0.352 0.984 -0.808 0.583 -0.264 -0.583 
Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1 CAND1 -0.213 -1.271 -2.367 -1.108 -0.903 1.108 
Q8IWU2 LMTK2 Serine/threonine-protein kinase LMTK2 LMTK2 1.347 0.066 -2.246 -1.331 -1.349 1.331 
Q8N7X1 RMXL3 RNA-binding motif protein, X-linked-like-3 RBMXL3 0.742 -0.228 -1.886 -1.019 -0.913 1.019 
Q8NC51 PAIRB Plasminogen activator inhibitor 1 RNA-binding protein SERBP1 -0.913 -2.180 -3.523 -1.317 -3.879 1.317 
Q8NHQ8 RASF8 Ras association domain-containing protein 8 RASSF8 -1.176 -0.098 2.028 1.029 1.728 -1.029 
Q8TEX9 IPO4 Importin-4 IPO4 0.525 -1.293 0.784 -1.867 0.540 1.867 
Q8WUF5 IASPP RelA-associated inhibitor PPP1R13L 0.594 1.433 0.008 0.790 -0.249 -0.790 
Q8WVX9 FACR1 Fatty acyl-CoA reductase 1 FAR1 0.645 0.430 -0.318 -0.264 -2.737 0.264 
Q8WWM7 ATX2L Ataxin-2-like protein ATXN2L 1.457 0.561 -2.610 -0.946 -2.596 0.946 
Q8WXF1 PSPC1 Paraspeckle component 1 PSPC1 0.834 1.854 0.111 0.970 -0.258 -0.970 
Q92616 GCN1L Translational activator GCN1 GCN1L1 -0.658 -0.931 -0.226 -0.323 0.106 0.323 
Q92734 TFG Protein TFG TFG -0.570 -1.106 1.827 -0.586 2.143 0.586 
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 DDX17 2.381 2.156 -2.280 -0.274 -1.596 0.274 
Q92878 RAD50 DNA repair protein RAD50 RAD50 0.348 -0.874 -2.370 -1.271 -1.886 1.271 
Q92896 GSLG1 Golgi apparatus protein 1 GLG1 1.455 2.786 0.898 1.281 -0.755 -1.281 
Q92900 RENT1 Regulator of nonsense transcripts 1 UPF1 2.158 1.637 0.072 -0.571 0.571 0.571 
Q92945 FUBP2 Far upstream element-binding protein 2 KHSRP -1.965 -1.115 -0.495 0.800 0.692 -0.800 
Q96HS1 PGAM5 Serine/threonine-protein phosphatase PGAM5, mitochondrial PGAM5 1.685 0.391 2.968 -1.343 0.164 1.343 
Q96KQ4 ASPP1 Apoptosis-stimulating of p53 protein 1 PPP1R13B -0.597 -0.159 -0.257 0.389 2.051 -0.389 
Q96MX6 WDR92 WD repeat-containing protein 92 WDR92 1.997 0.781 -1.356 -1.265 -0.045 1.265 
Q96P70 IPO9 Importin-9 IPO9 1.437 2.323 0.133 0.836 0.111 -0.836 
Q96PK6 RBM14 RNA-binding protein 14 RBM14 0.021 -0.952 -0.496 -1.023 -0.248 1.023 
Q96QC0 PP1RA Serine/threonine-protein phosphatase 1 regulatory subunit 10 PPP1R10 -3.341 -3.191 -1.354 0.101 -1.079 -0.101 
Q96RT1 LAP2 Protein LAP2 ERBB2IP 3.286 0.075 -3.616 -3.260 -5.314 3.260 
Q96SB3 NEB2 Neurabin-2 PPP1R9B 1.595 -0.818 0.614 -2.462 -0.705 2.462 
Q96SW2 CRBN Protein cereblon CRBN -0.222 1.127 -1.801 1.299 0.405 -1.299 
Q99623 PHB2 Prohibitin-2 PHB2 0.527 -0.712 0.732 -1.288 0.891 1.288 
Q99832 TCPH T-complex protein 1 subunit eta CCT7 0.117 3.594 -1.262 3.428 -2.541 -3.428 
Q99873 ANM1 Protein arginine N-methyltransferase 1 PRMT1 -0.306 -0.375 -0.571 -0.118 -1.058 0.118 
Q9BQE3 TBA1C Tubulin alpha-1C chain TUBA1C 0.597 0.592 -0.596 -0.055 -0.575 0.055 
Q9BQG0 MBB1A Myb-binding protein 1A MYBBP1A 2.976 3.831 0.311 0.806 -2.312 -0.806 
Q9BTT6 LRRC1 Leucine-rich repeat-containing protein 1 LRRC1 0.811 2.020 -0.300 1.160 -0.434 -1.160 
Q9BUF5 TBB6 Tubulin beta-6 chain TUBB6 0.250 1.009 -0.219 0.710 -2.430 -0.710 
Q9BUJ2 HNRL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPUL1 -3.096 -2.545 0.360 0.501 -0.410 -0.501 
Q9BZF9 UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats UACA -0.490 1.763 -0.408 2.204 -0.436 -2.204 
Q9BZL4 PP12C Protein phosphatase 1 regulatory subunit 12C PPP1R12C -2.418 0.798 -0.249 3.166 -0.992 -3.166 
Q9GZN8 CT027 UPF0687 protein C20orf27 C20orf27 4.227 1.269 -0.513 -3.007 -2.068 3.007 
Q9H1R3 MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle MYLK2 3.999 0.149 -1.409 -3.900 -1.867 3.900 
Q9H2D6 TARA TRIO and F-actin-binding protein TRIOBP 1.262 2.558 0.676 1.246 -1.079 -1.246 
Q9H361 PABP3 Polyadenylate-binding protein 3 PABPC3 0.894 -0.938 -1.688 -1.882 -2.741 1.882 
Q9H6T3 RPAP3 RNA polymerase II-associated protein 3 RPAP3 2.656 0.862 -1.652 -1.844 -4.053 1.844 
Q9H788 SH24A SH2 domain-containing protein 4A SH2D4A -0.783 -0.523 -0.116 0.210 -3.577 -0.210 
Q9H792 PEAK1 Pseudopodium-enriched atypical kinase 1 PEAK1 2.355 1.703 -1.414 -0.701 -1.764 0.701 
Q9HCE1 MOV10 Putative helicase MOV-10 MOV10 -3.112 -2.786 -0.260 0.276 -3.186 -0.276 
Q9NQ39 RS10L Putative 40S ribosomal protein S10-like RPS10P5  -0.894 -0.116 1.125 0.728 0.636 -0.728 
Q9NR30 DDX21 Nucleolar RNA helicase 2 DDX21 -0.948 -1.042 0.570 -0.144 1.122 0.144 
Q9NTJ3 SMC4 Structural maintenance of chromosomes protein 4 SMC4 -0.110 0.275 -1.336 0.335 -1.516 -0.335 
Q9NUG6 PDRG1 p53 and DNA damage-regulated protein 1 PDRG1 2.383 0.271 1.112 -2.162 0.667 2.162 
Q9NVI7 ATD3A ATPase family AAA domain-containing protein 3A ATAD3A  1.495 2.338 -0.408 0.793 -0.742 -0.793 
Q9NWS0 PIHD1 PIH1 domain-containing protein 1 PIH1D1 2.338 -0.790 -0.735 -3.178 -0.567 3.178 
Q9NX63 CHCH3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3 0.077 0.539 0.920 0.413 -0.017 -0.413 
Q9NYF8 BCLF1 Bcl-2-associated transcription factor 1 BCLAF1 -0.609 0.205 2.783 0.765 3.404 -0.765 
Q9NZI8 IF2B1 Insulin-like growth factor 2 mRNA-binding protein 1 IGF2BP1 0.356 -0.612 -1.391 -1.018 0.603 1.018 
Q9P035 HACD3 3-hydroxyacyl-CoA dehydratase 3 PTPLAD1 0.539 0.058 0.250 -0.530 -2.100 0.530 
Q9P0K7 RAI14 Ankycorbin RAI14 -1.550 2.634 -0.443 4.135 -0.514 -4.135 
Q9P2J5 SYLC Leucine--tRNA ligase, cytoplasmic LARS 3.616 5.330 -1.002 1.664 0.423 -1.664 
Q9P2K8 E2AK4 Eukaryotic translation initiation factor 2-alpha kinase 4 EIF2AK4 3.388 3.094 0.031 -0.344 -1.525 0.344 
Q9UHV9 PFD2 Prefoldin subunit 2 PFDN2 1.398 -0.396 -4.705 -1.844 0.300 1.844 
Q9UJS0 CMC2 Calcium-binding mitochondrial carrier protein Aralar2 SLC25A13 1.475 0.641 0.491 -0.884 -1.746 0.884 
Q9UMS4 PRP19 Pre-mRNA-processing factor 19 PRPF19 -1.017 -0.252 0.290 0.715 0.274 -0.715 
Q9UPQ9 TNR6B Trinucleotide repeat-containing gene 6B protein TNRC6B -0.919 0.034 0.206 0.903 0.380 -0.903 
Q9UQ80 PA2G4 Proliferation-associated protein 2G4 PA2G4 -0.076 -1.187 -0.697 -1.160 0.017 1.160 
Q9UQE7 SMC3 Structural maintenance of chromosomes protein 3 SMC3 2.611 2.613 -2.704 -0.047 -0.980 0.047 
Q9Y230 RUVB2 RuvB-like 2 RUVBL2 0.914 -0.354 -1.657 -1.317 0.789 1.317 
Q9Y262 EIF3L Eukaryotic translation initiation factor 3 subunit L EIF3L 0.734 1.054 -0.972 0.271 -1.421 -0.271 
Q9Y265 RUVB1 RuvB-like 1 RUVBL1 2.419 -0.647 -0.614 -3.116 0.385 3.116 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein 3 VDAC3 1.657 -0.772 -1.997 -2.479 -0.764 2.479 
Q9Y2W1 TR150 Thyroid hormone receptor-associated protein 3 THRAP3 -0.249 2.117 -0.699 2.316 0.839 -2.316 
Q9Y3F4 STRAP Serine-threonine kinase receptor-associated protein STRAP -0.133 -0.095 0.846 -0.011 -0.380 0.011 
Q9Y3I0 RTCB tRNA-splicing ligase RtcB homolog C22orf28 1.841 1.628 0.636 -0.263 0.208 0.263 
Q9Y3U8 RL36 60S ribosomal protein L36 RPL36 -1.081 -1.114 -0.551 -0.083 -0.025 0.083 
Q9Y6M1 IF2B2 Insulin-like growth factor 2 mRNA-binding protein 2 IGF2BP2 0.071 2.714 0.662 2.593 1.064 -2.593 
 
 
 
 
 
 
 
 
 
 
Appendix IVb 
Proteins listed in Appendix III were used to determine the ratio of the PP1 isoform preferences of each protein from the raw intensity values. 
The raw intensity values of were divided as follows: PP1 alpha/beta; alpha/gamma; beta/alpha; beta/gamma; gamma/alpha; gamma/beta. Values 
were converted to log 2 and plotted on the graphs shown below.  
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Appendix V 
Proteins that were captured on 14-3-3-Sepharose in lysates of HEK293 cells stimulated with forskolin or not, and in the presence or absence 
of H-89. Peptides were extracted from the SDS gel (Figure 4.1) and identified from the UniProt database (320 proteins were identified) 
(Uniprot; description). Peptides were quantitatively measured using the MS Quant software following the dimethyl labelling. The ratios of 
the peptide enrichment following the different treatment conditions are listed in the table below (SS-serum starved, Fsk-forskolin, H-89+ 
Fsk-H-89 and forskolin). (N.B.: The last lane refers to the ratio of H-89+FsK/SS: Fsk/SS). 
 
Uniprot Protein Descriptions Fsk/SS  
H-89 + 
Fsk/SS 
 H-89 + 
Fsk/Fsk 
P31946 1433B_HUMAN 14-3-3 protein beta/alpha YWHAB  0.54 -0.54 -0.95 
P62258 1433E_HUMAN 14-3-3 protein epsilon YWHAE  0.40 1.46 1.20 
Q04917 1433F_HUMAN 14-3-3 protein eta YWHAH  -1.56 1.83 3.52 
P27348 1433T_HUMAN 14-3-3 protein theta YWHAQ  0.20 -0.64 -0.70 
P63104 1433Z_HUMAN 14-3-3 protein zeta/delta YWHAZ  0.36 -1.45 -1.68 
P30153 2AAA_HUMAN Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform PPP2R1A  0.50 0.36 -0.01 
Q7L8J4 3BP5L_HUMAN SH3 domain-binding protein 5-like SH3BP5L  -0.22 0.00 0.35 
Q8IZP0 ABI1_HUMAN Abl interactor 1 ABI1  -1.84 2.72 4.69 
Q9NYB9 ABI2_HUMAN Abl interactor 2 ABI2  0.09 0.83 0.87 
P00519 ABL1_HUMAN Tyrosine-protein kinase ABL1 ABL1  0.37 4.11 3.88 
O14639 ABLM1_HUMAN Actin-binding LIM protein 1 ABLIM1  -0.76 2.35 3.24 
P05141 ADT2_HUMAN ADP/ATP translocase 2 SLC25A5  0.77 0.07 -0.57 
P55196 AFAD_HUMAN Afadin MLLT4  -1.16 -1.93 -0.63 
Q09666 AHNK_HUMAN Neuroblast differentiation-associated protein AHNAK AHNAK  -1.33 2.52 3.98 
Q12802 AKP13_HUMAN A-kinase anchor protein 13 AKAP13  -0.45 2.24 2.82 
Q96B36 AKTS1_HUMAN Proline-rich AKT1 substrate 1 AKT1S1  -0.35 -3.34 -2.86 
Q96Q42 ALS2_HUMAN Alsin ALS2  0.12 0.61 0.63 
Q92625 ANS1A_HUMAN Ankyrin repeat and SAM domain-containing protein 1A ANKS1A  -0.27 1.27 1.67 
Q92974 ARHG2_HUMAN Rho guanine nucleotide exchange factor 2 ARHGEF2  -0.58 -3.79 -3.07 
Q14155 ARHG7_HUMAN Rho guanine nucleotide exchange factor 7 ARHGEF7  0.01 -1.13 -1.01 
Q5VV41 ARHGG_HUMAN Rho guanine nucleotide exchange factor 16 ARHGEF16  -0.62 -1.02 -0.27 
Q7Z3C6 ATG9A_HUMAN Autophagy-related protein 9A ATG9A  4.83 2.62 -2.08 
Q9BSB4 ATGA1_HUMAN Autophagy-related protein 101 ATG101  0.03 2.36 2.46 
P25705 ATPA_HUMAN ATP synthase subunit alpha, mitochondrial ATP5A1  0.65 1.01 0.49 
P06576 ATPB_HUMAN ATP synthase subunit beta, mitochondrial ATP5B  -1.52 -0.73 0.92 
P36542 ATPG_HUMAN ATP synthase subunit gamma, mitochondrial ATP5C1  -0.06 0.08 0.28 
P48047 ATPO_HUMAN ATP synthase subunit O, mitochondrial ATP5O  1.84 0.70 -1.01 
O95816 BAG2_HUMAN BAG family molecular chaperone regulator 2 BAG2  1.20 0.07 -0.99 
Q9UQB8 BAIP2_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 2 BAIAP2  -0.75 0.70 1.58 
P35613 BASI_HUMAN Basigin BSG  1.12 0.19 -0.80 
P11274 BCR_HUMAN Breakpoint cluster region protein BCR  -0.22 0.22 0.57 
Q14457 BECN1_HUMAN Beclin-1 BECN1  0.20 0.10 0.04 
Q9UHR4 BI2L1_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 BAIAP2L1  0.91 3.34 2.57 
P78537 BL1S1_HUMAN Biogenesis of lysosome-related organelles complex 1 subunit 1 BLOC1S1  4.56 2.83 -1.59 
Q6QNY1 BL1S2_HUMAN Biogenesis of lysosome-related organelles complex 1 subunit 2 BLOC1S2  7.59 2.04 -5.41 
P62158 CALM_HUMAN Calmodulin CALM1  3.83 0.52 -3.18 
P27824 CALX_HUMAN Calnexin CANX  -1.44 -0.22 1.36 
Q08AD1 CAMP2_HUMAN Calmodulin-regulated spectrin-associated protein 2 CAMSAP1L1  1.34 -0.41 -1.62 
Q9P1Y5 CAMP3_HUMAN Calmodulin-regulated spectrin-associated protein 3 KIAA1543  -2.38 -0.56 1.95 
P47756 CAPZB_HUMAN F-actin-capping protein subunit beta CAPZB  -2.20 -1.18 1.16 
P52907 CAZA1_HUMAN F-actin-capping protein subunit alpha-1 CAPZA1  -0.24 -1.67 -1.29 
Q16204 CCDC6_HUMAN Coiled-coil domain-containing protein 6 CCDC6  1.84 -0.12 -1.83 
Q8ND76 CCNY_HUMAN Cyclin-Y CCNY  -1.39 -0.77 0.75 
Q8N7R7 CCYL1_HUMAN Cyclin-Y-like protein 1 CCNYL1  0.14 1.81 1.80 
Q16543 CDC37_HUMAN Hsp90 co-chaperone Cdc37 CDC37  0.51 0.42 0.05 
O94921 CDK14_HUMAN Cell division protein kinase 14 CDK14  2.01 2.65 0.77 
Q00536 CDK16_HUMAN Cell division protein kinase 16 CDK16  0.97 1.35 0.51 
Q00537 CDK17_HUMAN Cell division protein kinase 17 CDK17  0.52 0.37 -0.01 
Q07002 CDK18_HUMAN Cell division protein kinase 18 CDK18  1.50 1.10 -0.26 
Q01850 CDR2_HUMAN Cerebellar degeneration-related protein 2 CDR2  -0.51 0.99 1.64 
Q86X02 CDR2L_HUMAN Cerebellar degeneration-related protein 2-like CDR2L  -0.10 1.08 1.32 
Q5SW79 CE170_HUMAN Centrosomal protein of 170 kDa CEP170  -1.40 -0.28 1.25 
P10809 CH60_HUMAN 60 kDa heat shock protein, mitochondrial HSPD1  -0.03 0.13 0.30 
O14757 CHK1_HUMAN Serine/threonine-protein kinase Chk1 CHEK1  1.19 2.95 1.89 
Q9P2M7 CING_HUMAN Cingulin CGN  -1.72 -1.33 0.52 
O75390 CISY_HUMAN Citrate synthase, mitochondrial CS  -2.03 0.16 2.33 
Q14008 CKAP5_HUMAN Cytoskeleton-associated protein 5 CKAP5  0.98 -0.27 -1.11 
Q7Z460 CLAP1_HUMAN CLIP-associating protein 1 CLASP1  -1.74 -0.14 1.73 
O75122 CLAP2_HUMAN CLIP-associating protein 2 CLASP2  -1.16 0.64 1.93 
Q00610 CLH1_HUMAN Clathrin heavy chain 1 CLTC  0.27 -0.12 -0.26 
Q96DG6 CMBL_HUMAN Carboxymethylenebutenolidase homolog CMBL  -0.13 -1.13 -0.87 
A5YKK6 CNOT1_HUMAN CCR4-NOT transcription complex subunit 1 CNOT1  1.13 -1.61 -2.60 
Q9H3G5 CPVL_HUMAN Probable serine carboxypeptidase CPVL CPVL  -1.88 -0.78 1.23 
Q96GS4 CQ059_HUMAN Uncharacterized protein C17orf59 C17orf59  2.75 0.21 -2.41 
P46109 CRKL_HUMAN Crk-like protein CRKL  0.65 -0.16 -0.67 
Q6UUV9 CRTC1_HUMAN CREB-regulated transcription coactivator 1 CRTC1  -2.36 -0.44 2.05 
Q53ET0 CRTC2_HUMAN CREB-regulated transcription coactivator 2 CRTC2  -3.61 -0.06 3.68 
Q9BQD3 CS050_HUMAN UPF0459 protein C19orf50 C19orf50  4.19 0.53 -3.53 
O60716 CTND1_HUMAN Catenin delta-1 CTNND1  -2.08 -2.17 0.05 
Q6ICG6 CV009_HUMAN Uncharacterized protein C22orf9 C22orf9  0.31 1.89 1.72 
Q9Y3I0 CV028_HUMAN UPF0027 protein C22orf28 C22orf28  1.72 2.13 0.54 
Q7L576 CYFP1_HUMAN Cytoplasmic FMR1-interacting protein 1 CYFIP1  -0.45 -0.50 0.08 
Q96F07 CYFP2_HUMAN Cytoplasmic FMR1-interacting protein 2 CYFIP2  0.27 0.13 -0.01 
Q69YQ0 CYTSA_HUMAN Cytospin-A CYTSA  3.70 1.83 -1.74 
Q9NR28 DBLOH_HUMAN Diablo homolog, mitochondrial DIABLO  0.36 0.10 -0.13 
Q9UJU6 DBNL_HUMAN Drebrin-like protein DBNL  1.73 0.19 -1.41 
P61962 DCAF7_HUMAN DDB1- and CUL4-associated factor 7 DCAF7  -2.44 -2.12 0.46 
Q9NPI6 DCP1A_HUMAN mRNA-decapping enzyme 1A DCP1A  0.30 -1.82 -1.98 
Q8IZD4 DCP1B_HUMAN mRNA-decapping enzyme 1B DCP1B  1.10 -0.26 -1.23 
Q92499 DDX1_HUMAN ATP-dependent RNA helicase DDX1 DDX1  -0.02 0.63 0.79 
O75064 DEN4B_HUMAN DENN domain-containing protein 4B DENND4B  1.82 4.14 2.45 
Q5VZ89 DEN4C_HUMAN DENN domain-containing protein 4C DENND4C  2.55 -0.93 -3.34 
O75140 DEPD5_HUMAN DEP domain-containing protein 5 DEPDC5  -0.52 0.69 1.34 
P15924 DESP_HUMAN Desmoplakin DSP  1.11 1.28 0.31 
P21912 DHSB_HUMAN Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial SDHB  0.07 1.04 1.10 
Q9UBS4 DJB11_HUMAN DnaJ homolog subfamily B member 11 DNAJB11  -0.46 -0.74 -0.14 
Q09019 DMWD_HUMAN Dystrophia myotonica WD repeat-containing protein DMWD  -1.72 0.74 2.59 
Q5JSL3 DOC11_HUMAN Dedicator of cytokinesis protein 11 DOCK11  -0.36 0.32 0.81 
Q9H7D0 DOCK5_HUMAN Dedicator of cytokinesis protein 5 DOCK5  -0.38 -2.31 -1.79 
Q96HP0 DOCK6_HUMAN Dedicator of cytokinesis protein 6 DOCK6  -0.23 0.79 1.15 
Q96N67 DOCK7_HUMAN Dedicator of cytokinesis protein 7 DOCK7  -0.43 -1.12 -0.56 
Q9BZ29 DOCK9_HUMAN Dedicator of cytokinesis protein 9 DOCK9  -0.84 0.43 1.40 
Q9NRW4 DUS22_HUMAN Dual specificity protein phosphatase 22 DUSP22  -1.47 0.14 1.75 
P33316 DUT_HUMAN Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial DUT  -0.98 -0.85 0.27 
Q14204 DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 DYNC1H1  -0.51 0.28 0.92 
Q9Y2J2 E41L3_HUMAN Band 4.1-like protein 3 EPB41L3  2.82 0.12 -2.56 
Q5VYK3 ECM29_HUMAN Proteasome-associated protein ECM29 homolog ECM29  -2.45 -0.59 2.00 
Q96F86 EDC3_HUMAN Enhancer of mRNA-decapping protein 3 EDC3  0.44 -0.59 -0.90 
P68104 EF1A1_HUMAN Elongation factor 1-alpha 1 EEF1A1  -0.32 -0.19 0.26 
P26641 EF1G_HUMAN Elongation factor 1-gamma EEF1G  -0.97 -0.69 0.42 
Q15370 ELOB_HUMAN Transcription elongation factor B polypeptide 2 TCEB2  2.94 -0.80 -3.60 
Q32P44 EMAL3_HUMAN Echinoderm microtubule-associated protein-like 3 EML3  0.75 -3.27 -3.88 
P06733 ENOA_HUMAN Alpha-enolase ENO1  0.00 0.36 0.50 
O95208 EPN2_HUMAN Epsin-2 EPN2  -1.25 -2.38 -0.99 
Q9UI08 EVL_HUMAN Ena/VASP-like protein EVL  -4.67 -2.23 2.57 
Q96E09 F122A_HUMAN Protein FAM122A FAM122A  1.85 3.76 2.05 
Q7Z309 F122B_HUMAN Protein FAM122B FAM122B  -0.02 2.62 2.77 
O60825 F262_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 PFKFB2  1.66 0.49 -1.05 
Q16877 F264_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 PFKFB4  2.10 0.63 -1.34 
Q52LJ0 FA98B_HUMAN Protein FAM98B FAM98B  -5.29 -0.73 4.69 
Q9UK99 FBX3_HUMAN F-box only protein 3 FBXO3  -1.51 -1.43 0.22 
Q15007 FL2D_HUMAN Pre-mRNA-splicing regulator WTAP WTAP  -0.51 -0.25 0.39 
P21333 FLNA_HUMAN Filamin-A FLNA  1.16 -0.64 -1.67 
O75044 FNBP2_HUMAN SLIT-ROBO Rho GTPase-activating protein 2 SRGAP2  0.46 1.00 0.68 
P85037 FOXK1_HUMAN Forkhead box protein K1 FOXK1  0.17 -2.03 -2.07 
O43524 FOXO3_HUMAN Forkhead box protein O3 FOXO3  1.35 -1.85 -3.07 
O94915 FRYL_HUMAN Protein furry homolog-like FRYL  0.19 0.57 0.51 
Q92538 GBF1_HUMAN Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 GBF1  1.43 0.25 -1.05 
Q9Y2X7 GIT1_HUMAN ARF GTPase-activating protein GIT1 GIT1  0.03 -0.64 -0.53 
Q3V6T2 GRDN_HUMAN Girdin CCDC88A  -0.42 -1.32 -0.77 
P38646 GRP75_HUMAN Stress-70 protein, mitochondrial HSPA9  0.66 0.34 -0.19 
P11021 GRP78_HUMAN 78 kDa glucose-regulated protein HSPA5  -0.26 0.01 0.41 
P56524 HDAC4_HUMAN Histone deacetylase 4 HDAC4  -2.95 -3.05 0.03 
Q9UQL6 HDAC5_HUMAN Histone deacetylase 5 HDAC5  -1.90 -1.91 0.12 
Q9ULT8 HECD1_HUMAN E3 ubiquitin-protein ligase HECTD1 HECTD1  -3.56 -1.65 2.05 
Q9P2P5 HECW2_HUMAN E3 ubiquitin-protein ligase HECW2 HECW2  1.56 -0.58 -2.01 
P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha HSP90AA1  -1.17 -1.42 -0.12 
P08238 HS90B_HUMAN Heat shock protein HSP 90-beta HSP90AB1  -1.72 -4.03 -2.17 
P08107 HSP71_HUMAN Heat shock 70 kDa protein 1A/1B HSPA1A  -0.75 -0.46 0.43 
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein HSPA8  -0.54 -0.70 -0.02 
O60573 IF4E2_HUMAN Eukaryotic translation initiation factor 4E type 2 EIF4E2  0.69 0.02 -0.53 
P08069 IGF1R_HUMAN Insulin-like growth factor 1 receptor IGF1R  -0.36 -0.10 0.39 
Q9NRR6 INP5E_HUMAN 72 kDa inositol polyphosphate 5-phosphatase INPP5E  -1.50 -1.22 0.41 
Q9Y4H2 IRS2_HUMAN Insulin receptor substrate 2 IRS2  -0.49 1.70 2.32 
Q9NZM3 ITSN2_HUMAN Intersectin-2 ITSN2  -7.15 -4.29 3.00 
Q9Y4D8 K0614_HUMAN Probable E3 ubiquitin-protein ligase C12orf51 C12orf51  0.36 2.75 2.53 
P10644 KAP0_HUMAN cAMP-dependent protein kinase type I-alpha regulatory subunit PRKAR1A  2.20 0.36 -1.71 
P13861 KAP2_HUMAN cAMP-dependent protein kinase type II-alpha regulatory subunit PRKAR2A  -1.07 -0.04 1.16 
Q9NYR9 KBRS2_HUMAN NF-kappa-B inhibitor-interacting Ras-like protein 2 NKIRAS2  -2.38 -3.89 -1.38 
P12277 KCRB_HUMAN Creatine kinase B-type CKB  1.68 -1.07 -2.62 
Q9NQT8 KI13B_HUMAN Kinesin-like protein KIF13B KIF13B  -0.88 -3.56 -2.54 
O43896 KIF1C_HUMAN Kinesin-like protein KIF1C KIF1C  -0.36 0.60 1.09 
O60282 KIF5C_HUMAN Kinesin heavy chain isoform 5C KIF5C  -1.39 -3.14 -1.61 
P33176 KINH_HUMAN Kinesin-1 heavy chain KIF5B  -0.33 -3.75 -3.29 
Q8N5S9 KKCC1_HUMAN Calcium/calmodulin-dependent protein kinase kinase 1 CAMKK1  2.73 0.67 -1.93 
Q07866 KLC1_HUMAN Kinesin light chain 1 KLC1  -0.50 -0.41 0.23 
Q9H0B6 KLC2_HUMAN Kinesin light chain 2 KLC2  0.00 -0.39 -0.26 
Q6P597 KLC3_HUMAN Kinesin light chain 3 KLC3  -0.44 0.02 0.60 
Q9NSK0 KLC4_HUMAN Kinesin light chain 4 KLC4  -0.10 -0.84 -0.60 
Q969J3 L12R1_HUMAN Loss of heterozygosity 12 chromosomal region 1 protein LOH12CR1  4.66 2.02 -2.51 
Q6PKG0 LARP1_HUMAN La-related protein 1 LARP1  -1.90 -1.53 0.50 
Q14739 LBR_HUMAN Lamin-B receptor LBR  0.92 2.31 1.53 
Q13136 LIPA1_HUMAN Liprin-alpha-1 PPFIA1  -1.41 -0.02 1.52 
Q9HAR2 LPHN3_HUMAN Latrophilin-3 LPHN3  0.48 0.18 -0.17 
Q5VUJ6 LRCH2_HUMAN Leucine-rich repeat and calponin homology domain-containing protein 2 LRCH2  -1.34 -3.13 -1.66 
Q96II8 LRCH3_HUMAN Leucine-rich repeat and calponin homology domain-containing protein 3 LRCH3  -0.89 -1.58 -0.55 
Q6PJG9 LRFN4_HUMAN Leucine-rich repeat and fibronectin type-III domain-containing protein 4 LRFN4  0.91 0.77 -0.01 
Q9Y2U5 M3K2_HUMAN Mitogen-activated protein kinase kinase kinase 2 MAP3K2  -1.41 -4.53 -2.98 
O95382 M3K6_HUMAN Mitogen-activated protein kinase kinase kinase 6 MAP3K6  1.46 -0.01 -1.34 
Q96PK2 MACF4_HUMAN Microtubule-actin cross-linking factor 1, isoform 4 MACF1  -1.23 1.29 2.65 
O60307 MAST3_HUMAN Microtubule-associated serine/threonine-protein kinase 3 MAST3  1.30 3.32 2.15 
Q8N4C8 MINK1_HUMAN Misshapen-like kinase 1 MINK1  0.02 2.65 2.76 
Q7L9L4 MOL1A_HUMAN Mps one binder kinase activator-like 1A MOBKL1A  0.04 -3.18 -3.09 
Q02750 MP2K1_HUMAN Dual specificity mitogen-activated protein kinase kinase 1 MAP2K1  -0.80 0.50 1.43 
P36507 MP2K2_HUMAN Dual specificity mitogen-activated protein kinase kinase 2 MAP2K2  -3.86 -1.02 2.97 
P30307 MPIP3_HUMAN M-phase inducer phosphatase 3 CDC25C  0.08 1.87 1.93 
Q6WCQ1 MPRIP_HUMAN Myosin phosphatase Rho-interacting protein MPRIP  -0.55 -0.42 0.27 
Q13496 MTM1_HUMAN Myotubularin MTM1  -0.56 0.93 1.63 
Q9NXD2 MTMRA_HUMAN Myotubularin-related protein 10 MTMR10  -1.29 -2.55 -1.12 
Q765P7 MTSSL_HUMAN MTSS1-like protein MTSS1L  2.26 0.19 -1.94 
Q7Z401 MYCPP_HUMAN C-myc promoter-binding protein DENND4A  2.17 -1.58 -3.62 
P60660 MYL6_HUMAN Myosin light polypeptide 6 MYL6  1.10 1.22 0.25 
O14974 MYPT1_HUMAN Protein phosphatase 1 regulatory subunit 12A PPP1R12A  0.73 -1.68 -2.28 
O95544 NADK_HUMAN NAD kinase NADK  -2.22 -1.17 1.18 
Q6ZNJ1 NBEL2_HUMAN Neurobeachin-like protein 2 NBEAL2  0.05 -0.39 -0.31 
Q9Y2A7 NCKP1_HUMAN Nck-associated protein 1 NCKAP1  -0.59 -2.25 -1.52 
P15531 NDKA_HUMAN Nucleoside diphosphate kinase A NME1  -0.06 -1.36 -1.16 
O75489 NDUS3_HUMAN NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3  -0.70 0.03 0.86 
Q96PU5 NED4L_HUMAN E3 ubiquitin-protein ligase NEDD4-like NEDD4L  3.13 -0.90 -3.90 
P21359 NF1_HUMAN Neurofibromin NF1  2.66 -0.13 -2.65 
P07197 NFM_HUMAN Neurofilament medium polypeptide NEFM  -0.56 -0.17 0.52 
Q9UJF2 NGAP_HUMAN Ras GTPase-activating protein nGAP RASAL2  0.03 -1.09 -0.99 
Q8WTW4 NPRL2_HUMAN Nitrogen permease regulator 2-like protein NPRL2  -0.13 -2.49 -2.23 
Q12980 NPRL3_HUMAN Nitrogen permease regulator 3-like protein NPRL3  -0.76 0.99 1.88 
P49757 NUMB_HUMAN Protein numb homolog NUMB  -0.33 -1.91 -1.45 
Q9Y6R0 NUMBL_HUMAN Numb-like protein NUMBL  -1.05 -1.65 -0.47 
P04181 OAT_HUMAN Ornithine aminotransferase, mitochondrial OAT  0.37 -0.57 -0.80 
P36957 
ODO2_HUMAN Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial 
DLST  0.05 0.08 0.17 
O15294 OGT1_HUMAN UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit OGT  0.01 -4.72 -4.60 
Q9H4L5 OSBL3_HUMAN Oxysterol-binding protein-related protein 3 OSBPL3  -0.93 -4.10 -3.03 
Q9BZF3 OSBL6_HUMAN Oxysterol-binding protein-related protein 6 OSBPL6  -1.61 -3.22 -1.47 
P39656 OST48_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit DDOST  -3.00 -0.58 2.55 
Q8IYS1 P20D2_HUMAN Peptidase M20 domain-containing protein 2 PM20D2  -2.89 -1.00 2.03 
O00443 P3C2A_HUMAN Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit alpha PIK3C2A  0.02 0.84 0.95 
Q86VP3 PACS2_HUMAN Phosphofurin acidic cluster sorting protein 2 PACS2  1.30 0.77 -0.40 
O96013 PAK4_HUMAN Serine/threonine-protein kinase PAK 4 PAK4  -1.90 -1.26 0.77 
Q9BZ23 PANK2_HUMAN Pantothenate kinase 2, mitochondrial PANK2  1.02 0.79 -0.10 
Q8TEW0 PARD3_HUMAN Partitioning defective 3 homolog PARD3  -0.82 -0.28 0.67 
Q99497 PARK7_HUMAN Protein DJ-1 PARK7  -0.02 -0.22 -0.06 
P30101 PDIA3_HUMAN Protein disulfide-isomerase A3 PDIA3  1.58 0.19 -1.26 
Q9Y2S7 PDIP2_HUMAN Polymerase delta-interacting protein 2 POLDIP2  -0.07 0.36 0.56 
Q5EBL8 PDZ11_HUMAN PDZ domain-containing protein 11 PDZD11  -1.23 -2.27 -0.90 
Q6Y7W6 PERQ2_HUMAN PERQ amino acid-rich with GYF domain-containing protein 2 GIGYF2  1.77 2.22 0.59 
Q96HS1 PGAM5_HUMAN Serine/threonine-protein phosphatase PGAM5, mitochondrial PGAM5  -0.17 1.37 1.67 
O00264 PGRC1_HUMAN Membrane-associated progesterone receptor component 1 PGRMC1  0.49 0.16 -0.20 
P35232 PHB_HUMAN Prohibitin PHB  -0.05 0.23 0.42 
Q99623 PHB2_HUMAN Prohibitin-2 PHB2  -0.37 1.37 1.87 
Q99570 PI3R4_HUMAN Phosphoinositide 3-kinase regulatory subunit 4 PIK3R4  0.63 -0.15 -0.64 
Q9UBF8 PI4KB_HUMAN Phosphatidylinositol 4-kinase beta PI4KB  -0.63 -2.84 -2.07 
P22061 PIMT_HUMAN Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1  -0.04 -0.81 -0.64 
Q8NEB9 PK3C3_HUMAN Phosphatidylinositol 3-kinase catalytic subunit type 3 PIK3C3  0.29 -4.29 -4.44 
Q15149 PLEC_HUMAN Plectin PLEC  2.44 1.31 -0.99 
O00444 PLK4_HUMAN Serine/threonine-protein kinase PLK4 PLK4  -2.03 0.34 2.50 
Q9BZL4 PP12C_HUMAN Protein phosphatase 1 regulatory subunit 12C PPP1R12C  -0.86 -3.80 -2.80 
P62140 PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit PPP1CB  -0.13 -1.06 -0.80 
P24666 PPAC_HUMAN Low molecular weight phosphotyrosine protein phosphatase ACP1  1.20 -0.37 -1.44 
P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A PPIA  1.60 -0.01 -1.48 
Q9ULR3 PPM1H_HUMAN Protein phosphatase 1H PPM1H  2.09 1.16 -0.80 
O95685 PPR3D_HUMAN Protein phosphatase 1 regulatory subunit 3D PPP1R3D  -0.90 -0.04 1.00 
Q06830 PRDX1_HUMAN Peroxiredoxin-1 PRDX1  0.36 0.31 0.08 
P32119 PRDX2_HUMAN Peroxiredoxin-2 PRDX2  0.69 0.50 -0.06 
P78527 PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit PRKDC  -0.09 0.90 1.12 
P28066 PSA5_HUMAN Proteasome subunit alpha type-5 PSMA5  -0.04 -0.94 -0.77 
P60900 PSA6_HUMAN Proteasome subunit alpha type-6 PSMA6  -1.27 -2.96 -1.55 
Q8TAA3 PSA7L_HUMAN Proteasome subunit alpha type-7-like PSMA8  -3.17 -1.34 1.96 
P28072 PSB6_HUMAN Proteasome subunit beta type-6 PSMB6  1.08 0.03 -0.92 
O00231 PSD11_HUMAN 26S proteasome non-ATPase regulatory subunit 11 PSMD11  -1.78 -0.68 1.23 
Q9UNM6 PSD13_HUMAN 26S proteasome non-ATPase regulatory subunit 13 PSMD13  0.25 -0.28 -0.40 
O00487 PSDE_HUMAN 26S proteasome non-ATPase regulatory subunit 14 PSMD14  0.72 0.59 0.01 
Q15008 PSMD6_HUMAN 26S proteasome non-ATPase regulatory subunit 6 PSMD6  -2.89 -1.74 1.29 
Q12923 PTN13_HUMAN Tyrosine-protein phosphatase non-receptor type 13 PTPN13  -0.11 0.03 0.28 
P27708 PYR1_HUMAN CAD protein CAD  0.76 -1.51 -2.14 
Q96QF0 RAB3I_HUMAN Rab-3A-interacting protein RAB3IP  0.77 1.38 0.74 
P20340 RAB6A_HUMAN Ras-related protein Rab-6A RAB6A  0.87 0.59 -0.14 
P51149 RAB7A_HUMAN Ras-related protein Rab-7a RAB7A  0.28 -0.11 -0.26 
Q15276 RABE1_HUMAN Rab GTPase-binding effector protein 1 RABEP1  0.28 -2.82 -2.97 
Q9UJ41 RABX5_HUMAN Rab5 GDP/GTP exchange factor RABGEF1  -0.54 0.29 0.96 
P04049 RAF1_HUMAN RAF proto-oncogene serine/threonine-protein kinase RAF1  0.66 -0.03 -0.56 
Q9P0K7 RAI14_HUMAN Ankycorbin RAI14  -1.21 -3.26 -1.91 
P62826 RAN_HUMAN GTP-binding nuclear protein Ran RAN  -0.74 -1.75 -0.87 
P43487 RANG_HUMAN Ran-specific GTPase-activating protein RANBP1  -0.20 -0.81 -0.47 
Q15907 RB11B_HUMAN Ras-related protein Rab-11B RAB11B  -0.33 -0.20 0.26 
Q8IUD2 RB6I2_HUMAN ELKS/Rab6-interacting/CAST family member 1 ERC1  -1.59 -1.40 0.32 
Q92600 RCD1_HUMAN Cell differentiation protein RCD1 homolog RQCD1  -0.01 -3.67 -3.52 
Q6NUK4 REEP3_HUMAN Receptor expression-enhancing protein 3 REEP3  0.28 2.45 2.30 
Q9H6H4 REEP4_HUMAN Receptor expression-enhancing protein 4 REEP4  0.38 0.66 0.41 
Q6WKZ4 RFIP1_HUMAN Rab11 family-interacting protein 1 RAB11FIP1  -1.82 -0.42 1.54 
Q9BXF6 RFIP5_HUMAN Rab11 family-interacting protein 5 RAB11FIP5  0.23 0.69 0.59 
O15211 RGL2_HUMAN Ral guanine nucleotide dissociation stimulator-like 2 RGL2  -0.99 -3.48 -2.36 
Q8IWW6 RHG12_HUMAN Rho GTPase-activating protein 12 ARHGAP12  -1.42 -4.18 -2.62 
Q9Y4G8 RPGF2_HUMAN Rap guanine nucleotide exchange factor 2 RAPGEF2  -0.04 3.31 3.48 
Q8N122 RPTOR_HUMAN Regulatory-associated protein of mTOR RPTOR  -1.63 0.16 1.93 
P62269 RS18_HUMAN 40S ribosomal protein S18 RPS18  2.55 0.00 -2.41 
Q9Y6M7 S4A7_HUMAN Sodium bicarbonate cotransporter 3 SLC4A7  0.07 2.73 2.79 
O94885 SASH1_HUMAN SAM and SH3 domain-containing protein 1 SASH1  0.36 2.12 1.90 
Q9P0V9 SEP10_HUMAN Septin-10 SEPT10  4.47 2.60 -1.74 
Q9NVA2 SEP11_HUMAN Septin-11 SEPT11  4.15 2.35 -1.66 
Q15019 SEPT2_HUMAN Septin-2 SEPT2  5.28 4.15 -1.00 
Q16181 SEPT7_HUMAN Septin-7 SEPT7  5.05 2.81 -2.10 
O43175 SERA_HUMAN D-3-phosphoglycerate dehydrogenase PHGDH  2.33 2.19 -0.01 
Q5HYK7 SH319_HUMAN SH3 domain-containing protein 19 SH3D19  -0.07 1.90 2.10 
Q9H0K1 SIK2_HUMAN Serine/threonine-protein kinase SIK2 SIK2  0.37 -2.44 -2.67 
Q9GZT3 SLIRP_HUMAN SRA stem-loop-interacting RNA-binding protein, mitochondrial SLIRP  0.93 0.78 -0.02 
Q9NQG6 SMC7L_HUMAN Smith-Magenis syndrome chromosomal region candidate gene 7 protein-like SMCR7L  -1.44 -0.48 1.09 
O95295 SNAPN_HUMAN SNARE-associated protein Snapin SNAPIN  3.46 1.35 -1.97 
Q13813 SPTA2_HUMAN Spectrin alpha chain, brain SPTAN1  -0.13 0.54 0.81 
Q01082 SPTB2_HUMAN Spectrin beta chain, brain 1 SPTBN1  -0.14 1.11 1.38 
O15020 SPTN2_HUMAN Spectrin beta chain, brain 2 SPTBN2  -0.09 1.28 1.50 
Q7Z6B7 SRGP1_HUMAN SLIT-ROBO Rho GTPase-activating protein 1 SRGAP1  -1.33 -0.39 1.07 
Q9UQ35 SRRM2_HUMAN Serine/arginine repetitive matrix protein 2 SRRM2  0.20 3.73 3.67 
Q76I76 SSH2_HUMAN Protein phosphatase Slingshot homolog 2 SSH2  -3.59 -0.07 3.65 
P51571 SSRD_HUMAN Translocon-associated protein subunit delta SSR4  1.35 0.04 -1.17 
Q9UMX1 SUFU_HUMAN Suppressor of fused homolog SUFU  3.37 1.89 -1.35 
O15056 SYNJ2_HUMAN Synaptojanin-2 SYNJ2  1.69 1.51 -0.05 
Q5T011 SZT2_HUMAN Protein SZT2 SZT2  0.45 2.65 2.34 
Q15750 TAB1_HUMAN TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 TAB1  0.95 3.19 2.38 
Q9NYJ8 TAB2_HUMAN TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 TAB2  0.13 4.15 4.15 
Q4KMP7 TB10B_HUMAN TBC1 domain family member 10B TBC1D10B  1.31 -2.02 -3.19 
Q9NU19 TB22B_HUMAN TBC1 domain family member 22B TBC1D22B  2.55 4.51 2.09 
P68371 TBB2C_HUMAN Tubulin beta-2C chain TUBB2C  0.16 0.89 0.86 
P07437 TBB5_HUMAN Tubulin beta chain TUBB  0.42 0.79 0.50 
Q3MII6 TBC25_HUMAN TBC1 domain family member 25 TBC1D25  -0.67 -0.96 -0.15 
Q86TI0 TBCD1_HUMAN TBC1 domain family member 1 TBC1D1  0.78 0.76 0.11 
O60343 TBCD4_HUMAN TBC1 domain family member 4 TBC1D4  0.65 -1.11 -1.62 
Q92609 TBCD5_HUMAN TBC1 domain family member 5 TBC1D5  1.99 -2.14 -3.99 
Q9P0N9 TBCD7_HUMAN TBC1 domain family member 7 TBC1D7  -0.13 -0.67 -0.41 
P49368 TCPG_HUMAN T-complex protein 1 subunit gamma CCT3  0.68 0.78 0.24 
P10599 THIO_HUMAN Thioredoxin TXN  1.50 -2.50 -3.87 
Q13009 TIAM1_HUMAN T-lymphoma invasion and metastasis-inducing protein 1 TIAM1  -1.21 -2.57 -1.22 
Q8N9M5 TM102_HUMAN Transmembrane protein 102 TMEM102  0.92 1.32 0.53 
Q13049 TRI32_HUMAN E3 ubiquitin-protein ligase TRIM32 TRIM32  3.50 1.34 -2.02 
Q92574 TSC1_HUMAN Hamartin TSC1  0.28 1.10 0.96 
P49815 TSC2_HUMAN Tuberin TSC2  -0.16 -0.98 -0.69 
Q96AY4 TTC28_HUMAN Tetratricopeptide repeat protein 28 TTC28  2.21 2.55 0.47 
O95881 TXD12_HUMAN Thioredoxin domain-containing protein 12 TXNDC12  1.69 -0.08 -1.64 
Q8NBS9 TXND5_HUMAN Thioredoxin domain-containing protein 5 TXNDC5  -1.91 -2.05 -0.01 
Q96FH0 U402_HUMAN UPF0402 protein  4.72 3.25 -1.33 
P0CG48 UBC_HUMAN Polyubiquitin-C UBC  0.43 -0.04 -0.33 
P62068 UBP46_HUMAN Ubiquitin carboxyl-terminal hydrolase 46 USP46  -0.46 0.35 0.94 
P40818 UBP8_HUMAN Ubiquitin carboxyl-terminal hydrolase 8 USP8  -0.46 1.46 2.05 
A0JNW5 UH1BL_HUMAN UHRF1-binding protein 1-like UHRF1BP1L  2.96 -1.50 -4.33 
Q9P0L0 VAPA_HUMAN Vesicle-associated membrane protein-associated protein A VAPA  0.50 -0.61 -0.98 
P50552 VASP_HUMAN Vasodilator-stimulated phosphoprotein VASP  -2.26 -0.95 1.44 
P21796 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 VDAC1  -0.25 0.22 0.60 
P45880 VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2 VDAC2  0.37 0.14 -0.09 
P08670 VIME_HUMAN Vimentin VIM  -0.30 0.43 0.86 
Q9H9C1 VIPAR_HUMAN VPS33B-interacting protein VIPAR  0.86 3.79 3.06 
Q69YN4 VIR_HUMAN Protein virilizer homolog KIAA1429  -0.44 -3.96 -3.38 
Q9H267 VP33B_HUMAN Vacuolar protein sorting-associated protein 33B VPS33B  0.05 3.10 3.18 
Q92558 WASF1_HUMAN Wiskott-Aldrich syndrome protein family member 1 WASF1  -0.78 0.93 1.84 
Q9Y6W5 WASF2_HUMAN Wiskott-Aldrich syndrome protein family member 2 WASF2  -1.10 0.59 1.83 
Q9Y2I8 WDR37_HUMAN WD repeat-containing protein 37 WDR37  1.87 1.47 -0.26 
Q8TAF3 WDR48_HUMAN WD repeat-containing protein 48 WDR48  -1.39 -0.66 0.86 
O43379 WDR62_HUMAN WD repeat-containing protein 62 WDR62  -0.55 0.63 1.31 
P30291 WEE1_HUMAN Wee1-like protein kinase WEE1  0.04 -0.99 -0.89 
Q9H4A3 WNK1_HUMAN Serine/threonine-protein kinase WNK1 WNK1  2.41 1.70 -0.58 
Q9ULE0 WWC3_HUMAN Protein WWC3 WWC3  0.13 -0.22 -0.22 
P46937 YAP1_HUMAN Yorkie homolog YAP1  -0.25 0.16 0.54 
Q8NHG8 ZNRF2_HUMAN E3 ubiquitin-protein ligase ZNRF2 ZNRF2  1.52 -0.35 -1.73 
Q9C0D3 ZY11B_HUMAN Protein zyg-11 homolog B ZYG11B  -0.06 -0.42 -0.22 
  
  
 
 
 
 
 
 
 
 
 
Appendix VI 
Proteins were captured on 14-3-3-Sepharose in lysates of HEK293 cells stimulated with forskolin or not, and in the presence or absence of H-89. 
Peptides were extracted from the SDS gel (Figure 4.1) and phosphopeptides from the forskolin treated samples were enriched using titanium 
dioxide beads in C-8-Empore disks. The phosphopeptides identified from the forskolin treated samples are listed below. The phosphorylated 
residues identified in this screen are underlined in each peptide. In cases where the 14-3-3 binding sites were also identified in either the literature 
(SK) or in the MacKintosh group (S(CM)), a Y is listed next to that residue in the relevant column; in cases where sites are known but were not 
identified in this screen, those sites are listed in parentheses where relevant (e.g. Y(642)). For predicted sites, a P next to the relevant residues 
denotes a potential candidate residue based either on sequence comparison with amphioxus (SP) or based on the mode I and II consensus sequences 
(PC). SP ID: SwissProt ID; Prot id: SwissProt protein Id; pS/T: phosphorylated serine/threonine residue; pS/T Pos: phosphorylated serine/threonine 
position in the protein; Score: peptide score; p-value: peptide p-value; SK: site known-published 14-3-3-binding sites with their references; S(CM): 
sites identified by the MacKintosh group (unpublished); SP: sites predicted by comparing with the amphioxus sequence; PC: potential 14-3-3-
binding candidate based on mode I and mode II consensus motifs.  
 
SP Id Prot id Digestion product pS/T 
pS/T 
pos 
Score p-value Mass SK S(CM) SP 
P
C 
References 
Q7L8J4 3BP5L 
GLSDHVSLDGQELGTR 
S 358 51.0 0.00056 588.6     P   
S 362 66.3 1.80E-05 882.4     P     
ETPQGELRPEVVEDEVPRSPVAEEPGGGGSSSSEAK S 30 53.4 0.00085 1258.2           
Q8IZP0 ABI1 NTPYKTLEPVKPPTVPNDYMTSPAR 
T 200 43.2 0.0077 998.1           
T 215 38.0 0.025 998.1           
O14639 ABLM1 
RSSGREEDDEELLR S 587 46.1 0.0017 590.9           
GVSMPNMLEPK S 706 44.8 0.0012 657.8     P   
TASLPGYGR S 655 28.8 0.036 501.2     P P   
P55196 AFAD 
ADHRSSPNVANQPPSPGGK 
S 1172 55.9 0.00019 692.6           
S 1182 55.9 0.00019 692.6         
SSPNVANQPPSPGGK S 1173 47.5 0.001 758.8         
SQDADSPGSSGAPENLTFK S 1779 85.8 1.70E-07 994.4         
SQEELREDK S 1275 36.0 0.0081 607.3           
Q96B36 AKTS1 AATAARPPAPPPAPQPPSPTPSPPRPTLAR S 88 94.6 3.70E-08 1042.2          
T 90 61.5 7.80E-05 1042.2        
 
 
 
Kovacina et al., 
2003; Nascimento 
et al., 2010 
S 92 86.2 2.60E-07 1042.2       
T 97 94.6 3.70E-08 1042.2       
 
SLPVSVPVWGFK 
 
S 
 
183 
 
52.6 
 
0.0003 
 
698.4 
 
Y 
  
 
  
RTEARSSDEENGPPSSPDLDR 
T 198 35.5 0.023 825.7       
S 202 57.3 0.00015 825.7       
SSDEENGPPSSPDLDR 
S 203 70.2 2.30E-06 931.3       
S 211 78.1 6.60E-07 891.3       
S 212 84.1 1.70E-07 891.3       
LNTSDFQK T 246 51.1 0.00021 516.7 Y       
Q96Q42 ALS2 
SSSLVDIREEETEGGSR S 466 38.4 0.011 965.9     P     
RLSLPGLLSQVSPR 
S 492 52.0 0.00041 841.9         
S 483 52.0 0.00041 841.9     P P   
Q92625 ANS1A 
SLSKSDSDLLTCSPTEDATMGSR 
S 626 43.7 0.0047 852.0           
S 628 66.5 2.40E-05 852.0         
SPSFASEWDEIEK 
S 661 58.1 6.70E-05 802.8         
S 663 63.6 1.90E-05 802.8         
S 666 37.8 0.0047 842.8         
SESLSNCSIGK S 647 39.7 0.0032 631.3       P   
Q92974 ARHG2 
ILSQSTDSLNMR S 174 53.2 0.00026 722.8           
LSPPHSPR 
S 956 27.4 0.042 525.7         
S 960 27.4 0.042 525.7         
QELGSPEER S 932 34.6 0.008 562.7         
SESLESPR S 645 42.8 0.001 492.7         
SLPAGDALYLSFNPPQPSR S 886 53.8 0.00039 1055.5       P   
Q15052 ARHG6 MSGFIYQGK S 488 51.5 0.00019 555.7           
Q14155 ARHG7 MSGFIYQGK S 518 51.5 0.00019 555.7           
KPSDEEFASR S 694 40.2 0.0031 623.3           
Q7Z3C6 ATG9A 
RESDESGESAPDEGGEGAR 
S 735 82.6 2.30E-07 1007.9           
S 738 47.8 0.00019 1087.9         
 
S 
 
741 
 
47.8 
 
0.00019 
 
1087.9 
    
 
    
LEASYSDSPPGEEDLLVHVAEGSK S 18 43.3 0.006 870.4         
HPEPVPEEGSEDELPPQVHKV S 828 34.0 0.047 810.4           
Q9UQB8 BAIP2 
SSSTGNLLDKDDLAIPPPDYGAASR 
S 452 35 0.043 880.7 Y(360)     
Robens et al., 
2003 
S 454 60.4 0.00012 1320.6       
T 455 46.7 0.0029 880.7       
SSSMAAGLER S 366 61.5 1.70E-05 552.7       
SLSPPQSQSK S 325 32.6 0.019 569.8       
LSDSYSNTLPVR T 340 34.7 0.018 716.3 Y   P   
Q9H3Q1 BORG4 NAMSLPQLNEK S 118 33.6 0.018 670.8     P     
P15056 BRAF RDSSDDWEIPDGQITVGQR S 446 55.7 0.00028 1127.5           
Q08AD1 CAMP2 SISNEGLTLNNSHVSK S 464 51.5 0.00054 890.4     P     
Q16204 CCDC6 LDQPVSAPPSPR 
S 240 31.6 0.028 712.3         
  
S 244 31.6 0.028 712.3   Y P   
Q8ND76 CCNY SASADNLTLPR S 326 72.5 2.40E-06 612.8     P     
P06493 CDK1 IGEGTYGVVYK T 14 32.2 0.019 673.3           
O94921 CDK14 RHSSPSSPTSPK S 120 48.6 0.0007 449.9           
Q00536 CDK16 KISTEDINK S 110 41.9 0.0029 564.3           
Q00537 CDK17 RASLSEIGFGK S 180 60.9 3.90E-05 622.8     P     
Q07002 CDK18 RASLSDIGFGK S 130 46.7 0.001 615.8     P     
P24941 CDK2 IGEGTYGVVYK T 14 32.2 0.019 673.3           
Q00526 CDK3 IGEGTYGVVYK T 14 32.2 0.019 673.3           
Q01850 CDR2 SSSETILSSLAGSDIVK S 311 59.9 7.40E-05 887.4     P     
Q7Z7L8 CK096 STQSLSLQR T 407 52.7 0.00021 550.3           
S 406 45.2 0.0012 550.3         
LRNSLDSSDSDSAL S 425 46.0 0.0012 780.3           
Q7Z460 CLAP1 
RQSSGSATNVASTPDNR 
S 646 85.5 0.00000021 914.4           
S 647 49.2 0.00069 954.4         
S 649 46.7 0.0016 914.4         
T 651 36.7 0.016 914.4         
SRSDIDVNAAAGAK 
S 598 33.2 0.025  742.8     P     
S 600 90.1 5.30E-08 727.8         
O75122 CLAP2 SRSDIDVNAAAGAK 
S 368 38.2 0.0082 727.8           
S 370 90.1 5.30E-08 727.8     P     
Q96GS4 CQ059 
RATISSPLELEGTVSR 
T 196 39.7 0.0076 599.3           
S 199 49.6 0.00077 599.3         
SLDGLSEACGGAGSSGSAESGAGGGR S 168 88.1 1.20E-07 1167.5     P     
LQDSRSLDGLSEACGGAGSSGSAESGAGGGR S 166 86.5 3.00E-07 978.4           
O60716 CTND1 
VGGSSVDLHR S 268 76.8 8.40E-07 553.8           
GSLASLDSLR 
S 346 30 0.034 589.7         
S 349 31.8 0.022 589.7         
S 352 31.8 0.022 589.7           
Q69YQ0 CYTSA 
KGSSGNASEVSVACLTER 
S 384 73.9 3.40E-06 966.4           
S 385 37.5 0.015 966.4         
S 389 33.1 0.041 644.6         
RSSTSSEPTPTVK S 832 53.6 0.00025 728.8           
Q9UJU6 DBNL AMSTTSISSPQPGK T 270 61.8 3.40E-05 744.3           
Q9BUQ8 DDX23 RSSLSPGR 
S 109 48.1 0.0003 510.2           
S 107 48.1 0.0003 510.2           
Q09019 DMWD 
AEEAATAAGADGERSGEEEEEEPEAAGTGSAGGAPLS
PLPK 
S 397 89.3 2.30E-07 1325.9           
YHSLGNISR S 545 40.9 0.003 563.8     P     
SNSLPHPAGGGK S 495 34.4 0.015 601.3     P     
Q96N67 DOCK7 
KGSWSER S 432 38.4 0.003 465.2           
 
RNSSIVGR 
 
S 
 
439 
 
69.1 
 
4.70E-06 
 
484.7 
    
 
    
 
SMSIDDTPR 
S 
 
182 
 
35.1 
 
0.0053 
 
551.2 
    
 
P 
    
SLSNSNPDISGTPTSPDDEVR 
S 896 52.0 0.00046 1174.5         
S 900 111.7 6.20E-10 1134.5         
S 910 52.0 0.00046 1174.5         
SPSGSAFGSQENLR S 1438 41.9 0.0031 758.8           
Q9Y2J2 E41L3 GISQTNLITTVTPEKK 
S 460 36.4 0.02 945.5           
T 469 36.4 0.02 945.5           
Q96F86 EDC3 
SQDVAVSPQQQQCSK S 131 66.2 1.60E-05 885.4           
RHNSWSSSSR S 161 42.5 0.0019 642.3 Y   P     
Q32P44 EMAL3 AISSANLLVR S 176 77.8 7.60E-07 562.3 
 
Y 
(127, 
147) 
      
O95208 EPN2 GSSQPNLSTSHSEQEYGK 
S 173 59.4 6.30E-05 1048.4           
S 178 45.3 0.0022 1008.4         
S 182 59.4 6.30E-05 1048.4           
Q96E09 F122A 
SNSAPLIHGLSDTSPVFQAEAPSAR S 45 40.7 0.011 878.1   Y(37)       
RNSTTFPSR S 62 53.2 0.0002 573.3   Y     
RIDFIPVSPAPSPTR 
S 143 88.4 1.10E-07 906.9         
S 147 88.4 1.10E-07 906.9         
T 149 78.5 1.10E-06 906.9           
Q7Z309 F122B 
RNSTTIMSR 
S 50 42.9 0.002 573.3           
T 51 29.8 0.039 573.3         
LYSPK S 105 28.1 0.022 344.2         
RIDFTPVSPAPSPTRGFGK T 112 33.5 0.047 730.7         
RIDFTPVSPAPSPTR S 115 85.5 2.20E-07 900.9         
S 119 85.5 2.20E-07 900.9         
T 121 49.8 0.00081 600.9         
 
MFVSSSGLPPSPVPSPR 
 
S 
 
137 
 
69.1 
 
9.50E-06 
 
959.4 
    
 
    
S 141 69.1 9.50E-06 959.4           
Q14153 FA53B SSSFSLPSR S 167 46.5 0.00063 524.2           
Q9H019 FA54B NASVPNLR S 103 32.2 0.018 475.7           
P85037 FOXK1 
QSPGPALAR S 101 62.3 2.00E-05 488.7           
SAPASPTHPGLMSPR 
S 416 78.6 6.70E-07 833.3     P     
S 420 78.6 6.70E-07 833.3         
T 422 46.2 0.0012 841.3         
S 428 43.3 0.0014 881.3         
SGGLQTPECLSREGSPIPHDPEFGSK 
T 436 40.3 0.013 981.4         
S 441 42.8 0.0074 981.4         
S 445 42.8 0.0074 981.4         
YSQSAPGSPVSAQPVIMAVPPRPSSLVAK 
S 468 47.9 0.0022 1033.2     P P   
S 472 47.9 0.0022 1033.2           
Q96NE9 FRMD6 
GQSTDSLPQTICR 
T 523 45.0 0.0011 811.8       P   
S 525 45.0 0.0011 811.8     P P   
HSLSLDDIR S 544 39.8 0.0036 568.3     P     
Q9Y2X7 GIT1 
SLSSPTDNLELSLR S 362 55.9 0.00018 806.4           
SQSDLDDQHDYDSVASDEDTDQEPLR 
S 385 42.7 0.0036 1047.7         
S 388 61.5 4.60E-05 1047.4           
Q14161 GIT2 TINNQHSVESQDNDQPDYDSVASDEDTDLETTASK 
S 394 49.7 0.0013 1343.5           
S 397 49.7 0.0013 1343.5           
Q3V6T2 GRDN SSSQENLLDEVMK S 1701 60.0 5.00E-05 788.3           
Q58FF8 H90B2 
IEDVGSDEEDDSGKDK S 177 60.2 3.40E-05 909.3           
IEDVGSDEEDDSGKDKK S 183 49.2 0.00079 973.4           
Q9P2P5 HECW2 
ANSDTDLVTSESR S 48 62.5 2.40E-05 737.8     P     
SHSAGEVGEDSR S 1042 51.5 0.00018 655.8           
P08238 HS90B 
 
IEDVGSDEEDDSGKDK 
 
S 
 
255 
 
60.2 
 
3.40E-05 
 
909.3 
          
IEDVGSDEEDDSGKDKK S 261 49.2 0.00079 973.4           
P08069 IGF1R ASFDER S 1339 27.7 0.015 402.6           
Q9Y4H2 IRS2 
TASEGDGGAAAGAAAAGAR S 365 79.2 6.00E-07 806.3 Y(573)       
Neukamm et al., 
2012 
PVSVAGSPLSPGPVR 
S 388 43.5 0.0028 790.4       
S 391 43.5 0.0028 790.4       
RVSGDAAQDLDR S 560 59.7 5.00E-05 691.8     P   
KSSEGGVGVGPGGGDEPPTSPR S 1186 59.8 0.0001 702.0         
Q6ICG6 K0930 
VSTGDTSPCGTEEDSSPASPMHER S 267 32.7 0.034 877.3           
VTSFSTPPTPER 
S 289 48.7 0.00051 739.8         
T 293 48.7 0.00051 739.8         
SRSLSGTGR 
S 351 30.1 0.02 540.7     P   
S 353 30.1 0.02 540.7       P   
Q9NQT8 KI13B SISSPNVNR S 1381 38.4 0.0043 527.2       P   
Q8N5S9 KKCC1 
AASVIPGSTSR S 52 61.2 3.20E-05 563.3     P P   
KLSLQERPAGSYLEAQAGPYATGPASHISPR 
S 74 60.5 0.00011 833.9 Y       
S 82 39.1 0.015 833.9         
T 93 43.2 0.008 1138.2         
RPTIESHHVAISDAEDCVQLNQYK S 111 43.2 0.0071 964.1         
SFGNPFEPQAR S 458 62.8 2.10E-05 665.3         
SMSAPGNLLVK S 475 60.7 3.80E-05 606.8     P P   
EGFGEGGKSPELPGVQEDEAAS S 492 56.8 0.00019 1135.5           
Q07866 KLC1 SRESLNVDVVK 
S 521 55.7 0.00015 663.3         Johnson et al., 
2011 S 524 42.5 0.0031 663.3     P   
Q9H0B6 KLC2 KLDEDASPNEEK S 151 50.3 0.00042 727.8          
RSSRDMAGGAGPR S 508 59.9 4.80E-05 466.5        
 
 
Johnson et al., 
2011 
RSSEMLVK S 557 45.4 0.00094 515.2       
 
ASSLNFLNK 
 
S 
 
582 
 
38.8 
 
0.0051 
 
537.3 
 
Y 
  
 
  
TLSSSSMDLSR 
S 608 45.0 0.00067 672.3       
S 610 56.7 7.00E-05 632.3       
S 611 51.4 0.00026 632.3       
S 615 47.1 0.00041 672.3         
Q6P597 KLC3 
QYDPPAESQQSESPPRRDSLASLFPSEEEER S 167 43.0 0.0094 931.1         
Johnson et al., 
2011 
RDSLASLFPSEEEER S 173 78.4 1.10E-06 922.9       
AMSLNTLNVDAPR S 466 83.0 2.90E-07 749.3 Y   P   
TLSASTQDLSPH T 498 41.4 0.0032 668.8         
Q9NSK0 KLC4 
TSQEGPGDSVK T 518 34.3 0.011 592.7         
Johnson et al., 
2011 
RTSQEGPGDSVK S 519 47.2 0.0008 670.8       
SSELLVR 
S 565 46.8 0.00077 442.2       
S 566 50.6 0.00032 442.2       
AASLNYLNQPSAAPLQVSR S 590 56.6 0.00019 1040.5 Y   P   
GLSASTMDLSSSS 
S 611 85.2 8.40E-08 661.8       
T 612 34.2 0.011 669.8         
Q15139 KPCD1 RLSNVSLTGVSTIR 
S 205 33.7 0.031 831.9           
T 210 33.7 0.031 831.9           
Q6PKG0 LARP1 SLPTTVPESPNYR 
S 766 32.0 0.031 810.8     P     
S 774 32.0 0.031 810.8           
Q14739 LBR SASASHQADIK S 99 37.6 0.0064 597.8       P   
Q86X29 LSR SRSRDDLYDQDDSRDFPR S 530 38.0 0.015 581.7       P   
Q9Y2U5 M3K2 
RLSIIGPTSR S 153 35.1 0.013 590.3           
DRSSPPPGYIPDELHQVAR S 163 39.8 0.011 738.7     P   
AQSYPDNHQEFSDYDNPIFEK S 239 44.0 0.0039 875.4     P P   
RRGSDIDNPTLTVMDISPPSR 
S 331 53.4 0.00055 808.4     P P   
S 344 41.2 0.0093 835.0           
 
O43318 
 
M3K7 
 
SIQDLTVTGTEPGQVSSR 
S 
 
439 
 
80.3 
 
8.00E-07 
 
978.0 
          
Q6P0Q8 MAST2 SRSLSPGR 
S 299 35.9 0.0051 510.2     P P   
S 301 35.9 0.0051 510.2           
O60307 MAST3 RLSADIR S 747 31.5 0.021 455.7       P   
O15021 MAST4 
SRSLSPGR S 358 35.9 0.0051 510.2     P P   
RGSLGGALTGR S 166 55.6 0.00012 562.8       P   
Q8N4C8 MINK1 
SQSLQDQPTR S 601 41.9 0.0024 620.3     P P   
KGSVVNVNPTNTR S 993 51.5 0.0004 733.4       P   
Q6WCQ1 MPRIP AEEQQLPPPLSPPSPSTPNHR 
S 289 37.2 0.022 813.7           
S 292 37.2 0.022 813.7           
Q7Z401 MYCPP 
HKSDNETNLQQQVVWGNR S 1015 42.7 0.0055 745.0     P P   
SISTSGPLDKEDTGR 
S 1587 68.8 7.80E-06 821.9     P   
S 1589 65.1 2.00E-05 821.9       P   
O14974 MYPT1 
DKKSPLIESTANMDNNQSQK S 299 42.6 0.0063 782.0 Y(472)       
Koga and Ikebe, 
2008; Zagorska et 
al., 2010 
ISPKEEER S 422 31.6 0.022 534.2       
TGSYGALAEITASK 
T 443 92.4 3.20E-08 724.8       
S 445 106.4 1.30E-09 724.8       
RSTQGVTLTDLQEAEK 
S 695 71.9 5.50E-06 928.4       
T 696 73.2 4.00E-06 928.4     P 
T 700 53.2 0.0004 619.3     P   
STGVSFWTQDSDENEQEQQSDTEEGSNK 
S 862 85.0 2.30E-07 1108.1       
S 871 85.0 2.30E-07 1108.1       
T 873 58.6 0.00014 1081.4       
SGSYSYLEER S 910 52.4 0.00017 635.8     P 
O60237 MYPT2 RSTQGVTLTDLQEAEK T 650 53.2 0.0004 619.3     P     
Q96PU5 NED4L SLSSPTVTLSAPLEGAK 
S 446 62.9 3.40E-05 869.4           
S 448 79.4 7.80E-07 869.4 Y   P     
P18615 NELFE SISADDDLQESSR S 115 30.3 0.034 751.8     P     
P21359 NF1 SMSLDMGQPSQANTK 
S 2521 30.8 0.035 853.8     P     
S 2523 50.9 0.00035 853.8           
P07197 NFM 
PKSPVEEKGKSPV 
S 620 35.5 0.017 771.4           
S 628 35.5 0.017 771.4         
AKSPVPKSPVEEAK S 685 37.6 0.012 813.9           
Q9UJF2 NGAP 
SISGTSTSEKPNSMDTANTSPFK S 16 40.9 0.0097 828.4           
QNSTGQAQIR S 864 46.6 0.00077 591.8           
Q14978 NOLC1 IKLQTPNTFPK 
T 607 36.1 0.014 723.8           
T 610 36.1 0.014 723.8     P     
Q9H4L5 OSBL3 
QDSWEVVEGLR S 34 40.2 0.0044 699.3           
TYSAPAINAIQGGSFESPK 
T 249 83.9 3.80E-07 1009.5         
S 251 88.5 1.30E-07 1009.5         
LHSSNPNLSTLDFGEEK S 304 82.8 4.80E-07 984.4           
Q9BZF3 OSBL6 TASSSTEPSVSR S 44 35.2 0.0094 644.8           
Q86VP3 PACS2 ANSLDNER S 453 38.1 0.0028 499.7 Y(487)         
O96013 PAK4 
LAAGRPFNTYPR T 207 40.3 0.0056 721.9           
DKRPLSGPDVGTPQPAGLASGAK S 181 46.7 0.0018 767.1           
Q8TEW0 PARD3 
RSSDPALIGLSTSVSDSNFSSEEPSR 
S 144 55.0 0.00047 935.8     P     
S 154 45.1 0.0046 935.8         
SSLSASHPMVGK S 223 34.6 0.015 648.8         
RISHSLYSGIEGLDESPSR 
S 715 41.2 0.0078 728.3     P     
S 720 35.4 0.031 728.3           
Q6Y7W6 PERQ2 WRPHSPDGPR S 236 29.9 0.042 642.8           
Q9UBF8 PI4KB SKSDATASISLSSNLK S 275 98.6 1.10E-08 844.9 Y(294)         
S 277 89.3 9.10E-08 844.9     P     
STRSVENLPECGITHEQR T 426 36.6 0.022 731.7         
SVENLPECGITHEQR S 428 79.6 8.10E-07 924.9         
RLSEQLAHTPTAFK S 511 52.1 0.00043 560.3           
Q9HB20 PKHA3 SVSHPGSCSSER S 211 33.7 0.012 685.3     P     
Q9BZL4 PP12C 
TGSSGALGPPER S 427 58.2 5.70E-05 604.8           
SASSSWLEGTSTQAK S 452 70.6 4.90E-06 810.4     P     
RSTQGVTLTDLQEAEK T 560 73.2 4.00E-06 928.4           
Q12923 PTN13 AISTGSLASSTLNK 
S 908 47.6 0.001 755.3           
T 909 41.8 0.0037 755.3         
S 911 47.6 0.001 755.3           
Q15276 RABE1 
GSVHSLDAGLLLPSGDPFSK 
S 374 67.2 1.80E-05 1079.0           
S 377 67.2 1.80E-05 1079.0     P     
AQSTDSLGTSGSLQSK S 407 129.6 6.80E-12 823.9         
RAQSTDSLGTSGSLQSK 
T 408 88.3 9.50E-08 941.9         
S 410 88.3 9.50E-08 941.9         
T 413 46.2 0.0018 901.9           
Q9UJ41 RABX5 
QTSIETDR S 310 44.6 0.00075 515.2           
LDAQSLNLSQEDFDRYMSGQTSPR S 607 70.7 1.30E-05 952.1           
P04049 RAF1 RASDDGKLTDPSK S 43 33.8 0.021 490.6           
Q6NUK4 REEP3 SFSMHDLTTIQGDEPVGQRPYQPLPEAK 
S 150 47.1 0.0031 1079.8         
Tinti et al., 2012 
S 152 49.6 0.0017 1079.8 Y   P   
Q9H6H4 REEP4 SFSMQDLR S 152 37.0 0.0046 532.2 Y   P   Tinti et al., 2012 
Q9BXF6 RFIP5 
TYSDEANQMR S 307 32.6 0.0097 655.7           
SNSSSEAVLGQEELSAQAK 
S 397 36.1 0.022 1008.0         
S 395 77.8 1.50E-06 1008.0           
Q86X27 RGPS2 SVAAEGALLPQTPPSPR S 315 50.3 0.00075 925.9           
S 329 50.3 0.00075 925.9           
Q8IWW6 RHG12 ATTPPNQGRPDSPVYANLQELK 
T 230 37.3 0.025 852.7           
T 231 41.5 0.0093 852.7         
S 240 41.5 0.0093 852.7           
Q15019 SEPT2 IYHLPDAESDEDEDFKEQTR S 218 43.4 0.0049 839.7           
Q9BRG2 SH23A SFSEDTLMDGPAR S 125 58.7 5.30E-05 761.3     P     
Q9H0K1 SIK2 SSFPVEQR 
S 342 32.5 0.015 515.2           
S 343 35.1 0.0077 515.2           
Q01082 SPTB2 RPPSPEPSTK S 2102 30.0 0.044 588.3           
Q9UMX1 SUFU RLSGKDTEQIR S 301 35.7 0.015 691.8           
Q4KMP7 TB10B 
ALAAGADSPKTEEARPSPAPGPGTPTGTPTR S 132 43.9 0.0063 1040.1           
TEEARPSPAPGPGTPTGTPTR 
T 148 45.9 0.0025 746.3         
T 150 46.3 0.0023 746.3         
T 152 46.3 0.0023 746.3         
ALAAGADSPKTEEARPSPAPGPGTPTGTPTR T 154 43.9 0.0063 1040.1         
QQPPLGPSSSLLSLPGLK 
S 656 33.8 0.034 990.0         
S 657 57.2 0.00015 990.0         
S 658 60.0 8.10E-05 990.0         
S 661 60.0 8.10E-05 990.0     P     
AAGGAPSPPPPVR S 678 53.8 0.0002 627.3         
RASAGPAPGPVVTAEGLHPSLPSPTGNSTPLGSSK 
S 687 41.0 0.0086 1125.6         
T 697 36.1 0.029 844.4         
KLSLR S 780 30.9 0.024 348.7           
Q3MII6 TBC25 QASLDGLQQLR S 506 38.7 0.0058 654.8     P P   
O60343 TBCD4 
HASAPSHVQPSDSEK 
S 341 52.7 0.00032 828.9 Y   P   
Geraghty et al., 
2007 
S 344 55.1 0.00018 828.9 Y(642)     
LGSVDSFER S 588 66.4 6.60E-06 545.2       
S 591 44.4 0.00063 585.2       
DYSPGDSPPGTPPASPPSSAWQTFPEEDSDSPQFR T 613 49.6 0.0019 1271.9       
TSSTCSNESLSVGGTSVTPR 
S 750 39.2 0.0054 1133.9       
S 751 56.0 0.00017 1093.9       
T 752 56.0 0.00017 1093.9       
S 754 67.1 1.30E-05 1093.9       
S 757 67.1 1.30E-05 1093.9         
Q92609 TBCD5 
RTSSTLDSEGTFNSYR S 43 41.6 0.0059 950.9         
SESMPVQLNK S 522 55.6 0.0001 614.8         
NISSSPSVESLPGGR 
S 539 31.8 0.036 823.8         
S 541 44.0 0.0022 823.8         
S 544 44.0 0.0022 823.8         
EFTGSPPSSATK S 554 28.6 0.048 644.8           
Q13009 TIAM1 ANSLGDLYAQK S 231 54.2 0.00018 630.3     P     
P49815 TSC2 
SQSGTLDGESAAWSASGEDSR 
S 1420 85.8 1.60E-07 1089.4 
Y (939, 
1462) 
        
T 1422 75.4 1.80E-06 1089.4       
SPSGLRPR S 1452 27.9 0.047 475.2         
P40818 UBP8 SYSSPDITQAIQEEEK S 718 71.4 5.70E-06 952.9     P     
Q9H4A3 WNK1 
DVDDGSGSPHSPHQLSSK 
S 2027 50.8 0.0004 1005.4           
S 2029 50.8 0.0004 1005.4         
S 2032 32.7 0.025 1005.4         
RGSKGHMNYEGPGMAR S 2270 44.6 0.0022 620.6       P   
P46937 YAP1 
GDSETDLEALFNAVMNPK 
S 61 87.7 1.40E-07 1023.9       P 
Zhao et al., 2007; 
Schlegelmilch et 
al., 2011 
T 63 102.6 4.60E-09 1023.9       
SHSRQASTDAGTAGALTPQHVR 
S 103 59.0 0.00014 803.4       
S 105 50.2 0.001 803.4       
T 110 59.0 0.00014 803.4     P 
QASTDAGTAGALTPQHVR 
S 109 47.8 0.0013 621.0       
T 114 37.4 0.015 930.9     P   
AHSSPASLQLGAVSPGTLTPTGVVSGPAATPTAQHLR 
S 127 83.8 3.50E-07 1205.6 Y   P   
S 128 68.9 1.10E-05 904.5       
S 131 67.2 1.60E-05 904.5       
S 138 48.7 0.0019 924.5       
T 156 39.1 0.017 924.5         
Q8NHG8 ZNRF2 
AYSGSDLPSSSSGGANGTAGGGGGAR 
S 19 57.9 0.00012 1140.0 Y   P   
Hoxhaj et al., 2012 
S 21 40.0 0.0077 1140.0       
S 27 33.4 0.035 1140.0       
SLGGAVGSVASGAR S 82 88.7 6.70E-08 634.8 Y   P   
AAQSPFSIPNSSSGPYGSQDSVHSSPEDGGGGR 
S 113 64.3 3.60E-05 1153.8       
S 116 64.3 3.60E-05 1153.8       
S 119 81.2 7.30E-07 1153.8       
S 120 81.2 7.30E-07 1153.8       
DRPVGGSPGGPR S 135 55.3 0.00012 616.3         
 
 
 
 
 
 
 
 
 
 
 
 
Appendix VII 
Proteins were purified from lysates of cells stably expressing GFP-ATG9A using GFP-Trap® beads. Peptides were digested from the 
SDS gel (Figure 4.20) and identified from the SwissProt database (SPROT_ID; description) and their Mascot score (score) 
determined.  The corresponding gel band (band) in which each protein was identified is given, together with the molecular weight 
(Mass).  
 
SPROT_ID SPROT_description Score Mass Band 
sp|P78527|PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit  PRKDC   5952 473749 1 
sp|Q92616|GCN1L_HUMAN Translational activator GCN1  GCN1L1   5168 294967 1 
sp|Q00610|CLH1_HUMAN Clathrin heavy chain 1  CLTC   1209 193260 1 
sp|P42345|MTOR_HUMAN Serine/threonine-protein kinase mTOR  MTOR   572 290759 1 
sp|P49327|FAS_HUMAN Fatty acid synthase  FASN   513 275877 1 
sp|Q9NVI1|FANCI_HUMAN Fanconi anemia group I protein  FANCI   456 150769 1 
sp|P20020|AT2B1_HUMAN Plasma membrane calcium-transporting ATPase 1  ATP2B1   439 139637 1 
sp|Q9BQG0|MBB1A_HUMAN Myb-binding protein 1A  MYBBP1A   406 149731 1 
sp|O75976|CBPD_HUMAN Carboxypeptidase D  CPD   302 153919 1 
sp|Q13308|PTK7_HUMAN Inactive tyrosine-protein kinase 7  PTK7   279 119799 1 
sp|Q92621|NU205_HUMAN Nuclear pore complex protein Nup205  NUP205   272 230171 1 
sp|P07814|SYEP_HUMAN Bifunctional glutamate/proline--tRNA ligase  EPRS   261 172080 1 
sp|P27708|PYR1_HUMAN CAD protein  CAD   209 245167 1 
sp|P55011|S12A2_HUMAN Solute carrier family 12 member 2  SLC12A2   198 132048 1 
sp|Q5VYK3|ECM29_HUMAN Proteasome-associated protein ECM29 homolog  ECM29   161 205985 1 
sp|P21333|FLNA_HUMAN Filamin-A  FLNA   157 283301 1 
sp|O15439|MRP4_HUMAN Multidrug resistance-associated protein 4  ABCC4   134 150344 1 
sp|Q9UIQ6|LCAP_HUMAN Leucyl-cystinyl aminopeptidase  LNPEP   122 117787 1 
sp|P35579|MYH9_HUMAN Myosin-9  MYH9   115 227646 1 
sp|P53621|COPA_HUMAN Coatomer subunit alpha  COPA   102 139797 1 
sp|O15118|NPC1_HUMAN Niemann-Pick C1 protein  NPC1   101 144868 1 
sp|P11717|MPRI_HUMAN Cation-independent mannose-6-phosphate receptor  IGF2R   100 281155 1 
sp|Q7Z3C6|ATG9A_HUMAN Autophagy-related protein 9A  ATG9A   6086 95356 2 
sp|Q15155|NOMO1_HUMAN Nodal modulator 1  NOMO1   1143 135209 2 
sp|P05556|ITB1_HUMAN Integrin beta-1  ITGB1   786 91664 2 
sp|Q9BSJ8|ESYT1_HUMAN Extended synaptotagmin-1  ESYT1   527 123293 2 
sp|Q9HAV4|XPO5_HUMAN Exportin-5  XPO5   458 138332 2 
sp|Q86VP6|CAND1_HUMAN Cullin-associated NEDD8-dissociated protein 1  CAND1   295 137999 2 
sp|P23634|AT2B4_HUMAN Plasma membrane calcium-transporting ATPase 4  ATP2B4   288 139030 2 
sp|P08648|ITA5_HUMAN Integrin alpha-5  ITGA5   176 115605 2 
sp|P22413|ENPP1_HUMAN Ectonucleotide pyrophosphatase/phosphodiesterase family member 1  ENPP1   140 107024 2 
sp|O14980|XPO1_HUMAN Exportin-1  XPO1   2247 124447 3 
sp|P55060|XPO2_HUMAN Exportin-2  CSE1L   1734 111145 3 
sp|Q8N766|EMC1_HUMAN ER membrane protein complex subunit 1  EMC1   1454 112145 3 
sp|Q13423|NNTM_HUMAN NAD(P) transhydrogenase, mitochondrial  NNT   720 114564 3 
sp|Q9UIA9|XPO7_HUMAN Exportin-7  XPO7   699 125196 3 
sp|O95373|IPO7_HUMAN Importin-7  IPO7   416 120751 3 
sp|Q13263|TIF1B_HUMAN Transcription intermediary factor 1-beta  TRIM28   330 90261 3 
sp|Q9P2B2|FPRP_HUMAN Prostaglandin F2 receptor negative regulator  PTGFRN   266 99464 3 
sp|Q86XL3|ANKL2_HUMAN Ankyrin repeat and LEM domain-containing protein 2  ANKLE2   254 104905 3 
sp|P11279|LAMP1_HUMAN Lysosome-associated membrane glycoprotein 1  LAMP1   249 45367 3 
sp|O00410|IPO5_HUMAN Importin-5  IPO5   232 125032 3 
sp|Q92542|NICA_HUMAN Nicastrin  NCSTN   227 79103 3 
sp|Q5JPE7|NOMO2_HUMAN Nodal modulator 2  NOMO2   213 140435 3 
sp|Q4KMQ2|ANO6_HUMAN Anoctamin-6  ANO6   209 107180 3 
sp|P22314|UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1  UBA1   190 118858 3 
sp|O15397|IPO8_HUMAN Importin-8  IPO8   173 120945 3 
sp|Q99460|PSMD1_HUMAN 26S proteasome non-ATPase regulatory subunit 1  PSMD1   163 106795 3 
sp|Q9Y2U8|MAN1_HUMAN Inner nuclear membrane protein Man1  LEMD3   136 100790 3 
sp|Q14697|GANAB_HUMAN Neutral alpha-glucosidase AB  GANAB   124 107263 3 
sp|O00461|GOLI4_HUMAN Golgi integral membrane protein 4  GOLIM4   121 81888 3 
sp|P05023|AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1  ATP1A1   2991 114135 4 
sp|P02786|TFR1_HUMAN Transferrin receptor protein 1  TFRC   1571 85274 4 
sp|P46459|NSF_HUMAN Vesicle-fusing ATPase  NSF   1356 83055 4 
sp|P27824|CALX_HUMAN Calnexin  CANX   1340 67982 4 
sp|Q9UGP8|SEC63_HUMAN Translocation protein SEC63 homolog  SEC63   1255 88341 4 
sp|P16615|AT2A2_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  ATP2A2   1079 116336 4 
sp|Q14974|IMB1_HUMAN Importin subunit beta-1  KPNB1   999 98420 4 
sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta  HSP90AB1   934 83554 4 
sp|P07900|HS90A_HUMAN Heat shock protein HSP 90-alpha  HSP90AA1   893 85006 4 
sp|P13639|EF2_HUMAN Elongation factor 2  EEF2   568 96246 4 
sp|O96005|CLPT1_HUMAN Cleft lip and palate transmembrane protein 1  CLPTM1   526 76277 4 
sp|O94874|UFL1_HUMAN E3 UFM1-protein ligase 1  UFL1   447 89996 4 
sp|Q9Y4R8|TELO2_HUMAN Telomere length regulation protein TEL2 homolog  TELO2   427 92430 4 
sp|Q6ZXV5|TMTC3_HUMAN Transmembrane and TPR repeat-containing protein 3  TMTC3   408 104854 4 
sp|Q9Y5L0|TNPO3_HUMAN Transportin-3  TNPO3   394 105961 4 
sp|Q92973|TNPO1_HUMAN Transportin-1  TNPO1   299 103771 4 
sp|Q13724|MOGS_HUMAN Mannosyl-oligosaccharide glucosidase  MOGS   269 92032 4 
sp|Q9UBF2|COPG2_HUMAN Coatomer subunit gamma-2  COPG2   266 98700 4 
sp|P55072|TERA_HUMAN Transitional endoplasmic reticulum ATPase  VCP   254 89950 4 
sp|A0FGR8|ESYT2_HUMAN Extended synaptotagmin-2  ESYT2   241 102807 4 
sp|O14967|CLGN_HUMAN Calmegin  CLGN   181 70451 4 
sp|Q9Y4W6|AFG32_HUMAN AFG3-like protein 2  AFG3L2   180 88984 4 
sp|Q5ZPR3|CD276_HUMAN CD276 antigen  CD276   173 57941 4 
sp|Q9BUJ2|HNRL1_HUMAN Heterogeneous nuclear ribonucleoprotein U-like protein 1  HNRNPUL1   173 96250 4 
sp|P47897|SYQ_HUMAN Glutamine--tRNA ligase  QARS   172 88655 4 
sp|Q13740|CD166_HUMAN CD166 antigen  ALCAM   148 65745 4 
sp|O95202|LETM1_HUMAN LETM1 and EF-hand domain-containing protein 1, mitochondrial  LETM1   147 83986 4 
sp|P14625|ENPL_HUMAN Endoplasmin  HSP90B1   146 92696 4 
sp|Q86Y56|HEAT2_HUMAN HEAT repeat-containing protein 2  HEATR2   141 94774 4 
sp|P19338|NUCL_HUMAN Nucleolin  NCL   131 76625 4 
sp|P12814|ACTN1_HUMAN Alpha-actinin-1  ACTN1   121 103563 4 
sp|Q96J02|ITCH_HUMAN E3 ubiquitin-protein ligase Itchy homolog  ITCH   118 103593 4 
sp|Q6ZRP7|QSOX2_HUMAN Sulfhydryl oxidase 2  QSOX2   113 78221 4 
sp|Q9UH99|SUN2_HUMAN SUN domain-containing protein 2  SUN2   110 80490 4 
sp|P30825|CTR1_HUMAN High affinity cationic amino acid transporter 1  SLC7A1   107 68449 4 
sp|Q01813|K6PP_HUMAN 6-phosphofructokinase type C  PFKP   101 86454 4 
sp|P08107|HSP71_HUMAN Heat shock 70 kDa protein 1A/1B  HSPA1A   2721 70294 5 
sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein  HSPA8   2154 71082 5 
sp|P04843|RPN1_HUMAN Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1  RPN1   1754 68641 5 
sp|O95573|ACSL3_HUMAN Long-chain-fatty-acid--CoA ligase 3  ACSL3   1552 81338 5 
sp|P31040|DHSA_HUMAN Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial  SDHA   1227 73672 5 
sp|P38646|GRP75_HUMAN Stress-70 protein, mitochondrial  HSPA9   1107 73920 5 
sp|Q9NVI7|ATD3A_HUMAN ATPase family AAA domain-containing protein 3A  ATAD3A   1065 71610 5 
sp|Q07065|CKAP4_HUMAN Cytoskeleton-associated protein 4  CKAP4   1036 66097 5 
sp|Q15758|AAAT_HUMAN Neutral amino acid transporter B(0)  SLC1A5   1029 57018 5 
sp|P16435|NCPR_HUMAN NADPH--cytochrome P450 reductase  POR   874 77097 5 
sp|Q5T9A4|ATD3B_HUMAN ATPase family AAA domain-containing protein 3B  ATAD3B   771 73098 5 
sp|Q8WVM8|SCFD1_HUMAN Sec1 family domain-containing protein 1  SCFD1   737 72676 5 
sp|O94826|TOM70_HUMAN Mitochondrial import receptor subunit TOM70  TOMM70A   728 68096 5 
sp|A1L0T0|ILVBL_HUMAN Acetolactate synthase-like protein  ILVBL   597 68452 5 
sp|P11021|GRP78_HUMAN 78 kDa glucose-regulated protein  HSPA5   533 72402 5 
sp|P28288|ABCD3_HUMAN ATP-binding cassette sub-family D member 3  ABCD3   521 75941 5 
sp|Q9BU23|LMF2_HUMAN Lipase maturation factor 2  LMF2   452 79933 5 
sp|Q96S52|PIGS_HUMAN GPI transamidase component PIG-S  PIGS   450 61731 5 
sp|Q8WTV0|SCRB1_HUMAN Scavenger receptor class B member 1  SCARB1   404 61636 5 
sp|Q14108|SCRB2_HUMAN Lysosome membrane protein 2  SCARB2   397 54712 5 
sp|Q8IXI1|MIRO2_HUMAN Mitochondrial Rho GTPase 2  RHOT2   384 69101 5 
sp|P49748|ACADV_HUMAN Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  ACADVL   327 70745 5 
sp|Q8IYS2|K2013_HUMAN Uncharacterized protein KIAA2013  KIAA2013 323 69684 5 
sp|P29966|MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate  MARCKS   306 31707 5 
sp|Q9NRW7|VPS45_HUMAN Vacuolar protein sorting-associated protein 45  VPS45   277 65435 5 
sp|Q9UJS0|CMC2_HUMAN Calcium-binding mitochondrial carrier protein Aralar2  SLC25A13   270 74528 5 
sp|Q969N2|PIGT_HUMAN GPI transamidase component PIG-T  PIGT   270 66228 5 
sp|Q03519|TAP2_HUMAN Antigen peptide transporter 2  TAP2   246 76186 5 
sp|O00116|ADAS_HUMAN Alkyldihydroxyacetonephosphate synthase, peroxisomal  AGPS   240 73664 5 
sp|Q03518|TAP1_HUMAN Antigen peptide transporter 1  TAP1   234 87733 5 
sp|Q96QD8|S38A2_HUMAN Sodium-coupled neutral amino acid transporter 2  SLC38A2   234 56332 5 
sp|O00186|STXB3_HUMAN Syntaxin-binding protein 3  STXBP3   233 68633 5 
sp|O75027|ABCB7_HUMAN ATP-binding cassette sub-family B member 7, mitochondrial  ABCB7   225 82874 5 
sp|Q7Z434|MAVS_HUMAN Mitochondrial antiviral-signaling protein  MAVS   218 57063 5 
sp|P17812|PYRG1_HUMAN CTP synthase 1  CTPS1   201 67332 5 
sp|P08195|4F2_HUMAN 4F2 cell-surface antigen heavy chain  SLC3A2   186 68180 5 
sp|Q9NVH0|EXD2_HUMAN Exonuclease 3~-5~ domain-containing protein 2  EXD2   183 57165 5 
sp|Q4ZIN3|MBRL_HUMAN Membralin  C19orf6   172 68130 5 
sp|O14975|S27A2_HUMAN Very long-chain acyl-CoA synthetase  SLC27A2   165 71066 5 
sp|Q9Y639|NPTN_HUMAN Neuroplastin  NPTN   155 44702 5 
sp|P52272|HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M  HNRNPM   153 77749 5 
sp|Q9UKV5|AMFR2_HUMAN E3 ubiquitin-protein ligase AMFR  AMFR   144 73747 5 
sp|P28331|NDUS1_HUMAN NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  NDUFS1   142 80443 5 
sp|Q8TCJ2|STT3B_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B    134 94241 5 
sp|P43003|EAA1_HUMAN Excitatory amino acid transporter 1  SLC1A3   132 59705 5 
sp|P02768|ALBU_HUMAN Serum albumin  ALB   129 71317 5 
sp|Q13641|TPBG_HUMAN Trophoblast glycoprotein  TPBG   127 46573 5 
sp|Q92575|UBXN4_HUMAN UBX domain-containing protein 4  UBXN4   120 57028 5 
sp|P11940|PABP1_HUMAN Polyadenylate-binding protein 1  PABPC1   111 70854 5 
sp|Q7Z2K6|ERMP1_HUMAN Endoplasmic reticulum metallopeptidase 1  ERMP1   106 101023 5 
sp|P06576|ATPB_HUMAN ATP synthase subunit beta, mitochondrial  ATP5B   4458 56525 6 
sp|P25705|ATPA_HUMAN ATP synthase subunit alpha, mitochondrial  ATP5A1   3234 59828 6 
sp|P07437|TBB5_HUMAN Tubulin beta chain  TUBB   2751 50095 6 
sp|P68371|TBB4B_HUMAN Tubulin beta-4B chain  TUBB4B   2574 50255 6 
sp|Q9BVA1|TBB2B_HUMAN Tubulin beta-2B chain  TUBB2B   2018 50377 6 
sp|P04350|TBB4A_HUMAN Tubulin beta-4A chain  TUBB4A   2014 50010 6 
sp|P68363|TBA1B_HUMAN Tubulin alpha-1B chain  TUBA1B   1812 50804 6 
sp|Q71U36|TBA1A_HUMAN Tubulin alpha-1A chain  TUBA1A   1571 50788 6 
sp|Q9BQE3|TBA1C_HUMAN Tubulin alpha-1C chain  TUBA1C   1497 50548 6 
sp|P04844|RPN2_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2  RPN2   1377 69355 6 
sp|P10809|CH60_HUMAN 60 kDa heat shock protein, mitochondrial  HSPD1   990 61187 6 
sp|P42167|LAP2B_HUMAN Lamina-associated polypeptide 2, isoforms beta/gamma  TMPO   810 50696 6 
sp|Q9NTJ5|SAC1_HUMAN Phosphatidylinositide phosphatase SAC1  SACM1L   736 67437 6 
sp|Q9BUF5|TBB6_HUMAN Tubulin beta-6 chain  TUBB6   708 50281 6 
sp|P18031|PTN1_HUMAN Tyrosine-protein phosphatase non-receptor type 1  PTPN1   678 50505 6 
sp|Q9NRG9|AAAS_HUMAN Aladin  AAAS   669 60392 6 
sp|Q8NF37|PCAT1_HUMAN Lysophosphatidylcholine acyltransferase 1  LPCAT1   541 59741 6 
sp|Q969V3|NCLN_HUMAN Nicalin  NCLN   491 63106 6 
sp|Q8WVX9|FACR1_HUMAN Fatty acyl-CoA reductase 1  FAR1   418 59661 6 
sp|P48643|TCPE_HUMAN T-complex protein 1 subunit epsilon  CCT5   407 60089 6 
sp|Q14318|FKBP8_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP8  393 44990 6 
sp|P49257|LMAN1_HUMAN Protein ERGIC-53  LMAN1   389 57798 6 
sp|P35613|BASI_HUMAN Basigin  BSG   377 42573 6 
sp|P46977|STT3A_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A     356 81104 6 
sp|Q10471|GALT2_HUMAN Polypeptide N-acetylgalactosaminyltransferase 2  GALNT2   344 65433 6 
sp|P78371|TCPB_HUMAN T-complex protein 1 subunit beta  CCT2   334 57794 6 
sp|P50991|TCPD_HUMAN T-complex protein 1 subunit delta  CCT4   331 58401 6 
sp|Q9NRK6|ABCBA_HUMAN ATP-binding cassette sub-family B member 10, mitochondrial  ABCB10   303 79497 6 
sp|P14618|KPYM_HUMAN Pyruvate kinase isozymes M1/M2  PKM2   276 58470 6 
sp|Q96A33|CCD47_HUMAN Coiled-coil domain-containing protein 47  CCDC47   271 56123 6 
sp|Q16850|CP51A_HUMAN Lanosterol 14-alpha demethylase  CYP51A1   235 57169 6 
sp|P50990|TCPQ_HUMAN T-complex protein 1 subunit theta  CCT8   234 60153 6 
sp|Q99832|TCPH_HUMAN T-complex protein 1 subunit eta  CCT7   229 59842 6 
sp|Q5JTV8|TOIP1_HUMAN Torsin-1A-interacting protein 1  TOR1AIP1   205 66379 6 
sp|Q15392|DHC24_HUMAN Delta(24)-sterol reductase  DHCR24   195 60803 6 
sp|O43175|SERA_HUMAN D-3-phosphoglycerate dehydrogenase  PHGDH   194 57356 6 
sp|Q14739|LBR_HUMAN Lamin-B receptor  LBR   187 71057 6 
sp|P08670|VIME_HUMAN Vimentin  VIM   182 53676 6 
sp|Q15904|VAS1_HUMAN V-type proton ATPase subunit S1  ATP6AP1   180 52164 6 
sp|P49368|TCPG_HUMAN T-complex protein 1 subunit gamma  CCT3   178 61066 6 
sp|Q9C0E8|LNP_HUMAN Protein lunapark  LNP   171 48052 6 
sp|Q96S66|CLCC1_HUMAN Chloride channel CLIC-like protein 1  CLCC1   166 62667 6 
sp|P06744|G6PI_HUMAN Glucose-6-phosphate isomerase  GPI   165 63335 6 
sp|Q5VTE0|EF1A3_HUMAN Putative elongation factor 1-alpha-like 3  EEF1A1P5  163 50495 6 
sp|Q96CS3|FAF2_HUMAN FAS-associated factor 2  FAF2   151 52933 6 
sp|P17987|TCPA_HUMAN T-complex protein 1 subunit alpha  TCP1   150 60819 6 
sp|P80723|BASP1_HUMAN Brain acid soluble protein 1  BASP1   146 22680 6 
sp|P52429|DGKE_HUMAN Diacylglycerol kinase epsilon  DGKE  133 65482 6 
sp|Q96KA5|CLP1L_HUMAN Cleft lip and palate transmembrane protein 1-like protein  CLPTM1L   131 62531 6 
sp|P40227|TCPZ_HUMAN T-complex protein 1 subunit zeta  CCT6A   127 58444 6 
sp|Q9H845|ACAD9_HUMAN Acyl-CoA dehydrogenase family member 9, mitochondrial  ACAD9   120 69344 6 
sp|O95470|SGPL1_HUMAN Sphingosine-1-phosphate lyase 1  SGPL1   104 64053 6 
sp|P39656|OST48_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit  DDOST  1223 50940 7 
sp|P68104|EF1A1_HUMAN Elongation factor 1-alpha 1  EEF1A1   1091 50451 7 
sp|P22695|QCR2_HUMAN Cytochrome b-c1 complex subunit 2, mitochondrial  UQCRC2   1047 48584 7 
sp|P06733|ENOA_HUMAN Alpha-enolase  ENO1   927 47481 7 
sp|P04439|1A03_HUMAN HLA class I histocompatibility antigen, A-3 alpha chain  HLA-A   913 41100 7 
sp|P60709|ACTB_HUMAN Actin, cytoplasmic 1  ACTB   902 42052 7 
sp|P12277|KCRB_HUMAN Creatine kinase B-type  CKB   765 42902 7 
sp|P31930|QCR1_HUMAN Cytochrome b-c1 complex subunit 1, mitochondrial  UQCRC1   719 53297 7 
sp|O60664|PLIN3_HUMAN Perilipin-3  PLIN3   643 47217 7 
sp|P67809|YBOX1_HUMAN Nuclease-sensitive element-binding protein 1  YBX1   595 35903 7 
sp|P07099|HYEP_HUMAN Epoxide hydrolase 1  EPHX1   568 53143 7 
sp|O75844|FACE1_HUMAN CAAX prenyl protease 1 homolog  ZMPSTE24   561 55063 7 
sp|P37268|FDFT_HUMAN Squalene synthase  FDFT1   516 48597 7 
sp|Q96HY6|DDRGK_HUMAN DDRGK domain-containing protein 1  DDRGK1   459 35589 7 
sp|P49585|PCY1A_HUMAN Choline-phosphate cytidylyltransferase A  PCYT1A   447 42047 7 
sp|P01893|HLAH_HUMAN Putative HLA class I histocompatibility antigen, alpha chain H  HLA-H  421 41094 7 
sp|Q9UBM7|DHCR7_HUMAN 7-dehydrocholesterol reductase  DHCR7   420 55195 7 
sp|P20645|MPRD_HUMAN Cation-dependent mannose-6-phosphate receptor  M6PR   419 31487 7 
sp|Q8TCT9|HM13_HUMAN Minor histocompatibility antigen H13  HM13   415 41747 7 
sp|P26641|EF1G_HUMAN Elongation factor 1-gamma  EEF1G   411 50429 7 
sp|Q3ZCQ8|TIM50_HUMAN Mitochondrial import inner membrane translocase subunit TIM50  TIMM50   410 39850 7 
sp|Q29960|1C16_HUMAN HLA class I histocompatibility antigen, Cw-16 alpha chain  HLA-C   395 41240 7 
sp|P54709|AT1B3_HUMAN Sodium/potassium-transporting ATPase subunit beta-3  ATP1B3   394 31834 7 
sp|Q99536|VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog  VAT1   388 42122 7 
sp|Q9NX62|IMPA3_HUMAN Inositol monophosphatase 3  IMPAD1   383 38828 7 
sp|P18465|1B57_HUMAN HLA class I histocompatibility antigen, B-57 alpha chain  HLA-B   379 40541 7 
sp|Q92643|GPI8_HUMAN GPI-anchor transamidase  PIGK   378 45508 7 
sp|O94905|ERLN2_HUMAN Erlin-2  ERLIN2   371 38044 7 
sp|P16422|EPCAM_HUMAN Epithelial cell adhesion molecule  EPCAM   370 35594 7 
sp|P53985|MOT1_HUMAN Monocarboxylate transporter 1  SLC16A1   360 54593 7 
sp|O96008|TOM40_HUMAN Mitochondrial import receptor subunit TOM40 homolog  TOMM40   300 38211 7 
sp|Q9Y282|ERGI3_HUMAN Endoplasmic reticulum-Golgi intermediate compartment protein 3  ERGIC3   299 43765 7 
sp|Q9HCU5|PREB_HUMAN Prolactin regulatory element-binding protein  PREB   292 46010 7 
sp|Q9NQC3|RTN4_HUMAN Reticulon-4  RTN4   289 130250 7 
sp|P61619|S61A1_HUMAN Protein transport protein Sec61 subunit alpha isoform 1  SEC61A1   281 52687 7 
sp|Q99805|TM9S2_HUMAN Transmembrane 9 superfamily member 2  TM9SF2   281 76809 7 
sp|Q9BTV4|TMM43_HUMAN Transmembrane protein 43  TMEM43   259 44904 7 
sp|Q9HD45|TM9S3_HUMAN Transmembrane 9 superfamily member 3  TM9SF3   257 68584 7 
sp|Q8N2K0|ABD12_HUMAN Monoacylglycerol lipase ABHD12  ABHD12   251 45524 7 
sp|Q92604|LGAT1_HUMAN Acyl-CoA:lysophosphatidylglycerol acyltransferase 1  LPGAT1   212 43289 7 
sp|P04075|ALDOA_HUMAN Fructose-bisphosphate aldolase A  ALDOA   194 39851 7 
sp|Q15645|PCH2_HUMAN Pachytene checkpoint protein 2 homolog  TRIP13   185 48863 7 
sp|Q53EU6|GPAT3_HUMAN Glycerol-3-phosphate acyltransferase 3  AGPAT9   181 49187 7 
sp|Q9BT22|ALG1_HUMAN Chitobiosyldiphosphodolichol beta-mannosyltransferase  ALG1   178 53282 7 
sp|O75695|XRP2_HUMAN Protein XRP2  RP2   168 40471 7 
sp|Q8NBX0|SCPDL_HUMAN Saccharopine dehydrogenase-like oxidoreductase  SCCPDH   157 47464 7 
sp|Q96EY1|DNJA3_HUMAN DnaJ homolog subfamily A member 3, mitochondrial  DNAJA3   155 53083 7 
sp|P08962|CD63_HUMAN CD63 antigen  CD63   152 26474 7 
sp|O75306|NDUS2_HUMAN NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial  NDUFS2   149 52911 7 
sp|Q9NRX5|SERC1_HUMAN Serine incorporator 1  SERINC1   148 51488 7 
sp|O95674|CDS2_HUMAN Phosphatidate cytidylyltransferase 2  CDS2   146 51954 7 
sp|Q9HDC9|APMAP_HUMAN Adipocyte plasma membrane-associated protein  APMAP   145 46622 7 
sp|Q7Z7N9|T179B_HUMAN Transmembrane protein 179B  TMEM179B   145 24048 7 
sp|Q16563|SYPL1_HUMAN Synaptophysin-like protein 1  SYPL1   141 28889 7 
sp|P49006|MRP_HUMAN MARCKS-related protein  MARCKSL1   138 19574 7 
sp|P08865|RSSA_HUMAN 40S ribosomal protein SA  RPSA   136 32947 7 
sp|Q70UQ0|IKIP_HUMAN Inhibitor of nuclear factor kappa-B kinase-interacting protein  IKBIP   134 39399 7 
sp|Q99808|S29A1_HUMAN Equilibrative nucleoside transporter 1  SLC29A1   131 50757 7 
sp|Q9Y679|AUP1_HUMAN Ancient ubiquitous protein 1  AUP1   131 53508 7 
sp|P52597|HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F  HNRNPF   130 45985 7 
sp|Q96GC9|VMP1_HUMAN Vacuole membrane protein 1  VMP1   128 46607 7 
sp|P22234|PUR6_HUMAN Multifunctional protein ADE2  PAICS   124 47790 7 
sp|Q9P2W9|STX18_HUMAN Syntaxin-18  STX18   122 38821 7 
sp|O60884|DNJA2_HUMAN DnaJ homolog subfamily A member 2  DNAJA2   120 46344 7 
sp|P60842|IF4A1_HUMAN Eukaryotic initiation factor 4A-I  EIF4A1   120 46353 7 
sp|Q9UJZ1|STML2_HUMAN Stomatin-like protein 2  STOML2   114 38624 7 
sp|Q6NUK1|SCMC1_HUMAN Calcium-binding mitochondrial carrier protein SCaMC-1  SLC25A24   109 53548 7 
sp|P09543|CN37_HUMAN 2~,3~-cyclic-nucleotide 3~-phosphodiesterase  CNP   108 47948 7 
sp|P36578|RL4_HUMAN 60S ribosomal protein L4  RPL4   108 47953 7 
sp|Q99747|SNAG_HUMAN Gamma-soluble NSF attachment protein  NAPG   107 35066 7 
sp|Q8NBU5|ATAD1_HUMAN ATPase family AAA domain-containing protein 1  ATAD1   107 41060 7 
sp|O94766|B3GA3_HUMAN Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3  B3GAT3   106 37270 7 
sp|Q5T1Q4|S35F1_HUMAN Solute carrier family 35 member F1  SLC35F1   102 45659 7 
sp|P43686|PRS6B_HUMAN 26S protease regulatory subunit 6B  PSMC4   100 47451 7 
sp|P00387|NB5R3_HUMAN NADH-cytochrome b5 reductase 3  CYB5R3   1624 34441 8 
sp|P35232|PHB_HUMAN Prohibitin  PHB   1424 29843 8 
sp|Q99623|PHB2_HUMAN Prohibitin-2  PHB2   1251 33276 8 
sp|P54920|SNAA_HUMAN Alpha-soluble NSF attachment protein  NAPA   976 33667 8 
sp|P21796|VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1  VDAC1   945 30868 8 
sp|Q00325|MPCP_HUMAN Phosphate carrier protein, mitochondrial  SLC25A3   859 40525 8 
sp|P12236|ADT3_HUMAN ADP/ATP translocase 3  SLC25A6   783 33073 8 
sp|Q9H9B4|SFXN1_HUMAN Sideroflexin-1  SFXN1   771 35881 8 
sp|Q02978|M2OM_HUMAN Mitochondrial 2-oxoglutarate/malate carrier protein  SLC25A11   743 34211 8 
sp|Q53GQ0|DHB12_HUMAN Estradiol 17-beta-dehydrogenase 12  HSD17B12   721 34416 8 
sp|P36542|ATPG_HUMAN ATP synthase subunit gamma, mitochondrial  ATP5C1   704 33032 8 
sp|O15400|STX7_HUMAN Syntaxin-7  STX7   689 29911 8 
sp|O14828|SCAM3_HUMAN Secretory carrier-associated membrane protein 3  SCAMP3   652 38661 8 
sp|P05141|ADT2_HUMAN ADP/ATP translocase 2  SLC25A5  648 33059 8 
sp|P12235|ADT1_HUMAN ADP/ATP translocase 1  SLC25A4   643 33271 8 
sp|P45880|VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2  VDAC2   583 32060 8 
sp|Q12907|LMAN2_HUMAN Vesicular integral-membrane protein VIP36  LMAN2   573 40545 8 
sp|P30519|HMOX2_HUMAN Heme oxygenase 2  HMOX2   570 36181 8 
sp|P04406|G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase  GAPDH   564 36201 8 
sp|Q14165|MLEC_HUMAN Malectin  MLEC   531 32385 8 
sp|P50402|EMD_HUMAN Emerin  EMD   528 29033 8 
sp|Q86Y82|STX12_HUMAN Syntaxin-12  STX12   522 31736 8 
sp|P62873|GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  GNB1   514 38151 8 
sp|Q9P0L0|VAPA_HUMAN Vesicle-associated membrane protein-associated protein A  VAPA   478 28103 8 
sp|Q9P035|HACD3_HUMAN 3-hydroxyacyl-CoA dehydratase 3  PTPLAD1   446 43360 8 
sp|Q9Y277|VDAC3_HUMAN Voltage-dependent anion-selective channel protein 3  VDAC3   444 30981 8 
sp|O15126|SCAM1_HUMAN Secretory carrier-associated membrane protein 1  SCAMP1   431 38295 8 
sp|P43307|SSRA_HUMAN Translocon-associated protein subunit alpha  SSR1   325 32215 8 
sp|Q5VT66|MOSC1_HUMAN MOSC domain-containing protein 1, mitochondrial  MARC1   320 37989 8 
sp|P07195|LDHB_HUMAN L-lactate dehydrogenase B chain  LDHB   310 36900 8 
sp|Q15006|EMC2_HUMAN ER membrane protein complex subunit 2  EMC2   306 34982 8 
sp|Q8TC12|RDH11_HUMAN Retinol dehydrogenase 11  RDH11   301 35763 8 
sp|P53007|TXTP_HUMAN Tricarboxylate transport protein, mitochondrial  SLC25A1   281 34333 8 
sp|Q96G23|CERS2_HUMAN Ceramide synthase 2  CERS2   280 44961 8 
sp|P62258|1433E_HUMAN 14-3-3 protein epsilon  YWHAE   279 29326 8 
sp|Q9HBH5|RDH14_HUMAN Retinol dehydrogenase 14  RDH14   270 37184 8 
sp|Q9NZ01|TECR_HUMAN Trans-2,3-enoyl-CoA reductase  TECR   269 36410 8 
sp|Q9Y673|ALG5_HUMAN Dolichyl-phosphate beta-glucosyltransferase  ALG5   264 37150 8 
sp|Q6UWP7|LCLT1_HUMAN Lysocardiolipin acyltransferase 1  LCLAT1   258 49344 8 
sp|Q96AG4|LRC59_HUMAN Leucine-rich repeat-containing protein 59  LRRC59   255 35308 8 
sp|P62879|GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2  GNB2   252 38048 8 
sp|O15127|SCAM2_HUMAN Secretory carrier-associated membrane protein 2  SCAMP2   233 37082 8 
sp|O14662|STX16_HUMAN Syntaxin-16  STX16   233 37179 8 
sp|Q969X5|ERGI1_HUMAN Endoplasmic reticulum-Golgi intermediate compartment protein 1  ERGIC1   232 32971 8 
sp|Q9P0I2|EMC3_HUMAN ER membrane protein complex subunit 3  EMC3   218 29932 8 
sp|O75787|RENR_HUMAN Renin receptor  ATP6AP2   210 38983 8 
sp|Q07021|C1QBP_HUMAN Complement component 1 Q subcomponent-binding protein, mitochondrial  C1QBP   209 31742 8 
sp|P00338|LDHA_HUMAN L-lactate dehydrogenase A chain  LDHA   201 36950 8 
sp|P29692|EF1D_HUMAN Elongation factor 1-delta  EEF1D   194 31217 8 
sp|P84157|MXRA7_HUMAN Matrix-remodeling-associated protein 7  MXRA7   182 21509 8 
sp|P24534|EF1B_HUMAN Elongation factor 1-beta  EEF1B2   180 24919 8 
sp|P21912|DHSB_HUMAN Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  SDHB   180 32407 8 
sp|Q12846|STX4_HUMAN Syntaxin-4  STX4   178 34273 8 
sp|Q8NHW5|RLA0L_HUMAN 60S acidic ribosomal protein P0-like  RPLP0P6  177 34514 8 
sp|Q9H0V9|LMA2L_HUMAN VIP36-like protein  LMAN2L   177 39913 8 
sp|O43808|PM34_HUMAN Peroxisomal membrane protein PMP34  SLC25A17   172 34659 8 
sp|Q9H490|PIGU_HUMAN Phosphatidylinositol glycan anchor biosynthesis class U protein  PIGU   164 50361 8 
sp|O15121|DEGS1_HUMAN Sphingolipid delta(4)-desaturase DES1  DEGS1   163 38012 8 
sp|P08574|CY1_HUMAN Cytochrome c1, heme protein, mitochondrial  CYC1   160 35741 8 
sp|P23396|RS3_HUMAN 40S ribosomal protein S3  RPS3   154 26842 8 
sp|Q8NBQ5|DHB11_HUMAN Estradiol 17-beta-dehydrogenase 11  HSD17B11   150 33257 8 
sp|Q8NEW0|ZNT7_HUMAN Zinc transporter 7  SLC30A7   149 41941 8 
sp|O60499|STX10_HUMAN Syntaxin-10  STX10   143 28210 8 
sp|Q6IAN0|DRS7B_HUMAN Dehydrogenase/reductase SDR family member 7B  DHRS7B   143 35382 8 
sp|P63104|1433Z_HUMAN 14-3-3 protein zeta/delta  YWHAZ   141 27899 8 
sp|P40926|MDHM_HUMAN Malate dehydrogenase, mitochondrial  MDH2   137 35937 8 
sp|Q9H3N1|TMX1_HUMAN Thioredoxin-related transmembrane protein 1  TMX1   134 32170 8 
sp|Q9UBX3|DIC_HUMAN Mitochondrial dicarboxylate carrier  SLC25A10   133 31718 8 
sp|Q8TB61|S35B2_HUMAN Adenosine 3~-phospho 5~-phosphosulfate transporter 1  SLC35B2   129 48054 8 
sp|Q9Y3E0|GOT1B_HUMAN Vesicle transport protein GOT1B  GOLT1B   126 15415 8 
sp|Q9BUM1|G6PC3_HUMAN Glucose-6-phosphatase 3  G6PC3   125 39108 8 
sp|O00767|ACOD_HUMAN Acyl-CoA desaturase  SCD   122 41667 8 
sp|Q96FZ7|CHMP6_HUMAN Charged multivesicular body protein 6  CHMP6   116 23527 8 
sp|P0CG08|GPHRB_HUMAN Golgi pH regulator B  GPR89B   114 53167 8 
sp|Q9Y6C9|MTCH2_HUMAN Mitochondrial carrier homolog 2  MTCH2   114 33936 8 
sp|Q01650|LAT1_HUMAN Large neutral amino acids transporter small subunit 1  SLC7A5   107 55659 8 
sp|Q5BJH7|YIF1B_HUMAN Protein YIF1B  YIF1B   107 34527 8 
sp|O14579|COPE_HUMAN Coatomer subunit epsilon  COPE   105 34688 8 
sp|P51149|RAB7A_HUMAN Ras-related protein Rab-7a  RAB7A   1284 23760 09rerun 
sp|O75396|SC22B_HUMAN Vesicle-trafficking protein SEC22b   1265 24806 09rerun 
sp|Q9H0U4|RAB1B_HUMAN Ras-related protein Rab-1B  RAB1B   972 22328 09rerun 
sp|P61224|RAP1B_HUMAN Ras-related protein Rap-1b  RAP1B   892 21040 09rerun 
sp|P48047|ATPO_HUMAN ATP synthase subunit O, mitochondrial  ATP5O   882 23377 09rerun 
sp|P62820|RAB1A_HUMAN Ras-related protein Rab-1A  RAB1A   877 22891 09rerun 
sp|P51572|BAP31_HUMAN B-cell receptor-associated protein 31  BCAP31   842 28031 09rerun 
sp|P51148|RAB5C_HUMAN Ras-related protein Rab-5C  RAB5C   815 23696 09rerun 
sp|P49755|TMEDA_HUMAN Transmembrane emp24 domain-containing protein 10  TMED10   786 25131 09rerun 
sp|O75947|ATP5H_HUMAN ATP synthase subunit d, mitochondrial  ATP5H   723 18537 09rerun 
sp|P24539|AT5F1_HUMAN ATP synthase subunit b, mitochondrial  ATP5F1   707 28947 09rerun 
sp|P62834|RAP1A_HUMAN Ras-related protein Rap-1A  RAP1A   648 21316 09rerun 
sp|O00264|PGRC1_HUMAN Membrane-associated progesterone receptor component 1  PGRMC1   641 21772 09rerun 
sp|Q9BVK6|TMED9_HUMAN Transmembrane emp24 domain-containing protein 9  TMED9   640 27374 09rerun 
sp|Q7Z7H5|TMED4_HUMAN Transmembrane emp24 domain-containing protein 4  TMED4   578 26097 09rerun 
sp|O60762|DPM1_HUMAN Dolichol-phosphate mannosyltransferase  DPM1   552 29673 09rerun 
sp|Q15907|RB11B_HUMAN Ras-related protein Rab-11B  RAB11B   535 24588 09rerun 
sp|P61026|RAB10_HUMAN Ras-related protein Rab-10  RAB10   512 22755 09rerun 
sp|Q92520|FAM3C_HUMAN Protein FAM3C  FAM3C   511 24950 09rerun 
sp|O15260|SURF4_HUMAN Surfeit locus protein 4  SURF4   508 30602 09rerun 
sp|P61006|RAB8A_HUMAN Ras-related protein Rab-8A  RAB8A   474 23824 09rerun 
sp|Q15286|RAB35_HUMAN Ras-related protein Rab-35  RAB35   471 23296 09rerun 
sp|P20340|RAB6A_HUMAN Ras-related protein Rab-6A  RAB6A   469 23692 09rerun 
sp|Q15363|TMED2_HUMAN Transmembrane emp24 domain-containing protein 2  TMED2   467 22860 09rerun 
sp|P00403|COX2_HUMAN Cytochrome c oxidase subunit 2  MT-CO2   422 25719 09rerun 
sp|P51809|VAMP7_HUMAN Vesicle-associated membrane protein 7  VAMP7   395 25261 09rerun 
sp|Q9NP72|RAB18_HUMAN Ras-related protein Rab-18  RAB18   382 23248 09rerun 
sp|O95292|VAPB_HUMAN Vesicle-associated membrane protein-associated protein B/C  VAPB   364 27439 09rerun 
sp|O43819|SCO2_HUMAN Protein SCO2 homolog, mitochondrial  SCO2   359 29962 09rerun 
sp|Q9NRW1|RAB6B_HUMAN Ras-related protein Rab-6B  RAB6B   357 23561 09rerun 
sp|Q92930|RAB8B_HUMAN Ras-related protein Rab-8B  RAB8B   351 23740 09rerun 
sp|O43169|CYB5B_HUMAN Cytochrome b5 type B  CYB5B   351 16436 09rerun 
sp|Q99653|CHP1_HUMAN Calcium-binding protein p22  CHP   335 22442 09rerun 
sp|P61106|RAB14_HUMAN Ras-related protein Rab-14  RAB14   328 24110 09rerun 
sp|P47985|UCRI_HUMAN Cytochrome b-c1 complex subunit Rieske, mitochondrial  UQCRFS1   322 29934 09rerun 
sp|O15173|PGRC2_HUMAN Membrane-associated progesterone receptor component 2  PGRMC2   312 23861 09rerun 
sp|P60033|CD81_HUMAN CD81 antigen  CD81   310 26476 09rerun 
sp|P51153|RAB13_HUMAN Ras-related protein Rab-13  RAB13   300 22988 09rerun 
sp|P61586|RHOA_HUMAN Transforming protein RhoA  RHOA   298 22096 09rerun 
sp|Q8WUY1|THEM6_HUMAN UPF0670 protein THEM6  THEM6   293 24135 09rerun 
sp|Q9UL25|RAB21_HUMAN Ras-related protein Rab-21  RAB21   293 24731 09rerun 
sp|Q9Y3E5|PTH2_HUMAN Peptidyl-tRNA hydrolase 2, mitochondrial  PTRH2   293 19466 09rerun 
sp|P57088|TMM33_HUMAN Transmembrane protein 33  TMEM33   281 28302 09rerun 
sp|P61020|RAB5B_HUMAN Ras-related protein Rab-5B  RAB5B   270 23920 09rerun 
sp|P20339|RAB5A_HUMAN Ras-related protein Rab-5A  RAB5A   266 23872 09rerun 
sp|P46782|RS5_HUMAN 40S ribosomal protein S5  RPS5   264 23033 09rerun 
sp|Q99720|SGMR1_HUMAN Sigma non-opioid intracellular receptor 1  SIGMAR1   258 25169 09rerun 
sp|Q99943|PLCA_HUMAN 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha  AGPAT1   249 32038 09rerun 
sp|Q9UM00|TMCO1_HUMAN Transmembrane and coiled-coil domain-containing protein 1  TMCO1   242 21389 09rerun 
sp|P51151|RAB9A_HUMAN Ras-related protein Rab-9A  RAB9A   235 23108 09rerun 
sp|Q9UNK0|STX8_HUMAN Syntaxin-8  STX8   234 27004 09rerun 
sp|P60953|CDC42_HUMAN Cell division control protein 42 homolog  CDC42   230 21587 09rerun 
sp|Q15005|SPCS2_HUMAN Signal peptidase complex subunit 2  SPCS2   230 25272 09rerun 
sp|P84095|RHOG_HUMAN Rho-related GTP-binding protein RhoG  RHOG   228 21751 09rerun 
sp|O43760|SNG2_HUMAN Synaptogyrin-2  SYNGR2   228 25079 09rerun 
sp|Q9NX47|MARH5_HUMAN E3 ubiquitin-protein ligase MARCH5     225 31781 09rerun 
sp|P61019|RAB2A_HUMAN Ras-related protein Rab-2A  RAB2A   201 23702 09rerun 
sp|Q8N183|MIMIT_HUMAN Mimitin, mitochondrial  NDUFAF2   181 19844 09rerun 
sp|P32119|PRDX2_HUMAN Peroxiredoxin-2  PRDX2   177 22049 09rerun 
sp|Q9NYL4|FKB11_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP11   170 22337 09rerun 
sp|O75489|NDUS3_HUMAN NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial  NDUFS3   163 30337 09rerun 
sp|O15258|RER1_HUMAN Protein RER1  RER1   161 23057 09rerun 
sp|Q06830|PRDX1_HUMAN Peroxiredoxin-1  PRDX1   160 22324 09rerun 
sp|P26373|RL13_HUMAN 60S ribosomal protein L13  RPL13   151 24304 09rerun 
sp|O75352|MPU1_HUMAN Mannose-P-dolichol utilization defect 1 protein  MPDU1   150 26906 09rerun 
sp|O95816|BAG2_HUMAN BAG family molecular chaperone regulator 2  BAG2   150 23928 09rerun 
sp|P63000|RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1  RAC1   144 21835 09rerun 
sp|Q9Y5M8|SRPRB_HUMAN Signal recognition particle receptor subunit beta  SRPRB   142 29912 09rerun 
sp|P61009|SPCS3_HUMAN Signal peptidase complex subunit 3  SPCS3   141 20358 09rerun 
sp|Q9H3K2|GHITM_HUMAN Growth hormone-inducible transmembrane protein  GHITM   139 37352 09rerun 
sp|Q04760|LGUL_HUMAN Lactoylglutathione lyase  GLO1   132 20992 09rerun 
sp|O96011|PX11B_HUMAN Peroxisomal membrane protein 11B  PEX11B   129 28869 09rerun 
sp|Q07020|RL18_HUMAN 60S ribosomal protein L18  RPL18   126 21735 09rerun 
sp|P60174|TPIS_HUMAN Triosephosphate isomerase  TPI1   123 31057 09rerun 
sp|Q9BRX8|F213A_HUMAN Redox-regulatory protein FAM213A  FAM213A   122 25861 09rerun 
sp|P24390|ERD21_HUMAN ER lumen protein retaining receptor 1  KDELR1   116 24754 09rerun 
sp|Q9BRK0|REEP2_HUMAN Receptor expression-enhancing protein 2  REEP2   114 28243 09rerun 
sp|P11233|RALA_HUMAN Ras-related protein Ral-A  RALA   113 23723 09rerun 
sp|P19404|NDUV2_HUMAN NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  NDUFV2   113 27659 09rerun 
sp|P21926|CD9_HUMAN CD9 antigen  CD9   112 25969 09rerun 
sp|Q9Y3A6|TMED5_HUMAN Transmembrane emp24 domain-containing protein 5  TMED5   111 26102 09rerun 
sp|P21964|COMT_HUMAN Catechol O-methyltransferase  COMT   110 30474 09rerun 
sp|Q5SRD1|TI23B_HUMAN Putative mitochondrial import inner membrane translocase subunit Tim23B  TIMM23B  102 28315 09rerun 
sp|Q86YN1|DOPP1_HUMAN Dolichyldiphosphatase 1  DOLPP1   101 27127 09rerun 
sp|P31946|1433B_HUMAN 14-3-3 protein beta/alpha  YWHAB   100 28179 09rerun 
sp|Q9NWW5|CLN6_HUMAN Ceroid-lipofuscinosis neuronal protein 6  CLN6   100 36010 09rerun 
sp|P27348|1433T_HUMAN 14-3-3 protein theta  YWHAQ   59 28032 09rerun 
sp|Q15836|VAMP3_HUMAN Vesicle-associated membrane protein 3  VAMP3   717 11359 10 
sp|P63027|VAMP2_HUMAN Vesicle-associated membrane protein 2  VAMP2   523 12712 10 
sp|P05386|RLA1_HUMAN 60S acidic ribosomal protein P1  RPLP1   504 11621 10 
sp|P62937|PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A  PPIA   471 18229 10 
sp|O60831|PRAF2_HUMAN PRA1 family protein 2  PRAF2   466 19588 10 
sp|Q8N5K1|CISD2_HUMAN CDGSH iron-sulfur domain-containing protein 2  CISD2   449 15497 10 
sp|Q5QNW6|H2B2F_HUMAN Histone H2B type 2-F  HIST2H2BF   425 13912 10 
sp|Q9NS69|TOM22_HUMAN Mitochondrial import receptor subunit TOM22 homolog  TOMM22   372 15512 10 
sp|P18859|ATP5J_HUMAN ATP synthase-coupling factor 6, mitochondrial  ATP5J   358 12580 10 
sp|P13073|COX41_HUMAN Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  COX4I1   342 19621 10 
sp|P51571|SSRD_HUMAN Translocon-associated protein subunit delta  SSR4   332 19158 10 
sp|P62158|CALM_HUMAN Calmodulin  CALM1   332 16827 10 
sp|P30049|ATPD_HUMAN ATP synthase subunit delta, mitochondrial  ATP5D   318 17479 10 
sp|P0C0S8|H2A1_HUMAN Histone H2A type 1  HIST1H2AG   312 14083 10 
sp|Q15388|TOM20_HUMAN Mitochondrial import receptor subunit TOM20 homolog  TOMM20   311 16459 10 
sp|Q8WY22|BRI3B_HUMAN BRI3-binding protein  BRI3BP   307 27932 10 
sp|P62829|RL23_HUMAN 60S ribosomal protein L23  RPL23   291 14970 10 
sp|O75964|ATP5L_HUMAN ATP synthase subunit g, mitochondrial  ATP5L   269 11421 10 
sp|P20674|COX5A_HUMAN Cytochrome c oxidase subunit 5A, mitochondrial  COX5A   242 16923 10 
sp|Q8N5M9|JAGN1_HUMAN Protein jagunal homolog 1  JAGN1   227 21111 10 
sp|P0CW22|RS17L_HUMAN 40S ribosomal protein S17-like  RPS17L  227 15597 10 
sp|P10620|MGST1_HUMAN Microsomal glutathione S-transferase 1  MGST1   222 17644 10 
sp|P60468|SC61B_HUMAN Protein transport protein Sec61 subunit beta  SEC61B   219 10025 10 
sp|P15954|COX7C_HUMAN Cytochrome c oxidase subunit 7C, mitochondrial  COX7C   209 7298 10 
sp|Q96IX5|USMG5_HUMAN Up-regulated during skeletal muscle growth protein 5  USMG5   206 6510 10 
sp|P14174|MIF_HUMAN Macrophage migration inhibitory factor  MIF   205 12639 10 
sp|Q9NR77|PXMP2_HUMAN Peroxisomal membrane protein 2  PXMP2   204 22238 10 
sp|P56134|ATPK_HUMAN ATP synthase subunit f, mitochondrial  ATP5J2   204 11025 10 
sp|O15155|BET1_HUMAN BET1 homolog  BET1   198 13395 10 
sp|P67812|SC11A_HUMAN Signal peptidase complex catalytic subunit SEC11A    196 20612 10 
sp|Q3ZAQ7|VMA21_HUMAN Vacuolar ATPase assembly integral membrane protein VMA21   194 11347 10 
sp|Q04837|SSBP_HUMAN Single-stranded DNA-binding protein, mitochondrial  SSBP1   185 17249 10 
sp|Q96QV6|H2A1A_HUMAN Histone H2A type 1-A  HIST1H2AA   185 14225 10 
sp|P56385|ATP5I_HUMAN ATP synthase subunit e, mitochondrial  ATP5I   183 7928 10 
sp|Q04941|PLP2_HUMAN Proteolipid protein 2  PLP2   182 17022 10 
sp|Q9Y3D6|FIS1_HUMAN Mitochondrial fission 1 protein  FIS1   180 16984 10 
sp|P07737|PROF1_HUMAN Profilin-1  PFN1   179 15216 10 
sp|P62888|RL30_HUMAN 60S ribosomal protein L30  RPL30   179 12947 10 
sp|P24666|PPAC_HUMAN Low molecular weight phosphotyrosine protein phosphatase  ACP1   177 18487 10 
sp|P61803|DAD1_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1    174 12660 10 
sp|Q9BV40|VAMP8_HUMAN Vesicle-associated membrane protein 8  VAMP8   173 11488 10 
sp|O00483|NDUA4_HUMAN NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  NDUFA4   172 9421 10 
sp|O95406|CNIH_HUMAN Protein cornichon homolog  CNIH   171 17029 10 
sp|Q5J8M3|EMC4_HUMAN ER membrane protein complex subunit 4  EMC4   168 20244 10 
sp|Q9Y5U9|IR3IP_HUMAN Immediate early response 3-interacting protein 1  IER3IP1   166 9020 10 
sp|P60604|UB2G2_HUMAN Ubiquitin-conjugating enzyme E2 G2  UBE2G2   163 18725 10 
sp|P05387|RLA2_HUMAN 60S acidic ribosomal protein P2  RPLP2   162 11658 10 
sp|P60602|ROMO1_HUMAN Reactive oxygen species modulator 1  ROMO1   158 8405 10 
sp|P14927|QCR7_HUMAN Cytochrome b-c1 complex subunit 7  UQCRB   155 13522 10 
sp|P62805|H4_HUMAN Histone H4  HIST1H4A   155 11360 10 
sp|P46783|RS10_HUMAN 40S ribosomal protein S10  RPS10   154 18886 10 
sp|P27449|VATL_HUMAN V-type proton ATPase 16 kDa proteolipid subunit  ATP6V0C   149 15725 10 
sp|P14406|CX7A2_HUMAN Cytochrome c oxidase subunit 7A2, mitochondrial  COX7A2   146 9390 10 
sp|P30050|RL12_HUMAN 60S ribosomal protein L12  RPL12   144 17979 10 
sp|Q9BQB6|VKOR1_HUMAN Vitamin K epoxide reductase complex subunit 1  VKORC1   142 18622 10 
sp|Q8N4V1|MMGT1_HUMAN Membrane magnesium transporter 1  MMGT1   139 14734 10 
sp|O43759|SNG1_HUMAN Synaptogyrin-1  SYNGR1   139 25667 10 
sp|Q9Y2R0|CCD56_HUMAN Coiled-coil domain-containing protein 56  CCDC56   134 11724 10 
sp|P39210|MPV17_HUMAN Protein Mpv17  MPV17   132 19948 10 
sp|P39019|RS19_HUMAN 40S ribosomal protein S19  RPS19   131 16051 10 
sp|Q9BVK8|TM147_HUMAN Transmembrane protein 147  TMEM147   129 25586 10 
sp|Q9P2X0|DPM3_HUMAN Dolichol-phosphate mannosyltransferase subunit 3  DPM3   112 10258 10 
sp|Q5BJF2|TMM97_HUMAN Transmembrane protein 97  TMEM97   112 21005 10 
sp|Q9BUR5|APOO_HUMAN Apolipoprotein O  APOO   111 22385 10 
sp|Q9P0S9|TM14C_HUMAN Transmembrane protein 14C  TMEM14C   111 11557 10 
sp|P62269|RS18_HUMAN 40S ribosomal protein S18  RPS18   110 17708 10 
sp|Q6NXT2|H3C_HUMAN Histone H3.3C  H3F3C   109 15318 10 
sp|P63173|RL38_HUMAN 60S ribosomal protein L38  RPL38   109 8270 10 
sp|Q8N0U8|VKORL_HUMAN Vitamin K epoxide reductase complex subunit 1-like protein 1  VKORC1L1   108 20108 10 
sp|O95562|SFT2B_HUMAN Vesicle transport protein SFT2B  SFT2D2   108 18167 10 
sp|P63241|IF5A1_HUMAN Eukaryotic translation initiation factor 5A-1  EIF5A   106 17049 10 
sp|P62277|RS13_HUMAN 40S ribosomal protein S13  RPS13   106 17212 10 
sp|Q9Y3D7|TIM16_HUMAN Mitochondrial import inner membrane translocase subunit TIM16  PAM16   105 13816 10 
sp|P60660|MYL6_HUMAN Myosin light polypeptide 6  MYL6   105 17090 10 
sp|Q71UM5|RS27L_HUMAN 40S ribosomal protein S27-like  RPS27L   105 9813 10 
 
